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This research developed validated QSPKR and PK-AS models for predicting human 
systemic PK properties of three, preselected, pharmacological classes of drugs, namely opioids, 
β-adrenergic receptor ligands (β-ARL) and β-lactam antibiotics (β-LAs) using pertinent human 
and animal systemic PK properties (fu,, CLtot, Vdss, fe) and their biologically relevant unbound 
counterparts from the published literature, followed by an assessment of the effect of different 
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molecular descriptors on these PK properties and on the PK-AS slopes for CLtot and Vdss from 
two species (rat and dog).  
Lipophilicity (log (D)7.4) and molecular weight (MW) were found to be the most statistically 
significant and biologically plausible, molecular properties affecting the biologically relevant, 
systemic PK properties:   
For compounds with log (D)7.4 > -2.0 and MW < 350 D (e.g., most opioids and β-ARL), 
increased log (D)7.4 resulted in decreased fu and increased Vdssu, CLtotu and CLnonrenu, indicating 
the prevalence of hydrophobic interactions with biological membrane/proteins.  As result, the 
final QSPKR models using log (D)7.4 provided acceptable predictions for fu, Vdssu, CLtotu and 
CLnonrenu. CLnonrenu and CLtotu. For both the datasets, inclusion of drugs undergoing extrahepatic 
clearance worsened the QSPKR predictions.   
For compounds with log (D)7.4 < -2.0 and MW > 350 D (e.g., β-LA), increased MW 
(leading to more hydrogen bond donors/acceptors) resulted in a decrease in fu, likely indicating 
hydrogen bonding interactions with plasma proteins. In general, it was more difficult to predict 
PK parameters for β-LAs, as their Vdssu approached plasma volume and CLrenu and CLnonrenu 
were low - as a result of their high hydrophilicity and large MW, requiring specific drug 
transporters for distribution and excretion. 
The PK-AS analysis showed that animal body size accounted for most of the observed 
variability (r2> 0.80) in systemic PK variables, with single species methods, particularly those 
using dog, gave the best predictions. The fu correction of PK variables improved goodness of fit 
and predictability of human PK. There were no apparent effects of molecular properties on the 
predictions. CLren, CLrenu, CLnonren, and CLnonrenu were the most difficult variables to predict, 
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CHAPTER 1. INTRODUCTION  
 
1.  Introduction 
 
1.1.  Background and Significance 
 
The majority of chemical drug candidates entering clinical testing for safety and efficacy 
ultimately fail to reach the market place, among other things due to the lack of better 
understanding of their absorption, distribution, metabolism, and excretion (ADME) 
properties in early drug development.1, 2 The overall process of drug development is 
extremely time consuming and expensive, making early screening of drug candidates 
imperative.  Thus, the early in-silico prediction of human pharmacokinetic (PK) properties 
for new drug candidates has become an important step in drug discovery. For this, a variety 
of experimental approaches such as inter-species pharmacokinetic allometric scaling (PK-
AS) 3-5, physiologically based PK modeling6 and  in-vitro-in-vivo extrapolation (IVIVE)7 are 
used. On the other hand, there are in-silico aprroaches such as quantitative structure 
pharmacokinetic relationships (QSPKR), which can be used in the early drug discovery 
process as screening tools to eliminate chemicals likely lacking drug-like properties.8, 9 The 
aim of this research is to develop mathematical/statistical (“in-silico”) models for predicting 
human PK of existing opioid, β-adrenergic receptor ligand (β-ARL) and β-lactam antibiotic 
(β-LA) drugs using methods such as QSPKR modeling and interspecies allometric PK 
scaling (PK-AS).3-5 These models may then be generalized to assist during the drug 
  2
discovery process in the rational selection of new compounds as likely “druggable” chemical 
entities with more favorable human PK properties. 
 
1.2. Quantitative-structure pharmacokinetic relationships 
 
In the past, Hansch and co-workers10 studied relationships between the physicochemical 
properties and the in-vitro activity at the receptor for homologous series of compounds and 
innovated the field of quantitative structure activity relationship (QSAR), but this was limited 
to biological activity of chemicals. However, lack of ultimate therapeutic activity may not 
always be due to inadequate drug-receptor interaction, but can be due to inappropriate 
concentrations and/or concentration-time course of drug at the receptor. Structure-related 
properties of a chemical can be determined by experimental or computational means more 
efficiently than its PK properties using in vitro or in vivo approaches; a statistically validated 
QSPKR model is capable of predicting the PK properties of a new chemical within a 
homologous series as compared to the time-consuming and labor-intensive processes of 
chemical synthesis and biological evaluation. If applied judiciously, QSPKR may save 
substantial amounts of time, money, and human resources. Various computational techniques 
are used to calculate molecular descriptors for a compound11 and to predict human PK 
properties using in-silico QSPKR models.8, 12-16 QSPKR attempts to correlate chemical 
structure attributes with PK properties and to build models using statistical approaches. PK 
properties (which characterize ADME) are typical for a certain type of drug molecule 
similarly as are their aqueous solubility, melting point, electronic charge, pKa, lipophilicity, 
etc. The fundamental assumption of QSPKR is that variations in the PK parameters of a 
series of chemicals are dependent on variations in their structural, physical, and/or chemical 
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properties. Recently, ‘Lipinski’s Rule of Five’17 described the importance of molecular 
properties in ADME: He based his conclusions on a in-vitro GI solubility and GI 
permeability studies for 2245 compounds in United States Adopted Name (USAN) database, 
which includes names of compounds entering Phase II clinical testing. The rule states that a 
compound is likely to have poor pral absorption if molecular weight (MW) is more than 500 
D, clog P> 5, there are more than 5 hydrogen bond donors (HBD) and more than 10 
hydrogen bond acceptors (HBA). However, the molecular properties in the “Rule of Five” 
are not independent; increase in MW often leads to addition of more carbons and halogens, 
leading to higher clogP or additions of more hetero atoms, leading to higher hydrogen (H) 
bonding capacity. Higher H-bonding can result in a decrease in GI permeability and higher 
clogP can lead to lower GI solubility. The rule is based on compounds in the Pfizer pipeline 
which did not reach the market due to unfavorable physicochemical or PK-PD properties, 
does not consider in-vivo PK data and substrates for active transporters can be an exception 
to this rule.  
Most of the QSPKR studies in the literature are either on homologous series of 
compounds, resulting from systematic variation in the structure of the compounds or on 
datasets which have heterogenous compounds, from different structural and pharmacological 
classes predicted primary PK variables such as fu, CLtot and Vdss.16, 18-27 The use of 
homologous series results in a narrow range of molecular properties, which makes 
identification of important molecular properties difficult, and the widespread use of 
MLLR/univariate regression on the heterogenous datasets may neglect major interaction 
amongst the molecular properties. Studies carrying out discriminatory/trend analysis have 
divided the QSPKR databases into different categories such as charge/ionization state, 
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therapeutic area or into different ranges of MW bins.16, 21, 22 Such discriminatory analyses 
make it easier to assess in a qualitative fashion how changes in the physicochemical 
properties will impact the ADME properties in a particular physicochemical space, which is 
not possible using multivariate modeling methods. 
 Obach et al16 carried out a trend analysis on a database of 670 drugs (median MW: 342 
D (range 3-1816 D), median log (D)7.4: 0.42, median nRot: 5, median HBA: 6 and median 
HBD: 2), administered by I.V. route, they divided the dataset by ionization state into acid (n 
=159), base (n=271), neutral (n = 173) and zwiterionic drugs (n = 67). The median values for 
these molecular descriptors were well below “Lipinski’s Rule of Five”. It was found that 
acids showed lower median values volume of distribution at steady state (Vdss) than bases, 
with neutrals and zwitterions in between. Bases generally showed greater values for total 
body clearance (CLtot) than acids, neutrals or zwitterions.  
Gleeson 21 generated rules of thumb for a set of molecular properties based on clogP, 
MW and ionization state using a huge GSK database on rat in-vivo PK studies. The dataset 
was biased towards more lipophilic and high MW compounds. He found that molecules had 
more favorable systemtic PK properties if MW was less than 400 D and clogP less than 4, 
while they were classified as less favorable if one or more of the parameters was found to be 
above the cut-offs. Bases showed higher Vdss, followed by neutrals and zwitterions, while 
acids showed the lowest Vdss.  Acids showed mean CLtot considerably lower than neutral and 
zwitterions, which in turn was lower than bases. As MW increased, Vdss increased, PPB 
increased, while there was no relationhip between CLtot and MW. However, there was a 
relationship between clogP and CLtot, as the clog P increased; there was an increase in CLtot.  
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Varma et al22 analyzed  the effect of physicochemical properties on renal clearance 
(CLren) for a dataset of 370 drugs and found that lipophilicity showed a negative relationhip, 
while polar decsriptors like HBA, HBD showed a positive relationship with CLren.  Analysis 
of net tubularly secreted or net reabsorbed subsets revealed that ionized compounds show a 
greater probability of net secretion, fewer tendencies to be reabsorbed and likely interactions 
with renal uptake drug transporters. Van de Waterbeemd et al20 studied the effect of log 
(D)7.4 on oral absorption, brain uptake and various PK properties. It was found that increasing 
log (D), increased oral absorption, plasma protein binding (PPB) and volume of distribution 
(Vd), however, an increase in log (D)7.4 makes a molecule also more vulnerable to CYP450 
metabolism, leading to higher clearance (CLtot).  
In general, all these studies showed that lipophilicity determines partitioning and 
distribution processes, including cell membrane permeability, PPB, affinity for drug 
metabolizing enzymes, whereas the charge type governs ion-pair interactions with plasma 
proteins, lipids and drug metabolizing enzymes.  
Testa et al28 reviewed a number of QSPKR studies and examined the relationship of 
lipophilicity with different PK processes like membrane permeation, absorption, PPB, 
distribution and CLren. Amongst all the PK processes, relationhip between metabolism and 
lipophilicity was more complex, since biotransformation involves both low energy (enzyme 
binding) and high energy (catalysis) processes and lipophilicity can only be related to low 
energy processes. Testa et al28 described lipophilicity as a net result of intermolecular forces 
involving solute and the two phases between which it partitions and is based on its 
factorization into number of parameters like hydrophobicity (π), H-bond donor acidity, H-
bond acceptor basicity, hydrophobic and dispersion forces.  
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Veber et al29 studied the effect of molecular properties on rat PK properties of 1100 
compounds in a GSK database and found that the Lipinski’s MW cut-off of 500 D does not 
siginificantly differentiate compounds with poor oral bioavailability (Foral) from the 
compounds with acceptable Foral values. His observations suggest that compounds which 
have 10 or fewer nRot and 12 or fewer HBD/HBA will have a high probability of good Foral.  
Some QSPKR studies predict apparent clearance (CLtot/ Foral) and volume of distribution 
(Vdss/ Foral) since they used the PK data after oral administration.26, 30, 31 These studies 
showed that lipophilicty was an important determinant for PPB, CLtot/ Foral and Vdss/ Foral. 
Involvement of a complex phenomenon like oral bioavailability (Foral) can make these 
predictions difficult even more compared to systemic ADME due to confounding effects of 
incomplete absorption, first-pass effect or interspecies differences in absorption.  
This research concentrates only on intravenous (I.V.) PK studies for three classes of 
drugs (opioids, β-ARLs and β-LAs), each dataset has drugs that are structural analogs, act on 
a common pharmacological target and, at the same time, show considerable diversity in their 
physicochemical and PK properties. Initially, QSPKR analysis was done for individual 
datasets, followed by a trend analysis on the pooled dataset where all the the three datasets 
were pooled together. Construction of such QSPKR models not only requires sufficient 
information available in literature and reliable computational tools, but also databases whose 
elements have been compiled with critical evaluation of drug design, sampling methods, 
bioanalytical and PK analysis methods. The final dataset compiled after critical evaluation of 
literature in this research contained 146 drugs (38 opioids, 48 β-ARLs and 60 β-LAs) with a 
wide range of molecular properties; median clog(P): 1.2 (-6.1 to 7.2), median clog (D)7.4: -
0.95 (-7.3-3.7), median MW; 365 D (199-672), median: nRot: 7 (1-15), median HBD: 3 (0-7) 
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and median HBA: 6 (0-17). This database has a relatively small number of compounds and 
median values for clog(P), MW, HBD and HBAs are well below Lipinsiki’s ‘Rule of Five’ 
and median nRot values below the Veber29 cut-off for permeable compounds, however, it 
contains information about compounds which have been approved by FDA or which 
were/are used in clinical settings. Table 1.1 gives a comparison of the dataset in this research 
with the datasets in the published literature.  
In this approach, it is assumed that only unbound drug is available for distribution, 
excretion and metabolism. Thus, QSPKR models were built for the unbound PK properties. 
The term fu indicates the fraction of drug in plasma which is not bound to plasma proteins 
(e.g., albumin, alpha-acid glycoprotein) and, thus, is available for distribution, elimination 
and interaction with the target drug receptors. Highly plasma protein bound drugs are likely 
to have small Vdss and CLtot values even though their “true Vdss” may be high (indicating 
wide distribution of unbound drug) and “true CLtot” may be high (indicating high 
hepatic/renal extraction of unbound drug).  
In addition to considering binding to plasma proteins, the fraction of drug in whole blood 
that is bound to red blood cells (RBC) can also be important. The value for red cell partition 
coefficient (γ) can be estimated using the blood-to-plasma ratio (B:P) (Table 1.2); and γ 
assesses the fraction in blood that is bound to RBC and other cellular components after 
correction with PPB. 
 In addition, for the physiological assessment of the extent of  tissue distribution,  Vdss 
should be corrected for PPB to obtain the unbound volume of distribution at steady state 
(Vdssu) in order to compare with physiological spaces (plasma volume, blood volume, 
extracellular and intracellular spaces, total body water and body weight (BW)). 
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CLtot is the volume of plasma completely cleared of the drug per unit time.  It reflects the 
sum of all individual elimination pathways, i.e., CLren and non-renal clearance (CLnonren). 
CLren measures the contribution of renal elimination.  Since only unbound drug can be 
removed by renal glomerular filtration, CLren should be corrected for PPB to obtain unbound 
renal clearance (CLrenu) (Table 1.2). Physiological comparison of CLrenu to glomerular 
filtration rate (GFR) allows identification of net renal tubular secretion or reabsorption.  
Non-renal clearance (CLnonren) measures the contribution of all elimination pathways 
other than renal. It is usually assumed to be due to hepatic metabolism/biliary excretion 
(CLhep). However, it can be also due to extra-hepatic clearance (CLextrahep) in blood/other 
tissues.  
Usually, plasma drug concentrations are used for estimating PK properties. However, the 
body organs are perfused by blood, not plasma alone. Thus, blood clearance (CLnonrenblood) 
may be more physiologically relevant than plasma clearance, especially for hepatic 
clearance, where, clearance is compared to liver blood flow (LBF: 20 ml/min/kg32) in 
humans.  If CLnonrenblood exceeds the LBF, there is evidence of extra-hepatic metabolism. 
Thus, blood clearance was related to plasma clearance by B:P, and CLnonrenblood was 
estimated accordingly (Table 1.2).33   
Intrinsic clearance (CLint) is the intrinsic ability of the liver to remove the drug in absence 
of any blood flow restrictions.  CLintin-vivo can be estimated using the well-stirred model, 
assuming CLnonrenblood as the hepatic clearance (Table 1.2). 26 The hepatic extraction ratio 
(ERhep) is the intrinsic ability of the liver to extract the drug from blood, i.e., ratio of the 
arterio-venous concentration difference relative to the arterial concentration (including both 
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hepatic artery and portal vein).  Hepatic blood flow (Qhep), fu and CLint determine the hepatic 
extraction ratio (ERhep). 
Based on the above, the QSPKR study was carried out on the biologically relevant PK 
properties such as unbound volume of distribution at steady state (Vdssu), unbound total 
clearance (CLtotu), renal clearance (CLren), unbound renal clearance (CLrenu), non-renal 
clearance (CLnonren), unbound non-renal clearance (CLnonrenu), in-vivo intrinsic clearance 
(CLintin-vivo) and hepatic extraction ratio (ERhep). The effect of physicochemical properties 
such as pKa, MW, molar volume (MV), polar surface area (PSA), dipole moment, energy, 
clogP, % ionized at pH 7.4 and two dimensional molecular descriptors like HBD, HBA, 
nRot was studied on the PK variables. Distribution coefficient, Log (D), is the correct 
descriptor for ionizable systems and is at physiologically relevant pH. The distribution 
coefficient is the ratio of the sum of the concentrations of all forms of the compound 
(ionized plus un-ionized) in each of the two phases, 1-octanol and buffer (pH 7.4). Thus, log 
(D)7.4 was used. The % ionized at pH 6.3 allowed us to study if the ionization of compounds 
changed in urine (urinary pH: 6.3). These molecular properties were included based on the 











Table 1.1. Comparison of the Database in the Present QSPKR Study with the Databases in the Published 
QSPKR Studies 
 
 Published Literature Present QSPKR Study 





Homologous series – 
Databases which consisted 
of compounds which were a 
result of systematic 
structural variations. 
Three pharmacological classes 
PK variables - In-vitro/in-vivo PK 
variables in humans and 
animals.  
- Systemic as well as non-
systemic (oral) data. 
- Exposure metrics – AUC, 
t1/2,  MRT,  CLtot/Foral, 
Vdss/Foral, CLtot, Vdss 
- In-vitro/in-vivo PK variables in 
humans. 
 
- Systemic PK variables corrected 
for PPB, thus, QSPKR study was 













Table 1.2. Estimation of In-vitro and In-vivo PK Variables 
In-vitro/In-vivo systemic 





































22   
(assuming two compartment model) 
Vdssu Vdssu = Vdss/fu 
CLtot u CLtot u = CLtot/fu 
CLren CLren = CLtot *fe  
CLren = Ae∞/AUC0∞ , where Ae∞ is the amount excreted in urine and  
AUC0∞ is the area under the curve from the plasma concentration 
profile (after oral/IV  administration) 
CLren u CLren u = CLren/fu 
CLnonren CLnonren = CLtot-CLren 
CLnonrenblood CLnonrenblood = CLnonren/ (B:P) where CLnonrenblood  was assumed to be  
hepatic clearance (CLhep) 
CLintin-vivo CLintin-vivo = (Qhep*CLhep)/((fu/B:P)*(Qhep-CLhep)) 
where Qhep is the liver blood flow (assumed to be 20 ml/min/kg in 
humans) 
ERhep1 ERhep1 = CLnonrenblood/Qhep 
(assuming that liver is the only organ responsible for metabolism for 
CLnonren) 
ERhep2 ERhep2= 1-Foral 
(assuming that there is complete dissolution and permeation and 




Limitations of QSPKR modeling: 
• Sometimes, molecular descriptors used in QSPKR studies are collinear, which may cause 
redundancy in the information. PK properties like volume of distribution, clearance, 
protein binding are also interdependent, as they may depend on common factors. This can 
be addressed by using statistical techniques like partial least square analysis or artificial 
neural networks.  
• There are some descriptors like log (P) which are easily interpreted, but topological 
descriptors like molecular connectivities are difficult to interpret mechanistically.  
• An increase in number of molecular descriptors may lead to increase in statistical fit, but, 
there is always a chance of overfitting of data.  
• Available softwares packages provide a plethora of molecular descriptors, and 
appropriate selection of variables can be a limitation. To solve this, complex algorithms 
like genetic algorithms can be used. However, this increases the cost of the study. 
• Considerable bias in the available PK data like influence of age, smoking, disease states, 
etc. on the PK and lack of systemic PK studies within homologous series of drugs. Thus, 
QSPKR relies upon quality of the in-vivo PK data obtained.  
• QSPKR models as predictive tools work better only when the compounds in the training 
dataset have same structural backbone and wide range of physicochemical properties.  
• QSPKR models are based on a set of compounds with a certain range of physicochemical 
properties/structure attributes. Thus, it is more difficult, if not impossible, to predict PK 




1.3. Interspecies PK allometric scaling (PK-AS):  
 
In preclinical drug development, animal PK studies are carried out in atleast two species 
(rat, dog and /or monkey) to support toxicity studies.  The animal PK studies aid in 
identifying sources of variability such as elimination pathways (renal and/or hepatic), 
metabolic pathways, etc. In conjunction with toxicity and biological activity information, 
PK studies can be further used to predict dosing regimen. Once the human concentration 
response (i.e, dose-exposure) can be predicted, the challenge is to predict human systemic 
PK. Allometric Scaling (AS) is one of the most widely used approaches in predicting human 
PK parameters (CLtot, Vdss, t1/2) from the available in-vivo PK data in animal species. 3, 34, 35  
Allometric Scaling (AS) is the study of body size and its physiological consequences. It 
is based on the relationship between organ size, perfusion and body weight (BW), which can 
be explained by the equation: 
bBWaY )(= ,  
where Y is the parameter of interest (e.g., PK property like CLtot, Vdss, etc.) and a and b are 
the intercept and exponent (coefficient) of the allometric equation, respectively. For 
instance, an increase in body mass will cause reduction in the metabolic rate per unit mass, 
which, in turn, will influence the turn-over rate at the cellular level. Oxygen consumption 
also varies amongst animal species based on BW. Relative oxygen consumption increases as 
the BW decreases. This leads to increase in oxygen supply, and hence increased cardiac 
output. As a result, blood flow to 1 gm tissue will be 100 times greater in a mouse than in 
the elephant. It has shown that metabolic rate of an organism is proportional to the 0.75th  
power of the BW.36 It was also found that liver weight and LBF in all species scales well 
with BW (r > 0.99) and LBF was found to be directly proportional to liver weight.37 Blood 
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volume in terrestrial mammals scales with an exponent of 0.99 and skeletal mass with an 
exponent of 1.09. Volume of distribution is proportional with the BW across different 
species and the exponent is found to be close to 1.0. 38  
In the past few years, extensive research has been carried out to improve the accuracy of 
AS. Various modifications include maximum life span potential or brain weight correction39, 
rule of exponents40 and in-vitro correction41. Additionally, several quantitative 
methodologies using mechanistic correction factors based on  liver blood flow42 and 
glomerular filtration rate4 have been employed. Also, based on the mechanism of 
elimination of drugs, correction factors have been suggested for renally secreted 43 and 
biliary excreted drugs.44  
Prediction methodologies in the literature concentrate on more than one species because 
it is believed that high correlation amongst the PK parameters among three species is an 
indication of achieving better prediction of human PK. However, Boxenbaum showed that 
human antipyrine CLtot was poorly predicted despite high r2 values and use of multiple 
species.37 Similar observations have been made by Ward et al13 for a database of 103 
marketed compounds. Ward et al13 also was found that allometric scaling approaches using 
two species were less successful at predicting CLtot than LBF method in an individual 
species. In the past, scaling from monkey LBF method was proven to the accurate 
methodology when 124 compound dataset of structurally and pharmacologically diverse 
compounds was studied.45 A high r2 (> 0.90) does not guarantee that all data points will be 
close to the regression line. Thus, the extrapolation from this regression line based on 
limited number of species might have a considerable amount of uncertainty associated with 
it. Therefore, r2 alone does not offer a good measure for predictive ability of the allometric 
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relationship.36, 46 Power functions can create substantial errors in the data fitting and log-log 
tramsformations of the data visually minimize the deviations from the regression line. Thus, 
in this research, the predictive ability of the various allometric methods was assessed using 
% MPE for bias and % RMSE for imprecision.47  Predictive performance was also assessed 
using the number of compounds in the pre-selected fold error ranges of 0.5-2.0-fold.  
Intrinsic interspecies differences in drug disposition make the human PK prediction 
difficult, especially when active transport or extrahepatic metabolism is involved. Drug 
transporters play a key role in various ADME processes and can show remarkable 
interspecies differences.48 For drugs with high ERhep, LBF method or simple allometry may 
improve prediction, since LBF correlates well with BW. However, for the drugs, where 
clearance is not limited by LBF, but by hepatic CYP450 enzymes, allometry can be less 
predictive. Hepatic enzyme activity and expression can vary across species49. Thus, Lave et 
al41, 50 suggested a method of combining AS and IVIVE to improve the human predictions. 
Jolivette et al51 hypothesized that understanding of molecular properties for inliers or 
outliers for each species would increase the accuracy of the interspecies predictions. It was 
found that human extrapolation from rat and dog is more likely to accurately predict human 
CLtot for molecules that are relatively small and hydrophilic compared to larger, more 
lipophilic compounds.  
Jolivette et al51 also found that rat CLtot will not be predictive of human for molecules 
that have clog(P) value more than 0, and that molecules with high CLtot in rat but with 
clog(P) more than 3 will not have high CLtot in humans. A qualitative analysis of 102 
compounds (57 metabolized by liver - 29 low clearance, 17 intermediate clearance, 11 high 
clearance and 33 excreted by kidneys and 11 elminated by renal as well as by metabolism)  
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by Tang et al52 revealed the application of two potential rules for predicting the occurrence 
of large vertical allometry/overprediction in prediction of systemic CLtot,  ratio of unbound 
fraction of drug in plasma (fu) between rats and humans greater than 5; and clogP greater 
than 2. It was concluded that metabolic elimination could also serve as an additional 
indicator for expecting large vertical allometry. 
Most of the interspecies scaling studies in the literature are performed on heterogenous 
datasets, which have compounds from different structural and pharmacological classes, and 
they also predict typical primary PK variables like fu, CLtot and Vdss or CLtot/F and Vdss/F.51, 
53, 54 Mcginnity30 found that Foral estimated from oral rat PK studies was lower than the 
observed human absorption for most drugs, even when solubility and permeability were not 
the limiting factors, suggesting that the dog may be more representative of human for 
compounds absorbed via transcellular pathways.  
Feng et al55 found that scaling unbound CLtot across animal species improved the 
prediction of eight Parke-Davis compounds and 26 drugs from the literature. All these drugs 
were small molecules eliminated hepatically, renally or both. It was found that in general, 
human CLtotu was predicted more accurately and average error decreased. For drugs with 
significant variation in PPB across species, human prediction improved after PPB correction 
and overestimation only occurred for drugs which were mainly eliminated by metabolism.  
Hosea et al56 conducted a retrospective analysis using 50 proprietary compounds for 
which oral single dose human PK data was available. It was found that the use of single 
species lead to more accurate pedictions than using multiple species and use of unbound 
conentrations resulted in accurate predictions.  
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Using oral data may have add confounding factors such as interspecies differences in first 
pass gut metabolism and absorption to the predictions and hence this study used only I.V. 
data and inter-species scaling was done for biologically relevant systemic unbound PK 
parameters like CLtotu and Vdssu for the three datasets (opioids, β-ARLs and β-LAs). Several 
predictions methods such as one-species-BW method, two-species allometry were used for 
predicting human CLtot, Vdss, CLtotu and Vdssu and LBF method was used for CLtot, CLnonren, 
CLtotu and CLnonrenu and GFR ratio method for CLren and  CLrenu using rat and dog PK data.  
 
Assumptions: 
Overall, AS is based on the assumption that there are anatomical, physiological and 
biochemical similarities among animals, and they can be described by using mathematical 
models. AS can be done using various methods like one species-BW scaling, LBF method, 




One species-BW scaling without fu correction There are no qualitative interspecies differences in 
PPB, metabolic pathways and intrinsic clearance.  
One species-BW scaling with fu correction There are no interspecies differences in metabolic 
pathways and intrinsic clearance.  
LBF method without fu correction Clearance is primarily by hepatic route and that 
blood: plasma ratio is constant across the species. 
There are no interspecies differences in plasma 
protein binding.  
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Method Assumption 
LBF method with fu correction Clearance is primarily by hepatic route and that B:P 
ratio is constant across the species.  
GFR ratio method without fu correction Clearance is primarily by renal route and there are no 
interspecies differences in plasma protein binding and 
assumes no active tubular transport. 
GFR ratio method with fu correction Clearance is primarily by renal route and assumes no 
active tubular transport. 
For Vdss 
One species-BW scaling without fu correction There are no interspecies differences in plasma 
protein binding and tissue binding.  
One species-BW scaling with fu correction There are no interspecies differences in tissue 
binding. 
 
Limitations: 4, 57, 58 
• AS is empirical in nature 
• AS for clearance does not take into consideration species differences in the metabolic 
pathways that may have significant impact on the extrapolation from the preclinical data. 
• For accurate prediction, a certain range of body weights have to be used. Often, the species 
with lowest body weight has substantial leverage effect on the prediction.  
• AS ignores genetic polymorphisms in human drug metabolizing enzymes and other sources 
of variability by providing average (“typical”) values of clearance. 
• AS is more powerful tool for retrospective analysis than for prospective dose predictions. For 
first time in human dose studies, AS may give prediction intervals so wide that they are of 
limited use and thus, it is difficult to determine which drugs would fail a priori.  
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• It is difficult to predict human PK for drugs undergoing biliary excretion, extra-hepatic 




This dissertation is organized to address the prediction of human PK using QSPKR and 
interspecies scaling for datasets of drugs belonging to three different pharmacological classes 
of drugs: Opioids, β-ARLs and β-LAs. Chapter 2 states the individual hypothesis and the 
specific aims that will be addressed in the succeeding chapters. The dissertation can be 
divided into two parts:  
Part I describes the QSPKR study. It contains Chapter 3-6. Chapter 3 consists of a brief 
introduction on QSPKR and describes the overall methods use in the QSPKR study followed 
by Chapter IV, V and VI, which describe the results of QSPKR study on opioids, β-ARLs 
and β-LAs, respectively. Each chapter consists of a brief introduction, description of model 
building, evaluation and validation followed by a discussion section. 
Part II describes the Interspecies Scaling. It contains Chapter 7-10. Chapter 7 consists of a 
brief introduction on interspecies scaling and describes the overall methods used in the study 
followed by Chapter 8, 9 and 10 which describe intespecies scaling study on opioids, β-
ARLs and β-LAs, respectively. Each chapter consists of a brief introduction, results followed 
by discussion section. 
Chapter 11 describes the comparative analysis of molecular and PK properties of opioids, 
β-ARLs and β-LAs. Chapter 12 pools all the three datasets and discusses the pooled data 
analysis. Chapter 13 summarizes the overall conclusions from each chapter as it relates to the 
original hypotheses.  
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2. Research hypothesis 
Using available information for the three pharmacological classes of drugs, namely opioids, 
β-ARLs and β-LAs: 
 
• Hypothesis I: Molecular properties can be used to quantitatively  predict systemic human 
PK; however, the molecular properties responsible for the biologically relevant PK 
properties differ by class of drugs.  
For this hypothesis:  
o Literature was reviewed to collect pertinent, valid systemic PK properties in humans. 
o Biologically relevant PK variables were estimated. 
o Effect of different molecular descriptors was assessed on various PK properties. 
o QSPKR models were developed and validated for biologically relevant PK properties 
for individual dataset and trend analysis was done for the pooled dataset. 
 
• Hypothesis II: Human PK can be successfully allometrically scaled from rat and dog 
PK; however, the allometric scaling coefficient depends on the molecular properties drug 
properties.  
For this hypothesis:  
o Literature was reviewed to collect pertinent, valid systemic PK properties of opioids, 
β-ARLs and β-LAs in different species and relevant PK variables were estimated. 
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o PK properties of opioids were compared and assessed for differences across species. 
o Different allometric methods were evaluated for explaining these interspecies 
differences.  
o Different prediction methods were evaluated to predict human PK properties from 
animal PK. 


















CHAPTER 3. Quantitative-Structure Pharmacokinetic Relationships (QSPKR) 
 
3. Quantitative-Structure Pharmacokinetic Relationships (QSPKR) 
3.1. Introduction:  
Selection of an appropriate dataset, particularly the range and distribution of the structural 
attributes is critical for the success of any QSPKR study. It is a prerequisite that the data on 
physicochemical and biological properties are available for a sufficient number of analogs 
belonging to the same class of compounds. Opioids, β - β-ARLs and β–LAs were selected as 
the drug classes for this study because they are structural analogs, based on their 
pharmacological target and, at the same time, showed considerable diversity in 
physicochemical and PK properties. In-addition, published data on the in-vivo PK properties 
were available for a sufficient number of representatives of these classes of drugs. 
Furthermore, since no obvious PK nonlinearities were found for most of these drugs after 
I.V. administration, making it simple to compare PK properties for the different compounds. 
Thus, the objective of the present study was to develop QSPKR models which describe and 






3.2. Specific aims 
• Review the literature to collect pertinent, valid systemic PK properties in humans and 
animals. 
• Estimate biologically relevant PK variables. 
• Assess the effect of different molecular descriptors on various PK properties. 
• Develop and validate QSPKR models for biologically relevant PK properties. 
 
3.3. Methods I 
3.3.1. Collection of PK variables 
The biomedical literature was searched for original research and review articles on PK and 
PD properties of 38 opioids (34 agonists/partial agonists and 4 antagonists), 48 β-ARLs (43 
antagonists and 5 agonists) and 60 β-lactam antibiotics in humans. The search was further 
narrowed down to PK studies, urinary excretion studies (if available) in healthy humans after 
intravenous (I.V.) administration. In the literature, many articles focus on hepatic or renal 
dysfunction population and in such cases, data from the healthy control population was used. 
If necessary, I.V. PK data were obtained from absolute oral bioavailability (Foral) studies. Foral 
data were obtained from PK studies done after oral administration in healthy population. 
Values for fu in plasma was obtained from in-vitro PPB studies, using therapeutically 
relevant concentration ranges. B:P ratio was obtained from ex-vivo or in-vitro studies on 
whole blood and plasma from healthy humans. RBC partitioning (γ) was calculated from fu 
and    B: P information (Table 1.1).59, 60 Receptor affinities (Ki) at the µ-receptors for opioids 
were obtained from different in-vitro receptor binding studies on rat tissue homogenates and 
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were normalized using receptor affinity of a prototypical opioid like morphine to give 
relative receptor affinity (RRA). For β-ARLs, Ki values were obtained from in-vitro receptor 
binding studies in human β1,2,3 receptors.  
 In-vivo PK variables like CLtot, Vdss, and fraction excreted unchanged (fe) in urine after 
I.V. administration for each drug were compiled after critical evaluation of study design, 
dosing regimen, sampling schedule, assay procedures and PK analysis methods. Of all the 
PK variables, the way of reporting varied widely for volume of distribution (Vd), i.e., 
pseudo-steady state Vd (Vdβ), central compartment Vd (Vdcc) or Vdss. The papers which 
report Vdss were selected preferentially. Alternatively, Vdcc and micro-constants or macro-
rate constants were used to calculate Vdss (Table 1.2).61  If PK properties were not reported 
but concentration-time profiles were provided, then the concentration-time profile was read 
electronically, and Vdss and CLtot were estimated using non-compartmental analysis.33  
If the studies did not report BW-corrected PK properties, then the PK properties were 
corrected for BW using the mean value of BW of the subjects used in the study. In case, BW 
was not mentioned, a BW of 70 kg was assumed for humans.32 Since the PK properties were 
compiled from separate research articles, the data obtained were variable in terms of number 
of subjects, types of study subject, doses, sample collection intervals, methods of sample 
analysis and PK-PD analysis methods reported. The final PK parameters were the means of 
PK parameters obtained from different studies.  The tabulation of the final PK studies is 





3.3.2. Computation of molecular properties 
Physicochemical properties like pKa, molecular weight (MW), molar volume (MV), 
calculated logP (clogP), % ionized at pH 6.3 and pH 7.4  and two dimensional molecular 
descriptors like number of hydrogen bond donors (HBD), hydrogen bond acceptors (HBA), 
and number of rotatable bonds (nRot) were computed using ACD-solubility/DB 12.01. The 
chemical structures were drawn for each drug, and final energy minimization was conducted 
using Sybyl software V7.3 (Tripos, Inc., Louis, MO) to get molecular descriptors like polar 
surface area (PSA), energy and dipole moment. Log (P) is not an accurate determinant of 
lipophilicity for ionizable compounds because it correctly describes the partition coefficient 
of only neutral (uncharged) molecules. Since the majority of drugs are ionizable, log (P) is 
not an appropriate predictor of a compound's behavior in the changing pH environments of 
the body. The distribution coefficient, Log (D), is the correct descriptor for ionizable systems 
and is at physiologically relevant pH. The distribution coefficient is the ratio of the sum of 
the concentrations of all forms of the compound (ionized plus un-ionized) in each of the two 
phases, 1-octanol and buffer (pH 7.4). Thus, log(D)7.4 was obtained from ACD-solubility/DB 
12.01. % ionized at pH 6.3 was also calculated which allowed us to study if the ionization of 
compounds changed in urine (since average urinary pH is 6.3). 
 
3.3.3. Estimation of biologically relevant variables 
Biologically relevant variables such as Vdssu, CLtotu, CLren, CLrenu, CLnonren, CLnonrenu, CLintin-





3.3.4. PK classification of drugs 
For each class of drugs, molecular descriptors, primary in-vivo PK variables like CLtot, Vdss, 
CLren, fe, in-vitro variables like fu and estimated unbound parameters (CLtotu, Vdssu, CLnonrenu, 
CLrenu) for each compound were compared across all the drugs. The distribution of the 
molecular descriptors and PK variables was studied using means, medians, quartile ranges 
and standard deviations calculated across all the drugs to assess considered differences 
between compounds. The drugs in each class were further categorized using the criteria in 
Table 3.1.  
 
Table 3.1. PK Classification of Drugs 
Classification Criteria 
Based on plasma protein binding (PPB) 
High PPB fu < 20% 
Intermediate PPB   20% < fu < 80% 
Low PPB fu > 80% 
Based on route of elimination 
Highly metabolized drug and major route of 
metabolism is hepatic (assuming no extra-
hepatic metabolism) 
fe < 20% 
Based on hepatic extraction ratio 
Low extraction ratio (LER) ER1hep < 0.3 
Intermediate extraction ratio (IER) 0.3 < ER1hep < 0.7 
High extraction ratio (HER) ER1hep > 0.7 
Based on extrahepatic metabolism 
CLnonrenblood > Qhep   Drug undergoes extra-hepatic metabolism 
High Foral when high ERhep1  
Based on the renal handling 
Drug undergoes net tubular reabsorption CLrenu < GFR 
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Classification Criteria 
Based on plasma protein binding (PPB) 
High PPB fu < 20% 
Intermediate PPB   20% < fu < 80% 
Low PPB fu > 80% 
Based on route of elimination 
where GFR is the glomerular filtration rate 
(120 ml/min/kg) 
Drug undergoes net glomerular filtration CLrenu = GFR 
Drug undergoes net tubular secretion CLrenu > GFR 
 
3.4. Methods II – Statistical Analysis  
3.4.1. Descriptive statistics 
3.4.1.1.Covariate screening – Molecular descriptors 
Covariate screening: Correlation matrices amongst molecular descriptors were 
constructed to assess for collinearity. If two descriptors were collinear, i.e. r ≥ 0.8, 
only one of them was used in the final univariate/multivariate analysis. 
 
3.4.1.2.Correlation analysis – PK variables 
Correlation analysis: If the PK variable showed skewed distribution, then the PK 
variable was log transformed. Correlation matrices amongst PK variables were 
constructed to assess collinearity.  
 
3.4.2. QSPKR Model Building and Evaluation 
For opioids and β-ARLs, analyses were performed on two data sets: complete and reduced 
dataset (excluding opioids/β-ARLs known/suspected to undergo extra-hepatic metabolism). 
Univariate linear regression of all PK variables vs. each molecular descriptors was 
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performed.  Relationships which showed p<0.05 and r2≥0.30 were used further to build a 
final QSPKR model by multiple linear regression (JMP 8.0, SAS, Cary, NC). PK variables 
(except fe and fu) were log-transformed. Final QSPKR models were obtained from and 
evaluated on two datasets: complete and reduced (excluding opioids/β-ARLs 
known/suspected to undergo extrahepatic, nonrenal elimination, e.g., ester hydrolysis). 
Goodness of fit for the final QSPKR models was assessed by r2 (p<0.05), and their predictive 
performance was cross-validated in SAS 9.2 using the leave-one-out method (see below).  
 
3.4.3. Cross-validation 
Cross-validation was done using leave-out-one method in SAS 9.2. This method leaves a 
single observation from the original sample as the validation data, and the remaining 
observations are treated as the training data. This is repeated such that each observation in the 
sample is used exactly once as the validation data. For each model, the excluded observation 
is predicted, and the cross-validated explained variance (q2) is computed using the following 
formula:62  











      A model with a q2≥0.40 was considered acceptable. 
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CHAPTER 4. QSPKR OF OPIOIDS 
4. Opioids 
4.1. Background 
Opioids are first-line agents for the treatment of moderate to severe pain. They are generally 
used in anesthetic procedures (in combination with general anesthetics). They are highly 
effective and inexpensive and can be given by multiple routes of administration. However, 
there are some limitations as they can cause potentially life-threatening respiratory 
depression, gastrointestinal disturbances like constipation, CNS side effects like nausea, 
dizziness, and they have the potential to cause drug dependence. These drugs exert their 
pharmacological actions through interaction with three types of G-protein coupled receptors 
(GPCR), mu (µ1, µ2), kappa (κ1, κ2, κ3) and delta (δ1, δ2), which bind to endogenous ligands 
like endorphins, dynorphin and enkephalines, respectively (Figure 4.1). Figure 4.2 shows the 
common structural backbone of most of the opioids and structure of a prototypical opioid, 
morphine, and its important binding groups for the analgesic activity.63 Depending on the 
activity at the receptors, opioids are categorized into agonists, partial agonists and 
antagonists. Opioid agonists and antagonists are structurally similar, have similar molecular 
weights; however, there are considerable differences in their potency and PK properties. 
Table 4.1 shows the therapeutic I.V. doses of some opioids. There is a difference of more 
than 55000-fold difference in the therapeutic doses, indicating that 
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there are some opioids like sufentanil and remifentanil which are very potent (0.001 mg/kg), 
while there are opioids like dezocine which are least potent (5 mg/kg). Some of these 
differences are due to variability in the affinity to and intrinsic activity at the opioid (µ-) 
receptors, i.e., their PD properties; however, differences in their physicochemical and PK 
properties may be of importance as well.  To account for these differences, effect of the 
physicochemical properties on the PK-PD properties was studied. The PK-PD properties in 
humans were compared across different opioids and later on, the study was extended to 
comparison of PK of opioids across different animal species. This helped in understanding 
the similarities and dissimilarities in the PK of opioids across different animal species. In-
vivo PK data from preclinical studies are an important tool in drug discovery in 
understanding PK parameters as well as predicting human PK. However, often it is difficult 
to extrapolate PK from animals to humans because of the inherent differences in the 
physiology and metabolic pathways between animals and humans. Different allometric 
methods were used to explain these differences in opioids. Thus, objective of this meta-
analysis was to evaluate potential use of molecular properties to predict in-vivo human PK 
properties like total and unbound CLtot, Vdss, CLren and in-vitro PK properties like PPB and γ 
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Table 4.1.  Therapeutic doses for different opioids 
Drug Dose (I.V.) Dose (I.V.) AUC 
  [mg/kg] [µmoles] [µmoles/ml*min] 
        
M3G 0.40 56.3 3.496E-01 
M6G 0.01 2.0 1.618E-02 
Oxymorphone 0.01 1.7 1.185E-02 
Hydromorphone 0.02 5.3 3.502E-03 
Morphine 0.14 35.0 1.919E-02 
Oxycodone 0.07 15.9 2.013E-02 
Codeine 0.57 133.6 1.480E-01 
Tramadol 0.54 143.5 2.898E-01 
Nalbuphine 0.14 28.0 1.605E-02 
Heroin 4.71 893.3 6.429E-02 
Ketobemidone 0.14 39.6 4.640E-02 
Levorphanol 0.01 3.9 3.535E-03 
Remifentanil 0.001 0.1 4.203E-05 
Butorphanol 0.01 3.1 1.449E-03 
Meperidine 1.07 303.2 4.323E-01 
Methadone 0.14 32.3 1.710E-01 
Pentazocine 0.43 105.1 7.740E-02 
Alfentanil 0.01 2.4 9.282E-03 
Tilidine 0.60 153.6 1.425E-01 
Fentanyl 0.001 0.3 3.424E-04 
Sufentanil 0.0001 0.026 2.653E-05 
Buprenorphine 0.004 0.6 4.550E-04 
Meptazinol 0.35 105.0 6.028E-02 
Dezocine 5.00 1426.5 5.420E-01 
Piritramide 0.20 32.5 6.201E-02 
Dextropopoxyphene 3.43 707.0 7.537E-01 
Naltrexone 0.01 2.9 8.754E-04 
Methylnaltrexone 0.30 59.0 3.779E-02 
Naloxone 0.004 0.8 3.908E-04 
Nalmefene 0.01 2.9 2.811E-03 
Minimum 0.0001 0.03 2.653E-05 
Maximum 5.00 1426.48 7.537E-01 
Mean 0.61 143.18 0.11 
-fold range 35000 55140 28409 
n 30 30 30 
 
4.2. Results  
4.2.1. Comparison of Molecular Descriptors and PK Variables of Opioids  
Opioids (34 agonists/partial agonists and four antagonists) showed considerable diverse 
physicochemical and 2D molecular properties (Table 4.2). They are small molecules with 
molecular weights ranging from 230-500 Dalton. Morphine is a prototypical opioid and, out 
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of 38 opioids in the dataset, 17 opioids were found to have the typical morphine scaffold. 
Two active metabolites of morphine, morphine-3-glucuronide (M3G) and morphine-6-
glucuronide (M6G) are acidic and most polar in nature. Most of the opioids were found to 
have 2 pKas, pKa1 due to the basic group (-NH2 group) and pKa2 due to weakly acidic group 
(-OH group) and act as zwitterions in certain range of pH. % Ionized showed large 
differences, remifentanil showed the least (9%) while dezocine showed the most (100%) % 
ionized at pH 7.4. Descriptive statistics (Table 4.3) showed that for all the molecular 
descriptors (except log(D)7.4), the mean value is greater than the median value, and the 
distribution is skewed towards the right. High standard deviations indicate a considerable 
variation in molecular descriptors across the opioids. The predefined acceptance criterion for 
collinearity was r ≥ 0.80, but none of the descriptors were found to be collinear.  
The final mean PK variables obtained from different studies are shown in Table 4.4, and 
the estimated PK variables are shown in Table 4.5.  Descriptive statistics (Table 4.6) showed 
that for most PK variables (except fu and γ), the mean value is greater than the median value. 
For most of the PK variables, distribution was found to be skewed. High standard deviations 
show that PK variables show considerable variation across the opioids. Thus, for subsequent 
analyses, the PK variables (except fu and γ) were log-transformed. Some of the PK variables 
were strongly correlated with each other (Table 4.7).  
Based on the criteria outlined in Table 3.1, opioids were classified into different 
categories as shown in Table 4.8. In this dataset, opioids varied in their PPB from 8 % to 96 
%. Hydromorphone showed the highest fu and buprenorphine showed the lowest fu. The γ 
value depends on fu in plasma, since only unbound drug in plasma can partition into RBCs. 
Table 4.5 shows that remifentanil has the highest γ indicating that the fu is low due to high 
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PPB. On the other hand, nalbuphine has a low γ due to low PPB. M6G has negligible fu. For 
drugs with γ > 1.0, CLtot exceeds CLnonrenblood and for drugs with γ < 1.0, CLnonrenblood exceeds 
CLtot. The extent of distribution varied (more than 100-fold) across the opioids.  Polar 
compounds like morphine glucuronides showed the lowest Vdss, while more lipophilic ones 
like dextropropoxyphene, fentanyl, sufentanil, etc. showed high Vdss values. CLtotu varied 
across the opioids (more than 300-fold). High PPB tends to lower CLtot values. CLtot value 
for remifentanil was found to be exceeding LBF, while heroin and nicomorphine showed 
CLtot exceeding cardiac output (CO- 86 ml/min/kg) in humans, indicating extra-hepatic 
metabolism/ester hydrolysis in blood and other body tissues. Meperidine is also an ester and 
is likely to undergo hydrolysis in blood and other tissues by non-specific esterases. 
Mirfentanil and dextromethorphan also had CLtot values exceeding cardiac output, indicating 
extrahepatic/nonrenal clearance in blood and other body tissues. All of the opioids (except 
glucuronides and methylnaltrexone) were found to be highly metabolized (fe < 20%). 
Compounds like morphine glucuronides, and oxymorphone are low ER drugs while several 
have CLnonren approaching or exceeding LBF, indicating that they are high ER drugs. M6G, 
hydromorphone, oxycodone, tramadol, heroin, and sufentanil showed CLrenu less than GFR 
(GFR ~ 1.7 ml/min/kg32), indicating that they are mainly tubularly reabsorbed. On the other 
hand, M3G, piritramide and naltrexone showed CLrenu equal to GFR, indicating that they are 
excreted by net glomerular filtration in kidneys. Morphine, codeine, nalbuphine, butorphanol, 
meperidine, fentanyl and nalmefene showed CLrenu exceeding GFR, indicating that they 
undergo net tubular secretion. Morphine glucuronides and nalbuphine were found to have 
low BP ratio due to low γ, while alfentanil showed low BP ratio due to high PPB. BP ratio 
more than 1.0 indicated high PPB (e.g., butorphanol) or high γ (e.g. hydromorphone, 
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morphine). CLnonrenblood values for morphine, nalbuphine, butorphanol, tilidine and naltrexone 
were higher than LBF. In addition, drugs such as morphine, codeine and hydromorphone, 
had high Foral values (Table 4.4) although they had high apparent ERhep, indicating that they 
undergo extrahepatic clearance.  Thus, the major clearance mechanism for these opioids is 
hepatic and extrahepatic metabolism/clearance, and the ERhep estimates probably 
overestimate their hepatic extraction. M6G has estimated ERhep1 of 6 %, so we would expect 
a high bioavailability. However, studies showed that Foral is only 11%, indicating that there 






Table 4.2. Molecular Properties of Opioids (ordered by log (D)7.4) 
 




volume nRot HBA HBD PSA  
Dipole 
moment Energy 
   [D]     at pH 7.4 at pH 7.4 (cm3/mol)    (A2) (Debye) (kcal/mol) 
1 M3G 461 -1.56 2.8  -4.11 12 280 7 10 5 232 98 38 
2 M6G 461 0.69 2.8  -1.93 25 280 7 10 5 248 98 42 
3 Dihydrocodeine 301 0.61 8.4 14.2 -0.52 93 229 2 4 1 72 69 83 
4 Morphine 285 0.87 8.3 9.5 0.04 82 198 2 4 2 116 79 37 
5 Tramadol 263 2.32 9.6 14.5 0.29 99 251 5 3 1 12 66 27 
6 Ketobemidone 247 0.80 7.5 10.0 0.40 60 226 4 3 1 88 108 17 
7 Codeine 299 1.39 8.2 13.4 0.46 88 223 2 2 1 67 80 42 
8 Oxymorphone 301 1.15 7.6 9.2 0.74 56 200 2 5 2 130 80 31 
9 Oxycodone 315 1.15 7.6 13.1 0.74 56 225 2 5 1 89 82 33 
10 Nalbuphine 357 1.21 7.4 9.4 0.81 60 248 5 5 3 130 80 76 
11 Heroin 369 1.58 7.9  0.94 77 274 4 6 0 66 3 37 
12 Dezocine 245 3.68 10.6 10.1 0.99 100 227 2 2 3 103 77 34 
13 Tapentadol 221 3.02 9.3 10.1 1.00 99 228 6 2 1 55 82 20 
14 Hydromorphone 285 2.13 8.5 9.3 1.08 87 203 1 4 1 113 80 41 
15 Meptazinol 233 3.40 9.5 10.0 1.31 99 234 3 2 1 70 111 17 
16 Meperidine 247 2.19 7.8  1.61 97 234 4 3 0 32 90 18 
17 Levorphanol 257 3.26 9.1 10.1 1.71 96 219 1 2 0 68 81 26 
18 Dextromethorphan 271 3.26 9.1  1.71 96 244 1 1 0 28 78 18 
19 Remifentanil 360 1.79 6.7  1.75 9 321 9 0 7 71 95 25 
20 Buprenorphine 468 2.72 8.3 9.5 1.75 88 368 7 5 2 67 78 170 
21 Alfentanil 417 2.16 7.8  1.81 55 341 9 9 0 95 171 59 
22 Methadone 309 3.93 9.1  2.29 98 306 7 2 0 30 75 21 
23 Dextropopoxyphene 339 4.10 9.2  2.32 98 327 9 3 0 37 68 30 
24 Piritramide 431 2.78 7.4       2.37 61 374 7 5 2 122 256 55 
25 Dextromoramide 393 2.53 7.2  2.42 22 350 6 4 0 46 64 27 
26 Mirfentanil 376 3.77 9.0  2.61 93 308 6 6 0 65 101 46 
27 Pentazocine 285 4.15 8.9 10.1 2.61 97 275 3 2 1 61 97 25 
28 Fentanyl 336 3.68 8.9  2.61 92 309 6 3 0 22 86 25 
29 Butorphanol 327 3.54 8.0 10.1 2.77 83 263 4 3 2 79 82 57 
30 Nicomorphine 496 3.44 7.7  2.91 71 344 6 8 0 112 93 35 
31 Trefentanil 467 3.32 7.6  3.08 43 467 8 8 0 85 81 34 
32 Sufentanil 387 3.95 7.9  3.56 60 341 8 4 0 34 93 25 
33 Loperamide 477 4.15 7.8 13.9 3.61 71 402 8 4 1 62 143 28 
34 Tilidine 273 4.62 8.3  3.71 88 256 5 3 0 6 85 11 
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volume nRot HBA HBD PSA  
Dipole 
moment Energy 
   [D]     at pH 7.4 at pH 7.4 (cm3/mol)    (A2) (Debye) (kcal/mol) 
35 Methylnaltrexone 356 -3.30 8.6 12.0 -3.23 95   4 5 2 110 79 182 
36 Nalmefene 339 1.63 7.7 9.4 1.06 71 245 4 4 2 85 80 133 
37 Naltrexone 341 2.05 7.5 9.2 1.60 62 231 4 5 2 121 80 134 
38 Naloxone 327 1.78 6.7 9.2 1.66 21 228 4 5 2 123 81 32 
 Minimum 221 -3.30 2.8 9.2 -4.11 9 198 1 0 0 6 3 11 
 Maximum 496 4.62 10.6 14.5 3.71 100 467 9 10 7 248 256 182 
 Mean 340 2.31 8.0 10.8 1.33 73 278 5 4 1 83 90 47 
 -fold range 2 8 8 5 8 11 2 9     43 78 17 













 Table 4.3. Descriptive Statistics and Correlation Matrix for Molecular Descriptors of Opioids 
 
Descriptive statistics  
 N Mean SD 95%CI Minimum 10% 25% Median 75% 90% Maximum
MW 38 340.0 76.6 314.9-365.2 221.0 246.8 282.0 331.5 388.5 467.1 496.0 
log (D) 7.4 38 1.33 1.68 0.78-1.88 -4.11 -0.66 0.74 1.64 2.47 3.13 3.71 
MV 37 277.8 63.1 256.7-298.9 197.6 215.7 228.1 255.7 324.0 369.4 466.6 
nRot 38 4.8 2.4 4.04-5.6 1.0 1.9 2.8 4.5 7.0 8.1 9.0 
HBA 38 4.2 2.3 3.5-5.0 0.0 2.0 2.8 4.0 5.0 8.1 10.0 
HBD 38 1.3 1.6 0.8-1.9 0.0 0.0 0.0 1.0 2.0 3.2 7.0 
PSA 38 82.9 50.7 66.2-99.5 5.8 27.2 52.5 71.6 112.5 129.7 247.6 
Dipole moment 38 90.2 36.7 78.2-102.3 3.3 67.6 78.5 81.2 95.8 114.4 256.2 
Energy 38 47.0 41.0 38.5-60.5 10.6 17.5 24.8 33.5 47.8 132.7 182.1 
Correlation matrix 
 MW log(D) 7.4 MV  nRot HBA HBD PSA  Dipole moment 
 
Energy  
MW 1.0000 0.0287 0.7774 0.6558 0.7253 0.1919 0.4125 0.2878 0.2857 
log (D) 7.4 0.0287 1.0000 0.4592 0.2299 -0.3322 -0.5232 -0.6390 0.1561 -0.3279 
MV  0.7774 0.4592 1.0000 0.7973 0.3369 -0.1176 -0.1056 0.3499 0.0685 
nRot 0.6558 0.2299 0.7973 1.0000 0.3451 0.1330 0.0049 0.3295 -0.0021 
HBA 0.7253 -0.3322 0.3369 0.3451 1.0000 0.1294 0.6834 0.1660 0.2250 
HBD 0.1919 -0.5232 -0.1176 0.1330 0.1294 1.0000 0.6538 0.1028 0.2039 
PSA  0.4125 -0.6390 -0.1056 0.0049 0.6834 0.6538 1.0000 0.1947 0.2233 
Dipole 
moment  
0.2878 0.1561 0.3499 0.3295 0.1660 0.1028 0.1947 1.0000 -0.0315 
Energy  0.2857 -0.3279 0.0685 -0.0021 0.2250 0.2039 0.2233 -0.0315 1.0000 
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In-vivo PK parameters PD parameter 
S. 
No. Drug fu B/P  Vdss CLtot fe CLren CLnonren Foral RRA at µ-receptor  
   [%] ratio [l/kg] [ml/min/kg] [%] [ml/min/kg] [ml/min/kg] [%] relative to morphine 
1 M3G 85 0.5 0.3 2.3 64.3 1.5 0.8  30.9 
2 M6G 89 0.5 0.1 1.8 60.6 1.1 0.7 11 0.5 
3 Dihydrocodeine 75 1.0 1.1 4.5 46.4 2.1 2.4 21  
4 Morphine 70 1.2 2.7 26.1 6.6 1.7 24.4 20 1.0 
5 Tramadol 80   2.9 7.1 13.6 1.0 6.1 67  
6 Ketobemidone     4.9 12.2     34 2.3 
7 Codeine 44 1.0 2.8 12.9 13.3 1.7 13.3 81 206.9 
8 Oxymorphone 70   3.1 2.0     11 0.6 
9 Oxycodone 58   2.4 11.3 1.0 0.7 10.5 42 39.5 
10 Nalbuphine 50 0.6 3.7 24.9 5.1 1.3 23.6 16 0.04 
11 Heroin 70 1.1 1.0 198.5 0.1 0.3 198.3 29 92.9 
12 Dezocine 8   5.6 37.6        
13 Tapentadol 80     21.0     32  
14 Hydromorphone 92 1.4 3.8 21.4 6.0 1.3 20.2 62 0.5 
15 Meptazinol 73   2.4 24.9     9  
16 Meperidine 27 1.0 3.6 10.0 12.0 1.2 8.8 52 34.0 
17 Levorphanol 60   12.0 15.7       0.2 
18 Dextromethorphan     6.1 92.5 0.9 0.8 91.7    
19 Remifentanil 7 0.9 0.4 47.2        
20 Buprenorphine 4   3.9 18.8       0.03 
21 Alfentanil 8 0.6 0.4 3.7     0.4 3.3 
22 Methadone 10 0.8 6.1 2.7     80 0.9 
23 Dextropopoxyphene 24   12.8 13.4     57  
24 Piritramide 6   5.3 7.5 1.4 0.1 7.4   0.7 
25 Dextromoramide     0.01 2.0        
26 Mirfentanil     3.5 94.2        






In-vivo PK parameters PD parameter 
S. 
No. Drug fu B/P  Vdss CLtot fe CLren CLnonren Foral RRA at µ-receptor  
   [%] ratio [l/kg] [ml/min/kg] [%] [ml/min/kg] [ml/min/kg] [%] relative to morphine 
28 Fentanyl 16 1.0 2.3 12.4 6.4 0.7 11.7   0.3 
29 Butorphanol 17 1.1 9.5 30.1 4.5 0.6 29.6   0.55 
30 Nicomorphine     0.92 257.5        
31 Trefentanil     0.5 6.1        
32 Sufentanil 7 0.7 5.9 13.9 0.6 0.1 13.8   0.02 
33 Loperamide               
34 Tilidine   0.7 3.7 15.4 1.6 0.2 15.2 8  
35 Methylnaltrexone 54 1.2 3.0 27.9          
36 Nalmefene 80 1.0 2.6 47.8 2.8 1.3 46.5 40  
37 Naltrexone 66 1.3 8.3 15.0 8.8 1.3 13.6 40 0.54 
38 Naloxone     2.6 22.3 49.6 11.1 11.2   0.54 
 Minimum 4 0.5 0.0 1.8 0.1 0.1 0.7 0.4 0.02 
 Maximum 92 1.4 12.8 257.5 64 11.1 198.3 81 206.9 
 Mean 47 0.9 3.7 32.0 15 1.5 27.1 35 19.1 
 -fold range 23 3 1783 145 511 123 283 187 12931 
 n 29 20 36 37 21 21 21 21 22 
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CLtotu CLrenu CLnonrenu Vdssu CLnonrenblood CLint 
ERhep1 ERhep2 
   [ml/min/kg] [ml/min/kg] [ml/min/kg] [l/kg] [ml/min/kg] [ml/min/kg] [%] [%] 
M3G  2.7 1.7 1.0 0.3 1.5 1.0 8  
M6G 0.00 2.0 1.2 0.8 0.1 1.3 0.8 6 89 
Dihydrocodeine 1.31 6.0 2.8 3.2 1.5 2.4 3.6 12 79 
Morphine 2.05 37.3 2.4 34.8 3.9 20.3  99 80 
Tramadol  8.8 1.2 7.6 3.7      33 
Codeine 2.08 29.4 3.9 30.3 6.5 13.9 99.1 69 20 
Oxymorphone   2.9    4.4      89 
Oxycodone   19.3 1.2 18.1 4.1      58 
Nalbuphine 0.33 49.8 2.5 47.3 7.5 38.4    84 
Heroin 1.74 283.6 0.4 283.2 1.4 180.2    71 
Dezocine   447.6    66.7       
Tapentadol   26.3           68 
Hydromorphone 1.91 23.3 1.4 21.9 4.1 14.9 86.6 75 38 
Meptazinol   34.1    3.2      91 
Meperidine 4.03 37.1 4.4 32.7 13.2 8.5 56.7 42 48 
Levorphanol   26.2    20.0       
Remifentanil 12.15 673.6    5.2       
Buprenorphine  470.0    96.3       
Alfentanil 2.45 46.2    4.4      100 
Methadone 4.57 27.0    61.0      20 
Dextropopoxyphene   55.8    53.3      43 
Piritramide  124.8 1.7 123.1 88.3       
Pentazocine 2.90 49.7 1.6 48.1 3.8 17.7 417.9 88 82 
Fentanyl 5.77 77.5 4.1 73.4 14.2 12.2 187.6 61  
Butorphanol 7.67 177.2 3.3 173.9 56.0 25.9     
Sufentanil 6.24 199.0 1.3 197.7 83.9 18.7 2989.9 93  
Tilidine           21.6     92 
Methylnaltrexone 2.73 51.6     5.6         
Nalmefene 1.25 59.8 1.7 58.1 3.3 46.5    60 
Naltrexone 2.52 22.8 2.0 20.8 12.6 10.5 43.8 52 60 
Minimum 0.0 2.0 0.4 0.8 0.1 1.3 0.8 6 20 
Maximum 12.1 673.6 4.4 283.2 96.3 180.2 2989.9 102 100 
Mean 3.4 105.9 2.2 65.3 22.4 27.2 388.7 55 65 




CLtotu CLrenu CLnonrenu Vdssu CLnonrenblood CLint 
ERhep1 ERhep2 
   [ml/min/kg] [ml/min/kg] [ml/min/kg] [l/kg] [ml/min/kg] [ml/min/kg] [%] [%] 
n 18 29 18 18 28 16 10 11 21 
 44 
Table 4.6. Descriptive Statistics for PK variables of Opioids 
Descriptive statistics 
 
 n Mean SD 95%CI Minimum 10% 25% Median 75% 90% Maximum 
fu 29 0.47 0.31 0.4-0.6 0.04 0.07 0.13 0.54 0.74 0.85 0.92 
γ 18 3.4 2.9 1.9-4.9 0 0.29 1.6 2.5 4.9 8.1 12.2 
Vdss (l/kg) 36 3.6 3.1 2.6-4.7 0.01 0.4 1.2 2.9 5.2 8.7 12.8 
CLtot (ml/min/kg) 37 32.0 52.4 14.5-49.5 1.8 2.2 7.3 15.4 27.0 92.8 257.5 
CLren (ml/min/kg) 21 1.5 2.3 0.4-2.5 0.09 0.1 0.6 1.1 1.4 2.0 11.1 
CLnonren (ml/min/kg) 21 27.1 43.9 7.1-47.1 0.7 1.1 8.1 13.6 24.0 82.7 198.3 
CLtotu (ml/min/kg) 29 105.9 163.4 43.8-168.1 2.0 2.9 23.0 37.3 101.2 447.6 673.6 
CLren u (ml/min/kg) 18 2.2 1.1 1.6-2.7 0.4 1.1 1.3 1.7 2.9 4.1 4.4 
CL nonren u (ml/min/kg) 18 65.3 78.8 26.1-104.5 0.8 0.98 15.5 33.8 85.8 206.3 283.2 
Vdss u (l/kg) 28 22.4 30.7 10.5-34.3 0.1 1.3 3.7 5.4 44.9 84.3 96.3 
CLint (ml/min/kg) 10 388.7 922.6 -271.3-1048.7 0.8 0.9 2.9 71.6 245.2 2732.7 2989.9 
RRA at µ-receptor 22 19.1 47.4 -1.87-40.13 0.02 0.03 0.45 0.65 11.2 76.9 206.9 
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fu 1.0000 -0.7276 -0.2723 0.1006 0.4738 0.5935 0.1234 -0.5495 -0.4524 -0.4697 -0.7134 -0.5833 
γ -0.7276 1.0000 0.2169 -0.0214 -0.4315 -0.5695 -0.1188 0.7836 0.3821 0.4656 0.4474 0.6396 
Vdss  -0.2723 0.2169 1.0000 -0.1444 -0.5320 -0.1470 -0.0357 -0.0521 0.2089 0.3033 0.5161 0.3900 
CLtot 0.1006 -0.0214 -0.1444 1.0000 -0.3222 -0.1030 0.9986 0.3880 -0.3657 0.7220 -0.1241 0.2176 
fe 0.4738 -0.4315 -0.5320 -0.3222 1.0000 0.4784 -0.3454 -0.4862 -0.0450 -0.4851 -0.3561 -0.3921 
CLren 0.5935 -0.5695 -0.1470 -0.1030 0.4784 1.0000 -0.1539 -0.7250 0.3432 -0.7247 -0.6467 -0.7141 
CLnonren  0.1234 -0.1188 -0.0357 0.9986 -0.3454 -0.1539 1.0000 0.7244 -0.3645 0.7277 -0.1303 0.2554 
CLtot u  -0.5495 0.7836 -0.0521 0.3880 -0.4862 -0.7250 0.7244 1.0000 -0.2062 0.9999 0.4175 0.9480 
CLren u  -0.4524 0.3821 0.2089 -0.3657 -0.0450 0.3432 -0.3645 -0.2062 1.0000 -0.2148 0.0117 -0.3163 
CLnonren u -0.4697 0.4656 0.3033 0.7220 -0.4851 -0.7247 0.7277 0.9999 -0.2148 1.0000 0.5429 0.9520 
Vdss u -0.7134 0.4474 0.5161 -0.1241 -0.3561 -0.6467 -0.1303 0.4175 0.0117 0.5429 1.0000 0.9724 
CLint  -0.5833 0.6396 0.3900 0.2176 -0.3921 -0.7141 0.2554 0.9480 -0.3163 0.9520 0.9724 1.0000 
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Drug Metabolism PPB category ERhep1 category 
M3G Not highly metabolized  Low PPB LER 
M6G Not highly metabolized  Low PPB LER 
Mirfentanil  Extra-hepatic   
Hydromorphone Highly metabolized Extra-hepatic Low PPB HER 
Morphine Highly metabolized Extra-hepatic Intermediate PPB HER 
Oxymorphone   Intermediate  PPB  
Dihydrocodeine   Intermediate  PPB  
Codeine Highly metabolized Extra-hepatic Intermediate  PPB IER 
Nalbuphine Highly metabolized Extra-hepatic Intermediate PPB  
Tramadol Highly metabolized  Low PPB  
Ketobemidone     
Oxycodone Highly metabolized  Intermediate  PPB  
Heroin Highly metabolized Extra-hepatic Intermediate  PPB  
Meperidine Highly metabolized Extra-hepatic Intermediate  PPB IER 
Tapentadol   Low PPB  
Levorphanol   Intermediate PPB  
Dezocine   High PPB  
Meptazinol   Intermediate  PPB  
Remifentanil  Extra-hepatic High PPB  
Alfentanil   High PPB  
Tilidine Highly metabolized Extra-hepatic   
Methadone   High PPB  
Dextromethorphan  Extra-hepatic   
Buprenorphine   High PPB  
Butorphanol Highly metabolized Extra-hepatic High PPB  
Sufentanil Highly metabolized  High PPB HER 
Pentazocine Highly metabolized  Intermediate PPB HER 
Nicomorphine  Extra-hepatic   
Fentanyl Highly metabolized  High PPB IER 
Piritramide Highly metabolized  High PPB  
Dextropropoxyphene   Intermediate  PPB  
Naloxone   Intermediate PPB  
Naltrexone Highly metabolized Extra-hepatic Low PPB  
Nalmefene Highly metabolized  Intermediate PPB IER 
Methylnaltrexone Not highly metabolized    
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4.2.2.  QSPKR analysis, model building and evaluation 
The QSPKR analysis was done on two datasets, complete and reduced (after exclusion of 
drugs known/suspected of undergoing extra-hepatic metabolism), assuming that the same 
physicochemical properties responsible for hepatic metabolism/renal excretion may not be 
responsible for a drug’s tendency to be hydrolysed by non-specific esterases/amidases in 
tissues /blood. The results of univariate regression between PK parameters and molecular 
descriptors for complete dataset and reduced dataset are shown in Table 4.9 and Table 4.10. 
The relationships which showed r2 ≥ 0.30 and p < 0.05 were further used to build final 
multivariate QSPKR model by using log-linear and multiple log-linear regressions (MLLR). 
The final models from the QSPKR analysis are summarized in Table 4.11. In-vitro PK 
variables such as fu and γ are strongly dependent on log (D)7.4 (Table 4.9). PK variables, 
Vdssu, CLtotu, CLnonren and CLnonrenu, did show a significant relationship with log (D)7.4. Molar 
volume (MV) and log (D)7.4 combined showed a significant effect on fu (Figures 4.3-4.4). 
Secondary to fu, CLren decreased with MV and log (D)7.4 (Table 4.9, Figure 4.7). CLren is 
strongly related with log (D)7.4; however, CLren u is not affected by log (D)7.4 (Table 4.9, 
Figure 4.10). PPB increased strongly with log (D)7.4, as did Vdssu and CLtotu (Table 4.9, 
Figures 4.3, 4.9, 4.12). As a result of these offsetting effects, Vdss and CLtot were not affected 
by log (D)7.4 (Figures 4.5-4.6). Log (D)7.4 accounted for 52 % variability in the ERhep1 for the 
complete dataset (n = 11, slope = 0.11) and 84 % variability for reduced dataset (n = 7, slope 
= 0.12), although the regression was governed by extreme cases; polar morphine 
glucuronides with very low ERhep and highly lipophilic sufentanil and pentazocine with very 
high ERhep. 
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Univariate analysis showed a significant effect of HBA, HBD and PSA on CLnonren, 
CLnonrenu and Vdssu; however, the regression is leveraged by the extreme values for morphine 
glucuronides and, hence, these results were extremely sensitive to the inclusion of M3G and 
M6G. Log (D)7.4, ranging from -4.1 to 3.7, was the sole most important molecular property, 
affecting most of the biologically relevant PK variables of opioids. The slopes for all PK 
variables, remained similar across the analyses for the complete and reduced datasets, 
indicating that the effect of molecular descriptors on these parameters was similar; however, 
exclusion of the drugs undergoing extra-hepatic metabolism lead to improvement in r2, q2 
and a decrease in p-value and prediction errors (Table 4.9-4.11, Figures 4.13-4.20). Overall, 
the final QSPKR models developed provided acceptable predictions (q2 ≥ 0.40) for fu, Vdssu, 
CLnonrenu and CLren (Table 4.11). For CLnonrenu, the predictive ability improved after exclusion 
of drugs undergoing extra-hepatic, nonrenal elimination, indicating the importance of 
nonrenal clearance mechanisms (hepatic vs. extra-hepatic) on QSPKR clearance predictions.  
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Table 4.9. Log-linear Regression between Molecular Descriptors and PK Variables for Complete Dataset 
 











 (CLren u)  
Log  
(CL nonren u) 
Log 
(Vdss u)  
Log  
(CLint) 
      (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (Lkg) (ml/min/kg) 
n =29 n =18 n =36 n =37 n =21 n =21 n =29 n =18 n =18 n =28 n =10 
























(N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) ( p<0.05) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
n =29 n =18 n =37 n =37 n =21 n =21 n =29 n =18 n =18 n =28 n =10 











at pH 7.4 
(p<0.05) (p<0.05) (N.S.) (N.S.) (p<0.05) (p < 0.05) (p<0.05) (N.S.) (p<0.05) (p<0.05) (p < 0.05) 
Molar n =29 n =18 n =36 n =36 n =21 n =21 n =28 n =18 n =18 n =27 n =10 
 Volume r2=0.47 r2=0.26 r2=0.12 r2=0.01 r2=0.52 r2=0.02 r2=0.20 r2=0.03 r2=0.07 r2=0.13 r2=0.08 






















  (p<0.05) (p<0.05) (p <0.05) (N.S.) (p<0.05) (N.S.) (p<0.05) (N.S.) (N.S.) (N.S.) (N.S.) 
n =29 n =18 n =37 n =37 n =21 n =21 n =29 n =18 n =18 n =28 n =10 
























(p<0.05) (p<0.05) (p<0.05) (N.S.) (N.S.) ( p < 0.05.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
n =29 n =18 n =37 n =37 n =21 n =21 n =29 n =18 n =18 n =28 n =10 






















(N.S.) (p<0.05) (p<0.05) (N.S.) (N.S.) (p<0.05) (p < 0.05) (p < 0.05) (p<0.05) (p<0.05) (p < 0.05) 
HBD n =29 n =18 n =37 n =37 n =21 n =21 n =29 n =18 n =18 n =28 n =10 
 r2=0.01 r2=0.08 r2=0.06 r2=0.01 r2=0.11 r2=0.37 r2=0.001 r2=0.002 r2=0.42 r2=0.14 r2=0.66 
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 (CLren u)  
Log  
(CL nonren u) 
Log 
(Vdss u)  
Log  
(CLint) 
      (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (Lkg) (ml/min/kg) 











  (N.S.) (N.S.) (N.S) (N.S.) (N.S.) (p<0.05) (N.S.) (N.S.) (p<0.05) (p < 0.05) (p < 0.05) 
Energy n =29 n =18 n =37 n =37 n =21 n =21 n =29 n =18 n =18 n =28 n =10 
  r2=0.000
03 
r2=0.14 r2=0.01 r2=0.009 r2=0.05 r2=0.0002 r2=0.02 r2=0.005 r2=0.0003 r2=0.006 r2=0.07 




















  (N.S.) (N.S.) (N.S) (N.S) (N.S) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
 PSA n =29 n =18 n =36 n =37 n =21 n =21 n =29 n =18 n =18 n =28 n =10 
  r2=0.18 r2=0.25 r2=0.11 r2=0.06 r2=0.09 r2=0.31 r2=0.21 r2=0.03 r2=0.38 r2=0.34 r2=0.65 






















  (p<0.05) (p < 
0.05) 
(N.S.) (N.S.) (N.S.) (p<0.05) (p<0.05) (N.S.) (p<0.05) (p<0.05) (p < 0.05) 
Dipole n =29 n =18 n =37 n =37 n =21 n =21 n =29 n =18 n =18 n =28 n =10 
 moment r2=0.12 r2=0.01 r2=0.0004 r2=0.06      r2=0.13 r2=0.11 r2=0.0008 r2=0.05 r2=0.001 r2=0.04 r2=0.0002 






















  (N.S.) (N.S.) (N.S) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
 
*Criteria of selection for model building: r2 ≥ 0.30 and p<0.05 
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Figure 4.19.  CLnonren u vs log(D)7.4  (Opioids)                         Figure 4.20.  Vdss u vs log(D)7.4 (Opioids) 
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Table 4.10. Log-linear Regression between Molecular Descriptors and PK Variables for Reduced Dataset 
 











(CLren u)  
Log 
(CL nonren u) 
Log 
(Vdss u)  
Log 
(CLint) 
      (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (Lkg) (ml/min/kg) 
n = 20 n = 9 n = 23 n = 24 n = 11 n = 11 n = 20 n = 10 n = 10 n = 19 n = 7 
























(N.S.) (N.S.) (p < 
0.05) 
(p<0.05) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
log (D) n = 20 n = 9 n = 23 n = 24 n = 11 n = 11 n = 20 n = 10 n = 10 n = 19 n = 7 
at pH 7.4 r2=0.49 r2=0.79 r2=0.05 r2=0.04 r2=0.18 r2=0.67 r2=0.35 r2=0.02 r2=0.88 r2=0.50 r2=0.89 






Slope=0.04 Slope=-0.10 Slope=0.20 Slope=0.20 Slope=0.01 Slope=0.34 Slope= 
0.30 
Slope=0.47 
  (p<0.05) (p<0.05) (N.S.) (N.S.) (N.S.) (p<0.05) (p<0.05) (N.S.) (p<0.05) (p<0.05) (p < 0.05) 
Molar n = 20 n = 9 n = 22 n = 23 n = 11 n = 11 n = 19 n = 10 n = 10 n = 18 n = 6 
volume r2=0.50 r2=0.31 r2=0.07 r2=0.05 r2=0.67 r2= 
0.0000006 
r2=0.23 r2=0.006 r2=0.25 r2=0.19 r2=0.43 

















  (p<0.05) (N.S) (N.S) (N.S.) (p<0.05) (N.S.) (p < 0.05) (N.S.) (N.S.) (N.S.) (N.S.) 
n = 20 n = 9 n = 23 n = 24 n = 11 n = 11 n = 20 n = 10 n = 10 n = 19 n = 6 













(N.S.) (N.S.)       (N.S) (N.S.) (N.S.) (N.S) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
n = 20 n = 9 n = 23 n = 24 n = 11 n = 11 n = 20 n = 10 n = 10 n = 19 n = 6 












(N.S.) (N.S.) (p<0.05) (p < 0.05) (N.S.) (p<0.05) (N.S.) (N.S.) (p<0.05) (p<0.05) (p < 0.05) 
HBD n = 20 n = 9 n = 23 n = 24 n = 11 n = 11 n = 20 n = 10 n = 10 n = 19 n = 7 
 r2=0.17 r2=0.57 r2=0.05 r2=0.02 r2=0.08 r2=0.52 r2=0.14 r2=0.09 r2=0.56 r2=0.32 r2=0.69 
  Slope= Slope= Slope= Slope= Slope=0.1 Slope=-0.24 Slope=-0.17 Slope=-0.03 Slope=-0.35 Slope= Slope= 
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(CLren u)  
Log 
(CL nonren u) 
Log 
(Vdss u)  
Log 
(CLint) 
      (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (Lkg) (ml/min/kg) 
0.09 -0.93 -0.10 -0.04 -0.31 -0.53 
  (N.S.) (p<0.05) (N.S) (N.S.) (N.S.) (p<0.05) (N.S.) (N.S.) (p<0.05) (p<0.05) (p < 0.05) 
Energy n = 20 n = 9 n = 23 n = 24 n = 11 n = 11 n = 20 n = 10 n = 10 n = 19 n = 6 
  r2=0.02 r2=0.19 r2=0.004 r2=0.09 r2=0.02 r2=0.05 r2=0.08 r2=0.02 r2=0.0002 r2= 
0.0001 
r2=0.34 


















  (N.S.) (N.S.) (N.S) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
PSA n = 20 n = 9 n = 23 n = 24 n = 11 n = 11 n = 20 n = 10 n = 10 n = 19 n = 6 























  (N.S.) (p < 0.05) (N.S) (N.S.) (N.S.) (p<0.05) (p<0.05) (N.S.) (p < 0.05) (p<0.05) (p < 0.05) 
Dipole n = 20 n = 9 n = 23 n = 24 n = 11 n = 11 n = 20 n = 10 n = 10 n = 19 n = 6 
moment r2=0.11 r2=0.01 r2=0.002 r2=0.009 r2=0.34 r2=0.0003 r2=0.03 r2=0.001 r2=0.11 r2=0.02 r2=0.004 

















  (N.S.) (N.S.) (N.S) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
 









Table 4.11. Final, Multivariate QSPKR Models for Opioids 
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Opioid agonists and antagonists are structurally similar and have similar molecular weights; 
however, there are considerable differences in their PK-PD properties. The Vdss varies (more 
than 1000-fold) across the opioids. Vdssu values were found to be greater than body weight, 
indicating high tissue sequestration; on the other hand, this was counteracted by high PPB 
that lead to lower Vdss values. CLnonren indicates both high- and low- hepatic ER, latter due to 
low CLint and/or high PPB e.g., Alfentanil is a low ER drug due to high PPB while 
oxymorphone is a low ER drug due to its low CLint.  For the majority of opioids, the 
clearance is due to non-renal elimination, i.e., hepatic and extra-hepatic clearance. Literature 
evidence indicates that remifentanil and heroin are esters undergoing hydrolysis by non-
specific esterases in blood and tissues, explaining extra-hepatic clearance.64, 65 Meperidine is 
also an ester and may undergo hydrolysis by non-specific esterases in blood and tissues. 
Heroin, mirfentanil, nicomorphine and dextromethorphan showed CLtot values exceeding 
cardiac output (86 ml/min/kg) while morphine, nalbuphine, butorphanol, tilidine, naltrexone 
showed CLnonren exceeding LBF as well; thus, it was concluded that, they may undergo extra-
hepatic clearance. In-addition, drugs like morphine, codeine and hydromorphone, showed 
high Foral values although they have very high apparent ERhep values, indicating that at least 
part of their nonrenal clearance is extra-hepatic.  
Overall, opioids showed large diversity in their physicochemical (>10,000-fold), PK 
(100-1000-fold) and PD (13,000- fold) properties. Some of these differences were due to 
variability in the affinity to and intrinsic activity at the opioid (µ-) receptors66, i.e., their 
pharmacodynamic (PD) properties; however, differences in their physicochemical and PK 
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properties may be of importance as well.  To account for the differences, the effects of the 
physicochemical properties on the PK-PD properties were studied. Lipophilicity (log (D)7.4) 
was found to be the primary determinant of PK properties, since it governs the transport of 
the drug across several biological membranes. As the log (D)7.4 increased, there was a 
significant decrease in fu since the drugs bind to the plasma proteins by hydrophobic 
interactions. This finding is consistent with protein binding of various barbiturates in the rats 
67, penicillins in humans68 and β-blockers and anti-arrhythmic drugs in humans.19, 69 Laznicek 
et al70 studied plasma protein binding–lipophilicity relationship of some organic acids and 
found a sigmoidal relation between fu and log (D)7.4. The same data was analyzed using 
linear regression which showed a significant relation (slope = -18.7, r2 = 0.62). Obach et al16 
using  asset of 554 drugs suggested that increasing log (D)7.4 increased PPB because of 
hydrophobic forces interaction with albumin and α-acid glycoprotein. In addition to plasma 
protein binding, it is essential to consider binding to blood components like RBCs. Lipophilic 
drugs penetrate the RBCs by dissolving into the lipid bilayer membrane. Hence, a significant 
relation was found between γ and log (D)7.4. Similar results were found for γ of baribiturate 
series in rats 67 and for β-blockers in humans.19 High PPB decreased Vdss for highly plasma 
protein bound drugs. After correction for PPB, it was observed that Vdssu significantly 
increased with log (D)7.4. This showed that there are two opposing forces acting on Vdss; 
offset each other, indicating, as log (D)7.4 increases, sequestration in tissues increase. A 
similar relationship was seen for Vdssu for a series of sulfonamides in rats (n = 6, slope = 0.20 
units, r2 = 0.69)71 and β-blockers in human (n = 13, slope = 0.33 units, r2 = 0.71)19; with 
slopes similar to the slopes obtained in the present study on opioids (n = 28, slope = 0.37 
units, r2 = 0.59). Obach et al16 studied  PK in humans for a diverse data set of 670 drugs (159 
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acids, 267 bases, 173 neutrals amd 68 zwitterions) and found that there was an upward trend 
for Vdssu with increasing lipophilicity for bases, neutrals and zwitterions and it was found 
that bases had greater CLtot values than acids, neutrals or zwitterions. As the log (D)7.4 
increased, there was a significant decrease in CLren. This can be due to increase in passive 
reabsorption with increase in log (D)7.4, thus preventing renal ecretion. A similar trend was 
also observed between CLren and log (D)7.4 for a set of 391 compounds and β-blockers in 
human.72 In this data set, a significant relation was found between log (D)7.4 and PPB. 
However, when CLren was corrected for PPB, the relation between CLrenu and log (D)7.4 was 
insignificant. This might suggest that as the PPB increased, less amount of drug was 
available for glomerular filtration. In this dataset, there are many opioids which have CLrenu 
values exceeding GFR, indicating that they undergo tubular secretion. This showed that the 
effect of lipophilicity was stronger on the drugs which are highly plasma protein bound and 
undergo filtration. CLren decreased with molar volume, indicating that renal tubular 
reabsorption may also be limited by molecular size. This dataset was biased towards more 
lipophilic, hepatically metabolized compounds. Thus, for some drugs, especially with high 
log (D)7.4, fe and/or CLren may have been poorly estimated. Overall, PPB influenced CLtot and 
Vdss because only free drug is available for elimination and distribution. The use unbound 
counterparts of CLtot and Vdss removed the confounding impact of plasma protein binding 
and hence lead to significant relationships with higher r2 values.  
      Generally, increasd lipophilicity favors partitioning into the liver. When the drugs 
undergoing extra-hepatic clearance were excluded, as log (D)7.4 increased, CLnonren and 
CLnonrenu increased, which in turn, lead to increase in ERhep. This was consistent with the 
results obtained for a set of 12 β-blockers in human wherein it was found that there was a 
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significant increase in  CLnonren with increase in log (D)7.4.19 In-addition, CLtot is the 
combination of CLren and CLnonren. There were two opposing effects; CLren decreasing with 
log (D)7.4 and CLnonren increasing with log (D)7.4, which may offset each other. CLnonren is 
governed by fu and/or CLint. CLint increased significantly with log (D)7.4, and fu decreased 
with log (D)7.4; however, there was a significant relationship between CLnonren and log (D)7.4 
and CLnonren u and log (D)7.4 indicating dominance of CLint over CLnonren for most opioids. 
Irrespective of the dataset, the slopes remained similar indicating that the effect of log (D)7.4 
on the PK parameters was similar; however, exclusion of drugs undergoing extra-hepatic 
metabolism lead to improvement in r2, q2 and decrease in p-value indicating robustness of the 
analysis towards exclusion of outliers (Table 4.11). 
      Although log(D)7.4 can be effectively used in describing and predicting ADME 
properties, it is often seen that the transit of the drug in the body involves movement of drug 
across multiple biological membranes which are composed of phospholipids bi-layers as well 
as interaction with transporters, enzymes or receptors in order to elicit pharmacological 
action involving hydrophilic interactions is a result of an interplay amongst different 
molecular descriptors.15, 26, 73 Thus, in addition to log (D)7.4, other molecular descriptors like 
HBA, HBD, PSA, dipole moment, MV, and nRot were used to build a QSPKR model for 
opioids. Log–linear regression between the molecular descriptors and PK properties showed 
that as the PSA, HBA and HBD increased; there was a significant decrease in CLnonren, 
CLnonrenu, Vdssu and CLint; however, the regression was leveraged by the extreme values for 
polar morphine glucuronides and, hence, these results were extremely sensitive to the 
inclusion of M3G and M6G. Overall, for this study, log (D)7.4 was found to be the most 
important molecular descriptor in the prediction of systemic PK variables of opioids, 
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reflecting its role in the transfer across biological membranes during distribution and 
elimination. None of the molecular descriptors showed any significant relation with RRA at 
µ-receptor, the most plausible reason being that affinity at the µ-receptor depends on how an 
opioid molecule orients itself in the space at the receptor with the corresponding amino acid 
residues of the binding pocket rather than its physicochemical properties. Overall, as 
indicated by the q2 values, the QSPKR models developed provide useful predictions of 












CHAPTER 5. QSPKR OF β-ARLs 
 
5. β-adrenergic receptor ligands (β-ARLs)  
5.1. Background 
In both their chemical structures and biologically activities, β-ARLs constitute an extremely 
varied group of drugs who clinically utility includes treating life threatening conditions such 
as acute anxiety, angina pectoris, asthma, cardiac aryythmias and hypertension. Most of these 
varied drugs exert their therapeutic effects through interaction with adrenoceptors, G-protein 
coupled receptors, β1, β2 and β3 receptors, which bind neurotransmitters such as 
norepinephrine and epinephrine (Figure 5.1).74-76 Figure 5.2 and 5.3 depict common 














Figure 5.1. β-Adrenergic Receptors and their Pharmacological actions. 
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5.2.  Results 
5.2.1. Comparison of Molecular Descriptors and PK of β-ARLs in humans 
The Table 5.1 shows a dataset of a 48 β-adrenergic agonist/antagonist (43 antagonists/partial 
antagonists and five agonists) with considerable diverse physicochemical and 2D molecular 
properties. β-ARLs are small molecules with molecular weights ranging from 225-510 
Dalton. Depending on the selectivity at the α and β-receptors, the compounds can be 
classified into β1-agonist/antagonist, β2-agonist/antagonist and mixed α, β- blocker. Most of 
the β-ARLs have 2 pKas, pKa1 due to a basic group (-NH2 group) and pKa2 due to a weakly 
acidic group (-OH group) and act as zwitterions in certain range of pH. There are large 
differences (>1-billion-fold) in the lipophilicity as shown by log (D)7.4. The majority of the β-
ARLs are ionized at pH 7.4 with dacetyl metipranolol (100%) showing the highest % ionized 
and flestolol showing the lowest (82%). Descriptive statistics (Table 5.2) showed that for all 
the molecular descriptors (except nRot), the mean value is greater than the median value and 
the distribution is skewed towards the right. High standard deviations indicate a considerable 
variation in molecular descriptors across the opioids. The predefined acceptance criterion for 
colinearity was r ≥ 0.80. Molar volume and molecular weight showed strong correlation (r = 
0.8915) and thus, molar volume and not molecular weight, was selected for subsequent 
analysis. 
The final mean PK variables obtained from different studies are shown in Table 5.3 and 
the biologically relevant PK variables are shown in Table 5.4.  Descriptive statistics (Table 
5.5) showed that for most PK variables (except fu and γ), the mean value is greater than the 
median value. For most of the opioids, distribution was found to be skewed. High standard 
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deviations show that PK variables show considerable variation across the opioids. Thus, for 
subsequent analyses, the PK variables (except fu and γ) were log transformed. Some of the 
PK variables were strongly correlated with each other (Table 5.6). Based on the criteria in 
Table 3.1, opioids were classified into different PK categories as shown in Table 5.7. In this 
dataset, they vary in their PPB from 1 % to 98 %. Sotalol shows the highest fu (99%), and 
nebivolol shows the lowest fu (1.9%). Propranolol has the highest γ indicating that the fu is 
low due to high PPB. On the other hand, Sotalol has a low γ due to low PPB. There is 
considerable diversity in the PK properties amongst the β-ARLs. The Vdss varies (by more 
than 50-fold) across the β-ARLs. Vdssu values are greater than BW, indicating high tissue 
sequestration. High PPB lowers Vdss values. Relatively polar compounds such as β-
adrenergic agonists and some antagonists like xamoterol show low Vdss, while more 
lipophilic ones like bopindolol, nebivolol, dilevolol, etc. show high Vdss. CLtotu varies across 
the β-ARLs (more than 150-fold). High PPB lowers CLtot values. For the majority of β-
ARLs, clearance is due to non-renal elimination i.e. hepatic and extra-hepatic metabolism. 
Compounds like xamoterol, atenolol, sotalol, albuterol, terbutaline are low clearance drugs 
(CLnonren less than 30% of the LBF) while several have CLnonren approaching or exceeding 
LBF indicating that they are high clearance drugs. Some of the β-adrenergic antagonists have 
CLtot values exceeding CO, indicating blood or tissue metabolism (e.g. esmolol, flestolol). 
CLnonren indicates both high- and low- ERhep drug; latter due to the low CLint and/or high 
PPB, e.g., xamoterol, terbutaline–low ERhep due to low intrinsic clearance. Out of 48 β-
ARLs, on which data were available to determine the fe, 19 were found to be highly 
metabolized (fe < 20%). Hydrophilic β-blockers like sotalol and β-agonists like albuterol 
show high fe values while lipophilic drugs like bevantolol show fe < 20%. Talinolol, though a 
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lipophilic drug, has a  fe value of 50%, since it is a known P-glycoprotein (P-gp) substrate77 
and undergoes P-gp mediated renal tubular secretion. Lipophilic β-ARLs, such as labetalol, 
deacetyl metipranolol, propranolol, bufuralol tertatolol, betaxolol, penbutolol have CLrenu 
values less than GFR, indicating that they undergo net reabsorption. Sotalol has CLrenu value 
equal to GFR indicating it is excreted by net glomerular filtration. Rest all β-ARLs have 
CLrenu values greater than GFR indicating net tubular secretion. CLnonrenblood values for β-
ARLs like epanolol, landiolol, dilevolol, fenoterol nafetalol is higher than the LBF. 
Landiolol78, 79, esmolol80 and flestolol81 are esters and undergo hydrolysis by non-specific 
esterases in blood and tissue. For the remaining compounds, the exact mechanism is not 
known but based on high CLnonrenblood values, it can be concluded that these drugs undergo 
extra-hepatic clearance. Epanolol is an amide and may undergo hydrolysis by non-specific 
amidases in blood and tissues and shows CLtot exceeding LBF. Landiolol, dilevalol and 
labetalol showed CLnonren exceeding LBF, thus, it was concluded that, they undergo extra-
hepatic metabolism. In-addition, fenoterol, a β-agonist, shows CLtot exceeding LBF and it is 
suspected of undergoing extra-hepatic metabolism by catechol o-methyl transferases 
(COMT) in blood and tissues.  
On the PD side, β-ARLs also show large differences (100,000 fold) in the affinities at β1, 




Table 5.1. Molecular Properties of  β-ARLs (ordered by log (D)7.4) 
 
S.No. Drug Class MW clogP pKa1 pKa2 log (D) 
% 
Ionized nRot HBA HBD MV PSA Energy 
Dipole 
moment 
    
 




7.4       [cm3/mol] [A2] [Kcal/mol] [Debye] 
1 Xamoterol 
β1-selective 
blocker 339 -0.70 10.2 9.3 -2.05 95 10 8 4 268 164 12 13 
2 Atenolol 
β1-selective  
blocker 266 0.33 13.9 9.4 -1.76 99 9 5 4 237 122 46 47 
3 Sotalol 
Nonselective  
blocker 272 0.24 9.3 8.3 -1.68 89 6 5 3 220 150 9 28 
4 Nadolol 
Nonselective  
blocker 309 0.56 13.9 9.5 -1.54 99 9 5 4 260 130 19 13 
5 Diacetolol 
β1-selective  
blocker 308 0.75 13.8 9.4 -1.31 99 9 6 3 268 63 21 40 
6 Tertatolol 
Nonselective  
blocker 295 1.03 13.8 0.5 -1.05 99 7 3 2 266 62 19 57 
7 Landiolol 
Mixed α1/β1 
blocker 510 0.28 13.7 9.1 -1.01 95 15 11 3 424 150 28 94 
8 Pamatolol 
Nonselective  
blocker 310 1.10 12.4 9.4 -1.01 99 11 6 3 281 120 7 44 
9 Prenalterol 
β1-selective 
agonist 225 1.27 10.2 9.5 -0.89 99 8 4 3 201 115 11 38 
10 Carteolol 
Nonselective  
blocker 292 1.34 13.8 9.5 -0.74 99 7 5 3 259 116 11 88 
11 Timolol 
Nonselective  





blocker 267 1.76 11.1 9.7 -0.55 100 8 4 3 250 92 17 24 
13 Pindolol 
Nonselective  
blocker 248 1.66 13.9 9.5 -0.50 99 7 4 3 215 92 28 49 
14 Metoprolol 
β1-selective  
blocker 267 1.63 13.9 9.4 -0.47 99 10 4 2 259 68 13 37 
15 Pafenalol 
β1-selective  
blocker 337 1.66 13.9 9.4 -0.44 99 11 6 4 317 117 7 25 
16 Acebutolol 
β1-selective  
blocker 336 1.77 13.8 9.4 -0.30 99 11 6 3 301 141 13 50 
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S.No. Drug Class MW clogP pKa1 pKa2 log (D) 
% 
Ionized nRot HBA HBD MV PSA Energy 
Dipole 
moment 
    
 




7.4       [cm3/mol] [A2] [Kcal/mol] [Debye] 
17 Celiprolol 
Mixed α1/β1 
blocker 379 1.92 13.8 9.5 -0.22 99 11 7 3 341 69 32 56 
18 Bisoprolol 
β1-selective  
blocker 325 1.89 13.9 9.4 -0.20 99 13 5 2 315 61 15 34 
19 Esmolol 
β1-selective  
blocker 295 1.92 13.9 9.4 -0.18 99 11 5 2 272 92 10 40 
20 Levobunolol 
Nonselective  
blocker 291 1.96 13.8 9.5 -0.11 99 7 4 2 263 92 17 16 
21 Oxprenolol 
Nonselective  
blocker 265 2.15 13.9 9.4 0.04 99 10 4 2 255 68 15 30 
22 Mepindolol 
Nonselective  
blocker 262 2.30 13.9 9.6 0.11 99 7 4 3 232 88 26 21 
23 Epanolol 
Mixed α1/β1 
blocker 369 1.10 9.9 8.4 0.14 89 12 7 4 287 158 18 17 
24 Flestolol 
Nonselective  
blocker 327 0.90 13.4 8.4 0.17 82 10 7 5 327 140 10 24 
25 Betaxolol 
β1-selective  
blocker 307 2.53 13.9 9.4 0.43 99 12 4 2 288 52 116 61 
26 Amosulalol 
β1-selective  
blocker 380 1.50 10.1 8.2 0.71 84 10 7 4 300 59 22 7 
27 Medroxalol 
Mixed α1/β1 
blocker 372 2.57 9.2 8.2 0.76 83 10 7 5 285 228 29 25 
28 Propranolol 
Nonselective  
blocker 259 2.90 13.8 9.5 0.79 99 7 3 2 237 60 13 13 
29 Talinolol 
β1-selective  
blocker 363 3.20 13.8 9.5 0.80 99 9 6 4 325 109 17 121 
30 Alprenolol 
Nonselective  
blocker 249 2.91 13.9 9.4 0.81 99 9 3 2 247 59 16 14 
31 Labetalol 
Mixed α1/β1 
blocker 328 2.72 9.3 8.2 0.83 83 10 5 5 274 192 11 12 
32 Dilevalol 
Nonselective  
blocker 328 2.72 9.2 8.2 0.83 83 10 5 5 274 191 12 25 
33 Tolamolol 
Nonselective  
blocker 344 2.03 13.8 8.1 1.18 86 11 6 4 290 172 11 32 
34 Nafetolol  β1-selective  319 3.38 10.6 9.5 1.29 99 8 4 3 281 103 26 39 
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S.No. Drug Class MW clogP pKa1 pKa2 log (D) 
% 
Ionized nRot HBA HBD MV PSA Energy 
Dipole 
moment 
    
 








blocker 345 3.00 13.9 8.9 1.39 98 11 5 2 311 78 18 93 
36 Bufuralol 
Nonselective  
blocker 261 3.54 13.7 9.6 1.46 99 6 3 2 245 58 32 89 
37 Ro31-1118 
Mixed α1/β1 
blocker 391 3.65 13.9 9.5 1.52 99 14 5 2 348 97 26 46 
38 Penbutolol 
Nonselective  
blocker 291 4.02 13.9 9.5 1.86 99 8 3 2 283 45 23 14 
39 Bornaprolol 
Nonselective  
blocker 303 4.21 13.9 9.4 2.11 99 8 3 2 283 54 34 30 
40 Adimolol 
Nonselective  
blocker 420 4.28 12.3 9.7 2.24 99 10 6 3 348 115 34 12 
41 Nebivolol 
β1-selective  
blocker 405 4.08 14.3 8.7 2.75 95 8 5 3 310 97 24 23 
42 Bopindolol 
Mixed α1/β1 
blocker 380 4.82 17.6 9.4 2.82 99 9 5 2 333 61 19 46 
43 Carvedilol 
Mixed α1/β1 
blocker 406 4.07 13.9 8.2 3.06 90 11 6 3 325 95 35 28 
44 Reproterol 
β2-selective 
agonist 389 -1.30 9.4 8.9 -2.85 95 10 10 4 263 224 41 105 
45 Albuterol 
β2-selective 
agonist 239 0.69 10.0 9.62 -1.44 99 8 4 4 208 146 18 66 
46 Terbutaline 
β2-selective 
agonist 225 0.70 9.7 9.1 -1.44 98 7 4 4 192 162 8 121 
47 Bambuterol 
β2-selective 
agonist 367 1.04 13.7 9.6 -1.05 99 9 8 2 318 108 15 95 
48 Fenoterol 
β2-selective 
agonist 303 1.33 9.3   -0.33 96 10 5 5 235 221 12 44 
 Mean   321 2.0 12.7 9.0 0.1 96 9 5 3 279 112 22 43 
 Maximum   510 4.8 17.6 9.7 3.1 100 15 11 5 424 228 116 121 
 Minimum   225 -1.3 9.2 0.5 -2.9 82 6 3 2 192 45 7 7 
 N   48 48.0 48.0 47.0 48.0 48 48 48 48 48 48 48 48 
 fold range   2 6 8 9 6 1 3 4 3 2 5 18 18 
                         . . . 
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Table 5.2. Molecular Descriptor Correlations and Distributions for β-ARLs 
Descriptive statistics  
 n Mean SD 95%CI Minimum 10% 25% Median 75% 90% Maximum 
MW 48 320.5 57.8 303.7-337.3 225.0 248.9 268.3 313.0 366.0 392.4 510.0 
log (D)7.4 48 0.09 1.35 -0.29-0.48 -2.9 -1.5 -0.98 -0.15 0.83 2.1 3.1 
MV 48 278.6 44.1 265.8-291.5 192.2 219.3 251.4 273.5 310.7 333.5 424.4 
nRot 48 9.4 1.9 8.8-9.9 6.0 7.0 8.0 9.5 11.0 12.0 15.0 
HBA 48 5.3 1.7 4.8-5.8 3.0 3.0 4.0 5.0 6.0 7.1 11.0 
HBD 48 3.1 1.0 2.8-3.4 2.0 2.0 2.0 3.0 4.0 5.0 5.0 
PSA 48 112.3 48.6 98.2-126.4 45.1 58.9 67.8 105.3 144.8 190.7 227.6 
Dipole moment 48 43.1 30.1 34.4-51.9 6.7 12.7 23.4 35.5 54.3 94.4 121.3 
Energy 48 21.8 16.8 16.9-26.7 6.5 9.4 11.9 17.6 27.6 34.2 116.5 
Correlation matrix 
 
 MW log (D) 7.4 nRot HBA HBD MV PSA Energy Dipole Moment 
MW 1.0000 0.3026 0.6424 0.7452 0.1416 0.8915 0.2033 0.1435 0.0776 
log (D)7.4 0.3026 1.0000 0.0757 -0.3017 -0.2213 0.4023 -0.3506 0.1276 -0.2657 
nRot 0.6424 0.0757 1.0000 0.5461 0.0998 0.6991 0.1543 0.1609 0.0110 
HBA 0.7452 -0.3017 0.5461 1.0000 0.3749 0.5563 0.5102 0.0067 0.2174 
HBD 0.1416 -0.2213 0.0998 0.3749 1.0000 -0.0767 0.7865 -0.1922 -0.0586 
MV  0.8915 0.4023 0.6991 0.5563 -0.0767 1.0000 -0.0963 0.1304 0.0669 
PSA 0.2033 -0.3506 0.1543 0.5102 0.7865 -0.0963 1.0000 -0.2076 0.0964 
Energy  0.1435 0.1276 0.1609 0.0067 -0.1922 0.1304 -0.2076 1.0000 0.1181 









In-vivo PK parameters PD parameter 
Drug fu B/P  Vdss CLtot fe CLren CLnonren Foral log (Ki) ( Human CHO-K1)[nM] 
  [%] ratio [l/kg] [ml/min/kg] [%] [ml/min/kg] [ml/min/kg]  [%] β1 β2 β3 
Xamoterol 97.0  0.6 3.0 61.6 1.8 1.2 5 -7.2 -6.1 -4.5 
Atenolol 97.2 1.1 1.1 2.6 94.1 2.4 0.2 58 -6.7 -6.0 -4.1 
Sotalol 99.0 0.2 1.2 2.2 77.3 1.7 0.5 100 -5.8 -6.9 -5.1 
Nadolol 86.0  1.8 2.9 59.6 1.7 1.2 36 -7.2 -8.6 -6.2 
Diacetolol 92.5  0.3 3.8 65.6 2.4 1.4 43       
Tertatolol 7.4  0.3 1.9 1.0 0.02 1.8 60       
Landiolol 95.7  3.0 37.3 7.9 2.9 34.4         
Pamatolol   8.4 2.4      88       
Prenalterol 95.0 1.1 2.2 19.6 60.0 11.9 7.7 26       
Carteolol 85.0  4.9 10.1 65.0 6.6 3.5 84       
Timolol 40.3 0.6 1.7 8.2 26.4 2.5 5.7 61 -8.3 -9.7 -6.8 
Deacetyl 
Metipranolol 30.3  3.1 15.8 12.3 2.5 13.3         
Pindolol 42.8 0.7 2.1 7.4 38.9 3.3 4.1 75       
Metoprolol 91.8 1.1 3.4 12.7 14.5 1.8 10.9 40 -7.3 -6.9 -5.2 
Pafenalol   1.0 4.0 55.0 2.2 1.8 28       
Acebutolol 74.3 0.6 1.3 7.6 34.7 2.6 5.0 34 -6.5 -6.1 -4.4 
Celiprolol 75.0  7.7 4.6 50.7 2.3 2.2 28       
Bisoprolol 70.5  2.7 3.7 62.5 2.3 1.4 80 -7.8 -6.7 -5.7 
Esmolol 61.4  1.2 285.0 0.5 1.4 283.6         
Levobunolol     11.0 13.0 1.5 9.5 75       
Oxprenolol 8.0 0.8 0.9 5.9 2.2 0.1 5.7 38       
Mepindolol 51.0  2.3 6.2 28.4 2.1 4.1 82       
Epanolol   4.3 26.8 26.0 7.0 19.8 7       
Flestolol   1.9 181.0 2.5 4.5 176.5         
Betaxolol 50.0  6.6 3.9 18.4 0.7 3.2 84 -8.2 -7.4 -6.0 
Amosulalol   0.4 2.2 34.1 0.7 1.5 100       
Medroxalol   8.6 16.4 8.2 1.3 15.1 27       
Propranolol 7.5 0.7 3.2 13.1 0.4 0.05 13.1 18 -8.2 -9.1 -6.9 





In-vivo PK parameters PD parameter 
Drug fu B/P  Vdss CLtot fe CLren CLnonren Foral log (Ki) ( Human CHO-K1)[nM] 
  [%] ratio [l/kg] [ml/min/kg] [%] [ml/min/kg] [ml/min/kg]  [%] β1 β2 β3 
Alprenolol 23.9 1.0 3.5 16.7      26 -7.8 -9.0 -6.9 
Labetalol 50.0 1.4 8.0 21.2 0.4 0.1 21.1 26 -7.6 -8.0 -6.2 
Dilevalol  1.2 13.9 26.5 3.0 0.7 25.8 30       
Tolamolol 8.9 0.6 3.2 14.2      32       
Nafetolol   0.8 2.8 19.6 14.0 2.8 16.8         
Bevantolol 2.0  0.7 5.5 0.7 0.04 5.5 57       
Bufuralol 19.0  2.5 8.2 1.6 0.1 8.1 71       
Ro31-1118   9.0 5.7      57       
Penbutolol 12.0  2.3 5.6 2.8 0.16 5.5         
Bornaprolol 10.2  2.1 14.4      46       
Adimolol   1.6 2.5      43       
Nebivolol 1.9  11.2 14.1              
Bopindolol   2.3 5.4      70       
Carvedilol  0.7 1.7 7.8 10.3 0.8 7.0 22 -8.8 -9.4 -8.3 
Reproterol       11.0               
Albuterol 93.0  1.9 7.9 58.3 4.60 3.3 53 -4.7 -6.1 -4.3 
Terbutaline 80.5 1.4 1.7 3.0 64.5 1.94 1.1 14 -3.8 -5.6 -3.9 
Bambuterol 55.0  1.6 17.1 11.0 1.88 15.2 9       
Fenoterol 62.5  0.7 37.9              
Mean 53.4 0.9 3.3 19.8 30.0 2.3 19.5 48 -7.1 -7.4 -5.6 
Maximum 99.0 1.4 13.9 285.0 94.1 11.9 283.6 100 -3.8 -5.6 -3.9 
Minimum 1.9 0.2 0.3 1.9 0.4 0.0 0.2 5 -8.8 -9.7 -8.3 
N 34.0 16.0 46.0 48.0 38.0 38.0 38.0 39.0 15.0 15.0 15.0 
fold range 52 8 53 153 269 640 1350 22 5.0 4.1 4.4 







Table 5.4. Biologically Relevant In-vitro and In-vivo PK variables (ordered by log (D)7.4) 
 
Drug γ CLtotu CLrenu CLnonrenu Vdssu CLnonrenblood CLint ERhep1 ERhep2 
   [ml/min/kg] [ml/min/kg] [ml/min/kg] [l/kg] [ml/min/kg] [ml/min/kg] [%] [%] 
Xamoterol  3.1 1.9 1.2 0.7       95.5 
Atenolol 0.73 2.7 2.5 0.2 1.1 0.2 0.23 1.0 42.0 
Sotalol 0.66 2.2 1.7 0.5 1.2 2.6 0.10 12.9 0.0 
Nadolol   3.4 2.0 1.4 2.0      64.2 
Diacetolol   4.1 2.6 1.5 0.3      57.4 
Tertatolol   25.1 0.3 24.9 4.1      40.0 
Landiolol   39.0 3.1 35.9 3.1       
Pamatolol              12.2 
Prenalterol 1.4 20.6 12.5 8.1 2.3 6.8 15.02 33.8 74.0 
Carteolol   11.9 7.7 4.2 5.8      16.3 
Timolol 0.81 20.3 6.1 14.2 4.2 9.8 11.71 49.0 39.0 
Deacetyl 
Metipranolol   52.1 8.2 44.0 10.2       
Pindolol 1.7 17.4 7.8 9.6 4.9 6.0 8.34 29.8 24.9 
Metoprolol 1.00 13.8 2.0 11.8 3.7 9.6 29.24 48.0 60.0 
Pafenalol              72.5 
Acebutolol 3.1 10.2 3.6 6.7 1.7 8.0 5.48 40.2 66.0 
Celiprolol   6.1 3.1 3.0 10.3      72.4 
Bisoprolol   5.2 3.2 2.0 3.9      20.0 
Esmolol   464.2 2.3 461.8 1.9       
Levobunolol              25.0 
Oxprenolol 0.99 73.4 0.2 71.7 10.8 7.2 80.47 35.9 62.0 
Mepindolol   12.2 4.1 8.1 4.5      17.9 
Epanolol              92.9 
Flestolol               
Betaxolol   7.8 1.5 6.3 13.1      16.0 
Amosulalol              0.0 
Medroxalol              72.8 
Propranolol 6.9 174.7 0.6 174.1 42.0 17.6 370.87 88.2 82.2 
Talinolol   12.5 7.2 5.4 8.4      45.0 
Alprenolol 4.7 69.9   14.7      73.7 
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Drug γ CLtotu CLrenu CLnonrenu Vdssu CLnonrenblood CLint ERhep1 ERhep2 
   [ml/min/kg] [ml/min/kg] [ml/min/kg] [l/kg] [ml/min/kg] [ml/min/kg] [%] [%] 
Labetalol 3.6 42.4 0.2 42.2 16.1 15.5  77.6 74.0 
Dilevalol         20.8  99 70.4 
Tolamolol 6.3 159.6   35.5      67.6 
Nafetolol          20.5  99  
Bevantolol   275.0 2.0 273.1 33.0      43.0 
Bufuralol   43.2 0.7 42.5 13.1      29.0 
Ro31-1118              43.0 
Penbutolol   46.9 1.3 45.6 19.4       
Bornaprolol   141.2   20.6      54.0 
Adimolol              57.1 
Nebivolol   742.1   589.5       
Bopindolol              30.2 
Carvedilol         10.1  50.7 78.0 
Reproterol                   
Albuterol   8.5 4.9 3.5 2.0      47.0 
Terbutaline 2.4 3.7 2.4 1.3 2.1 0.7 2.02 3.7 85.8 
Bambuterol   31.1 3.4 27.7 2.8      91.1 
Fenoterol   60.6   1.2       
Mean 2.6 76.7 3.4 45.9 26.2 9.7 52.3 48.4 51.6 
Maximum 6.9 742.1 12.5 461.8 589.5 20.8 370.9 99 95.5 
Minimum 0.7 2.2 0.2 0.2 0.3 0.2 0.1 1.0 0.0 
N 13.0 34.0 29.0 29.0 34.0 14.0 10.0 14.0 39.0 
fold range 10 340 78 2138 2097 106 3843 99  
















 N Mean SD 95%CI Minimum 10% 25% Median 75% 90% Maximum 
fu 34 0.53 0.34 0.4-0.7 0.02 0.07 0.17 0.53 0.87 0.96 0.99 
γ 13 2.6 2.2 1.3-3.9 0.66 0.69 0.9 1.7 4.1 6.6 6.9 
Vdss (l/kg) 46 3.3 3.1 2.4-4.2 0.3 0.7 1.3 2.3 3.4 8.5 13.9 
CLtot (ml/min/kg) 48 19.8 46.9 6.2-33.4 1.9 2.5 3.9 7.9 16.4 27.9 285.0 
CLren (ml/min/kg) 38 2.3 2.3 1.5-3.0 0.02 0.09 0.7 1.9 2.7 4.8 11.9 
CLnonren (ml/min/kg) 38 19.5 52.4 2.3-36.7 0.2 1.9 1.8 5.5 13.8 26.7 283.6 
CLtotu (ml/min/kg) 34 76.7 150.3 24.2-129.1 2.2 3.3 7.4 20.5 62.9 224.9 742.1 
CLren u (ml/min/kg) 29 3.4 2.9 2.3-4.5 0.2 0.3 1.6 2.5 4.5 7.8 12.5 
CL nonren u (ml/min/kg) 29 45.9 98.8 8.4-83.5 0.2 1.2 2.5 8.1 42.4 174.1 461.8 
Vdss u (l/kg) 34 26.2 100.2 -8.7-61.1 0.3 1.2 2.0 4.4 13.5 34.3 589.5 
CLint (ml/min/kg) 10 52.3 114.5 -29.5-134.2 0.1 0.1 1.6 10.0 42.0 341.8 370.9 
log Ki (β1) 15 -7.1 1.4 -7.8 to -6.3 -8.8 -8.5 -8.2 -7.3 -6.5 -4.3 -3.8 
log Ki (β2) 15 -7.4 1.4 -6.6 to -8.2 -9.7 -9.5 -9.0 -6.9 -6.1 -5.8 -5.6 




Table 5.6. Correlation Matrix for PK Variables of  β-ARLs 
 
















fu 1.0000 -0.2275 0.0910 0.5196 0.0654 -0.4558 0.3331 -0.4505 -0.3653 
Vdss (L/kg) -0.2275 1.0000 -0.0747 -0.0692 -0.0714 0.5294 -0.7071 0.5569 0.7314 
CLtot 
(ml/min/kg) 
0.0910 -0.0747 1.0000 0.0766 0.9988 0.4112 0.0349 0.3713 -0.0414 
CLren 
(ml/min/kg) 
0.5196 -0.0692 0.0766 1.0000 0.0270 -0.1768 0.2047 -0.1836 -0.1197 
CLnonren 
(ml/min/kg) 
0.0654 -0.0714 0.9988 0.0270 1.0000 0.4211 0.0247 0.3815 -0.0355 
CLtotu 
(ml/min/kg) 
-0.4558 0.5294 0.4112 -0.1768 0.4211 1.0000 -0.8242 0.9982 0.8401 
CLrenu 
(ml/min/kg) 
0.3331 -0.7071 0.0349 0.2047 0.0247 -0.8242 1.0000 -0.8564 -0.9894 
CLnonrenu 
(ml/min/kg) 
-0.4505 0.5569 0.3713 -0.1836 0.3815 0.9982 -0.8564 1.0000 0.8696 









Table 5.7. Categorization of β-ARLs based on Elimination Route and PPB (ordered by log (D)7.4) 
 
Drug Metabolism PPB category ERhep1 category 
Xamoterol   Low PPB  
Atenolol   Low PPB LER 
Sotalol   Low PPB LER 
Nadolol   Low PPB  
Diacetolol   Low PPB  
Tertatolol  Highly metabolized High PPB  
Landiolol Extrahepatic  Highly metabolized Low PPB  
Pamatolol     
Prenalterol   Low PPB IER 
Carteolol   Low PPB  
Timolol   Intermediate PPB IER 
Deacetyl 
Metipranolol  Highly metabolized Intermediate PPB  
Pindolol   Intermediate PPB IER 
Metoprolol  Highly metabolized High PPB IER 
Pafenalol     
Acebutolol   Intermediate PPB IER 
Celiprolol   Intermediate PPB  
Bisoprolol   Intermediate PPB  
Esmolol Extrahepatic  Highly metabolized Intermediate PPB  
Levobunolol  Highly metabolized   
Oxprenolol  Highly metabolized High PPB IER 
Mepindolol   Intermediate PPB  
Epanolol  Extrahepatic     
Flestolol 
                 
Extrahepatic  Highly metabolized   
Betaxolol  Highly metabolized Intermediate PPB  
Amosulalol     
Medroxalol  Highly metabolized   
Propranolol  Highly metabolized High PPB HER 
Talinolol   Intermediate PPB  
Alprenolol   Intermediate PPB  
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Drug Metabolism PPB category ERhep1 category 
Labetalol Extrahepatic  Highly metabolized Intermediate PPB HER 
Dilevalol Extrahepatic  Highly metabolized  HER 
Tolamolol   High PPB  
Nafetolol  Extrahepatic  Highly metabolized  HER 
Bevantolol  Highly metabolized High PPB  
Bufuralol  Highly metabolized High PPB  
Ro31-1118     
Penbutolol  Highly metabolized High PPB  
Bornaprolol   High PPB  
Adimolol     
Nebivolol   High PPB  
Bopindolol     
Carvedilol  Highly metabolized  HER 
Reproterol        
Albuterol   Low PPB  
Terbutaline   Low PPB LER 
Bambuterol  Highly metabolized Intermediate PPB  










5.2.2. QSPKR Analysis, Model Building and Evaluation 
Similar to data analysis for opioids, the QSPKR analysis was done on two datasets, complete 
and reduced (after exclusion of drugs known/suspected of undergoing extra-hepatic 
metabolism). The results of univariate regression between PK variables and molecular 
descriptors for the complete dataset and reduced dataset are shown in Table 5.8 and Table 
5.9, respectively. The relationships which showed r2 ≥ 0.30 and p < 0.05 were further used to 
build final multivariate model by using log-linear and MLLR. The final models from the 
QSPKR analysis are summarized in Table 5.10. In-vitro PK variables like γ and fu are 
strongly dependent on log (D)7.4 with log log (D)7.4 accounting for more than 60 % 
variability. Biologically relevant PK variables like Vdssu, CLtotu and CLnonrenu (Figure 5.9, 
5.11-5.12) did show a significant increase with log (D)7.4, with log (D)7.4 accounting for more 
than 30 % variability. As a result of these offsetting effects, Vdss and CLtot were not affected 
by log (D)7.4 (Figures.5.5-5.6). CLren significantly decreased and CLnonren increased with log 
(D)7.4, however, the relationships did not meet the pre-specified criteria of r2 ≥ 0.30 to build 
final log- linear model. Secondary to fu, CLren decreased with log (D) (Figure 5.7). Log (D) 
accounted for 50 % variability in the ERhep1, although the regression was governed by 
extreme cases; polar β-ARLs like sotalol and atenolol with very low ERhep and highly 
lipophilic carvedilol with very high ERhep. 
 Univariate analysis showed a significant effect of HBA, HBD and PSA on CLren and fu (r2 
= 0.10-0.20, p < 0.05) and HBD on CLnonrenu (r2 = 0.28, p < 0.05). Log (D)7.4, ranging from -
2.9 to 3.1, was the sole most important molecular property, affecting most of the biologically 
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relevant PK variables of β-ARLs. The slopes for all PK variables vs. log (D)7.4, remained 
similar across the complete and reduced dataset indicating that the effect of molecular 
descriptors on these variables was similar; however, exclusion of the drugs undergoing extra-
hepatic clearance lead to improvement in r2, q2 and decrease in p-value and prediction errors 
(Table 5.9, Figures 5.13-5.21). Overall, the final QSPKR models developed provided 
acceptable predictions (q2 ≥ 0.40) for fu, Vdssu, CLnonrenu and CLren (Table 5.10). For CLnonrenu, 
the predictive ability improved after exclusion of drugs undergoing extra-hepatic, nonrenal 
elimination, indicating the importance of nonrenal clearance mechanisms (hepatic vs. extra-












Table 5.8. Log-linear Regression between Molecular Descriptors and PK variables for Complete Dataset of  β-ARLs 
 


















descriptor     (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (L/kg) (ml/min/kg) 
MW n = 34 n = 34 n = 46 n = 48 n = 38 n = 38 n = 34 n = 29 n = 29 n = 34 n = 10 
  r2 = 
0.00004 
r2 = 0.37 r2 = 
0.03 
r2 = 0.004 r2 = 0.004 r2 = 0.05 r2 = 0.03 r2 = 0.0005 r2 = 0.01 r2 = 0.04 r2 = 0.08 






















  (N.S.) (p 
<0.05) 
(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
log (D) n = 34 n = 13 n = 46 n = 48 n = 38 n = 38 n = 34 n = 29 n = 29 n = 34 n = 10 
at pH 7.4 r2 = 0.63 r2 = 0.66 r2 = 
0.11 
r2 = 0.02 r2 = 0.17 r2 = 0.15 r2 = 0.54 r2 = 0.09 r2 = 0.43 r2 = 
0.75 
r2 = 0.90 






Slope = 0.04 Slope = 
-0.25 












(N.S.) (N.S.) (p < 0.05) ( p < 0.05) (p < 0.05) (N.S.) (p <0.05) (p<0.05) (p < 0.05) 
nRot n = 34 n = 13 n = 46 n = 48 n = 38 n = 38 n = 34 n = 29 n = 29 n = 34 n = 10 
  r2 = 0.03 r2 = 0.06 r2 = 
0.04 
r2 = 0.02 r2 = 0.01 r2 = 0.06 r2 = 0.004 r2 = 0.0003 r2 = 0.02 r2 = 
0.003 
r2 = 0.05 














  (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
HBA n = 34 n = 13 n = 46 n = 48 n = 38 n = 38 n = 34 n = 29 n = 29 n = 34 n = 10 
  r2 = 0.18 r2 = 0.01 r2 = 
0.0004 
r2 = 0.01 r2 = 0.15 r2 = 0.02 r2 = 0.03 r2 = 0.07 r2 = 0.02 r2 = 0.08 r2 = 0.004 












Slope =  
-0.06 
Slope =  
-0.10 
Slope =  
-0.05 
  (p < 0.05) (N.S.) (N.S.) (N.S.) ( p < 0.05) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
HBD n = 34 n = 13 n = 46 n = 48 n = 38 n = 38 n = 34 n = 29 n = 29 n = 34 n = 10 
  r2 = 0.17 r2 = 0.10 r2 = 
0.008 
r2 = 0.03 r2 = 0.11 r2 = 0.00003 r2 = 0.09 r2 = 0.02 r2 = 0.28 r2 = 0.07 r2 = 0.03 
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descriptor     (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (L/kg) (ml/min/kg) 


















  (p < 0.05) (N.S.) (N.S.) (N.S.) ( p < 0.05) (N.S.) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) 
Molar 
volume 
n = 34 n = 13 n = 46 n = 48 n = 38 n = 38 n = 34 n = 29 n = 29 n = 34 n = 10 
  r2 = 0.01 r2 = 0.27 r2 = 
0.03 
r2 = 0.008 r2 = 
0.0000002 
r2 = 0.08 r2 = 0.04 r2 = 0.0003 r2 = 0.05 r2 = 0.06 r2 = 0.18 






















  (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
PSA n = 34 n = 13 n = 46 n = 48 n = 38 n = 38 n = 34 n = 29 n = 29 n = 34 n = 10 
  r2 = 0.17 r2 = 0.03 r2 = 
0.03 
r2 = 0.07 r2 = 0.11 r2 = 0.02 r2 = 0.03 r2 = 0.02 r2 = 0.12 r2 = 0.12 r2 = 0.20 

















Slope =  
-0.007 
Slope =  
-0.005 
Slope =  
-0.02 
  (p < 0.05) (N.S.) (N.S.) (N.S.) ( p < 0.05) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
Energy n = 34 n = 13 n = 46 n = 48 n = 38 n = 38 n = 34 n = 29 n = 29 n = 34 n = 10 




r2 = 0.04 r2 = 0.003 r2 = 0.02 r2 = 0.02 r2 = 0.0005 r2 = 0.02 r2 = 0.02 r2 = 0.06 
  Slope =  
-0.001 
Slope = 




















  (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S) (N.S) (N.S.) 
Dipole 
moment 
n = 34 n = 13 n = 46 n = 48 n = 38 n = 38 n = 34 n = 29 n = 29 n = 34 n = 10 
  r2 = 0.02 r2 = 0.12 r2 = 
0.0003 
r2 = 0.003 r2 = 0.002 r2 = 0.01 r2 = 0.02 r2 = 0.06 r2 = 
0.000001 
r2 = 0.01 r2 = 0.09 
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Figure 5.6. CLtot vs. log (D)7.4  (β-ARLs) 
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Table 5.9. Log-linear Regression between Molecular Descriptors and PK Variables for Reduced Dataset of  β-ARLs 
 









 (CLtot u) 
log 




 (Vdss u) 
log 
 (CLint) 
descriptor     (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (L/kg) (ml/min/kg) 
n = 30 n = 12 n = 38 n = 40 n = 31 n = 31 n = 30 n = 26 n = 26 n = 30 n = 10 
r2 = 
0.04 
r2 = 0.06 r2 = 
0.02 
r2 = 0.009 r2 = 0.001 r2 = 0.001 r2 = 0.04 r2 = 0.003 r2 = 0.0002 r2 = 
0.099 
























(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
n = 30 n = 12 n = 38 n = 40 n = 31 n = 31 n = 30 n = 26 n = 26 n = 30 n = 10 
r2 = 
0.64 
r2 = 0.65 r2 = 
0.10 
r2 = 0.05 r2 = 0.21 r2 = 0.24 r2 = 0.66 r2 = 0.05 r2 = 0.51 r2 = 
0.77 


























(N.S.) (N.S.) (p < 0.05) (p < 0.05) (p < 0.05) (N.S.) (p <0.05) (p 
<0.05) 
(p < 0.05) 
n = 30 n = 12 n = 38 n = 40 n = 31 n = 31 n = 30 n = 26 n = 26 n = 30 n = 10 
r2 = 
0.005 
r2 = 0.03 r2 = 
0.03 
r2 = 0.02 r2 = 0.003 r2 = 0.004 r2 = 0.004 r2 = 
0.000002 
r2 = 0.004 r2 = 
0.0004 






















(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
n = 30 n = 12 n = 38 n = 40 n = 31 n = 31 n = 30 n = 26 n = 26 n = 30 n = 10 
r2 = 
0.14 
r2 = 0.05 r2 = 
0.006 
r2 = 0.009 r2 = 0.15 r2 = 0.02 r2 = 0.09 r2 = 0.12 r2 = 0.11 r2 = 
0.09 


























(N.S.) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 







r2 = 0.03 r2 = 0.23 r2 = 0.17 r2 = 0.19 r2 = 0.18 r2 = 0.48 r2 = 
0.11 


































 (CLtot u) 
log 




 (Vdss u) 
log 
 (CLint) 
descriptor     (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (L/kg) (ml/min/kg) 
(p < 
0.05) 
(N.S.) (N.S.) (N.S.) ( p < 0.05) (p < 0.05) (p < 0.05) (p < 0.05) (p < 0.05) (N.S.) (N.S.) 
n = 30 n = 12 n = 38 n = 40 n = 31 n = 31 n = 30 n = 26 n = 26 n = 30 n = 10 
r2 = 
0.09 
r2 = 0.09 r2 = 
0.03 
r2 = 0.01 r2 = 0.02 r2 = 0.009 r2 = 0.06 r2 = 0.002 r2 = 0.03 r2 = 
0.12 

























(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 







r2 = 0.007 r2 = 0.22 r2 = 0.02 r2 = 0.12 r2 = 0.18 r2 = 0.30 r2 = 
0.13 
r2 = 0.20 
Slope = 
0.004 























(N.S.) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (p < 0.05) (p < 0.05) (N.S.) (N.S.) 
n = 30 n = 12 n = 38 n = 40 n = 31 n = 31 n = 30 n = 26 n = 26 n = 30 n = 10 
r2 = 
0.005 
r2 = 0.13 r2 = 
0.04 
r2 = 0.006 r2 = 0.006 r2 = 0.002 r2 = 0.009 r2 = 0.007 r2 = 0.005 r2 = 
0.02 
























(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
n = 30 n = 12 n = 38 n = 40 n = 31 n = 31 n = 30 n = 26 n = 26 n = 30 n = 10 
r2 = 
0.006 




r2 = 0.0002 r2 = 0.002 r2 = 0.02 r2 = 0.02 r2 = 0.0006 r2 = 
0.007 
r2 = 0.09 
Slope = 
0.0009 
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β-ARLs are structurally similar and have similar molecular weights; however, there are 
considerable differences in their PK-PD properties. The Vdss varies (more than 2000-fold) 
across the β-ARLs. Vdssu values were found to be greater than BW, indicating high tissue 
sequestration; on the other hand, this was counteracted by high PPB that lead to lower Vdss 
values. For the majority of β-ARLs, clearance is due to non-renal elimination, i.e., hepatic 
and extra-hepatic metabolism. 
To account for the differences in the PK-PD properties of β-ARLs, the effect of the 
physicochemical properties on the PK-PD properties was studied. Log (D)7.4 was found to be 
the primary determinant of biologically relevant PK properties like CLtotu, CLnonrenu and Vdss u 
for β-ARLs. As the log (D)7.4 increased, there was a significant decrease in fu since the drugs 
bind to the plasma proteins by hydrophobic interactions. This finding is consistent with 
protein binding of various barbiturates in the rats67, penicillins in humans68 and anti-
arrhythmic drugs in humans.19, 69 Obach et al16 using  a set of 554 drugs suggested that 
increasing log (D)7.4 increased PPB because of hydrophobic forces interaction with albumin 
and α-acid glycoprotein. In addition to PPB, a significant relation was found between γ and 
log (D)7.4. Similar results were found for γ of baribiturate series in rats. 67 PPB decreased 
Vdss for highly plasma protein bound drugs. After correction for PPB, it was observed that 
Vdssu significantly increased with log (D)7.4. This showed that these two opposing forces 
acting on Vdss; offset each other. A similar relationship was seen for Vdssu for a series of 
sulfonamides in rats (n = 6, slope = 0.20, r2 = 0.69)71 and β-blockers in human (n = 13, slope 
= 0.33, r2 = 0.71).19 van de Waterbeemd et al20 studied the effect of log (D)7.4 on ten β-
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adrenergic antagonists and found that Vdssu increased with log (D)7.4 indicating that 
compound’s ability to interact with the lipid core of the membrane as well as the ability of 
the basic nitrogen to interact with the ionized groups. Obach et al16 studied  PK in humans for 
a diverse data set of 670 drugs (159 acids, 267 bases, 173 neutrals amd 68 zwitterions) and 
found that there was Vdssu  increased with lipophilicity for bases, neutrals and zwitterions and 
it was found that bases had greater CLtot values than acids, neutrals or zwitterions. As the log 
(D)7.4 increased, there was a significant decrease in CLren. Similar trend was also observed 
between CLren and log (D)7.4 for a set of 391 compounds and β-blockers in human.19, 72 
However, when CLren was corrected for PPB, the relation between CLrenu and log (D)7.4 was 
insignificant. For a set of ten β-adrenergic antagonists, van de Waterbeemd et al20 showed 
CLrenu was approximately constant with log (D)7.4. This may suggest that as the PPB 
increased, less amount of drug was available for glomerular filtration. In this dataset, there 
are many β-ARLs which have CLrenu values exceeding GFR which indicating that they may 
undergo net tubular secretion. This showed that the effect of log (D)7.4 was stronger on the 
drugs which are highly plasma protein bound and undergo filtration. The amount excreted in 
the urine declines with log (D)7.4 due to increased importance of metabolic clearance, making 
the estimates for fe less accurate. Hinderling et al19 studied the effect of lipophilicty on PK of 
14 β-blockers and found that there was a significant relation between in-vitro parameters like 
fu and γ and log (D) and a significant effect of log (D) on Vdssu, CLren and CLnonren. Yamada 
et al31 predicted therapeutic doses for 18 β-blockers based on QSPKR and it was found that 
there was a significant relation between PK parameters like fu, CLtot/F, Vdssu/F, and log(D). 
        When the drugs undergoing extra-hepatic metabolism were excluded, as lipophilicity 
increased, CLnonren and CLnonrenu increased, which in turn, lead to increase in ERhep, indicating 
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that increase in log (D)7.4 favors partitioning into the liver. This was consistent with the 
results obtained for a set of 12 β-blockers in human wherein it was found that there was a 
significant increase in  CLnonren with increase in lipophilicity.19 In-addition, CLtot is the 
combination of CLren and CLnonren. There were two opposing effects; CLren decreasing with 
log (D)7.4 and CLnonren increasing with log (D)7.4, which offset each other. CLnonren is governed 
by fu and/or CLint. CLint increased significantly with log (D)7.4, and fu decreased with log 
(D)7.4; however, there was a significant effect of log (D)7.4 on CLnonren and  CLnonren u 
indicating dominance of CLint over CLnonren for β-ARLs. Van de Waterbeemd20 showed that 
there was a strong positive correlation between distribution coefficient of ten β-blockers and 
their unbound hepatic intrinsic clearance.  
Irrespective of the dataset, the slopes remained similar indicating that the effect of log 
(D)7.4 on the PK parameters was similar; however, exclusion of drugs undergoing extra-
hepatic metabolism lead to improvement in r2, q2 and decrease in p-value indicating 
robustness of the analysis towards exclusion of outliers (Table 5.10). None of the molecular 
descriptors showed any significant relation with log (Ki) at β1, β2 and β3-receptor, the most 
plausible reason being that affinity at the β-receptor depends on how the drug orients itself in 
the space at the receptor rather than its physicochemical properties 
 Overall, for this study, log (D)7.4 was found to be the most important descriptor in the 
prediction of systemic PK variables of β-ARLs, reflecting its role in the transfer across 
biological membranes during distribution and elimination. In the past, there have been in-
vitro diffusion studies with six β-blockers which indicated that human skin permeation could 
be explained by parabolic relation to the partition coefficients83. It was also shown by 
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Kawazu et al84 that there was a sigmoidal relation between permeability coefficient and 
lipophilicity for eight –blockers across rabbit corneal epithelial cells.  
Overall, in this research, as indicated by the q2 and % MPE and % RMSE values, the 
QSPKR models developed provide useful predictions of relevant systemic PK properties of 
β-ARLs in humans. 
 
5.2.4.   Comparison of QSPKR Study of Opioids and β-ARLs 
Both opioids and β-ARLs are basic drugs, targeting GPCR.  Both datasets showed a wide 
range of physicochemical as well as PK properties: The opioid dataset was more biased 
towards more lipophilic compounds, and most of them were cleared by nonrenal elimination, 
i.e., hepatic and extrahepatic clearance.  Out of 38 opioids, only two opioids, M3G and M6G, 
showed fe > 50%, while all others were mainly non-renally cleared (fe < 50%); 14 opioids 
showed CLtot or CLnonrenblood values exceeding LBF or even cardiac output, indicating 
extrahepatic/nonrenal clearance, e.g., ester hydrolysis in blood and other body tissues, while 
some had high Foral values although they had high apparent ERhep, indicating that they 
undergo extrahepatic clearance as well.  Most of the opioids (except M3G and M6G) were 
intermediate-to- high ERhep drugs.  Glucuronidation and phase I metabolism were the main 
metabolic pathways.  Amongst them, UGT2B7 and CYP2D6, CYP3A, CYP2C9, CY2C19 
play the major role in opioid metabolism.  In addition, membrane transporters like P-gp are 
known to determine the transport of some opioids like morphine, alfentanil, fentanyl, 
loperamide and sufentanil across membranes (GI, kidney, CNS, liver).85 
        Compared to the opioids, the β-ARL dataset was a combination of more hydrophilic as 
well as lipophilic compounds:  Out of 48 β-ARL, 14 compounds showed fe > 50% while all 
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others were mainly metabolized (fe < 50%), and seven compounds showed CLtot or 
CLnonrenblood value exceeding LBF or CO, indicating extrahepatic/nonrenal clearance.  Thus, 
for most β-ARL, similar to opioids, CLtot was primarily due to nonrenal elimination, i.e., 
hepatic and extrahepatic clearance.  Glucuronidation and phase I metabolism (CYP2D6, 
CYP3A4) were the main metabolic pathways.  Membrane transporters like P-gp, OCTs and 
MRP2 are known to be involved in the transport of some β-ARL.86, 87 For both the datasets, 
PPB was highly variable, Vdssu values indicated high tissue sequestration for most 
compounds; however, this was counteracted by high PPB, leading to lower Vdss values. 
          Table 5.11 shows a comparison of univariate effects of log (D)7.4 on the PK variables 
for opioids and β-ARLs: For both classes, PPB increased strongly with log (D)7.4, as did 
Vdssu, CLtotu, and CLnonrenu.  As net result, the observed/reported CLtot, Vdss and CLnonren were 
not affected by log (D)7.4.  Secondary to fu, CLren decreased as log (D)7.4  increased. β-ARLs 
had a widerange of log (D)7.4  values since β-ARL dataset had a combination of hydrophilic 
and lipophilic compounds as opposed to opioid dataset, which was biased towards relatively 
lipophilic compounds. As a result, the slopes obtained in the univariate log–linear regression 
between log (D)7.4 and PK variables of β-ARLs were steeper than those obtained for opioids.  
For opioids, the final QSPKR models developed provided acceptable predictions for fu, Vdssu, 
CLnonrenu and CLren. For β-ARL, QSPKR models showed acceptable predictive performance 
for fu, Vdssu, CLnonrenu and CLtotu.  CLnonrenu and CLtotu, for both classes, using the reduced 
dataset showed improved r2 and q2, indicating the importance of extrahepatic clearance on 
QSPKR predictions.  The results obtained in this study were consistent with published 
studies19, 31, however, the dataset in the present study was much larger, included more recent 
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(mainly lipophilic) β-ARL, antagonists and agonists, and the QSPKR analysis studied the 
effect of various molecular descriptors other than log (D)7.4 more systematically.  
 
Overall, for both pharmacological classes of drugs: 
• Lipophilicity, log (D)7.4, was found to be the biologically plausible and, statistically, 
the most significant molecular property affecting the biologically relevant, systemic 
PK variables, fu, Vdssu, CLnonrenu. 
• QSPKR models using log (D)7.4 showed good predictive performance (q2 >0.40) 
during cross-validation for fu , Vdssu  and CLnonren u. 
• Poor predictive ability (q2 < 0.40) was obtained for CLtotu for opioids indicating that 
lipophilicity, a bulk property, is only one of many properties influencing nonrenal 
drug elimination (primarily hepatic metabolism and possibly biliary excretion). 
• Presence of extra-hepatic clearance (e.g., hydrolysis in blood/tissues) worsened the 
predictive ability of log (D)7.4 on CLnonrenu and CLtotu, but not fu, as expected. This is 
consistent with the idea that extrahepatic clearance (e.g., ester hydrolysis) does not 
depend on log (D)7.4. 
• For opioids, MV and log (D)7.4 combined showed a significant effect on fu.  
Secondary to fu, CLren decreased with MV and log (D)7.4.  In addition, H-bonding 
(HBD and HBA) and PSA showed a significant effect on CLnonren, Vdssu, CLnonrenu 
(r2=0.30-0.70, n=18-28), however, the regression was leveraged by the extreme 
values for M3G and M6G and hence, these results were extremely sensitive to the 
inclusion of M3G and M6G.  
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• For the both the classes, none of the molecular descriptors had any effect on the 
affinity at the receptors. 
 
              Table  5.11. Univariate effects of log (D)7.4: Opioids  vs. β-ARLs  
 
  Opioids β-ARLs 












































































CHAPTER 6. QSPKR OF β-LAs 
 
 
6. β-lactam antibiotics  
6.1.  Background 
 β-lactam antibiotics (β-LAs), unlike opioids and β-ARLs, are acidic molecules, more 
polar in nature and are primarily eliminated by renal excretion in humans and  is a widely 
used family of therapeutic agents. β-LAs are suggested to be not only filtered but also 
actively secreted by the proximal tubules.88. β-LAs are structural analogs and thus, it was 
thought that QSPKR study may provide insight in understanding the relation between 
structural properties and disposition of β-LAs. Depending on the structure/mechanism of 
action, the dataset was classified into cephalosporins (1st generation, 2nd generation, 3rd 
generation, 4th generation and 5th generation), carbapenems, beta lactamase inhibitors and 
penicillins, where compounds within each class are more closely related structural analogs. 
β-LA structures evolved over time of half a century in the quest of achieving better broad 
spectrum antibacterial activity, improved acid stability, improved β-lactamase resistance or 
spcificity. Unlike opioids and β-ARLs, most of the β-LAs act by inhibiting the crosslinking 
step in the cell wall formation by bacteria. Below is a brief account on the structure-activity 
relationship (SAR) of β-LAs from early penicillins to broader spectrum penicillins to 














Figure 6.1. Common Structural Backbone and Important Functional Groups of β-LA 
 
 
Acid sensitivity of penicillins is due to: 
• Bicyclic system adds ring strain which is relieved by acid catalysed reaction. 
• Highly reactive lactam ring carbonyl group. 
• Acyl side chain can cause opening up of lactam ring.  
 
Acid resitant penicillins: Addition of electron withdrawing group (ewg) on side chain draws 




















































































Second generation cephalosporins 
 
Introduction of methyl group at position 7 e.g. Cefoxitin (Figure 6.7) or introduction of 
iminomethoxy group at the alpha position of the acyl side chain e.g. Cefuroxime (Figure 6.8), 


































Figure 6.8. Example of Second-Generation Cephalosporin, Cefuroxime 
 
 
Third generation cephalosporins 
Replacing the furan ring with aminothiazole ring lead to increases penetration through outer 

























Fourth generation cephalosporins 
Some are zwitterionic, positively charged substituent at the 3-position and a negatively charged 
group at the 4-position leads to increased penetration in the outer membrane of gram negative 



















































































Double bond leading to 
high ring strain and 
increase in lactam 
reactivity 
 Side chain – plays role in 
beta lactamase resistance 
 
Opposite stereochemistry to 
penicillins – lactamase resistant 
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Beta lactamase inhibitors –suicide inhibitors  
Mechanism based inhibitors – fit in active site of beta lactamase and binds irreversibly. It has a 
strained beta lactam ring, enol ether, the double bond has Z configuration, no side chain and R- 




























Figure 6.14.  Structure of Sulbactam 
 
Turner et al 73 predicted PK properties for 20 cephalosporins using ANN model and found 
molar volume and energy the major determinants of renal clearance and PPB, respectively. 
Karalis et al 90 developed multiple linear and nonlinear models using molecular descriptors to 
predict PK properties for 23 cephalosporins and found that non-linear models were superior to 
linear models. Thus, in literature, so far, QSPKR models have been developed only for 
cephalosporins. This research carried out a more comprehensive study using all the available β-
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lactam antibiotics including β-lactamase inhibitors and secondary analyses even reviewed sub-










6.2.1. Comparison of molecular descriptors and PK of β-lactam antibiotic (β-LAs) in 
humans 
The Table 6.1 and 6.2 show a dataset of 60 β-LAs with considerable diverse physicochemical 
and two dimensional molecular properties (1-12 fold range). β-LA are molecules, having a 
wide range of molecular weight from 199-672. Depending on the structure and mechanism of 
actions, the dataset can be classified into cephalosporins (1st generation, 2nd generation, 3rd 
generation, 4th generation and 5th generation), carbapenems, beta lactamase inhibitors and 
penicillins. Most of the β-LAs are negatively charged while some act as zwitterions in 
physiological range of pH. Most of β-LAs are polar and show a relatively small range (-0.2 to 
-7.3) of log (D)7.4 (except temocillin with log (D) 7.4  of 2.47). The majority of the β-LAs are 
completely ionized at plasma pH 7.4 and urinary pH 6.3. β-LAs which are zwitterions at pH 
7.4 and 6.3 are neutral/partly neutral and hence show higher percentage of non-ionized form. 
β-LAs show higher number of nRot (mean = 6.9) and HBAs (mean = 10.6). Descriptive 
statistics (Table 6.3) show that some molecular descriptors like MW, PSA and energy have 
mean values greater than the median and the distribution is skewed towards the right. High 
standard deviations indicate diversity in molecular descriptors across the β-LAs, however, 
the diversity is less than opioids and β-ARLs. HBA, nRot, molar volume are highly 
correlated with MW (r ≥ 0.80). PSA and HBA were also found to be collinear (r ≥ 0.80).  
The final mean PK variables obtained from different studies are shown in Table 6.4 and 
the biologically relevant PK parameters are shown in Table 6.5. Descriptive statistics (Table 
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6.6) showed that for most PK variables (except fu), the mean value is greater than the median 
value. Though the variation in PK variables across the β-LAs was less than opioids and β-
ARLs, for most of the variables, distribution were found to be skewed. Thus, for subsequent 
analyses, the PK variables (except fu) were log transformed. Some of the PK variables such 
as CLnonren, CLren were strongly correlated with CLtot (Table 6.7). Most of the β-LAs are 
mainly excreted by kidneys (fe > 50 %). Cefpiramide showed fe value of 20%, indicating that 
it is highly metabolized and/biliary excreted. PPB varies from 4 % to 97 %. Imipenem shows 
the highest fu (96 %), while cefpiramide shows the lowest fu (3 %). There is diversity in the 
PK properties amongst the β-LAs. The Vdss varies (30- fold) across the β-LAs. Vdssu values 
for majority of β-LAs is less than BW, indicating that they are not widely distributed into 
body tissues. CLtotu varies across the β-LAs (more than 66-fold). High PPB lowers CLtot 
values. For the majority of β-LAs, clearance is due to renal excretion. All the β-LAs are low 
hepatic clearance drugs (CLnonren ranging from 0.1- 4.8 ml/min/kg, less than 30% of the 
LBF). The CLtotu and Vdssu values varied more than the total PK parameters, but not as much 
as for opioids and β-ARLs. All β-LAs show CLrenu exceeding GFR, indicating net tubular 
secretion (except ertapenem and ceftriaxone, which show CLrenu < GFR, indicating that they 




Table 6.1. Physicochemical Properties of β-LAs (Ordered by Sub-class) 
 
Drug Class MW clogP log(D) log (D) % Ionized % Ionized  Charge   Charge   
        at pH 7.4 at pH 6.3 at pH 7.4 at pH 6.3 at pH 6.3 at pH 7.4 
Cefatrizine 1st generation 463 -1.21 -4.21 -3.76 72 14 AZ AZ 
Cefroxadine 1st generation 365 0.36 -1.52 -1.11 71 16 AZ AZ 
Cefapirin 1st generation 423 -0.41 -4.11 -3.76 100 99 A A 
Ceftezole 1st generation 440 -0.76 -4.47 -4.18 100 100 A A 
Cefacetrile 1st generation 339 -1.60 -6.63 -6.01 100 100 A A 
Cefazedone 1st generation 548 -0.42 -4.13 -3.86 100 100 A A 
Cefazolin 1st generation 455 -0.70 -4.41 -4.12 100 100 A A 
Cefalexin 1st generation 347 0.35 -2.93 -2.31 90 42 AZ AZ 
Cefradine 1st generation 349 0.48 -2.52 -2.08 74 18 AZ AZ 
Cefalothin 1st generation 396 0.08 -3.62 -3.29 100 100 A A 
Cefaloridine 1st generation 415 -2.10 -1.5 -1.5 0 0 Z Z 
Cefonicid 2nd generation 543 -0.45 -7.04 -7.04 100 100 A A 
Cefotiam 2nd generation 526 0.23 -2.36 -2.28 19 0 Z AZ 
Cefprozil 2nd generation 389 -0.60 -3.76 -3.22 84 29 AZ AZ 
Cefuroxime 2nd generation 424 0.26 -3.48 -3.20 100 100 A A 
Ceforanide 2nd generation 520 0.60 -3.87 -3.86 100 100 A A 
Cefoxitin 2nd generation 427 0.00 -3.71 -3.42 100 100 A A 
Cefmetazole 2nd generation 472 -0.62 -4.33 -4.04 100 100 A A 
Cefotetan 2nd generation 576 2.34 -3.43 -3.43 100 100 A A 
Cefamandole 2nd generation 463 -0.04 -3.75 -3.45 100 100 A A 
Ceftriaxone 3rd generation 555 -0.54 -5.32 -5.20 100 100 A A 
Ceftizoxime 3rd generation 383 -0.65 -4.35 -3.84 100 100 A A 
Cefpodoxime 3rd generation 427 0.38 -3.36 -2.98 100 100 A A 
Cefpiramide 3rd generation 613 0.17 -3.35 -3.32 100 100 A A 
Cefexime 3rd generation 453 -0.10 -4.89 -4.85 100 100 A A 
Cefotaxime 3rd generation 455 -0.51 -4.26 -3.92 100 100 A A 
Cefmenoxime 3rd generation 512 -0.91 -4.66 -4.33 100 100 A A 
Cefoperazone 3rd generation 646 -1.11 -4.82 -4.52 100 100 A A 
Moxalactam 3rd generation 520 -2.56 -7.31 -7.28 100 100 A A 
Cefatamet 3rd generation 397 1.18 -3.92 -3.36 100 100 A A 
Cefodizime 3rd generation 585 0.52 -4.26 -4.19 100 100 A A 
Cefpimizole 3rd generation 672 -5.02 -5.42 -5.42 100 100 A A 
Cefsulodin 3rd generation 533 -5.99 -6.39 -6.39 100 100 A A 
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Drug Class MW clogP log(D) log (D) % Ionized % Ionized  Charge   Charge   
        at pH 7.4 at pH 6.3 at pH 7.4 at pH 6.3 at pH 6.3 at pH 7.4 
Ceftazidime 3rd generation 547 -2.50 -2.95 -2.90 100 100 A A 
Cefepime 4th generation 482 -2.84 -2.29 -2.25 0 0 Z AZ 
Cefpirome 4th generation 516 -2.08 -1.53 -1.48 12 1 Z AZ 
Ceftobiprole 5th generation 535 -0.14 -3.13 -2.72 75 19 AZ AZ 
Tazobactam beta lactamase inhibitors 300 -0.60 -3.13 -2.94 100 100 A A 
Clavulanic acid beta lactamase inhibitors 199 -0.32 -3.73 -2.87 100 100 A A 
Sulbactam beta lactamase inhibitors 233 0.39 -3.32 -3.03 100 100 A A 
Doripenem Carbapenam 421 -3.26 -5.76 -5.76 1 1 Z Z 
Meropenem Carbapenam 383 -1.23 -3.82 -3.69 30 3 AZ AZ 
Imipenem Carbapenam 299 -2.95 -5.45 -5.44 0 1 Z Z 
Ertapenem Carbapenam 476 -0.72 -4.54 -4.20 100 99 A A 
Biapenem Carbapenam 351 -6.14 -5.54 -5.55 0 0 Z Z 
Aztreonam Monobactam 435 0.49 -4.32 -4.26 100 100 A A 
Sulbenicillin Penecillins 505 0.87 -3.88 -3.88 100 100 A A 
Mezlocillin Penecillins 540 0.33 -3.4 -3.17 100 100 A A 
Azlocillin Penecillins 461 0.83 -2.89 -2.67 100 100 A A 
Amoxicillin Penecillins 365 0.88 -2.32 -1.76 85 31 AZ AZ 
Ticarcillin Penecillins 384 1.24 -3.51 -3.51 100 100 A A 
Carbenicillin Penecillins 378 1.13 -3.62 -3.62 100 100 A A 
Furazlocillin Penecillins 571 1.48 -2.24 -2.02 100 100 A A 
Ampicillin Penecillins 349 1.48 -1.84 -1.23 90 42 AZ AZ 
Piperacillin Penecillins 518 1.00 -2.73 -2.5 100 100 A A 
Oxacillin Penecillins 401 2.55 -1.18 -0.99 100 100 A A 
Temocillin Penecillins 414 7.22 2.47 2.47 100 100 A A 
Nafcillin Penecillins 414 2.60 -1.13 -0.93 100 100 A A 
Mecillinam Penecillins 325 2.33 -0.21 -0.17 8 1 Z AZ 
Azidocillin Penecillins 375 2.28 -1.45 -1.22 100 100 A A 
N   60 60 60 60 60 60     
Mean   447 -0.3 -3.6 -3.4 83.5 75.3    
Maximum   672 7 2 2 100 100    
Minimum   199 -6 -7 -7 0.0 0.0    
fold-range   3.4 13.0 9.0 9.0         





Table 6.2. Molecular Properties of β-LAs (Ordered by Sub-class) 




moment Energy PSA 
        [cm3/mol] [Debye] KCal/mole A2 
Cefatrizine 9 11 6 266 46.7 36.4 341.6 
Cefroxadine 6 8 4 243 44.9 54.7 214.2 
Cefapirin 8 9 2 269 34.8 56.1 264.7 
Ceftezole 7 12 2 210 28.5 63.8 352.7 
Cefacetrile 6 9 2 213 37.2 51.6 273.8 
Cefazedone 7 10 2 307 9.6 41.6 239.3 
Cefazolin 7 12 2 225 33.5 72.4 303.1 
Cefalexin 5 7 4 231 43.1 42.6 209.2 
Cefradine 5 7 4 237 43.3 43.2 197.8 
Cefalothin 7 8 2 253 37.9 59.5 239.4 
Cefaloridine 6 7 2  32.0 53.7 186.7 
Cefonicid 10 14 4 281 105.9 71.1 396.9 
Cefotiam 10 13 4 292 24.5 62.1 351.8 
Cefprozil 7 8 5 254 39.8 50.7 247.1 
Cefuroxime 8 12 4 241 36.7 153.7 291.8 
Ceforanide 11 13 5 290 77.4 61.9 378.7 
Cefoxitin 8 10 4 262 35.6 65.2 269.8 
Cefmetazole 9 12 2 268 31.8 64.1 311.7 
Cefotetan 9 15 5 278 27.5 70.0 446.6 
Cefamandole 8 11 3 263 34.3 68.0 269.8 
Ceftriaxone 8 15 5 282 37.3 84.9 403.8 
Ceftizoxime 5 10 4 202 32.9 56.7 299.0 
Cefpodoxime 7 11 4 240     
Cefpiramide 11 15 5 350 43.8 56.1 337.7 
Cefexime 8 12 5 244 30.2 70.4 377.9 
Cefotaxime 8 12 4 253 37.3 74.6 343.9 
Cefmenoxime 8 14 4 260 28.2 67.3 371.0 
Cefoperazone 10 17 4 364 34.9 86.9 352.2 
Latamoxef 
(Moxalactam) 10 15 4 293 23.0 86.3 296.4 
Cefatamet 5 10 4 217 27.9 60.2 290.6 
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moment Energy PSA 
        [cm3/mol] [Debye] KCal/mole A2 
Cefodizime 10 13 5 322 66.4 59.2 419.9 
Cefpimizole 12 16 6  42.0 78.5 396.2 
Cefsulodin 8 12 5  41.1 82.4 333.6 
Ceftazidime 9 13 5  15.7 90.1 346.4 
Cefepime 7 11 4  23.3 78.3 300.1 
Cefpirome 7 11 4  30.9 71.3 301.8 
Ceftobiprole 7 14 6 266 44.2 120.2 428.9 
Tazobactam 3 9 1 156 28.4 71.0 168.6 
Clavulanic acid 3 6 2 120 29.7 56.7 172.6 
Sulbactam 1 6 1 143 36.2 65.1 156.1 
Doripenem 7 10 6 263 33.0 97.4 289.3 
Meropenem 6 8 3 269 33.3 96.6 176.7 
Imipenem 7 7 4 184 42.8 81.9 256.3 
Ertapenem 8 10 5 306 32.3 94.1 279.0 
Biapenem 5 8 2 237 29.2 121.9 167.4 
Aztreonam 7 13 5 237 31.1 60.2 363.3 
Sulbenicillin 7 9 3 328 20.3 56.7 279.0 
Mezlocillin 6 13 3 330 30.0 51.5 192.8 
Azlocillin 5 11 4 297 33.4 41.8 243.3 
Amoxicillin 6 8 5 236 44.5 74.0 255.6 
Ticarcillin 5 8 3 236 22.7 43.0 251.0 
Carbenicillin 5 8 3 246 28.3 55.5 216.2 
Furazlocillin 8 14 4 344 33.3 58.2 235.6 
Ampicillin 5 7 4 239 42.9 63.6 203.1 
Piperacillin 6 12 3 341 28.0 55.3 202.1 
Oxacillin 4 8 2 268 28.8 55.0 177.2 
Temocillin 6 9 3 258 60.5 56.2 250.0 
Nafcillin 5 7 2 290 34.3 56.2 150.2 
Mecillinam 2 6 1 225 31.8 66.5 117.6 
Azidocillin 5 9 2 234 30.9 46.9 202.8 
N 60 60 60 54 59 59 59 
Mean 6.9 10.6 3.6 258.6 36.1 67.6 277.8 
Maximum 12 17 6 364 106 154 447 
Minimum 1 6 1 120 10 36 118 




Table 6.3. Molecular Descriptor Distributions and Correlations for β-LAs (Ordered by Sub-class) 
Descriptive statistics 
 
 N Mean SD 95%CI Minimum 10% 25% Median 75% 90% Maximum 
MW 60 446.8 95.6 422.1-471.5 199 339.8 383 437.5 520 569.4 672 
log (D) at pH 7.4 60 -3.6 1.7 -4.0 to -3.2 -7.3 -5.5 -4.4 -3.7 -2.8 -1.5 2.5 
Molar Volume 54 258.6 48.7 245.3-271.9 120 206 236 259 290 329 3.6 
nRot 60 6.9 2.2 6.4-7.5 1 5 5 7 8 10 12 
H-bond acceptors 60 10.6 2.8 9.9-11.3 6 7 8 10.5 13 14.9 17 
H-Bond donors 60 3.6 1.3 3.3-3.9 1 2 2 4 5 5 6 
PSA 59 277.8 79.4 57.1-298.5 117.6 172.6 209.2 273.8 343.9 396.2 446.6 
Dipole moment 59 36.1 14.2 32.4-39.8 9.6 23.3 28.8 33.3 41.1 44.9 105.9 
Energy 59 67.6 20.9 62.2-73.1 36.4 43.2 55.5 63.6 74.6 94.1 153.7 
Correlation matrix 
 
 MW log (D) 
at  pH 7.4 
log (D) at 
pH 6.3 
% Ionized 














MW 1.0000 -0.2227 -0.2731 0.1933 0.2523 0.8145 0.8795 0.5140 0.8720 0.1297 0.0938 0.6929
log (D) pH 7.4 -0.2227 1.0000 0.9923 -0.1366 -0.2140 -0.4182 -0.3913 -0.2615 -0.0096 -0.2800 -0.0835 -0.4455
log (D) pH 6.3 -0.2731 0.9923 1.0000 -0.0975 -0.2078 -0.4533 -0.4254 -0.2693 -0.0561 -0.3026 -0.0872 -0.4682
% Ionized at pH 
7.4 
0.1933 -0.1366 -0.0975 1.0000 0.8904 0.1366 0.2887 0.0122 0.1386 -0.2524 0.1000 0.2167
% Ionized at pH 
6.3 
0.2523 -0.2140 -0.2078 0.8904 1.0000 0.1618 0.3570 -0.1395 0.1470 -0.1622 -0.0043 0.2196
nRot 0.8145 -0.4182 -0.4533 0.1366 0.1618 1.0000 0.7891 0.6124 0.6350 0.2014 0.2872 0.7856
HBA 0.8795 -0.3913 -0.4254 0.2887 0.3570 0.7891 1.0000 0.5287 0.5979 0.2678 0.1181 0.8037
HBD 0.5140 -0.2615 -0.2693 0.0122 -0.1395 0.6124 0.5287 1.0000 0.3568 0.2346 0.2756 0.6815
Molar Volume 
(cm3/mol) 
0.8720 -0.0096 -0.0561 0.1386 0.1470 0.6350 0.5979 0.3568 1.0000 -0.0235 0.0677 0.3126
Dipole moment 
(Debye) 
0.0938 -0.0835 -0.0872 0.1000 -0.0043 0.2872 0.1181 0.2756 0.0677 -0.0090 1.0000 0.2763
Energy 
(KCal/mol) 
0.1297 -0.2800 -0.3026 -0.2524 -0.1622 0.2014 0.2678 0.2346 -0.0235 1.0000 -0.0090 0.2331
PSA (A2) 0.6929 -0.4455 -0.4682 0.2167 0.2196 0.7856 0.8037 0.6815 0.3126 0.2331 0.2763 1.0000
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In-vivo PK variable 
 
Drug fu  Vdss  CLtot  fe CLren  CLnonren  
  (%) (l/kg) (ml/min/kg) (%) (ml/min/kg) (ml/min/kg) 
Cefatrizine 38 0.22 5.39 80.9 4.36 1.03 
Cefroxadine 94 0.24 3.77 98.0 3.69 0.08 
Cefapirin 38 0.22 9.35 48.5 4.53 4.82 
Ceftezole 31 0.17 3.41 81.0 2.76 0.65 
Cefacetrile 85 0.46 3.87 71.8 2.78 1.09 
Cefazedone   0.14 1.18 84.0 0.99 0.19 
Cefazolin 11 0.12 0.88 85.5 0.75 0.13 
Cefalexin 85 0.18 4.74 80.0 3.79 0.95 
Cefradine 86 0.24 4.46 86.0 3.84 0.62 
Cefalothin 35 0.13 5.83 37.6 2.19 3.64 
Cefaloridine 54 0.31 2.96 77.0 2.28 0.68 
Cefonicid 18 0.16 0.49 67.3 0.33 0.16 
Cefotiam 56 0.27 5.42 53.0 2.87 2.55 
Cefprozil 58 0.22 2.88 71.9 2.07 0.81 
Cefuroxime 55 0.29 3.59 93.9 3.37 0.22 
Ceforanide 19 0.17 1.10 75.8 0.83 0.27 
Cefoxitin 47 0.17 2.28 86.0 1.96 0.32 
Cefmetazole 67 0.15 1.52 86.0 1.31 0.21 
Cefotetan 14 0.15 0.63 83.3 0.52 0.11 
Cefamandole 51 0.19 5.96 41.4 2.47 3.49 
Ceftriaxone 21 0.11 0.28 39.3 0.11 0.17 
Ceftizoxime 69 0.17 2.23 88.0 1.96 0.27 
Cefpodoxime 79 0.36 2.35 81.7 1.92 0.43 
Cefpiramide 3 0.12 0.45 20.0 0.09 0.36 
Cefexime 33 0.22 0.91 45.3 0.41 0.50 
Cefotaxime 60 0.32 5.18 44.0 2.28 2.90 
Cefmenoxime 23 0.23 3.44 74.1 2.55 0.89 
Cefoperazone 10 0.17 1.48 21.6 0.32 1.16 






In-vivo PK variable 
 
Drug fu  Vdss  CLtot  fe CLren  CLnonren  
  (%) (l/kg) (ml/min/kg) (%) (ml/min/kg) (ml/min/kg) 
(Moxalactam) 
Cefatamet 78 0.31 2.09 85.2 1.78 0.31 
Cefodizime 22 0.13 0.86 59.3 0.51 0.35 
Cefpimizole   0.23 1.69 81.1 1.37 0.32 
Cefsulodin 85 0.24 1.93 58.0 1.12 0.81 
Ceftazidime 81 0.19 1.81 85.1 1.54 0.27 
Cefepime 84 0.24 1.64 85.5 1.40 0.24 
Cefpirome 88 0.23 1.80 86.7 1.56 0.24 
Ceftobiprole 83 0.26 1.48 71.7 1.06 0.42 
Tazobactam 79 0.18 5.32 69.0 3.67 1.65 
Clavulanic acid 88 0.16 2.26 41.3 0.93 1.33 
Sulbactam 62 0.25 3.80 75.5 2.87 0.93 
Doripenem 92 0.26 4.70 83.0 3.90 0.80 
Meropenem 92 0.27 5.17 58.7 3.03 2.14 
Imipenem 96 0.46 7.87 53.3 4.19 3.68 
Ertapenem 95 0.12 0.45 38.9 0.18 0.28 
Biapenem 93 0.30 2.90 52.6 1.53 1.37 
Aztreonam 70 0.18 1.45 71.3 1.03 0.42 
Sulbenicillin 30 0.16 3.92 33.9 1.33 2.59 
Mezlocillin 65 0.25 5.24 65.6 3.44 1.80 
Azlocillin 73 0.22 3.15 60.0 1.89 1.26 
Amoxicillin 83 0.33 4.79 56.4 2.70 2.09 
Ticarcillin 34 0.17 1.69 91.5 1.55 0.14 
Carbenicillin 30 0.35 2.82 59.2 1.67 1.15 
Furazlocillin 34 0.15 3.87 26.9 1.04 2.83 
Ampicillin 78 0.19 4.01 72.9 2.92 1.09 
Piperacillin 78 0.39 5.26 75.7 3.98 1.28 
Oxacillin 31 0.16 3.97 46.1 1.83 2.14 
Temocillin 26 0.17 0.59 76.8 0.45 0.14 
Nafcillin 11 0.21 3.33 16.8 0.56 2.77 
Mecillinam 93 0.23 3.50 71.0 2.49 1.02 
Azidocillin   0.24 8.53 48.8 4.16 4.37 
N 57 60 60 60 60 60 






In-vivo PK variable 
 
Drug fu  Vdss  CLtot  fe CLren  CLnonren  
  (%) (l/kg) (ml/min/kg) (%) (ml/min/kg) (ml/min/kg) 
Maximum 96 0.5 9.4 98 4.5 4.8 
Minimum 3 0.1 0.3 17 0.1 0.1 






Table 6.5. Biologically Relevant In-vivo PK variables of β-LAs (Ordered by Sub-class) 
Drug Vdssu  CLtot u CLrenu  CLnonrenu  
  (l/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
Cefatrizine 0.59 14.37 11.63 2.75 
Cefroxadine 0.26 4.02 3.94 0.08 
Cefapirin 0.58 24.61 11.93 12.67 
Ceftezole 0.55 11.00 8.91 2.09 
Cefacetrile 0.54 4.55 3.27 1.28 
Cefazolin 1.14 8.38 7.17 1.22 
Cefalexin 0.21 5.61 4.49 1.12 
Cefradine 0.27 5.17 4.45 0.72 
Cefalothin 0.37 16.66 6.26 10.40 
Cefaloridine 0.57 5.48 4.22 1.26 
Cefonicid 0.91 2.78 1.88 0.91 
Cefotiam 0.49 9.76 5.17 4.59 
Cefprozil 0.38 4.97 3.57 1.40 
Cefuroxime 0.52 6.48 6.09 0.40 
Ceforanide 0.88 5.64 4.28 1.37 
Cefoxitin 0.36 4.83 4.15 0.68 
Cefmetazole 0.22 2.27 1.95 0.32 
Cefotetan 1.11 4.67 3.89 0.78 
Cefamandole 0.38 11.80 4.89 6.91 
Ceftriaxone 0.51 1.36 0.53 0.83 
Ceftizoxime 0.25 3.23 2.84 0.39 
Cefpodoxime 0.46 2.97 2.43 0.54 
Cefpiramide 4.53 16.98 3.40 13.58 
Cefexime 0.65 2.73 1.24 1.50 
Cefotaxime 0.53 8.63 3.80 4.83 
Cefmenoxime 1.00 14.96 11.09 3.87 
Cefoperazone 1.77 15.42 3.33 12.08 
Latamoxef 
(Moxalactam) 0.72 3.17 1.93 1.24 
Cefatamet 0.40 2.68 2.28 0.40 
Cefodizime 0.60 3.98 2.36 1.62 
Cefsulodin 0.28 2.27 1.93 0.95 
Ceftazidime 0.23 2.23 1.89 0.33 
Cefepime 0.29 1.96 1.68 0.28 
Cefpirome 0.26 2.05 1.77 0.27 
Ceftobiprole 0.32 1.79 1.28 0.51 
Tazobactam 0.23 6.78 4.68 2.10 
Clavulanic acid 0.19 2.57 1.06 1.51 
Sulbactam 0.40 6.13 4.63 1.50 
Doripenem 0.28 5.11 4.24 0.87 
Meropenem 0.29 5.62 3.30 2.32 
Imipenem 0.48 8.22 4.38 3.84 
Ertapenem 0.13 0.47 0.18 0.29 
Biapenem 0.32 3.12 1.64 1.48 
Aztreonam 0.26 2.08 1.48 0.60 
Sulbenicillin 0.53 13.07 4.43 8.63 
Mezlocillin 0.38 8.06 5.29 2.77 
Azlocillin 0.30 4.34 2.61 1.74 
Amoxicillin 0.40 5.77 3.25 2.52 
  122
Drug Vdssu  CLtot u CLrenu  CLnonrenu  
  (l/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
Ticarcillin 0.51 5.04 4.62 0.43 
Carbenicillin 1.17 9.40 5.57 3.83 
Furazlocillin 0.44 11.38 3.06 8.32 
Ampicillin 0.25 5.17 3.77 1.40 
Piperacillin 0.50 6.74 5.10 1.64 
Oxacillin 0.52 13.02 6.00 7.02 
Temocillin 0.67 2.31 1.78 0.54 
Nafcillin 1.98 31.42 5.28 26.13 
Mecillinam 0.25 3.78 2.69 1.10 
N 57 57 57 57 
Mean 0.6 7.0 3.9 3.1 
Maximum 4.5 31.4 11.9 26.1 
Minimum 0.1 0.5 0.2 0.1 





Table 6.6. Descriptive Statistics for PK variables  and Correlations of  β-LAs  
Descriptive statistics 
 N Mean SD 95%CI Minimum 10% 25% Median 75% 90% Maximum 
fu 57 0.57 0.28 0.49-0.64 0.03 0.17 0.31 0.60 0.84 0.92 0.96 
Vdss  60 0.22 0.08 0.20-0.24 0.11 0.13 0.17 0.22 0.26 0.33 0.46 
CLtot  60 3.15 2.05 2.62-2.68 0.28 0.65 1.49 2.93 4.64 5.41 9.35 
CLren  60 1.99 1.25 1.67-2.32 0.09 0.41 1.0 1.86 2.87 3.89 4.53 
CLnonren  60 1.16 1.16 0.86-1.46 0.08 0.16 0.27 0.81 1.58 2.89 4.82 
CLtotu  57 7.0 5.86 5.45-8.55 0.47 2.07 2.88 5.17 9.02 15.05 31.42 
CLren u  57 3.95 2.49 3.29-4.61 0.18 1.44 1.94 3.77 4.79 6.44 11.93 
CL nonren u  57 3.07 4.53 1.86-4.27 0.08 0.33 0.64 1.4 3.3 8.99 26.13 


















Vdss  1.0000 0.4117 0.4861 0.2038 0.4767 -0.0784 0.0493 -0.1294 -0.1731 
CLtot  0.4117 1.0000 0.8608 0.8382 0.2809 0.5119 0.6095 0.3324 -0.2543 
CLren  0.4861 0.8608 1.0000 0.4441 0.4553 0.2179 0.5882 -0.0406 -0.3581 
CLnonren  0.2038 0.8382 0.4441 1.0000 0.0071 0.6676 0.4426 0.6285 -0.0643 
fu 0.4767 0.2809 0.4553 0.0071 1.0000 -0.4917 -0.3366 -0.4557 -0.6082 
CLtotu -0.0784 0.5119 0.2179 0.6676 -0.4917 1.0000 0.7020 0.9195 0.4792 
CLrenu 0.0493 0.6095 0.5882 0.4426 -0.3366 0.7020 1.0000 0.3658 0.1249 
CLnonren -0.1294 0.3324 -0.0406 0.6285 -0.4557 0.9195 0.3658 1.0000 0.5570 




6.2.2. QSPKR Analysis, Model Building and Evaluation for β-LAs 
The results of univariate regression between PK variables and molecular descriptors are 
shown in Table 6.7. None of the relationships showed r2 ≥ 0.30 and p < 0.05, and none of the 
relationships met the criteria of r2 ≥ 0.30 to build final log-linear/multiple log-linear model. 
Nevertheless, in-vitro PK variable like fu and in-vivo variables like CLren, CLtot and Vdssu 
were found to have a significant relationship with MW, with MW accounting for 26%, 23% 
and 19% variability, respectively. CLren and CLnonren significantly decreased with MW while 
Vdssu increased with MW. There was no significant relationship between any of the PK 
variables and log (D)7.4. Molecular descriptors like nRot, HBA, MV and PSA showed 
significant relationship with CLren and fu, though they accounted for only 10-20 % variability 
on an average.  
Depending on the structure/mechanism of action, the dataset was classified into 
cephalosporins (1st generation, 2nd generation, 3rd generation, 4th generation and 5th 
generation), carbapenems, beta lactamase inhibitors and penicillins; compounds within each 
class are structural analogs. Hence, the effect of molecular descriptors on PK variables was 
studied by class (Table 6.8-6.13). Univariate analysis showed that molecular descriptors like 
MW, nRot, molar volume, HBA, HBD and PSA accounted for a higher variability (r2 = 30-
90%, p < 0.05) in the PK variables when the entire β-LA dataset was analyzed by class 





Effect of molecular descriptors on PK parameters by class:  
Overall, as the MW increased, fu decreased (Table 6.8). The relationship between fu and MW 
for carbapenems and penicillins was not significant; however, the slopes were negative and 
smaller in magnitude than for cephalosporins. As the MW increased, Vdssu increased for 
cephalosporins, however, for carbapenems, as MW increased, Vdssu decreased. For 
penicillins, the relation between MW and Vdssu showed a positive trend as cephalosporins, 
however, it was not significant. As nRot increased, fu decreased for cephalosporins and 
penicillins, however, carbapenems showed a positive relationship between nRot and fu (Table 
6.9). As nRot increased, Vdssu increased, except for carbapenems, which showed a negative 
slope. For Vdssu and HBA, there was a positive trend observed for the cephalposporins and a 
negative trend for penicillins, beta lactamase inhibitors and carbapenems (Table 6.10). For 
Vdssu and PSA, there was a positive trend observed for the cephalposporins and a negative 
trend for penicillins, beta lactamase inhibitors and carbapenems (Table 6.11). Overall, since 
the number of cephalosporins was more than all the other classes put together, the 
relationships for the complete dataset were dominated by cephalosporins (Table 6.7).  
The effect of molecular descriptors on PK parameters was also studied by charge at pH 





Table 6.7. Univariate Log-linear Regression Between Molecular Descriptors and PK Variables for β-LAs  
Molecular fu log (Vdss) log (CLtot ) log (CLren) log (CLnonren) log (CLtot u) log (CLrenu) log (CLnonrenu) log (Vdss u) 
descriptor  (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (L/kg) 
n = 57 n = 60 n = 60 n = 60 n = 60 n = 57 n = 57 n = 57 n = 57 
r2 = 0.24 r2 = 0.09 r2 = 0.23 r2 = 0.26 r2 = 0.08 r2 = 0.0002 r2 = 0.01 r2 = 0.01 r2 = 0.19 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
-0.002 -0.0005 -0.002 -0.002 -0.001 0.00004 -0.0004 0.0007 0.001 
MW 
(p < 0.05) (N.S.) (p < 0.05) (p < 0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) (p < 0.05) 
n = 57 n = 60 n = 60 n = 60 n = 60 n = 57 n = 57 n = 57 n = 57 
r2 = 0.002 r2 = 0.002 r2 = 0.03 r2 = 0.03 r2 = 0.003 r2 = 0.009 r2 = 0.01 r2 = 0.001 r2 = 0.006 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
0.008 -0.004 0.04 0.04 0.01 0.02 0.02 -0.01 -0.01 
log (D)  
at pH 7.4 
(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
n = 57 n = 60 n = 60 n = 60 n = 60 n = 57 n = 57 n = 57 n = 57 
r2 = 0.007 r2 = 0.002 r2 = 0.04 r2 = 0.04 r2 = 0.005 r2 = 0.01 r2 = 0.02 r2 = 0.002 r2 = 0.01 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
0.01 -0.003 0.04 0.05 0.02 0.02 0.02 -0.01 -0.02 
log (D) at pH 
6.3 
(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
n = 57 n = 60 n = 60 n = 60 n = 60 n = 57 n = 57 n = 57 n = 57 
r2 = 0.21 r2 = 0.15 r2 = 0.06 r2 = 0.08 r2 = 0.01 r2 = 0.01 r2 = 0.0008 r2 = 0.02 r2 = 0.06 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
-0.004 -0.002 -0.002 -0.003 -0.002 0.001 0.0003 0.002 -0.002 
% Ionized at 
pH 7.4 
(p < 0.05) (p < 0.05) (N.S.) (p <0.05) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
n = 57 n = 60 n = 60 n = 60 n = 60 n = 57 n = 57 n = 57 n = 57 
r2 = 0.28 r2 = 0.15 r2 = 0.09 r2 = 0.14 r2 = 0.009 r2 = 0.01 r2 = 0.0007 r2 = 0.04 r2 = 0.09 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
-0.004 -0.001 -0.003 -0.004 -0.001 0.0008 -0.0002 0.002 0.002 
% Ionized at 
pH 6.3 
(p < 0.05) (p < 0.05) (p < 0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) (N.S.) (p < 0.05) 
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Molecular fu log (Vdss) log (CLtot ) log (CLren) log (CLnonren) log (CLtot u) log (CLrenu) log (CLnonrenu) log (Vdss u) 
descriptor  (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (L/kg) 
n = 57 n = 60 n = 60 n = 60 n = 60 n = 57 n = 57 n = 57 n = 57 
r2 = 0.20 r2 = 0.05 r2 = 0.17 r2 = 0.18 r2 = 0.07 r2 = 0.0001 r2 = 0.003 r2 = 0.008 r2 = 0.17 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
-0.06 -0.01 -0.07 -0.08 -0.05 0.005 -0.009 0.02 0.05 
nRot 
(p < 0.05) (N.S.) (p < 0.05) (p < 0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) (p < 0.05) 
n = 57 n = 60 n = 60 n = 60 n = 60 n = 57 n = 57 n = 57 n = 60 
r2 = 0.20 r2 = 0.06 r2 = 0.25 r2 = 0.24 r2 = 0.10 r2 = 0.005 r2 = 0.02 r2 = 0.0003 r2 = 0.16 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
-0.05 -0.01 -0.06 -0.07 -0.05 -0.009 -0.02 -0.003 0.04 
HBA 
(p < 0.05) (N.S.) (p < 0.05) (p < 0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) (p < 0.05) 
n = 57 n = 60 n = 60 n = 60 n = 60 n = 60 n = 57 n = 57 n = 60 
r2 = 
0.000006 
r2 = 0.0004 r2 = 0.12 r2 = 0.07 r2 = 0.10 r2 = 0.09 r2 = 0.09 r2 = 0.06 r2 = 0.0007 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
0.0005 -0.002 -0.09 -0.08 -0.11 -0.08 -0.07 -0.09 0.005 
HBD 
(N.S.) (N.S.) (p < 0.05) (p < 0.05) (p < 0.05) (p < 0.05) (p < 0.05) (N.S.) (N.S.) 
n = 52 n = 54 n = 54 n = 54 n = 54 n = 52 n = 52 n = 52 n = 52 
r2 = 0.19 r2 = 0.06 r2 = 0.07 r2 = 0.17 r2 = 0.0004 r2 = 0.04 r2 = 0.001 r2 = 0.10 r2 = 0.18 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
-0.003 -0.0008 -0.002 -0.003 -0.0002 0.001 -0.0003 0.003 0.001 
Molar volume 
(p < 0.05) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (N.S.) (p < 0.05) (p < 0.05) 
n = 56 n = 59 n = 59 n = 59 n = 59 n = 56 n = 56 n = 56 n = 56 
r2 = 0.16 r2 = 0.06 r2 = 0.30 r2 = 0.21 r2 = 0.19 r2 = 0.04 r2 = 0.04 r2 = 0.02 r2 = 0.09 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
-0.001 -0.0005 -0.002 -0.002 -0.003 -0.0009 -0.0007 -0.0009 0.001 
PSA 
(p < 0.05) (N.S.) (N.S.) (p < 0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) (p < 0.05) 
n = 56 n = 59 n = 59 n = 59 n = 59 n = 56 n = 56 n = 56 n = 59 
r2 = 0.04 r2 = 0.03 r2 = 0.02 r2 = 0.02 r2 = 0.02 r2 = 0.09 r2 = 0.09 r2 = 0.04 r2 = 0.01 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Energy 
0.003 0.001 -0.003 -0.002 -0.003 -0.005 -0.005 -0.005 -0.001 
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Molecular fu log (Vdss) log (CLtot ) log (CLren) log (CLnonren) log (CLtot u) log (CLrenu) log (CLnonrenu) log (Vdss u) 
descriptor  (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) (L/kg) 
(N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (p < 0.05) ( p < 0.05) ( N.S.) (N.S.) 
n = 59 n = 59 n = 59 n = 59 n = 59 n = 56 n = 56 n = 56 n = 56 
r2 = 0.05 r2 = 0.01 r2 = 0.07 r2 = 0.05 r2 = 0.03 r2 = 0.005 r2 = 0.003 r2 = 0.002 r2 = 0.04 
Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
-0.005 -0.001 -0.007 -0.006 -0.006 -0.002 -0.001 -0.002 0.004 
Dipole 
moment 










Table 6.8. Log-linear Regression Between MW and PK Variables by Class of β-LAs  
 
Molecular Class log 
(Vdss) 
log (CLtot ) log (CLren) log 
(CLnonren) 
log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
fu 
(L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
MW 1st generation n = 11 n = 11 n = 11 n = 11 n = 10 n = 10 n = 10 n = 10 n = 10 
    r2 = 
0.29 
r2 = 0.28 r2 = 0.34 r2 = 0.05 r2 = 0.81 r2 = 0.57 r2 = 0.42 r2 = 0.67 r2 = 0.17 
Mean 412.7 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 339-548 -0.001 -0.002 -0.002 -0.002 -0.006 0.004 0.004 0.004 0.005 
Median 415 (N.S.) (N.S.) (N.S.) (N.S.) (p <0.05) (p < 0.05) (p < 0.05) (p < 0.05) (N.S.) 
  2nd generation n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 
    r2 = 
0.17 
r2 = 0.35 r2 = 0.50 r2 = 0.07 r2 = 0.52 r2 = 0.49 r2 = 0.01 r2 = 0.05 r2 = 0.02 
Mean 482.2 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 389-596 -0.0007 -0.004 -0.004 -0.002 -0.002 0.003 -0.0004 -0.0007 0.0009 
Median 472 (N.S.) (N.S.) (p < 0.05) (N.S.) (p <0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) 
  3rd generation n = 14 n = 14 n = 14 n = 14 n = 13 n = 13 n = 13 n = 13 n = 13 
    r2 = 
0.26 
r2 = 0.17 r2 = 0.25 r2 = 0.0008 r2 = 0.44 r2 = 0.35 r2 = 0.15 r2 = 0.00008 r2 = 0.38 
Mean 521.2 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 383-672 -0.0009 -0.002 -0.003 -0.0001 -0.002 0.003 0.002 -0.00003 0.004 
Median 526.5 (N.S.) (N.S.) (N.S.) (N.S.) (p <0.05) (p < 0.05) (N.S.) (N.S.) (p < 0.05) 
  Carbapenems n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 
    r2 = 
0.90 
r2 = 0.63 r2 = 0.49 r2 = 0.88 r2 = 0.05 r2 = 0.89 r2 = 0.62 r2 = 0.49 r2 = 0.87 
Mean 386 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 299-476 -0.003 -0.006 -0.006 -0.006 -0.00006 -0.003 -0.006 -0.006 -0.006 
Median 383 (p < 
0.05) 
(p < 0.05) (N.S.) (p < 0.05) (N.S.) (p < 0.05) (N.S.) (N.S.) (p < 0.05) 
  Penicillins n = 14 n = 14 n = 14 n = 14 n = 13 n = 13 n = 13 n = 13 n = 13 
    r2 = 
0.01 
r2 = 0.02 r2 = 0.006 r2 = 0.06 r2 = 0.03 r2 = 0.0004 r2 = 0.09 r2 = 0.02 r2 = 0.11 
Mean 412.7 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
  130
Molecular Class log 
(Vdss) 
log (CLtot ) log (CLren) log 
(CLnonren) 
log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
fu 
(L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
Range 339-548 -0.0002 0.0005 -0.0003 0.001 -0.0006 0.00006 0.001 0.0002 0.0002 




Table 6.9. Log-linear Regression Between nRot and PK Variables by Class of β-LAs  
 
 
Molecular Class log(Vdss) log (CLtot ) log (CLren) log 
(CLnonren) 
fu log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg)   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
nRot 1st generation n = 11 n = 11 n = 11 n = 11 n = 10 n = 10 n = 10 n = 10 n = 10 
    r2 = 0.07 r2 = 0.008 r2 = 0.002 r2 = 0.06 r2 = 0.51 r2 = 0.37 r2 = 0.64 r2 = 0.75 r2 = 0.30 
Mean 6.6 Slope = Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 5 to 9 -0.04 0.02 -0.01 0.11 -0.17 0.1 0.17 0.14 0.27 
Median 7 (N.S.) (N.S.) (N.S.) (N.S.) (p < 0.05) -0.05 (p < 0.05) (p < 0.05)   
  2rd generation n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 
    r2 = 0.07 r2 = 0.21 r2 = 0.28 r2 = 0.04 r2 = 0.31 r2 = 0.28 r2 = 0.02 r2 = 0.04 r2 = 0.007 
Mean 8.9 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 7 to 11 -0.02 -0.14 -0.15 -0.09 -0.09 0.09 -0.02 -0.03 0.03 
Median 9 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  3rd  generation n = 14 n = 14 n = 14 n = 14 n = 13 n = 13 n = 13 n = 13 n = 13 
    r2 = 0.11 r2 = 0.12 r2 = 0.19 r2 = 0.004 r2 = 0.42 r2 = 0.42 r2 = 0.18 r2 = 0.002 r2 = 0.43 
Mean 8.5 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 5 to 12 -0.03 -0.06 -0.1 0.009 -0.11 0.13 0.08 0.007 0.19 
Median 8 (N.S.) (N.S.) (N.S.) (N.S.) (p < 0.05) (p < 0.05) (N.S.) (N.S.) (p < 0.05) 
  Carbapenems n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 
    r2 = 0.25 r2 = 0.21 r2 = 0.19 r2 = 0.26 r2 = 0.26 r2 = 0.26 r2 = 0.22 r2 = 0.20 r2 = 0.28 
Mean 6.6 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 5 to 8 -0.09 -0.19 -0.22 -0.19 0.008 -0.09 -0.2 -0.23 -0.2 
Median 7 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  Penicillins n = 14 n = 14 n = 14 n = 14 n = 13 n = 13 n = 13 n = 13 n = 13 
    r2 = 0.02 r2 = 0.0001 r2 = 0.05 r2 = 0.02 r2 = 0.10 r2 = 0.03 r2 = 0.05 r2 = 0.0006 r2 = 0.07 
Mean 5.4 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 2 to 8 -0.01 -0.002 -0.05 0.04 -0.06 0.03 0.04 -0.003 0.09 




Table 6.10. Log-linear Regression Between MV and PK Variables by Class of β-LAs  
 
 
Molecular Class log (Vdss) log (CLtot ) log (CLren) log (CLnonren) fu log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg)   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
MV 1st generation n = 10 n = 10 n = 10 n = 10 n = 10 n = 9 n = 10 n = 9 n = 9 
    r2 = 0.09 r2 = 0.004 r2 = 0.02 r2 = 0.0008 r2 = 0.03 r2 = 0.005 r2 = 0.36 r2 = 0.27 r2 = 0.15 
Mean 245.4 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 210-307 -0.002 -0.007 -0.001 0.0006 -0.002 -0.0008 0.008 0.005 0.01 
Median 240 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  2nd generation n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 
    r2 = 0.12 r2 = 0.14 r2 = 0.27 r2 = 0.002 r2 = 0.27 r2 = 0.22 r2 = 0.0004 r2 = 0.05 r2 = 0.13 
Mean 269.9 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 241-292 -0.002 -0.009 -0.01 0.001 -0.006 0.006 -0.0003 -0.002 0.009 
Median 268 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  3rd n = 11 n = 11 n = 11 n = 11 n = 11 n = 11 n = 11 n = 11 n = 11 
  generation r2 = 0.30 r2 = 0.24 r2 = 0.48 r2 = 0.02 r2 = 0.70 r2 = 0.67 r2 = 0.28 r2 = 0.002 r2 = 0.60 
Mean 275.2 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 202-364 -0.002 -0.003 -0.007 0.0009 -0.004 0.005 0.004 0.0003 0.008 
Median 260 (N.S.) (N.S.) (p < 0.05) (N.S.) (p < 
0.05) 
(p < 0.05) (N.S.) (N.S.) (p < 0.05) 
  beta lactamase 
inhibitors 
n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 
    r2 = 0.16 r2 = 0.99 r2 = 0.96 r2 = 0.05 r2 = 0.24 r2 = 0.16 r2 = 0.93 r2 = 0.88 r2 = 0.59 
Mean 139.7 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 120-156 0.002 0.01 0.02 0.002 -0.004 0.004 0.01 0.02 0.004 
Median 143 (N.S.) (p < 0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  Carbapenems n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 
    r2 = 0.87 r2 = 0.57 r2 = 0.47 r2 = 0.72 r2 = 0.14 r2 = 0.86 r2 = 0.56 r2 = 0.46 r2 = 0.71 
Mean 251.8 Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  Slope =  
Range 184-306 -0.004 -0.008 -0.009 -0.008 -0.0002 -0.004 -0.008 -0.009 -0.008 
  133
Molecular Class log (Vdss) log (CLtot ) log (CLren) log (CLnonren) fu log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg)   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
Median 263 (p < 0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (N.S.) 
  Penicillins n = 14 n = 14 n = 14 n = 14 n = 13 n = 13 n = 13 n = 13 n = 13 
    r2 = 0.005 r2 = 0.04 r2 = 0.008 r2 = 0.11 r2 = 0.03 r2 = 0.007 r2 = 0.18 r2 = 0.04 r2 = 0.21 
Mean 276.6 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 225-344 -0.0002 0.001 -0.0006 0.003 -0.001 0.0005 -0.04 0.0008 0.005 





Table 6.11. Log-linear Regression Between HBA and PK Variables by Class of β-LAs  
 
Molecular Class log 
(Vdss) 
log (CLtot ) log (CLren) log (CLnonren) fu log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg)   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
HBA 1st generation n = 11 n = 11 n = 11 n = 11 n = 10 n = 10 n = 10 n = 10 n = 10 
    r2 = 0.15 r2 = 0.19 r2 = 0.19 r2 = 0.05 r2 = 0.51 r2 = 0.55 r2 = 0.17 r2 = 0.40 r2 = 0.04 
Mean 9.1 Slope = Slope = Slope = Slope = Slope = Slope =  Slope = Slope =  Slope = 
Range 7 to 12 -0.04 -0.07 -0.06 -0.07 -0.1 0.08 0.06 0.06 0.06 
Median 9 (N.S.) (N.S.) (N.S.) (N.S.) (p < 0.05 (p < 0.05) (N.S.) (p < 0.05) (N.S.) 
  2nd generation n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 
    r2 = 0.08 r2 = 0.33 r2 = 0.38 r2 = 0.18 r2 = 0.43 r2 = 0.47 r2 = 0.02 r2 = 0.02 r2 = 0.008 
Mean 12 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 8 to 15 -0.01 -0.1 -0.1 -0.11 -0.06 0.07 -0.02 -0.01 -0.02 
Median 12 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (N.S.) 
  3rd generation n = 14 n = 14 n = 14 n = 14 n = 9 n = 13 n = 13 n = 13 n = 13 
    r2 = 0.18 r2 = 0.17 r2 = 0.29 r2 = 0.003 r2 = 0.60 r2 = 0.45 r2 = 0.20 r2 = 0.00005 r2 = 0.45 
Mean 13.2 Slope = Slope = Slope =  Slope = Slope = Slope =  Slope = Slope = Slope =  
Range 10 to 17 -0.03 -0.06 -0.12 0.008 -0.11 0.11 0.08 0.0009 0.17 
Median 13 (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (p < 0.05) 
  Beta 
lactamase 
inhibitors 
n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 
    r2 = 0.07 r2 = 0.64 r2 = 0.41 r2 = 0.62 r2 = 0.03 r2 = 0.07 r2 = 0.34 r2 = 0.26 r2 = 0.99 
Mean 7 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 6 to 9 -0.02 0.09 0.12 0.06 0.01 -0.03 0.08 0.11 0.05 
Median 6 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  Carbapenems n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 
    r2 = 0.65 r2 = 0.42 r2 = 0.28 r2 = 0.83 r2 = 0.08 r2 = 0.64 r2 = 0.41 r2 = 0.27 r2 = 0.82 
Mean 8.6 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 7 to 10 -0.13 -0.23 -0.22 -0.29 -0.004 -0.12 -0.23 -0.23 -0.29 
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Molecular Class log 
(Vdss) 
log (CLtot ) log (CLren) log (CLnonren) fu log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg)   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
Median 8 (N.S.) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (N.S.) (N.S.) (p < 0.05) 
  Penicillins n = 14 n = 14 n = 14 n = 14 n = 13 n = 13 n = 13 n = 13 n = 13 
    r2 = 
0.0008 
r2 = 0.03 r2 = 0.01 r2 = 0.04 r2 = 
0.0007 
r2 = 0.03 r2 = 0.002 r2 = 0.0003 r2 = 0.01 
Mean 9.2 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 6 to 14 0.002 0.02 0.01 0.04 0.003 -0.02 0.005 -0.001 0.02 




Table 6.12. Log-linear Regression Between HBD and PK Variables by Class of β-LAs  
 
Molecular Class log (Vdss) log (CLtot ) log (CLren) log (CLnonren) fu log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg)   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
HBD 1st generation n = 11 n = 11 n = 11 n = 11 n = 10 n = 10 n = 10 n = 10 n = 10 
    r2 = 0.01 r2 = 0.10 r2 = 0.30 r2 = 0.01 r2 = 
0.11 
r2 = 0.16 r2 = 0.02 r2 = 0.01 r2 = 0.11 
Mean 2.9 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 2 to 6 0.02 0.07 0.1 -0.04 0.07 -0.06 -0.02 0.02 -0.14 
Median 2 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  2nd generation n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 0 
    r2 = 0.02 r2 = 0.07 r2 = 0.06 r2 = 0.04 r2 = 
0.34 
r2 = 0.50 r2 = 0.03 r2 = 0.13 r2 = 0.008 
Mean 4 Slope = Slope = Slope = Slope = Slope = Slope =  Slope = Slope = Slope = 
Range 2 to 5 0.01 -0.1 -0.08 -0.1 -0.12 0.16 0.04 0.06 0.04 
Median 4 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (N.S.) 
  3rd generation n = 14 n = 14 n = 14 n = 14 n = 13 n = 13 n = 13 n = 13 n = 13 
    r2 = 0.17 r2 = 0.23 r2 = 0.12 r2 = 0.17 r2 = 
0.03 
r2 = 0.0002 r2 = 0.10 r2 = 0.28 r2 = 0.001 
Mean 4.6 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 4 to 6 -0.1 -0.25 -0.26 -0.2 -0.1 0.009 -0.23 -0.3 -0.04 
Median 4.5 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  Beta lactamase 
inhibitors 
n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 
Mean 1.3 r2 = 0.49 r2 = 0.85 r2 = 0.97 r2 = 0.02 r2 = 
0.59 
r2 = 0.49 r2 = 0.99 r2 = 0.99 r2 = 0.24 
Range 1 to 2 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Median 1 -0.12 -0.3 -0.54 0.03 0.18 -0.2 -0.4 -0.64 -0.07 
    (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  Carbapenems n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 
    r2 = 0.13 r2 = 0.04 r2 = 0.01 r2 = 0.25 r2 = 
0.008 
r2 = 0.13 r2 = 0.04 r2 = 0.01 r2 = 0.25 
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Molecular Class log (Vdss) log (CLtot ) log (CLren) log (CLnonren) fu log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg)   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
Mean 4 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 2 to 6 -0.05 -0.06 -0.04 -0.14 0.001 -0.05 -0.06 -0.04 -0.14 
Median 4 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  Penicillins n = 14 n = 14 n = 14 n = 14 n = 14 n = 13 n = 14 n = 13 n = 13 
    r2 = 0.01 r2 = 0.0006 r2 = 0.003 r2 = 0.001 r2 = 
0.04 
r2 = 0.06 r2 = 0.04 r2 = 0.05 r2 = 0.01 
Mean 3 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 1 to 5 0.01 -0.006 0.01 -0.01 0.06 -0.06 -0.05 -0.03 -0.05 












Table 6.13. Log-linear Regression Between PSA and PK Variables by Class of β-LAs  
 
Molecular Class log (Vdss) log (CLtot ) log (CLren) log 
(CLnonren) 
fu log (Vdss u) log (CLtot u) log (CLrenu) log 
(CLnonrenu) 
descriptor   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg)   (L/kg) (ml/min/kg) (ml/min/kg) (ml/min/kg) 
PSA 1st generation n = 11 n = 11 n = 11 n = 11 n = 11 n = 11 n = 11 n = 10 n = 10 
    r2 = 0.04 r2 = 0.006 r2 = 0.008 r2 = 0.005 r2 = 0.40 r2 = 0.38 r2 = 0.25 r2 = 0.48 r2 = 0.11 
Mean 256.6 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope =  Slope = 
Range 186.7-352.7 -0.0006 -0.0004 -0.0004 0.0007 -0.003 0.002 0.002 0.002 0.003 
Median 239.4 (N.S.) (N.S.) (N.S.) (N.S.) (p < 0.05) (N.S.) (N.S.) (p < 0.05) (N.S.) 
  2nd generation n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 n = 9 
    r2 = 0.16 r2 = 0.54 r2 = 0.61 r2 = 0.25 r2 = 0.65 r2 = 0.66 r2 = 0.06 r2 = 0.06 r2 = 0.008 
Mean 329.4 Slope = Slope =  Slope =  Slope = Slope = Slope =  Slope = Slope = Slope = 
Range 247.1-446.6 -0.0006 -0.004 -0.004 -0.004 -0.002 0.003 -0.0008 -0.0006 -0.0006 
Median 311.7 (N.S.) (p < 0.05) (p < 0.05) (N.S.) (p < 0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) 
  3rd generation n = 13 n = 13 n = 13 n = 13 n = 13 n = 13 n = 13 n = 12 n = 12 
    r2 = 0.24 r2 = 0.14 r2 = 0.11 r2 = 0.01 r2 = 0.28 r2 = 0.02 r2 = 
0.000006 
r2 = 0.04 r2 = 0.06 
Mean 351.4 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 290.6-419.9 -0.002 -0.003 -0.004 -0.0008 -0.004 0.001 0.00002 -0.002 0.003 
Median 346.4 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  Beta lactamase 
Inhibitors 
n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 n = 3 
    r2 = 0.99 r2 = 0.12 r2 = 0.31 r2 = 0.67 r2 = 0.99 r2 = 0.99 r2 = 0.38 r2 = 0.47 r2 = 0.09 
Mean 165.8 Slope = Slope = Slope = Slope = Slope =  Slope =  Slope =  Slope =  Slope =  
Range 156.1-172.6 -0.02 -0.008 -0.02 0.01 0.01 -0.01 -0.02 -0.03 0.003 
Median 168.6 (p < 0.05) (N.S.) (N.S.) (N.S.) (p < 0.05) (p < 0.05) (N.S.) (N.S.) (N.S.) 
  Carbapenems n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 n = 5 
    r2 = 0.09 r2 = 0.07 r2 = 0.04 r2 = 0.21 r2 = 0.15 r2 = 0.09 r2 = 0.07 r2 = 0.04 r2 = 0.22 
Mean 233.7 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 167.4-289.3 -0.001 -0.002 -0.002 -0.003 0.0001 -0.001 -0.002 -0.002 -0.004 
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Median 256.3 (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) (N.S.) 
  Penicillin n = 14 n = 14 n = 14 n = 14 n = 13 n = 13 n = 13 n = 13 n = 13 
    r2 = 0.03 r2 = 0.08 r2 = 0.03 r2 = 0.06 r2 = 0.04 r2 = 0.004 r2 = 0.05 r2 = 0.05 r2 = 0.04 
Mean 212.6 Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = Slope = 
Range 117.6-279 -0.0005 -0.002 -0.001 -0.002 -0.001 -0.0003 -0.001 -0.0008 -0.002 






β-LAs are structurally similar, hydrophilic molecules with molecular weights ranging 
from 300-600 Dalton (except clavulanic acid, which, has a molecular weight of 199). All the 
β-LAs are low clearance drugs with PPB ranging from 4% to 97%. Overall, there was an 
upward trend between MW and PPB. Similar results were obtained from an analysis of 2939 
diverse molecules with in-vitro PPB data in GSK database; as MW increased, PPB 
increased.21 Most of the β-LAs show Vdssu values less than 1.0 L/kg, indicating that they little 
tissue distribution. It was seen that as MW increased, Vdssu increased. This was consistent 
with the results obtained for rat PK data on a large dataset of compounds in the GSK 
database where in distribution increased with increase in MW.21 Literature studies which 
showed that clogP generally lead to an increase in Vdss for acids and neutrals, however, the 
effect was not seen for acids and zwitterions.21, 91, 92 There was a positive relation obtained 
between Vdssu and MV which was consistent with the results obtained for a set of 20 
cephalosporins.73 Majority of the β-LAs are completely ionized at plasma pH 7.4 and urinary 
pH 6.3. They also show higher number of nRot (mean = 6.9), HBAs (mean = 10.6) and 
higher PSA. For the majority of β-LAs, clearance is due to renal excretion, with fe > 50% for 
most of the β-LAs. This observation is consistent with the results obtained for a dataset of 
391 compounds, which showed that higher renal clearances were associated with a high PSA, 
high nRot and high hydrogen bond count.22   
All the β-LAs have CLrenu greater than GFR indicating net tubular secretion (except 
ertapenem and ceftriaxone, which show CLrenu < GFR, indicating that they might undergo net 
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reabsorption). Literature studies show that cephalosporins and penicillins show net secretion, 
and it is has been reported that some cephalosporins interact with hOAT1, hOAT2 and 
hOAT3.22, 93, 94  Jariyawat et al88 showed inhibition of p-aminohippurate transport via rat-
OAT1 by penicllins and cephalosporins. It is generally seen that hydrophobicity and acidity 
are associated with OAT interaction, however, often it is found that high affinity substrates 
are hydrophilic and high hydrogen bonding ability adds to the stability of the substrate –
transporter complex.22, 95 Varma et al22 showed that hydrophilic and ionized compounds with 
hydrogen bonding capacity are secreted because of their ability to interact with renal 
transporters in the proximal tubule and inability to undergo reabsorption. β-LAs are 
hydrophilic compounds with a core β-lactam ring  and anionic group which can interact with 
the renal OATs and hence get secreted.  
Univariate analysis showed that molecular descriptors like MW, nRot, MV, HBA, 
HBD and PSA accounted for a higher variability (r2 = 30-90%, p < 0.05) in the PK 
parameters when the entire β-LA dataset was analyzed by class (cephalosporins, 
carbapenems, beta lactamase inhibitors and penicillins), the most plausible reason being that 
within each class, the drugs are structural analogs and hence, relations with higher r2 values 
were obtained.  Carbapenems were the outliers, which always showed an opposite trend to 
cephalosporins, however, this cannot be mechanistically explained. None of the relationships 
showed r2 ≥ 0.30 and p < 0.05 and the relationships did not meet the criteria of r2 ≥ 0.30 to 
build final log linear/multiple log linear model. The effect of molecular descriptors on Vdssu 
and fu was physiologically interpretable. However, in general, PK parameters were more 
difficult to predict as compared to the PK of the opioids and β-ARLs, most probably due to 
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involvement of specific renal transporters, whose contribution cannot be accounted for by 




CHAPTER 7.  INTERSPECIES SCALING  
 
7. Part II: Interspecies PK Scaling  
7.1. Specific Aims 
• Review the literature to collect pertinent, valid systemic PK properties of opioids, β-
ARLs and β-LAs in different species and estimate relevant PK variables. 
• Compare PK properties of all the three classes across species and assess for differences 
across species. 
• Evaluate if interspecies differences can be explained by different allometric methods. 
• Evaluate different prediction methods to predict human PK properties from animal PK. 
 
7.2. Methods 
7.2.1. Data collection – Animal PK studies 
A comprehensive primary literature review was carried out. For the purposes of this study, 
data were collected without restrictions on gender or strain of dogs or rats. Data were only 
selected from those studies where the compounds were administered by the IV route to 
healthy individuals. Many articles studied hepatic or renal dysfunction population and in 




were used. Other sources of IV PK data were absolute oral bioavailability studies. PK variables 
like CLtot, Vdss, fu were derived from plasma exposure across all species, while variables like fe 
and CLren were obtained from urinary excretion studies, if available. Of all the PK variables 
reported in the studies, the way of reporting varied the most for the volume of distribution. Most 
of the studies reported the terminal phase volume of distribution (Vdβ), central compartment 
volume of distribution (Vdcc) or steady state volume (Vdss). The papers which reported Vdss were 
selected. In some studies, micro-rate constants from compartmental analysis were reported but 
Vdss was not calculated. In such cases, the reported Vdcc and micro-constants (k12, k21) were used 








kVdVd ccss  
This equation assumed two compartment model and k12 is the rate of distribution from 
compartment 1 to compartment 2 and k21 is the rate of redistribution from compartment 2 to 
compartment 1.  
In some cases, where macro-rate constants (α, β) and intercepts A and B from the biexponential 
equation describing the plasma concentration (Cp)-time (t) profile (Cpt = Ae-αt + Be-βt), the 















In a few studies, PK parameters were not calculated, but concentration-time profiles were 
reported. In such cases, the plots were digitally read, and Vdss and CLtot was calculated using 
non-compartmental analysis.33  
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If the studies did not report BW corrected PK parameters, then the parameters were 
corrected for BW using the mean BW of the animals used in the study. In case, the BW was not 
mentioned, the following BWs were used by default34 (Table 7.1): 
 
                     Table 7.1.  Body Weight Across Species 
Species Body weight (kg) 
Rat 0.25 
Dog 10 
Human 70  
 
The in-vitro PK variable fu was obtained from in-vitro PPB studies after careful scrutiny of the 
method and appropriate concentration range. 
 
Estimation of in-vivo PK variables: 
Variables such as Vdssu, CLtotu, CLren, CLrenu were estimated using the following formulae: 
Vdssu = Vdss/fu 
CLtot u = CLtot/fu 
CLren = CLtot *fe 
CLren u = CLren/fu 
Some studies used compartmental analysis, whereas others used non-compartmental analysis and 
the amount of detail describing the conduct of the study varied across the studies. Thus, critical 
evaluation of study design, dosing regimen, sampling schedule, assay procedures and PK 
analysis methods was done before including the information with the analysis. 
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All relevant studies are compiled in Addendum II (A-C). The studies which were ultimately 
included in the analysis marked in the addendum. Using these methods, a total of 22 opioids, 24 
β-ARLs and 27 β-LAs were used. Depending on the amount of information available in the 
literature, number of compounds used in each method varied. 
 
7.2.2.  Descriptive PK across species 
Interspecies comparison: For the compounds in all the three datasets, preliminary in-vivo PK 
variables like CLtot, Vdss, CLren, fe, dose, AUC, in-vitro variable, i.e., fu and their respective 
unbound variables (CLtotu, Vdssu, CLrenu) for each compound were compared across different 
animal species. For each PK variable, the fold range across the species was calculated to 
assess variation across species. Simple linear regression was done between fu (human)-fu (rat) 
and fu (human)-fu (dog); goodness of fit assessed as r2.  
Since most of the opioids and β-ARLs are hepatically cleared, they were classified 
qualitatively as low clearance, intermediate clearance and high clearance in human, rats and 
dog.  For each species, reported CLtot values were compared to liver blood flow (LBF) in that 
particular species (Table 7.2).  The following criteria were used51: 
– low hepatic clearance  




- intermediate hepatic clearance 


















7.2.3. Simple Allometry 
It is the study of body size and its physiological consequences. It is developed based on the 
relationship between organ size, perfusions and body weight, which can be explained by the 
equation: baWY = ,  
where Y is the parameter of interest (e.g. PK parameter like CLtot, Vdss, etc.) and a and b are 
the intercept coefficient and exponent of the allometric equation, respectively. It is known 
that physiological parameters like LBF, kidney blood flow and GFR scale well with body 
weight (Figure 7.1-7.3). 
Simple allometry was used for all available species and only three species (rat and dog), both 
including human. The following equation was used3, 7: 
log (PK variable) = b*log (BW) + log (a) 
Where BW is the body weight (kg), a and b represent the intercept and allometric exponent. 
Goodness of fit was assessed using coefficient of determination (r2). The exponents obtained 
were compared to scaling factors 0.75 and 1.0 for CLtot and Vdss, respectively. 
















Liver blood flow 
(ml/min) 
1.8 13.8 177 218 309 1033 1450 
Liver blood flow 
(ml/min/kg) 












 Figure 7.1 Interspecies scaling of LBF 
 
 


























































Figure 7.3 Interspecies scaling of glomerular filtration rate 
 
7.3.  Prediction Methods 
7.3.1. One-species BW Scaling 
Using PK data from one animal, the following equations were used to predict human PK: 34 
                                     
                                
 
7.3.2. Two-species BW Scaling 
The two-species approach was used to predict human CLtot, Vdss, CLtotu, Vdssu using PK from 
two common animal species by AS. 15 Log-log regression was carried out using two species 
(rat and dog) to estimate the allometric parameters a and b, and the following equation was 














































Log (CLtot or Vdss) = b *log (BW) + log (a) 
 
7.3.3. LBF method  for opioids and β-adrenergic receptor ligands 
Scaling of CLtot and CLtotu from each available species to humans was conducted using CLtot 
values as a percentage of LBF. Assuming that clearance is primarily by hepatic route and that 
B:P is constant across the species, the human clearance was predicted using the following 
equation: 13 
 
Scaling of CLnonren and CLnonrenu from each available species to humans was conducted using 
this method for β-ARLs. 
 
7.3.4. GFR ratio method for β-lactam antibiotics and β-adrenergic receptor ligands 
The GFR values vary considerably among species from 1.7 ml/min/kg in humans to 10 
ml/min/kg in mice. The species differences are mainly attributed to their relative number of 
glomeruli (or nephrons) per kg body weight. The mouse has the largest relative number of 
nephrons and the largest GFR. It is belived that GFR reflects the renal function, thus CLren  in 
humans can be predicted by using the ratio of GFR in animals (rats or dogs) to that in 
humans. 
Scaling of CLren and CLrenu from each available species to humans was performed using 
CLren values as a percentage of GFR. Assuming that clearance is primarily by renal route, 
human clearance was predicted using the following equation: 4 
⎟⎟⎠
⎞











                   
 
7.4.  Statistical Analysis 
The predictive ability of the various allometric methods was assessed using % MPE for bias 
and % RMSE for imprecision.47 The following equations were be used:  
( )∑ ⎟⎠⎞⎜⎝⎛ ×
−= 100%
observed










For visual inspection, log (predicted PK variable) was plotted against log(observed PK 
variable). Goodness of fit was assessed using r2 value. Residual plots were used to evaluate if 
the residuals are homoscedastic. In addition, predictive performance was assessed using the 
number of compounds whose human predicted values were within the pre-selected error 
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CHAPTER 8. INTERSPECIES SCALING OF OPIOIDS 
 
8. Opioids  
8.1. Results 
8.1.1. Comparative pharmacokinetics of opioids across different species 
There were large differences in reported, BW-corrected, CLtot and Vdss values across 
species (range: 1 to 40-fold, 1 to 100-fold, respectively) for opioids (Table 8.1). Only 
unbound drug can diffuse through biological membranes and this may affect the distribution 
of drugs in the body. Opioids are weak bases and they not only bind to albumin but also to 
α1- acid glycoprotein. The albumin concentrations in rats and humans are similar 4, 96 while 
α1- acid glycoprotein concentration is higher in rats as compared to human (Table 8.2). 
Species differences in PPB of opioids were minor (Table 8.3). Figure 8.1 and 8.2 show a 
significant relationship between human fu – rat fu (r2 = 0.93) and human fu – dog fu (r2 = 
0.89). Slopes just below 1.0 indicate slight overall under-prediction (Table 8.4). Small 
changes in fu for highly plasma protein bound drugs may cause large changes in 
concentrations. Thus, PPB was also compared between humans and rats for only highly 
plasma protein bound drugs (fu ≤ 0.20 in humans) and it was found that a significant relation 
existed between human fu-rat fu (r2 = 0.56). For dog, fu information was available for only 




alfentanil and sufentanil), of which alfentanil showed differences in fu between dog and 
human. This finding was consistent even when human fu and rat fu are compared.  
Table 8.5 shows hepatic clearance category for each drug in each species. Hepatic 
clearance in each species was compared with the LBF in that respective species. Morphine 
glucuronides were found to be low clearance in all the species. All opioids (except morphine 
glucuronides) were high clearance in rats and high or intermediate in dogs. Most of the 
opioids, except glucuronides, alfentanil and methadone, were found to be high clearance in 
human. Methadone, a low clearance drug in humans, was found to be high clearance in rat 
and dog. Alfentanil was found to be low clearance in human, high clearance in rat and 
intermediate clearance in dog. All the opioids, except morphine glucuronides, were found to 
be high clearance in rat. Hepatic categorization method assumes that CLtot represents CLhepatic 
and the contribution of CLren is negligible.  Although most of the opioids are high clearance 
drugs, there are some hydrophilic opioids like the morphine glucuronides, which show a 
significant renal contribution towards the CLtot.  In such cases, this assumption may have 







Table 8.1. In-vivo and In-vitro PK Parameters of Opioids in Different Species 
 
In-vivo PK 
Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren 
     (kg) 
 
(mg/kg) (ml/min/kg) (ml/min) 
 
(L/kg)  (L)   (ml/min/kg) 
 
(L/kg)  (%)  (ml/min/kg) 
                
Morphine Rats 0.3 0.0 29.5 8.1 4.9 1.4 0.9 34.4 5.7  4.4 
  Dogs 11.0 0.2 41.1 452.1 4.0 44.1 0.9 46.7 4.6  10.3 
  Human 67.0 0.1 33.6 2251.2 2.1 142.0 0.7 48.0 3.0  2.3 
  Cat 3.7 0.2 24.1 88.0 2.6 9.5 0.9 27.4 3.0    
  Sheep 48.0 0.2 32.9 1579.2   0.8 38.9   4.8 
  Llamas 144.0 0.2 149.3 21505.0 1.1 158.4       
  Horse 496.0 0.1 8.6 4265.6 12.0 5952.0 0.8 10.4 14.5    
  Goat 29.9 0.1 33.9 1013.6 1.2 34.4 0.9 39.4 1.3    
  Mice                       
Mean   100.0 0.1 44.1 3895.3 4.0 906.0 0.8 35.0 5.4  5.5 
SD  166.7 0.1 43.6 7251.3 3.8 2226.0 0.1 12.9 4.7  3.4 
Fold range  1803.6 50.0 17.4 2650.8 10.9 4408.9 1.3 4.6 10.9  4.5 
COV   166.8 49.8 98.8 186.2 95.5 245.7 7.5 36.9 88.5     
                
Remifentanil Rats 0.3 0.03 390.0 126.8 0.4 0.1       
  Dogs 13.0 0.0004 47.9 622.7 0.4 4.7       
  Human 81.1 0.0020 50.6 4103.7 0.3 24.2       
  Swine 26.0 0.010 73.1 1900.6 1.2 30.2           
Mininum  0.3 0.0004 47.9 126.8 0.3 0.1       
Maximum  81.1 0.03 390.0 4103.7 1.2 30.2      
Mean   30.1 0.01 140.4 1688.4 0.5 14.8      
SD  35.6 0.01 166.8 1775.1 0.4 14.6      
Fold range  249.5 69.4 8.1 32.4 3.9 250.1      
COV   118.2 120.5 118.8 105.1 74.9 99.0           
                
Alfentanil Rat 0.3 3.1 37.0 10.2 0.8 0.2 0.16 225.6 4.6    
  Dog 8.6 0.1 18.7 159.9 0.6 5.1 0.27 69.0 2.2    
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In-vivo PK 
Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren 
     (kg) 
 
(mg/kg) (ml/min/kg) (ml/min) 
 
(L/kg)  (L)   (ml/min/kg) 
 
(L/kg)  (%)  (ml/min/kg) 
  Human 59.0 0.1 3.1 182.9 0.2 13.0 0.08 38.8 2.8    
  Rabbit 3.4 0.1 19.4 66.0 0.9 3.1 0.32 60.6 2.8    
  sheep 36.4 0.3 13.3 483.5 0.7 26.2       
  Horse 422.0 0.1 14.1 5950.2 0.3 144.7       
  Cat 5.3 0.1 1.0 5.2 11.6 61.3       
  Mice                       
Mininum  0.3 0.1 1.0 5.2 0.2 0.2 0.1 38.8 2.2   
Maximum  422.0 3.1 37.0 5950.2 11.6 144.7 0.3 225.6 4.6   
Mean  76.4 0.5 15.2 979.7 2.2 36.2 0.2 98.5 3.1    
SD  153.9 1.2 12.0 2197.9 4.2 52.3 0.1 85.7 1.0    
Fold range  1534.5 62.8 38.0 1152.6 52.3 701.8 4.0 5.8 2.1    
COV   201.4 216.8 78.6 224.3 192.5 144.3 51.6 87.0 33.2     
                
Fentanyl Rat 0.3 0.2 42.0 11.6 2.9 0.8 0.17 253.0 17.5    
  Dog 8.9 0.0 47.9 426.3 4.0 36.0 0.22 219.7 18.5  0.7 
  Human 70.0 0.0 13.9 973.0 2.3 158.9 0.16 86.9 14.2    
  Cat 3.9 0.0 19.8 77.8 2.6 10.1       
  Goat 40.4 0.0 2.1 84.4 1.5 61.0       
  Horse 524.0 0.0 5.9 3091.6 0.7 356.3       
  Monkey 11.8 0.0 32.5 381.9 7.0 82.3       
  Pig       0.24      
  Mice                       
Mininum   0.3 0.0 2.1 11.6 0.7 0.8 0.2 86.9 14.2    
Maximum  524.0 0.2 47.9 3091.6 7.0 356.3 0.2 253.0 18.5   
Mean  94.2 0.0 23.4 720.9 3.0 100.8 0.2 186.5 16.7   
SD   191.2 0.1 17.8 1096.0 2.1 124.5 0.0 87.9 2.3    
Fold range   1905.5 60.0 22.9 267.7 10.3 445.3 1.4 2.9 1.3    
COV   203.0 166.4 75.8 152.0 68.7 123.6 20.0 47.1 13.6     
                
Hydromorphone Cat 5.9 0.1 24.6 145.1 3.0 17.4       
  Rabbit 3.0 5.0 21.6 63.7 6.2 18.3       
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In-vivo PK 
Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren 
     (kg) 
 
(mg/kg) (ml/min/kg) (ml/min) 
 
(L/kg)  (L)   (ml/min/kg) 
 
(L/kg)  (%)  (ml/min/kg) 
  Human 72.7 0.0 22.8 1657.6 4.1 294.4           
Mininum   3.0 0.0 21.6 63.7 3.0 17.4       
Maximum  72.7 5.0 24.6 1657.6 6.2 294.4      
Mean  27.2 1.7 23.0 622.1 4.4 110.1      
SD   39.4 2.8 1.5 897.6 1.6 159.7       
Fold range   24.6 125.0 1.1 26.0 2.1 16.9       
COV   145.1 166.7 6.6 144.3 37.5 145.1           
                
Meperidine Rat 0.2 8.7 253.0 50.6 10.1 2.0       
  Dog 10.5 5.0 42.6 448.1 1.9 20.2       
  Human 77.5 0.3 7.7 593.7 4.4 343.3       
  Pig 22.4 4.4 36.1 806.8         
  Mice                       
Mininum   0.2 0.3 7.7 50.6 1.9 2.0           
Maximum   77.5 8.7 253.0 806.8 10.1 343.3       
Mean   27.6 4.6 84.8 474.8 5.5 121.8       
SD   34.4 3.5 113.1 318.9 4.2 192.0       
Fold range   387.5 31.1 33.0 15.9 5.3 170.0       
COV   124.6 75.3 133.4 67.2 76.4 157.6           
                
Methadone Rat 0.3 0.3 62.4 17.2         
  Dog 10.2 1.4 25.1 255.2 3.5 35.1    3.6% 1.6 
  Human 67.8 0.3 2.7 183.1 6.1 413.6       
  Mice             
Minimum   0.3 0.3 2.7 17.2 3.5 35.1           
Maximum  67.8 1.4 62.4 255.2 6.1 413.6       
Mean  26.1 0.6 30.1 151.8 4.8 224.3       
SD   36.5 0.6 30.2 122.0 1.9 267.6       
Fold range     23.1 14.9 1.8 11.8       
COV   139.9 94.4 100.2 80.4 39.1 119.3           
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In-vivo PK 
Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren 
     (kg) 
 
(mg/kg) (ml/min/kg) (ml/min) 
 
(L/kg)  (L)   (ml/min/kg) 
 
(L/kg)  (%)  (ml/min/kg) 
Tramadol Rat 0.3 20.0 62.5 15.6 4.2 1.1     2.5 
  Dog 9.5 3.9 54.6 519.0 3.0 28.6       
  Human 80.6 0.5 7.4 595.6 2.9 237.0       
  Rabbit 3.5 10.0 4.1 14.4 1.4 4.9       
  Cat  3.3 2.0 13.7 44.6 1.9 6.1       
  Horse 445.0 2.5 10.9 4846.1 0.6 280.4           
Minimum  0.3 0.5 4.1 14.4 0.6 1.1       
Maximum  445.0 20.0 62.5 4846.1 4.2 280.4      
Mean  90.3 6.5 25.5 1005.9 2.3 93.0      
SD  176.4 7.4 25.9 1899.5 1.3 129.4      
Fold range  1780.0 37.0 15.1 337.7 6.7 267.0      
COV   195.3 113.9 101.4 188.8 54.8 139.2           
                
Dextropopoxyphene Rat 0.3 0.0 61.4 18.7 10.5 3.2       
  Dog 20.5 1.8 19.9 408.0 4.7 96.4 0.1      
  Human 71.6 0.9 13.4 959.4 12.8 915.0       
Minimum   0.3 0.0 13.4 18.7 4.7 3.2           
Maximum  71.6 1.8 61.4 959.4 12.8 915.0      
Mean  30.8 0.9 31.6 462.0 9.3 338.2      
SD   36.7 0.9 26.0 472.7 4.2 501.7       
Fold range   234.8 216.9 4.6 51.2 2.7 286.8       
COV   119.3 98.9 82.5 102.3 44.7 148.4           
                
Nalbuphine Rat 0.3 10.0 129.0 35.5 6.4 1.8       
  Dog 10.5 1.0 46.0 483.0         
  Human 73.5 0.1 21.6 1587.6 3.7 274.2       
  Rabbit 3.1 9.1 46.6 144.5 4.3 13.4       
Minimum   0.3 0.1 21.6 35.5 3.7 1.8           
Maximum  73.5 10.0 129.0 1587.6 6.4 274.2      
Mean  21.8 5.1 60.8 562.6 4.8 96.4      
SD  34.7 5.2 46.9 709.4 1.4 154.0       
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In-vivo PK 
Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren 
     (kg) 
 
(mg/kg) (ml/min/kg) (ml/min) 
 
(L/kg)  (L)   (ml/min/kg) 
 
(L/kg)  (%)  (ml/min/kg) 
Fold range  267.3 71.4 6.0 44.8 1.7 156.0       
COV   158.9 103.0 77.2 126.1 29.0 159.7           
                
Butorphanol Rat 0.3 10.0 76.0 20.9 4.1 1.1       
  Dog 23.0 0.1 137.9 3171.0 27.6 634.3       
  Llama 103.0 0.1 50.0 5150.0 0.8 84.7       
  Cow 314.0 0.3 34.6 10864.4 3.1 979.7       
  Horse 450.0 0.1 21.0 9450.0 1.0 463.5       
  Human 76.3 0.0 28.7 2186.1 8.3 629.8       
Minimum   0.3 0.0 21.0 20.9 0.8 1.1           
Maximum  450.0 10.0 137.9 10864.4 27.6 979.7       
Mean  161.1 1.8 58.0 5140.4 7.5 465.5       
SD  180.2 4.0 43.7 4246.2 10.2 368.9       
Fold range  1636.4 555.6 6.6 519.8 33.6 860.5       
COV  111.9 230.1 75.3 82.6 136.2 79.3       
                          
Buprenorphine Dog 22.1 0.7 16.8 371.3 0.5 11.5    0.35% 16.80 
  Rat 0.2 1.0 45.0 8.6 8.4 1.6       
  Human 67.7 0.0 18.8 1272.8 2.8 189.6       
  cat 3.7 0.0 16.1 58.8 7.1 25.9       
  mice 0.03 2.4 2.0 0.1 6.5 0.2           
Minimum  0.03 0.00 1.97 0.05 0.52 0.18      
Maximum  67.7 2.4 45.0 1272.8 8.4 189.6      
Mean  18.7 0.8 19.7 342.3 5.1 45.7      
SD  28.9 1.0 15.6 542.1 3.3 81.0      
Fold range  2461.8 600.0 22.9 23505.4 16.1 1060.5       
COV   154.0 119.0 79.2 158.4 64.8 177.2           
                
Pentazocine Rat 0.2 2.5 71.1 13.5 14.1 2.7       
  Dog 13.1 0.3 4.0 52.8 0.6 7.2       
  Monkey 4.3 0.5 48.2 207.3 7.3 31.4       
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In-vivo PK 
Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren 
     (kg) 
 
(mg/kg) (ml/min/kg) (ml/min) 
 
(L/kg)  (L)   (ml/min/kg) 
 
(L/kg)  (%)  (ml/min/kg) 
  Human 71.0 0.4 19.4 1377.4 1.4 100.8       
  Rabbit 3.2  40.6 128.0   0.4    4.2 
  Horse 450.0 1.0 28.7 12915.0 3.9 1732.5 0.2      
Minimum   0.2 0.3 4.0 13.5 0.6 2.7           
Maximum  450.0 2.5 71.1 12915.0 14.1 1732.5       
Mean  90.3 1.0 35.3 2449.0 5.4 374.9       
SD  178.2 0.9 23.5 5153.1 5.5 759.9       
Fold range  2368.4 8.3 17.6 956.0 25.6 646.7       
COV   197.4 94.9 66.4 210.4 101.1 202.7           
                
Dezocine Dog 12.1 1.0 65.8 796.2 8.4 101.6    0.6% 0.006 
  Monkey 7.7 1.0 54.8 422.0 7.6 58.5    2.1% 0.02 
  Human 91.4 5.0 29.6 2704.0 5.8 529.8       
Minimum   7.7 1.0 29.6 422.0 5.8 58.5           
Maximum  91.4 5.0 65.8 2704.0 8.4 529.8       
Mean  37.1 2.3 50.1 1307.4 7.3 230.0       
SD  47.1 2.3 18.6 1223.9 1.3 260.6       
Fold range  11.9 5.0 2.2 6.4 1.4 9.1       
COV   127.1 99.0 37.1 93.6 18.3 113.3           
                
Naltrexone Dog 10.0 5.0 98.8 987.5 10.3 103.2 0.7 133.8 14.0 7.1% 3.6 
  Monkey 5.4 10.0 65.7 351.5   0.8 83.5   1.5 
  Human 70.0 0.0 47.8 3346.0 2.6 184.8 0.8 59.8 3.3    
  Goat 46.0 4.0 816.0 37536.0 258.0 11868.0       
Minimum   5.4 0.0 47.8 351.5 2.6 103.2 0.7 59.8 3.3     
Maximum  70.0 10.0 816.0 37536.0 258.0 11868.0 0.8 133.8 14.0    
Mean  32.8 4.8 257.1 10555.2 90.3 4052.0 0.8 92.3 8.6    
SD  30.7 4.1 373.2 18033.2 145.3 6769.0 0.0 37.8 7.6    
Fold range  13.1 769.2 17.1 106.8 97.7 115.0 1.1 2.2 4.2    
COV   93.6 86.4 145.2 170.8 160.8 167.1 4.2 41.0 87.4     
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In-vivo PK 
Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren 
     (kg) 
 
(mg/kg) (ml/min/kg) (ml/min) 
 
(L/kg)  (L)   (ml/min/kg) 
 
(L/kg)  (%)  (ml/min/kg) 
Naloxone Rat  0.3 4.5 103.0 28.3 6.6 1.8 0.3 321.9 20.6    
  Dog  10.0 5.0 69.5 694.6 5.9 59.1 0.7 99.2 8.4 4.40% 2.0 
  Human 63.8 0.4 28.4 1811.9 2.4 153.1 0.5 52.6 4.4    
Minimum   0.3 0.4 28.4 28.3 2.4 1.8 0.3 52.6 4.4     
Maximum  63.8 5.0 103.0 1811.9 6.6 153.1 0.7 321.9 20.6    
Mean  24.7 3.3 67.0 844.9 5.0 71.3 0.5 157.9 11.2    
SD  34.2 2.6 37.4 901.3 2.3 76.4 0.2 143.9 8.4    
Fold range  232.0 13.9 3.6 64.0 2.8 84.4 2.2 6.1 4.6    
COV  138.6 77.5 55.8 106.7 45.3 107.1 36.7 91.1 75.4    





Table 8.2. Physiological Parameters in Various Species 
 
  Mouse Rat Rabbit Monkey Dog Human 
Plasma albumin (µM) 495 479 586 747 398 633 
Plasma α-acid glycoprotein (µM) 313 453 33 60 93 45 
CYP1A (pmol/gm)   2897    3798 
CYP2C (pmol/gm)   63897    5598 
CYP3A (pmol/gm)   16597    8798 
 









        
M3G 0.85 0.92 0.98 
M6G 0.89 0.85   
Morphine 0.70 0.86 0.88 
Oxycodone 0.58 0.74   
Codeine 0.92 0.92 0.90 
Heroin 0.70   0.60 
Meperidine 0.27 0.57   
Methadone 0.10 0.17   
Alfentanil 0.08 0.16 0.27 
Fentanyl 0.16 0.17 0.22 
Sufentanil 0.07 0.07 0.07 
Buprenorphine 0.04 0.07   
Dextropropoxyphene 0.24       0.13 
Naltrexone 0.80 0.80 0.74 
Nalmefene       
Naloxone 0.54 0.62 0.70 
Mean 0.48 0.53 0.55 
 







  Regression 
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Table 8.5. Hepatic Clearance Categorization 
 








M3G 12.1 Low 3.37  Low  2.3 Low  
M6G 13.3 Low    1.8 Low 
Hydromorphone     21.4 High  
Morphine 29.5 High 41.1 High  33.6 High  
Oxycodone 81.6 High    10.9 Intermediate 
Codeine 103.3 High    10.8 Intermediate  
Tramadol 62.5 High 54.6 High  7.4 Intermediate 
Nalbuphine 129.0 High  46.0 High  21.6 High  
Heroin   214.5 High  198.5 High  
Remifentanil 390.0 High 47.9 High 50.6 High  
Butorphanol 76.0 High 137.9 High  28.7 High  
Meperidine 253.0 High  42.6 High  11.5 Intermediate  
Methadone 62.4 High  25.1 High  2.7 Low  
Pentazocine 71.1 High  4.0  19.4 High  
Alfentanil 37.0 High  18.7 Intermediate 3.1 Low  
Fentanyl 42.0 High  47.9 High  13.9 Intermediate  
Sufentanil 77.0 High    12.7 Intermediate 
Buprenorphine 45.0 High 16.8 Intermediate 18.8 High 
Dezocine   65.8 High  29.6 High 
Dextropropoxyphene 61.4 High 19.9 Intermediate 13.4 Intermediate  
Naltrexone     98.8 High  25.0 High  
Nalmefene   67.0 High  16.0 High 












8.1.2. Simple Allometry 
For a set of 18 opioids, simple allometry was conducted using all available species and using 
only three species, both including human. Table 8.6 shows the allometric coefficients for 
CLtot and Vdss for 18 opioids. Allometric plots are shown in the Appendix III (a). The 
exponents obtained were compared with a scaling factor 0.75 for CLtot and 1.0 for Vdss. 
Figure 8.3-8.4 shows interspecies scaling plots for a prototypical opioid like morphine. For 
CLtot, allometric coefficients for meperidine and remifentanil were found to be very low for n 
=3 as well as for n = all available animals (Figure 8.5 and 8.6). Hence, they were excluded 
from allometric scaling. Butorphanol was suspected to undergo extra-hepatic metabolism and 
was excluded as well. Methadone showed a very low allometric coefficient with no obvious 
explanation. 
 For Vdss, allometric coefficients for morphine glucuronides were found to be low (< 
0.8). For some opioids like alfentanil, low allometric coefficients were obtained for Vdss. 
However, when Vdss was corrected for PPB, the allometric coefficient increased. For opioids 
like fentanyl, morphine and butorphanol, allometric coefficient increased above 1.0 when 
Vdss was corrected for PPB.  
For the remaining opioids, CLtot (mean slope: 0.79, 0.47-1.31) and Vdss (mean slope: 
0.90, 0.64-1.14) scaled well with BW, regardless of the number of species. For some opioids, 
like alfentanil and fentanyl, fu correction improved allometric scaling and both these drugs 





Table 8.6. Allometric PK Scaling of Opioids 
 
 
Note: For CLtot and CLtotu, 0.6 > allometric exponents > 1.2 are highlighted 









Drug (ml/min) n r2 Slope ± SE (L) n r2 Slope ± SE 
Morphine-3-
glucuronide 
CLtot 3 0.9970 0.69 ± 0.04 Vdss  3 0.9259 0.64± 0.18 
  4 0.9986 0.70 ± 0.02  4 0.9592 0.79 ± 0.12 
Morphine-6-
glucuronide 
CLtot  3 0.9893 0.73 ± 0.07 Vdss  3 0.9964 0.82 ± 0.05 
Morphine CLtot  3 0.9977 1.03 ± 0.05 Vdss  3 0.9800 1.11 ± 0.16 
  8 0.8977 0.99 ± 0.14  7 0.9305 1.14 ± 0.14 
 CLtotu  3 0.9997 1.06 ± 0.02 Vdssu  3 0.9879 1.14 ± 0.13 
  7 0.9531 0.91 ± 0.09  6 0.9612 1.23 ± 0.12 
Remifentanil CLtot  3 0.9432 0.60 ± 0.15 Vdss  3 0.9994 0.97 ± 0.02 
  4 0.9443 0.61 ± 0.11  4 0.9426 1.04 ± 0.18 
Alfentanil CLtot  3 0.8991 0.57 ± 0.19 Vdss  3 0.9789 0.79 ± 0.12 
  7 0.7360 0.87 ± 0.23  7 0.7143 0.78 ± 0.22 
 CLtotu  3 0.9996 0.67 ±0.01 Vdssu  3 0.9904 0.89 ± 0.09 
  4 0.9769 0.68 ± 0.07  4 0.9897 0.89 ± 0.06 
Fentanyl CLtot 3 0.9565 0.84 ± 0.18 Vdss  3 0.9785 0.98 ± 0.09 
  7 0.7761 0.69 ± 0.17  7 0.9138 0.82 ± 0.11 
 CLtotu  3 0.9796 1.92 ± 0.28 Vdssu  3 0.9982 2.24 ±  0.09 
Hydromorphone CLtot  3 0.9982 1.01 ± 0.04 Vdss 3 0.9535 0.94 ± 0.21 
Meperidine CLtot  3 0.9475 0.43 ± 0.10 Vdss  3 0.9400 0.82 ± 0.21 
  4 0.9054 0.47 ± 0.11     
Methadone CLtot  3 0.8034 0.47 ± 0.23     
Tramadol CLtot 3 0.8879 0.67 ± 0.24 Vdss  3 0.9995 0.94 ± 0.02 
  6 0.8285 0.81 ± 0.18  6 0.9476 0.83 ± 0.10 
Dextropropoxyphene CLtot  3 0.9998 0.72 ± 0.01 Vdss 3 0.9657 0.98 ± 0.18 
Nalbuphine CLtot  3 0.9985 0.69 ± 0.03 Vdss  3 0.9987 0.91 ± 0.03 
  4 0.9910 0.69 ± 0.05     
CLtot  3 0.8175 0.99 ± 0.47 Vdss  3 0.8845 1.30 ± 0.47 Butorphanol 
CLtot  6 0.8383 0.83 ± 0.18 Vdss  6 0.6504 0.83 ± 0.30 
Buprenorphine CLtot 3 0.9967 0.83 ± 0.05 Vdss  3 0.8097 0.69 ± 0.33 
  5 0.9134 1.20 ± 0.21  5 0.8861 0.77 ± 0.16 
Pentazocine CLtot 3 0.7902 0.69 ± 0.40 Vdss  3 0.7704 0.54 ± 0.30 
  6 0.8574 0.84 ± 0.17  5 0.8085 0.77 ± 0.22 
Dezocine CLtot  3 0.9712 0.71 ± 0.12 Vdss  3 0.9950 0.87 ± 0.06 
CLtot 3 0.9434 0.82 ± 0.20 Vdss  3 0.1737 1.05 ± 2.30 
 4 0.6296 1.30 ± 0.71     
Naltrexone 
CLtotu 3 0.9251 0.80 ± 0.23     


















































Figure 8.4. Interspecies Allometric Scaling of Vdss for Morphine 
 










































































8.1.3. Prediction of PK of opioids 
8.1.3.1. One-species BW Scaling 
8.1.3.1.1. One-species BW Scaling from rat PK 
Table 8.7 shows the observed human PK parameters and predicted human PK 
parameters from rat PK. Table 8.8-8.9 and Figure 8.7-8.10 show that CLtot and 
CLtotu were predicted more accurately and precisely when drugs undergoing extra-
hepatic metabolism were excluded as indicated by their %MPE and %RMSE. In 
contrast, Vdss and Vdssu are predicted more accurately and precisely when drugs 
undergoing extra-hepatic metabolism were not excluded, indicating that extra-
hepatic metabolism does not affect distribution and the higher accuracy and 
precision is obtained due to higher number of drugs. PPB correction for both, Vdss 
and CLtot, increased r2 value indicating improvement in the goodness of fit. CLtotu 
and Vdssu were predicted accurately and precisely as compared to the CLtot and 
Vdss (Table 8.8 and 8.9). In terms of no. of compounds in the 0.5- 2 fold error 
range, only 1 out 15 opioids (7 %) showed predicted CLtot in 0.5-2 fold error 
range, while 2 out of 11 opioids (18%) showed predicted CLtotu in 0.5-2 fold error 
range. Out of 14, 7 opioids (50 %) showed predicted Vdss in 0.5-2 fold error 
range. Out of 10, 5 opioids (50%) showed Vdssu in 0.5-2 fold error range. Overall, 
there was over-prediction of total as well as unbound CLtot and Vdss. fu-correction 




Table 8.7. One species scaling from rat PK 

















Vdssu % Prediction error 
  [ml/min] [L] [ml/min] [L] [ml/min] [L] [ml/min] [L] CLtot Vdss CLtotu Vdssu 
            [ml/min] [L] [ml/min] [L] 
M3G 162 20 190 24 847 118 921 128 424% 487% 384% 443% 
M6G 134 9 150 10 931 32 1095 37 597% 256% 630% 273% 
Morphine 2251 142 3216 203 2065 95 2401 110 -8% -33% -25% -46% 
Oxycodone 763 182 1316 314 5712 196 7688 264 649% 8% 484% -16% 
Codeine 859 175 933 190 7231 245 7860 266 742% 140% 742% 40% 
Tramadol 595 237 744 296 4375 294    635% 24%   
Remifentanil 4104 24   27300 26    565% 7%   
Nalbuphine 1588 274   9030 447    469% 63%   
Butorphanol 2186 630   5320 290    143% -54%   
Meperidine 594 343 2199 1272 17710 707 31070 1240 2883% 106% 1313% -2% 
Methadone 183 414 1831 4136 4368  25694   2286%  1304%  
Pentazocine 1377 100 3532 257 4977 987    261% 884%   
Alfentanil 183 13 2286 163 2590 53 16188 328 1316% 303% 608% 101% 
Fentanyl 973 159 6081 993 2940 204 17294 1198 202% 28% 184% 21% 
Sufentanil 900 124 12859 1767 5390 387 78116 5610 499% 213% 507% 217% 
Buprenorphine 1272 190 31804 4740 3150 586 45000 8370 148% 209% 41% 77% 
Dextropropoxyphene 959 895 3998 3728 4298 732     348% -18%   





















   Prediction errors 




















4.20 (± 1.25) 0.41 1/18 
(6 %) 
 Vdss 17 166 (± 57%) 281 
 
0.55 (± 0.28) 0.21 8/17 
(47 %) 
 CLtotu 12 535 







 Vdssu 11 106 








   Prediction errors Regression  





%RMSE Slope (±SE) r2 
No. of 
compounds 












0.17 1/15  
(7 %) 
 Vdss 14 198(± 176%) 206 
 
0.62 (± 0.32) 0.23 7/14 
(50 %) 
 CLtotu 11 464 







 Vdssu 10 117 
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8.1.3.1.2. One-species BW Scaling from dog PK 
Table 8.10 shows the observed human PK parameters and predicted human PK 
parameters from dog PK. Table 8.12-8.13 and Figure 8.11-8.14 show that CLtotu 
was predicted more accurately and precisely than CLtot as indicated by %MPE 
and %RMSE. For both CLtot and Vdss, PPB correction with exclusion of drugs 
undergoing extrahepatic metabolism resulted in more number of compounds in 
the acceptable 0.5-2.0 fold error range.  
In terms of no. of compounds in the 0.5- 2 fold error range, only 4 out 14 
opioids (29 %) showed predicted CLtot in 0.5-2 fold error range, while 6 out of 7 
opioids (86 %) showed predicted CLtotu in 0.5-2 fold error range. Out of 12, 6 
opioids (50 %) showed predicted Vdss in 0.5-2 fold error range. Out of 7, 5 
opioids (71 %) showed Vdssu in 0.5-2 fold error range. Overall, there was an over-












Table 8.10. One Species Scaling using Dog PK 
Drug Observed Predicted  
  
Human 














Vdssu % Prediction error 
  [ml/min] [L] [ml/min] [L] [ml/min] [L] [ml/min] [L] CLtot Vdss CLtotu Vdssu 
                  [ml/min] [L] [ml/min] [L] 
M3G 162 20 190 24 236 15 241 15 46% -24% 26% -34% 
M6G 134 9 150 10          
Morphine 2251 142 3216 203 2877 281 3269 319 28% 98% 2% 57% 
Tramadol 595 237 744 296 3824 211   543% -11%   
Heroin 13697 70 19567 100 15015 683 25025 1138 10% 876% 28% 1038% 
Remifentanil 4104 24   3353 25.2   -18% 4%   
Nalbuphine 1588 274   3220    103%    
Butorphanol 2186 630   9651 1931    207%   
Meperidine 594 343 2199 1272 2978.5 134.4   402% -61%   
Methadone 183 414 1831 4136 1757 242   860% -41%   
Pentazocine 1377 100 3532 257 282 39   -80% -61%   
Alfentanil 183 13 2286 163 1309 42 4848 156 616% 222% 112% -5% 
Fentanyl 973 159 6081 993 3353 282 15241 1283 245% 78% 151% 29% 
Sufentanil 900 124 12859 1767          
Buprenorphine 1272 190 31804 4740 1176 35   -8% -82%   
Dezocine 2704 530   4606 588   70% 11%   
Dextropropoxyphene 959 895 3998 3728 4298 732 33062 5632 348% -18% 727% 51% 
Naltrexone 3500 185 4375 231 6913 722 9341 976 98% 291% 114% 323% 
Nalmefene 1248 640   4690    276%    
Naloxone 1812 153 3355 284 4862 414 6946 591 168% 170% 107% 108% 
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   Prediction errors 
   Bias Imprecision 
Regression 
Method Parameter n %MPE 
(±SE) 











CLtot 17 218 
(± 63 %) 
334 
 
0.96 (± 0.16) 0.69 6/17 
(35 %) 




1.17 (± 0.42) 0.36 7/16 
(44 %) 
 CLtotu 8 158 
(± 83 %) 
271 
 
1.09 (± 0.64) 0.32 3/8 
(38 %) 
 Vdssu 8 196 







   Prediction errors 
   Bias Imprecision 
Regression 
Method Parameter n %MPE 
(±SE) 










CLtot 14 237 (± 72 %) 352 
 
1.33 (± 0.42) 0.45 4/14 
(29 %) 
 Vdss 12 52 (± 35 %) 126 
 
0.72 (± 0.24) 0.47 6/12 
(50 %) 
 CLtotu 7 177 (± 94 %) 290 
 
3.28 (± 2.28) 0.29 6/7 
(86 %) 
 Vdssu 7 76 (± 45 %) 133 
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8.1.3.2. Two-species BW Scaling 
Table 8.13 and 8.14 shows the observed human PK parameters and predicted human 
PK parameters from two species, rat and dog, for CLtot and Vdss.  Table 8.15-8.16 and 
Figure 8.15-8.16 show that CLtot and Vdss were predicted more accurately and 
precisely when drugs undergoing extra-hepatic metabolism were excluded as 
indicated by their %MPE and %RMSE.   
In terms of no. of compounds in the 0.5-2 fold error range, only 5 out 11 opioids 
(45%) showed predicted CLtot in 0.5-2 fold error range, while 1 out of 9 opioids (11 
%) showed predicted Vdss in 0.5-2 fold error range. PPB for opioids was found to be 
fairly constant across opioids with exception of alfentanil (Table 8.3). PPB correction 
for CLtot and Vdss resulted in very high % prediction errors (Table 8.17). Rat and dog 
CLtotu and Vdssu differed to a great extent with rat showing lower CLtotu and Vdssu.  
Highly species dependent tissue binding and extra-hepatic metabolism in tissues may 




Table 8.14. Prediction of CLtot 
 










Morphine 8.1 452.1 1.5 1.08 3398 2251 
Remifentanil 126.8 622.7 2.3 0.43 1288 4104 
Alfentanil 10.2 159.9 1.4 0.81 870 183 
Fentanyl 11.5 426.3 1.6 1.04 3625 973 
Butorphanol 22.8 3171.7 2.1 1.41 46554 2186 
Meperidine 50.6 448.1 2.1 0.55 1273 594 
Methadone 17.2 255.2 1.6 0.75 1081 183 
Pentazocine 13.5 52.8 1.4 0.32 91 1377 
Tramadol 15.7 518.9 1.8 0.96 3551 595 
Dextropropoxyphene 18.7 407.9 1.6 0.73 999 959 
Nalbuphine 35.5 483 1.9 0.72 1882 1588 
Buprenorphine 8.6 371.3 1.5 0.83 1145 1272 
Naloxone 28.3 694.6 1.9 0.89 3928 1812 
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Table 8.15. Prediction of Vdss 
 




Morphine 0.4 44.1 0.3 1.29 485.5 142.0 
Alfentanil 0.2 5.1 -0.2 0.93 36.3 13.0 
Fentanyl 0.8 35.9 0.5 1.09 342.8 158.9 
Remifentanil 0.1 4.7 -0.4 0.99 24.8 24.3 
Meperidine 2.0 20.2 0.7 0.58 60.9 343.3 
Tramadol 1.0 28.6 0.6 0.91 175.5 237.0 
Buprenorphine 1.6 11.1 0.5 0.41 17.8 189.6 
Naloxone 1.8 59.1 0.8 0.97 389.7 153.1 
M3G 0.5 2.4 -0.07 0.43 5.2 20.0 
Butorphanol 1.2 634.8 0.9 1.72 13119.4 630.0 
Pentazocine 2.7 7.2 0.6 0.23 10.6 100.3 
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   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds in 
0.5-2 fold error 
range 
Method Parameter n %MPE 
(±SE) 




CLtot 14 270 (± 145) 590 2.90 
(± 3.13) 
0.07 5/14  
(36 %) 




   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds 
in 0.5-2 fold 
error range 
Method Parameter n %MPE 
(±SE) 
%RMSE Slope r2  
Two species  
approach 












Table 8.18. Prediction of CLtotu and Vdssu using Two-species Method 
 
  Human Rat Dog Prediction of CLtotu Prediction of  Vdssu 











(ml/min)   
M3G 190 24 4.0 0.6 37.8 2.4 61737 32342% 39 65% 
Morphine 3216 203 9.5 0.4 513.8 50.1 3809 18% 546 169% 
Alfentanil 2286 163 62.0 1.3 590.0 18.8 2358 3% 97 -40% 
Fentanyl 6081 993 69.6 4.8 1727.8 297.2 2290174038 37659494% 137869065 13882248% 





8.1.3.3. LBF method   
Table 8.18 and 8.19 show the observed human PK parameters and predicted human 
PK parameters from rat and dog PK, respectively. Table 8.20-8.21 and Figure 8.17 
and 8.18 shows that LBF method using dog PK data predicted CLtot accurately and 
precisely. When the drugs undergoing extra-hepatic metabolism were excluded, 
prediction errors decreased for predictions using rat PK. In terms of no. of 
compounds predicted in the 0.5- 2 fold error range, from rat PK, only 5 out 15 opioids 
(33 %) showed predicted CLtot in 0.5-2 fold error range, while from dog PK, 7 out of 
14 opioids (50%) showed predicted CLtot in 0.5-2 fold error range.  
Table 8.22-8.24 and Figure 8.19-8.20 indicate that when CLtot was corrected for 
PPB, lower %MPE and %RMSE were obtained for predictions from both rat and dog 
PK. PPB correction for CLtot increased r2 value indicating improvement in the 
goodness of fit. In terms of no. of compounds predicted in the 0.5- 2 fold error range, 
from rat PK, only 3 out of 11 opioids (27 %) showed predicted CLtotu  in 0.5-2 fold 
error range, while from dog PK, 7 out of 8 opioids (88 %) showed predicted CLtotu in 
































































































LBF (ml/min/kg) 21 50   
M3G 2.3 12.1 5.1 
M6G 1.8 13.3 5.6 
Morphine 33.6 29.5 12.4 
Oxycodone 10.9 81.6 34.3 
Codeine 10.8 103.3 43.4 
Tramadol 7.4 62.5 26.3 
Nalbuphine 21.6 129.0 54.2 
Remifentanil 50.6 390.0 163.8 
Meperidine 11.5 253.0 106.3 
Butorphanol 28.7 76.0 31.9 
Methadone 2.7 62.4 26.2 
Pentazocine 19.4 71.1 29.9 
Alfentanil 3.1 37.0 15.5 
Fentanyl 13.9 42.0 17.6 
Sufentanil 12.7 77.0 32.3 
Buprenorphine 18.8 45.0 18.9 
Propoxyphene 13.4 61.4 25.8 
Naloxone 28.4 103.0 43.3 
Line of  identity Line with slope = 0.5 Line with slope = 2.0
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LBF (ml/min/kg) 21 30       
M3G 2.3 3.37 2.4 0.04 1.9% 
Morphine 33.6 41.1 28.8 -4.83 -14.4% 
Tramadol 7.4 54.6 38.2 30.85 417.5% 
Nalbuphine 21.6 46.0 32.2 10.60 49.1% 
Heroin 198.5 214.5 150.2 -48.35 -24.4% 
Remifentanil 50.6 47.9 33.5 -17.07 -33.7% 
Butorphanol 28.7 137.9 96.5 67.81 236.3% 
Meperidine 11.5 42.6 29.8 18.32 159.7% 
Methadone 2.7 25.1 17.6 14.87 550.7% 
Pentazocine 19.4 4.0 2.8 -16.58 -85.5% 
Alfentanil 3.1 18.7 13.1 9.99 322.3% 
Fentanyl 13.9 47.9 33.5 19.63 141.2% 
Buprenorphine 18.8 16.8 11.8 -7.04 -37.4% 
Dezocine 29.6 65.8 46.1 16.46 55.6% 
Dextropropoxyphene 13.4 19.9 13.9 0.53 4.0% 
Naltrexone 25.0 98.8 69.1 44.13 176.5% 
Nalmefene 16.0 67.0 46.9 30.90 193.1% 
Naloxone 28.4 69.5 48.6 20.22 71.2% 
Line with slope = 2.0 Line with slope = 0.5 Line of  identity
  186























   Prediction errors 
   Bias Imprecision 
Regression 
Method Parameter n %MPE 
(±SE) 






















   Prediction errors 
   Bias Imprecision 





Method Parameter n %MPE 
(±SE) 




































































Human CLtotu from rat 
[ml/min/kg] 
 
% Prediction error 
LBF (ml/min/kg) 21 50   
M3G 2.7 13.2 5.5 102.9% 
M6G 2.0 15.6 6.6 224.9% 
Morphine 48.0 34.3 14.4 -70.0% 
Oxycodone 18.8 109.8 46.1 145.4% 
Codeine 11.7 139.0 58.4 397.4% 
Methadone 27.0 367.1 154.2 471.0% 
Alfentanil 38.8 231.3 97.1 150.6% 
Fentanyl 86.9 247.1 103.8 19.4% 
Sufentanil 180.9 1115.9 468.7 159.2% 
Buprenorphine 470.0 642.9 270.0 -42.6% 
Naloxone 52.6 166.1 69.8 32.7% 
Line with slope = 2.0 Line with slope = 0.5 Line of  identity
  188
 
























































































LBF (ml/min/kg) 21 30   
M3G 2.7 3.4 2.4 -11.6% 
Morphine 48.0 46.7 32.7 -31.9% 
Heroin 283.6 357.5 250.3 1.4% 
Alfentanil 38.8 69.3 48.5 25.1% 
Fentanyl 86.9 217.7 152.4 75.4% 
Dextropropoxyphene 55.8 153.1 107.2 91.9% 
Naltrexone 31.3 133.4 93.4 198.9% 
Naloxone 52.6 99.2 69.5 32.1% 



































   Prediction errors 
   Bias Imprecision 
Regression 
Method Parameter n %MPE 
(±SE) 
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Excluding 
heroin 












   Prediction errors Regression 




In the 0.5-2 
fold error 
range 
Parameter n %MPE %RMSE Slope r2 
One species 
approach 























Two species  
approach 





(from rat data) 






7/14 (50 %) CLtot 14 122  (± 50) 217 0.99 
(± 0.47) 
0.28 






2/11 (18 %) CLtotu 11 464 































6/7 (86 %) CLtotu 7 
 
















   Prediction errors Regression  




In the 0.5-2 
fold error 
range 














6/12 (50%) Vdss 12 52 (± 35 %) 126 
 




1/9 (11%) Vdss  9 38 (± 44) 131 0.17 
(± 0.26) 
0.06 






5/10 (50 %) Vdssu 10 117 












5/7 (71 %) Vdssu 7 76 (± 45 %) 133 
 






8.1.4.  Discussion 
There were large differences in reported, BW-corrected, CLtot and Vdss values across species 
(range: 1 to 40-fold, 1 to 100-fold, respectively) for opioids. A significant relationship 
between human fu - rat fu (r2 = 0.93) and human fu - dog fu (r2 = 0.89) was found. Sawada et 
al99 compared PPB for nine weakly acidic and six weakly basic drugs and a significant 
relation was obtained between fu – human and fu – rat (n = 14, Slope = 1.17, r2= 0.92). 
Sawada et al100 reported plasma protein binding values for  10 basic drugs in  different 
species and found that the interspecies differences in distribution maybe attributed to the 
differences in fu. Hepatic clearance categorization of opioids showed that there were 
interspecies differences in metabolism of opioids. All the opioids were high clearance in rats, 
while some were intermediate and high in humans and dogs. Bjorkman et al101 compared 
CLtot with hepatic blood flow for fentanyl and alfentanil and it was found that fentanyl was 
high extraction ratio drug is all species except human while alfentanil was high extraction 
ratio in rats while it was medium-to-low extraction in larger animals and human. Most of the 
opioids are metabolized by CYP450 (mainly CYP3A and CYP2C isoforms) and UGTs. 
Some opioids like remifentanil, heroin and meperidine are esters and are known/suspected to 
undergo extra-hepatic metabolism by nonspecific esterases in blood and tissues. De Wazier 
et al97 found that hepatic enzyme levels of CYP1A, CYP2C and CYP3A  in rats were 
approximately 28, 638 and 165 pmol/gm microsomal protein while Guengerich et al98 
reported corresponding values for humans as 37, 55, 87 pmol/gm of microsomal protein 
(Table 8.2). Similarly, Clarke et al102 found that there were interspecies differences in UGT 
activities in rat and humans. Soars et al103 looked at in-vitro glucuronidation of a range of 
  193
structurally diverse chemicals in hepatic and renal microsomes from human and dogs and 
found that gluronidation was several fold more rapid in dog liver microsomes than human 
liver microsomes. In-addition, they found regioselective differences in morphine 
glucuronidation. Quon et al104 found that blood esmolol esterase activity is higher in rats and 
dogs as compared to humans. Sawada et al99 compared unbound intrinsic clearance in rat and 
human for nine weakly acidic and six weakly acidic drugs and found that these drugs are 
metabolized ten times more rapidly in rat than in human. Overall, in addition to species 
differences in amino acid sequences and substrate specificity, different enzyme activities may 
result in differences in clearance category.   
 Remifentanil and meperidine are esters and are known/suspected to undergo extra-hepatic 
metabolism. For CLtot, their allometric coefficients were found to be very low for n =3 as 
well as for n = all available animals. Butorphanol was suspected to undergo extra-hepatic 
metabolism and is excluded as well. Hence, these drugs were excluded from AS. It was 
found in a study carried out on 36 marketed oral drugs that for drugs like nitrendipine 
(metabolized extrahepatically by esterases) and granisetron (metabolized extrahepatically by 
CYP1A1), predicted clearance from hepatic metabolism unserestimated the total clearance.30 
Thus, this shows the importance of a priori knowledge of metabolic routes. Bjorkman et al101  
used body weight, brain weight and MLP method to predict CLtot and CLtotu and body weight 
to scale Vdss and Vdssu in humans for five anaesthetic drugs: fentanyl, alfentanil, 
methoxitone, thiopentone and ketamine. Scaling to body weight gave an allometric exponent 
of 0.89 (r2 = 0.982) and 0.76 (r2 = 0.971) for fentanyl and alfentanil, respectively. Prediction 
of CLtotu was not accurate by any of the methods used. Predictions of Vdss of alfentanil by AS 
was successful (within ± 30 % of the true value), however, Vdssu invariably failed to give 
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accurate predictions in humans. Sawada et al100 found a significant correlation between 
human and animal Vdss (r = 0.748, p < 0.001) and the relation improved when human and 
animal Vt/fut  were compared (r = 0.944, p < 0.001) for ten weak basic drugs indicating that 
there is little difference in the tissue distribution of these drugs. Sawada et al99 studied nine 
weakly acidic and six weakly basic drugs across different species and found that interspecies 
differences in metabolic clearance and Vdss maybe attributed to differences in fu. In the 
present research on opioids, in general, Vdss was scaled well with body weight, however, 
there were some exceptions like morphine glucuronides, for which, allometric coefficients 
were found to be low. This maybe because morphine glucuronides are polar in nature and 
this limits their distribution. For the remaining opioids, CLtot (mean slope: 0.79, 0.47-1.31) 
and Vdss (mean slope: 0.90, 0.64-1.14) scaled well with body weight, regardless of the 
number of species. For some opioids, fu correction improved AS.  
  Table 8.25 and 8.26 shows the summary for the prediction of PK variables. Table 8.27 
gives the best prediction methods for total and unbound PK parameters. For CLtot prediction, 
LBF method from dog was found to be the best method. This finding was consistent with 
prediction of human PK for 103-compound dataset of structurally diverse compounds; it was 
found that allometric scaling approaches using two species were less successful at predicting 
CLtot than LBF method in an individual species.13 In the past, scaling from monkey LBF 
method was proven to the accurate methodology when 124 compound dataset of structurally 
diverse compounds was studied.45 In general, fu correction for CLtot and Vdss increased r2 
value indicating improvement in the goodness of fit, resulted in more accurate and precise 
predictions as indicated by lower %MPE and % RMSE and resulted in more number of 
compounds in the 0.5-2.0 fold error range. Feng et al55 predicted human systemic CLtot using 
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unbound concentrations for eight Parke Davis compounds and 26 literature drugs. These all 
drugs were small molecules eliminated hepatically, renally and with mixed functions. It was 
found that in general, human CLtotu was predicted more accurately with the average fold error 
reduced from 2.8 to 2.2. For drugs with significant variation in PPB across species, the fold 
error decreased from 3.3-15.8 to 0.99-2.0, and overestimation only occurred for drugs which 
were mainly eliminated by metabolism. All the methods used for the prediction of opioids in 
this research showed an overall overprediction as indicated by the positive % MPEs. A 
qualitative analysis of 102 compounds (57 metabolized by liver - 29 low clearance, 17 
intermediate clearance, 11 high clearance and 33 excreted by kidneys and 11 elminated by 
renal as well as by metabolism)  by Tang et al52 revealed the application of two potential 
rules for predicting the occurrence of large vertical allometry/overprediction in prediction of 
systemic CLtot,  ratio of unbound fraction of drug in plasma (fu) between rats and humans 
greater than 5; and clogP greater than 2. It was concluded that metabolic elimination could 
also serve as an additional indicator for expecting large vertical allometry. With the 
exception of fu ratio criteria, opioids followed these rules; since most of them were 
eliminated by liver and showed clogP more than 2.0. 
         In terms of number of compounds predicted in 0.5-2.0 fold error range, LBF method 
using dog data was the best prediction method for CLtot and CLtotu. For Vdss, one species-rat 
and one species-dog, both, predicted 50% compounds fall in 0.5-2.0 fold error range. For 
Vdssu, one-species-dog predicted 71% compounds predicted in 0.5-2.0 fold error range. 
Overall, the rat, dog, rat-dog methods provided reasonable predictions. Thus, use of three or 
more species may not be necessary. Similar conclusion was made by by Tang et al5 when 
one- or two- species based methods were used to predict human CLtot from rat, dog and 
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monkey in a 26-Wyeth compound test dataset using a 102-compound training dataset. The 
authors compared their newly deviced data driven one – and two- species approach for 
prediction CLtot with LBF method and allometrically based rule of exponents (ROE). It was 
found that the rat, dog, monkey, rat-dog, and rat-monkey methods provided improved 
predictions relative to the ROE for 17 of 26, 14 of 21, 5 of 9, 14 of 21 and 7 of 9 compounds, 
respectively. Hosea et al56 conducted a retrospective analysis using 50 proprietary 
compounds for which oral single dose human PK data was available. It was found that use of 
single species lead to more accurate pedictions than using multiple species and use of 
unbound conentrations resulted in accurate predictions.  Feng et al55 carried out a direct 
CLtotu correlation between single animal species and human for 37 diverse set of compounds 
and found a good correlation between human-monkey (n = 16, r2= 0.93) and human-rat (n= 
37, r2 = 0.89), with monkey and rat predicting 75 % and 63 % compounds in 0.5-2 fold error 
range, respectively. Data were found to be more scattered for dog and rabbit data. Based on 
this, they suggested that rat and and monkey should be considered first for preclinical studies 
while dog should be the third species of selection.  In contrast to this finding, Tang et al36 
used Monte Carlo simulations for different combinations of species to select the “best” or 
optimal combination of species and found that the predicted values were heavily dependent 
on certain species like dog, whereas, parameter values from rat made no contribution to the 
predicted human values, as long as the rat was not the smallest species used.  
          In this research, for most of the opioids, only rat and dog PK data was available. 
Overall, dog was found to be the species giving best prediction of clearance as well as 
volume of distribution. Acceptable predictions were obtained after interspecies scaling using 
single-species methods; however, overall, there was a positive bias. This suggests non-rodent 
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species in preclinical PK may be useful and for most opioids, body size accounts for most of 
the observed variability in systemic PK 
 
 






















PK variable Method n %MPE %RMSE 
Vdss Dog -BW 12 52 126 
Vdssu Dog-BW 7 76 133 
CLtot Dog-LBF 14 122 217 




CHAPTER 9. INTERSPECIES SCALING OF β- ARLS 
 
9. β-adrenergic receptor ligands  (β- ARL) 
9.1. Results 
9.1.1. Comparative pharmacokinetics of β-adrenergic receptor ligands  across 
different species 
There were large differences in reported, BW-corrected, CLtot and Vdss values across species 
(range: 6 to 80-fold, 3 to 50-fold, respectively) (Table 9.1). A significant relationship 
between human fu – rat fu (n = 10, r2 = 0.74) and human fu – dog fu (n = 4, r2 = 0.97) was 
found (Figure 9.1-9.2 and Table 9.2-9.3). Amongst all the β-ARL, propranolol and 
oxprenolol showed major species differences in the fu.  
Table 9.4 shows hepatic clearance categorization for each drug in each species. 
Xamoterol, sotalol, atenolol and bisoprolol were found to be low clearance in dog and 
human. All the β-ARLs (except timolol and landiolol) were found to be high clearance in rats 
and this finding was similar to our finding for interspecies scaling of opioids. In this method, 
CLtot is compared to the liver blood flow in each species. Many of the β-ARLs are high 
clearance drugs, however, some hydrophilic β-ARL like xamoterol, sotalol are mainly 
excreted by kidneys. This method assumes that CLtot represents CLhepatic and the contribution 
of CLren is negligible. This assumption might lead to some misclassification of the 




Table 9.1. In-vivo and in-vitro PK parameters of β-ARLs in Different Species 
 
Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren CLren 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L)   (ml/min/kg)  (L/kg)  (%) 
 
(ml/min/kg)  (ml/min) 
Xamoterol Dog 14.9 1 4.5 66.9 3.2 46.9          
  Human 75 0.19 3.0 224.3 0.6 48.0 97% 3.1 0.66 61.6% 1.8 138.0 
Timolol Rat 0.275 0.2 6.5 1.8 2.2 0.6          
  Human 54 0.067 9.2 497.9 1.7 91.8 40% 22.9 4.22 26.4% 2.5 132.8 
Carteolol Rat 0.275 30 16.0 4.4 4.8 1.3 97% 16.6 4.97     
  Human 62 0.21 10.1 628.1 4.9 306.7 85% 12.0 5.85 65.0% 6.6 406.7 
Propranolol Rat 0.47 1 54.0 25.2 2.7 1.3 11% 490.9 24.9 0.02% 0.01 0.005 
  Dog 10 0.6 50.3 503.0 6.6 65.7 15% 330.9 43.2 4.8% 2.4 24.1 
  Rabbit 4 1 85.5 342.1 8.7 34.7 36% 237.6 24.1     
  Monkey           0.8%        
  Horse 533 0.2 22.9 12179.1 3.0 1625.1          
  Human 66.5 0.15 13.6 904.4 2.9 194.2 8% 181.3 0.04 0.35% 0.0 3.2 
Minimum   0.47 0.15 13.60 25.22 2.7 1.28 0.8% 181.33 0.04 0.02% 0.01 0.0 
Maximum   533 1.00 86 12179 8.7 1625 36.0% 491 43 4.8% 2.4 24 
Mean   123 0.59 45 2791 4.8 384 14.1% 310 23 1.7% 0.8 9 
SD   231 0.41 28 5258 2.7 698 0.13 135 18 0.03 1.4 13 
Fold range   1141 7 6 483 3 1270 45 3 984 259 241 5161 
COV   188 70 63 188 56 182 95 44 77 155 167 144 
Sotalol Rat 0.36 5 22.5 8.0 2.5 0.9 95.0% 23.6 2.7 74.6% 16.7 6.0 
  Dog 11.8 3 4.5 53.6 1.6 18.5 99.0% 4.6 1.6 72.0% 4.21 49.7 
  Human 69.5 1 2.2 150.1 1.2 84.1 99.0% 2.2 1.2 77.3% 1.67 116.1 
Minimum   0.4 1.0 2.2 8.0 1.2 0.9 95.0% 2.2 1.2 72.0% 1.7 6.0 
Maximum   69.5 5.0 22.5 150.1 2.5 84.1 99.0% 23.6 2.7 77.3% 16.7 116.1 
Mean   27.2 3.0 9.7 70.6 1.8 34.5 97.7% 10.1 1.8 74.6% 7.5 57.2 
SD   37.1 2.0 11.1 72.6 0.7 43.8 0.02 11.8 0.7 0.03 8.1 55.4 
Fold range   195 5 10 19 2 93 1 11 2 1 10 19 
COV   136 67 114 103 39 127 2 116 41 4 107 97 
Atenolol Rat 0.5 2 33.4 16.8 2.7 1.3 99.0% 33.7  66.7% 23.4 11.8 
  Dog 15.5 12.9 4.3 66.3 1.4 21.0      83.3% 3.6 55.3 
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Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren CLren 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L)   (ml/min/kg)  (L/kg)  (%) 
 
(ml/min/kg)  (ml/min) 
  Cat 2.9 2 4.3 12.5 1.1 3.1          
  Rabbit 1.9 2.5 7.7 14.6 3.4 6.5 68.0%        
  Human 74.1 0.70 2.4 178.6 1.1 77.8 97.2% 2.48 1.1 94.10% 2.3 168.2 
Minimum   0.5 0.7 2.4 12.5 1.1 1.3 68.0% 2.5 1.1 66.7% 2.3 11.8 
Maximum   74.1 12.9 33.4 178.6 3.4 77.8 99.0% 33.7 1.1 94.1% 23.4 168.2 
Mean   19.0 4.0 10.4 57.8 1.9 22.0 88.1% 18.1 1.1 81.4% 9.7 78.4 
SD   31.4 5.0 13.0 71.2 1.1 32.2 0.17 22.1  0.14 11.8 80.7 
Fold range   147 18 14 14 3 58 1 14 1 1 10 14 
COV   165 125 125 123 56 147 20 122 0 17 122 103 
Metoprolol Rat 0.27 5 73.4 19.8 2.1 0.6 91.6% 80.1 2.3     
  Dog 12 0.4 35.8 429.8 4.7 56.8      5.7% 2.0 24.5 
  Cat 3.25 2.6 108.3 351.8 8.3 27.0          
  Rabbit 2.75 3.2 62.0 170.5 2.8 7.6 68.0% 91.2 4.1 1.0% 0.7 1.8 
  Human 74 0.27 10.8 799.9 3.2 236.8 91.8% 11.8 3.5 14.5% 1.6 116.0 
Minimum   0.27 0.27 10.81 19.82 2.13 0.58 68.0% 11.78 2.33 1.0% 0.65 1.79 
Maximum   74 5 108.3 799.9 8.3 236.8 91.8% 91.2 4.1 14.5% 2.0 116.0 
Mean   18.5 2.3 58.1 354.4 4.2 65.8 83.8% 61.0 3.3 7.1% 1.4 47.4 
SD   31.4 2.0 37.1 295.8 2.5 98.1 0.14 43.0 0.9 0.07 0.7 60.5 
Fold range   274 19 10 40 4 412 1 8 2 14 3 65 
COV   170 87 64 83 58 149 16 70 27 96 50 127 
Amosulalol Mice 0.02 10 178.3 3.6 19.8 0.4      16.6% 29.6 0.6 
  Rat 0.205 1 56.7 11.6 10.7 2.2      17.1% 9.7 2.0 
  Dog 12 1 33.3 399.6 5.5 66.0      13.4% 4.5 53.5 
  Monkey 4.65 1 10.0 46.5 1.2 5.6      14.8% 1.5 6.9 
  Human 62.1 0.16 2.2 134.8 0.4 24.8       34.1% 0.7 46.0 
Minimum   0.02 0.16 2.17 3.57 0.40 0.40      13.4% 0.74 0.59 
Maximum   62.1 10 178.33 399.6 19.79 66      34.1% 29.6 53.5 
Mean   15.8 2.6 56.1 119.2 7.5 19.8      19.2% 9.2 21.8 
SD   26.3 4.1 71.6 165.1 8.0 27.6      0.08 11.9 25.8 
Fold range   3105 63 82 112 49 167      3 40 90 
COV   167 157 128 139 106 139       44 130 118 
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Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren CLren 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L)   (ml/min/kg)  (L/kg)  (%) 
 
(ml/min/kg)  (ml/min) 
Nafetolol Dog 11 0.5 30.4 334.0 4.0 44.4      5.0% 1.5 16.5 
  Human 58.5 0.02 19.6 1146.6 2.8 166.1       14.0% 2.7 160.5 
Acebutolol Rat 0.25 10 60.2 15.1 5.8 1.5 90.8% 66.3 6.4 25.2% 15.2 3.8 
  Human 70 1 6.8 478.1 1.2 81.6 74.3% 9.2 1.6 40.5% 2.8 193.6 
Pafenolol Rat 0.25   42.0 10.3 8.0 2.0      50.0% 21.0 5.1 
  Human 73.50 0.07 4.3 317.5 1.0 72.0      55.6% 2.4 176.5 
Bisoprolol Rat 0.25 1.8 50.7 12.7 2.4 0.6 85.5% 59.3 2.8 30.0% 15.2 60.8 
  Dog 10.4 1 7.0 72.8 2.5 26.0 69.7% 10.0 3.6 32.0% 2.2 23.3 
  Monkey 4.5 1 11.1 49.7 3.2 14.4 74.5% 14.8 4.3     
  Human 70 0.14 3.7 259.7 2.7 190.4 70.5% 5.3 3.9 62.5% 2.3 162.3 
Minimum   0.3 0.1 3.7 12.7 2.4 0.6 69.7% 5.3 2.8 30.0% 2.2 23.3 
Maximum   70 1.8 50.7 259.7 3.2 190.4 85.5% 59.3 4.3 62.5% 15.2 162.3 
Mean   21.3 1.0 18.1 98.7 2.7 57.8 75.1% 22.4 3.6 41.5% 6.6 82.1 
SD   32.7 0.7 21.9 110.1 0.4 89.0 0.07 24.9 0.6 0.18 7.5 71.9 
Fold range   280 13 14 20 1 323 1 11 2 2 7 7 
COV   154 69 121 112 13 154 10 112 18 44 113 88 
Pindolol Rat 0.225 3 48.5 10.9 2.1 0.5 52.8% 91.9 3.9     
  Human 65 0.08 7.4 483.0 2.1 136.5 42.8% 17.4 4.9 38.9% 2.9 187.9 
Celiprolol Dog 10 5 46.2 462.0 7.0 70.1          
  Human 69 0.14 4.6 314.0 7.7 530.6       50.7% 2.30 159.0 
Labetalol Sheep 74.9 1.34 29.0 2172.1 6.9 517.6      1.6% 0.47 35.0 
  Human 76.5 1.2 23.2 1774.8 9.9 757.4 50.0% 46.4 19.8     
Carvedilol Rat 0.23 1 114.8 26.4 8.26 1.9          
   Dog 10 0.16 26.3 262.7 2.6 25.9          
  Human 70 0.07 7.6 532.0 2.2 152.6      12.7% 0.81 56.4 
Minimum   0.2 0.1 7.6 26.4 2.2 1.9          
Maximum   70.0 1.0 114.8 532.0 8.3 152.6          
Mean   26.7 0.4 49.6 273.7 4.3 60.1          
SD   37.8 0.5 57.3 253.0 3.4 81.0          
Fold range   304 14 15 20 4 80          
COV   141 125 116 92 78 135          
Landiolol Rat 0.25 1 9.3 2.3 0.5 0.1 96.3% 9.7 0.5 2.4% 1.98 0.5 
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Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren CLren 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L)   (ml/min/kg)  (L/kg)  (%) 
 
(ml/min/kg)  (ml/min) 
  Dog 10 3 82.5 825.0 0.4 3.7 82.0% 100.6 0.5 5.9% 0.48 4.8 
  Human 65 0.03 37.3 2424.5 0.2 10.7 95.7% 39.0 0.2 7.9% 2.93 190.5 
Minimum   0.25 0.03 9.30 2.33 0.16 0.11 82.0% 9.66 0.17 2.4% 0.48 0.50 
Maximum   65 3 82.5 2424.5 0.5 10.7 96.3% 100.6 0.5 7.9% 2.9 190.5 
Mean   25.1 1.3 43.0 1083.9 0.3 4.8 91.3% 49.7 0.4 5.4% 1.8 65.2 
SD   34.9 1.5 36.9 1231.7 0.2 5.4 0.08 46.4 0.2 0.03 1.2 108.4 
Fold range   260 100 9 1043 3 94 1 10 3 3 6 385 
COV   139 113 86 114 45 111 9 93 46 51 69 166 
Epanolol Dog 10 15 2.0 19.5 4.7 47.0      23.8% 0.46 4.6 
  Human 78.4 0.06 26.8 2101.1 4.3 336.3       26.0% 6.97 546.3 
Oxprenolol Rat 0.205 5 280.0 57.4 13.4 2.7 41.5%        
  Dog           27.0%        
  Rabbit           75.0%        
  Human 65.2   5.9 381.4 0.9 56.1 8.0%           
Esmolol Rat           77.1%        
  Dog 20 
0.025 
mg/kg/min 355.0 7100.0    73.5% 483.0      
  Human 70 
0.4 
mg/kg/min 285.0 19950.0 1.2 83.3 61.4% 464.2         
Betaxolol Rat 0.25 1 205.0 51.3 20.7 5.2          
  Dog 9 1 20.0 180.0 6.3 56.4          
  Human 67 0.15 3.8 254.6 6.0 398.7          
Minimum   0.25 0.15 3.8 51.25 5.95 5.175          
Maximum   67 1 205 254.6 20.7 398.65          
Mean   25.4 0.7 76.3 162.0 11.0 153.4          
SD   36.3 0.5 111.8 102.9 8.4 213.9          
Fold range   268 7 54 5 3 77          
COV   268 7 54 5 3 77             
Albuterol Rat 0.2 10 39.2 7.84 1.0 0.19          
  Dog  24.5 0.02 12.6 308.7 0.8 20.3          
  Rabbit 2.5 0.06 62.3 155.8 2.6 6.5          
  Human 75 0.002 7.8 585.0 1.9 141.8       4.60  
  203
Drug Species BW Dose CLtot  CLtot  Vdss Vdss fu  CLtotu  Vdssu fe CLren CLren 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L)   (ml/min/kg)  (L/kg)  (%) 
 
(ml/min/kg)  (ml/min) 
Minimum   0.2 0.002 7.8 7.84 0.83 0.19          
Maximum   75 10 62.3 585 2.6 141.75          
Mean   25.6 2.5 30.5 264.3 1.6 42.2          
SD   34.7 5.0 25.3 246.6 0.8 66.9          
Fold range   375 5000 8 75 3 746          
COV   136 198 83 93 53 159             
Fenoterol Rat 0.263 1 53.8 14.1 1.0 0.2          
  Human 56 0.03 37.9 2122.4 0.7 40.9             
Terbutaline Rat 0.25              23.1%    
  Dog 10 0.5 10.6 106 1.31 13.1      79.7% 8.4 84.5 
  Horse 452.5   31.7 14344.3 0.9 407.3 88.5%        
  Human 70 0.003 3.4 238.0 1.79 125.3 80.5% 4.22 2.2 56.2% 1.91 133.8 
Minimum   0.25 0.003 3.4 106 0.9 13.1      0.23 1.9 84.5 
Maximum   452.5 0.5 31.7 14344.3 1.8 407.3      0.80 8.4 133.8 
Mean   133.2 0.3 15.2 4896.1 1.3 181.9      0.53 5.2 109.1 
SD   215.1 0.4 14.7 8182.6 0.4 203.1      0.28 4.6 34.8 
Fold range   1810 167 9 135 2 31      3 4 2 


























































fu Dog fu 
Carteolol 0.85 0.97  
Propranolol 0.08 0.11 0.15 
Sotalol 0.99 0.95 0.99 
Atenolol 0.97 0.99   
Metoprolol 0.92 0.92   
Acebutolol 0.74 0.91   
Bisoprolol 0.71 0.86 0.70 
Pindolol 0.43 0.53   
Landiolol 0.96 0.96 0.82 
Oxprenolol 0.80 0.42  
Mean 0.71 0.76 0.66 
  Regression 
     







(0.4, 1.2) 0.74 
Human fu- 
Dog fu   
4 1.15 
(SE ± 0.14) 
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Drug Human  Rat Dog 
 
CLtot 
(ml/min/kg) Category  
CLtot 
(ml/min/kg) Category  
CLtot 
(ml/min/kg) Category  
Xamoterol 3.0 Low    4.49 Low  
Timolol 9.2 Intermediate  6.5 Low    
Carteolol 10.1 Intermediate  16.0 High    
Propranolol 13.6 Intermediate  54.0 High  50.3 High  
Sotalol 2.2 Low  22.5 Intermediate  4.5 Low  
Atenolol 2.4 Low  33.4 Intermediate  4.3 Low  
Metoprolol 10.8 Intermediate  73.4 High 35.8 High  
Amosulalol 2.2 Low  56.7 High  33.3 High  
Nafetolol 19.6 High    30.4 High  
Acebutolol 6.8 Intermediate  60.2 High    
Pafenolol 4.3 Low  42 High    
Bisoprolol 3.7 Low  50.7 High  7.0 Low  
Pindolol 7.4 Intermediate  48.5 High    
Celiprolol 4.6 Low    46.2 High  
Carvedilol 7.6 Intermediate  114.8 High  26.3 High 
Landiolol 37.3 High  9.3 Low  82.5 High 
Epanolol 26.8 High    2.0 Low  
Oxprenolol 5.9 Low  280 High    
Esmolol 285 High    355 High  
Betaxolol 3.8 Low  205 High  20 Intermediate 
Albuterol 7.8 Intermediate  39.2 High  12.6 Intermediate 
Fenoterol 37.9 High  53.8 High    
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9.1.2. Simple Allometry 
For a set of 10 β-ARLs, simple allometry was conducted using all available species and using 
only three species (rat, dog), both including human. Allometric plots are shown in the 
Appendix III (b). Table 9.5 shows the allometric coefficients for CLtot and Vdss for β-ARLs. 
The exponents obtained were compared with a scaling factor 0.75 for CLtot and 1.0 for Vdss. 
Figure 9.2-9.3 shows interspecies scaling plots for a prototypical β-ARL like propranolol. 
Sotalol and atenolol showed their allometric coefficients to be very low for n =3 as well as 
for n = all available animals for CLtot. Amosulalol, bisoprolol, carvedilol and betaxolol show 
a very low allometric coefficient (< 0.60). Out of these β-ARLs showing allometric 
coefficients < 0.60 for CLtot, CLren information across species was available on only sotalol, 
atenolol and amosulalol, hence, for these drugs, allometric scaling was carried out for CLren 
too. Table 9.6 shows that low allometric coefficients were obtained even for CLren for sotalol, 
atenolol and amosulalol. 
 For Vdss, allometric coefficients for amosulalol, carvediolol and betaxolol were found to 
be low. For the remaining β-ARL, CLtot (mean slope: 0.62, 0.46-1.31) and Vdss (mean slope: 














Table 9.5. Allometric PK scaling of  β-ARLs 
 
 
Note: For CLtot and CLtotu, 0.6 > allometric exponents > 1.2 are highlighted 
          For Vdss and Vdssu, 0.8 > allometric exponents > 1.2 are highlighted 
 
 

















Drug (ml/min) n r2 Slope ± SE (L) n r2 Slope ± SE 
Propranolol CLtot 3 0.9455 0.75 ± 0.18 Vdss 3 0.9673 1.04 ± 0.19 
  5 0.9473 0.80 ± 0.11  5 0.9608 0.95  ± 0.11 
 CLtotu 3 0.9960 0.81 ± 0.05 Vdssu 3 0.9967 1.10 ± 0.06 
  4 0.9850 0.82 ± 0.07  4 0.9922 1.11 ± 0.07 
Sotalol CLtot 3 0.9997 0.55 ± 0.01 Vdss 3 0.9999 0.86 ± 0.003 
 CLtotu 3 0.9995 0.55 ± 0.01 Vdssu 3 0.9999 0.85 ± 0.0002 
Atenolol CLtot 3 0.9858 0.46 ± 0.06 Vdss 3 0.9999 0.82 ± 0.006 
  5 0.8284 0.54 ± 0.14  5 0.9431 0.80 ± 0.11 
 CLtotu 3 0.9701 0.50 ± 0.09 Vdssu 3 0.9448 0.77 ± 0.19 
Metoprolol CLtot 3 0.9728 0.68 ± 0.11 Vdss 3 0.9915 1.09 ± 0.10 
  5 0.8702 0.65 ± 0.14  5 0.9509 1.07 ± 0.14 
 CLtotu 3 0.9206 0.64 ± 0.19 Vdssu 3 0.9934 1.07 ± 0.09 
Amosulalol CLtot 3 0.6927 0.51 ± 0.34 Vdss 3 0.7119 0.50 ± 0.32 
  5 0.8411 0.53 ± 0.13  5 0.8428 0.57 ± 0.14 
Bisoprolol CLtot 3 0.9911 0.53 ± 0.05 Vdss 3 0.9999 1.02 ± 0.008 
  4 0.9896 0.53 ± 0.04  4 0.9975 1.02 ± 0.04 
 CLtotu 3 0.9963 0.56 ± 0.03 Vdssu 3 0.9999 1.06 ± 0.008 
  4 0.9952 0.56 ± 0.03  4 0.9973 1.06 ± 0.04 
Carvedilol CLtot 3 0.9869 0.54 ± 0.06 Vdss 3 0.9948 0.76 ± 0.05 
Landiolol CLtot 3 0.9634 1.30 ± 0.25 Vdss 3 0.9869 0.84 ± 0.09 
 CLtotu 3 0.9546 1.31± 0.28 Vdssu 3 0.9760 0.87 ± 0.14 
Betaxolol CLtot 3 0.9760 0.29 ± 0.05 Vdss 3 0.9892 0.76 ± 0.08 
Albuterol CLtot 3 0.9983 0.74 ± 0.03 Vdss 3 0.9871 1.06 ± 0.12 
  4 0.9176 0.69 ± 0.15  4 0.9630 1.03 ± 0.14 
Drug (ml/min) n r2 Slope ± SE 
Sotalol CLren 3 0.9968 0.57 ± 0.03 
 CLrenu 3 0.9973 0.56 ± 0.03 
Atenolol CLren 3 0.9859 0.52 ± 0.06 
Amosulalol CLren 3 0.8986 0.59 ± 0.20 


























































9.1.3. Prediction of PK of β-ARls 
9.1.3.1.One-species BW Scaling 
9.1.3.1.1. One-species BW Scaling from rat PK 
Table 9.7 shows the observed human PK parameters and predicted human PK 
parameters from rat PK. Table 9.8-9.9 and Figure 9.5-9.8 show that large 
overprediction from rat PK and even exclusion of drugs undergoing extra-hepatic 
metabolism, does not decrease %MPE and %RMSE for CLtot CLtotu, Vdss and 
Vdssu.  
PPB correction for Vdss increased r2 value indicating improvement in the 
goodness of fit and brought more number of compounds in the 0.5-2.0 fold error 





Table 9.7. One species scaling using rat PK for  β-ARLs 
 
Drug Observed Predicted 
 
Human 
 CLtot  
Human 













  [ml/min] [l] [ml/min] [l] [ml/min] [l] [ml/min] [l] 
% Prediction error 
            CLtot Vdss CLtotu Vdssu 
               [ml/min] [l] [ml/min] [l] 
Timolol 497.9 91.8 742.4 362.5 457.8 152.6 1160.6 348.2 -40.1 60.8   
Carteolol 628.1 306.7 12058.7 2589.3 1120 336 34363.6 1718.2 491.9 29.3 418.2 -14.3 
Propranolol 904.4 194.2 151.6 84.9 3780 189 1657.9 184.2 2875.6 -5.2 22305.0 -871.2 
Sotalol 150.1 84.1 183.7 80.0 1575 175 2361.6 190.9 1424.9 90.9 1506.3 99.3 
Atenolol 178.6 77.8 871.4 258.0 2338 189 5609.2 160.5 2159.4 111.2 2177.9 110.9 
Metoprolol 799.9 236.8     5138 147    4338.1 -89.8 4737.8 -97.5 
Amosulalol 134.8 24.8     3969 749    3834.2 724.2   
Nafetolol 1146.6 166.1 643.5 109.8     4641.0 447.1      
Acebutolol 478.1 81.6     4214 406    3735.9 324.4 3997.5 337.3 
Pafenolol 317.5 72.0 368.4 270.1 2940 560 4150.9 196.5 2622.5 488   
Bisoprolol 259.7 190.4 1128.5 318.9 3549 168 6429.9 278.4 3289.3 -22.4 3782.5 -73.6 
Pindolol 483 136.5     3395 147    2912 10.5 5301.4 -40.5 
Carvedilol 532 152.6 2533.4 11.2 8036 578.2 676.0 36.3 7504 425.6   
Landiolol 2424.5 10.7     651 35    -1773.5 24.3 -1857.4 25.2 
Epanolol 2101.1 336.3 476.8 70.1     47228.9 2260.2      
Oxprenolol 381.4 56.1 32491.9 135.7 19600 938 1160.6 348.2 19218.6 881.9 46752.2 2190.1 
Betaxolol 254.6 398.7 742.4 362.5 14399 1449   14144.4 1050.3   
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Drug Observed Predicted 
 
Human 
 CLtot  
Human 













  [ml/min] [l] [ml/min] [l] [ml/min] [l] [ml/min] [l] 
% Prediction error 
            CLtot Vdss CLtotu Vdssu 
               [ml/min] [l] [ml/min] [l] 
Albuterol 585 141.8   2744 70   2159 -71.8   
























Table 9.9. One Species Method using Rat PK (Reduced dataset excluding nafetolol, landiolol, esmolol and 
fenoterol) 
   Prediction errors Regression  





%RMSE Slope (±SE) r2 
No. of 
compounds 








CLtot 17 1282 







 Vdss 17 391  
(± 185 %) 
835 
 
0.34 (± 0.27) 0.09 7/17 
(41 %) 
 CLtotu 10 1482 







 Vdssu 10 380 









   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds  
In the 0.5-2 
fold error 
range 










CLtot 15 1452 









 Vdss 15 423  
(± 208 %) 
887 
 
0.01 (± 0.32) 0.0001 4/15 
(27 %) 
 CLtotu 9 1654 







 Vdssu 9 397 











































Observed human CLtot (ml/min)
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9.1.3.1.2. One-species BW Scaling using dog PK 
Table 9.10 shows the observed human PK parameters and predicted human PK 
parameters from dog PK. Table 9.11-9.12 and Figure 9.9-9.12 show that CLtotu 
and Vdssu were predicted more accurately and precisely than CLtot and Vdss as 
indicated by % MPE and % RMSE. PPB correction resulted in more number of 
compounds in the acceptable 0.5-2.0 fold error range. However, fu information 
was available on only for 5 β-ARLs.  
In terms of no. of compounds in the 0.5- 2 fold error range, only 6 out 16 
β-ARLs (38 %) showed predicted CLtot in 0.5-2 fold error range, while 2 out of 5 
β-ARLs (40 %) showed predicted CLtotu in 0.5-2 fold error range. Out of 15, 10 β-
ARLs (67 %) showed predicted Vdss in 0.5-2 fold error range. Out of 4, 3 β-ARLs 
(75 %) showed Vdssu in 0.5-2 fold error range. Overall, there was an 
overprediction and it was more pronounced when CLtot and Vdss were not 
corrected for PPB, however, % MPE and % RMSEs were lower than those 





Table 9.10. One Species Method using Dog PK for β-ARLs 
 
 
Drug Observed Predicted 
 
Human 
 CLtot  
Human 













  [ml/min] [l] [ml/min] [l] [ml/min] [l] [ml/min] [l] % Prediction error 
            CLtot Vdss CLtotu Vdssu 
               [ml/min] [l] [ml/min] [l] 
Xamoterol 224.3 48   314.3 220.5   40.1% -359.4%   
Timolol 497.9 91.8 1235.5 227.8            
Carteolol 628.1 306.7 742.4 362.5            
Propranolol 904.4 194.2 12058.7 2589.3 3521 462 23164.5 3039.5 289.3% -137.9% 192.1% -17.4% 
Sotalol 150.1 84.1 151.6 84.9 315 112 318.2 113.1 109.9% -33.2% 209.9% -33.2% 
Atenolol 178.6 77.8 183.7 80.0 301 98     68.5% -26.0%   
Metoprolol 799.9 236.8 871.4 258.0 2506 329     213.3% -38.9%   
Amosulalol 134.8 24.8     2331 385     1629.2% 
-
1452.4%   
Nafetolol 1146.6 166.1     2128 280     85.6% -68.6%   
Bisoprolol 259.7 190.4 368.4 270.1 490 175 703.0 251.1 88.7% -8.1% 90.8% -7.0% 
Celiprolol 314 530.6     3234 490     929.9% -7.7%   
Landiolol 2424.5 10.7 2533.4 11.2 5775 28 7042.7 34.1 138.2% 161.7% 178.0% 205.4% 
Epanolol 2101.1 336.3     140 329     -93.3% -2.2%  -17.4% 
Oxprenolol 381.4 56.1 476.8 70.1             -33.2% 
Esmolol 19950 83.3 32491.9 135.7 24850   0.7   24.6%  -100.0%  
Betaxolol 254.6 398.7   1400 441   449.9% 10.6% 192.1%  
Albuterol 585 141.8   882 56   50.8% -60.5% 209.9%  
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Drug Observed Predicted 
 
Human 
 CLtot  
Human 













  [ml/min] [l] [ml/min] [l] [ml/min] [l] [ml/min] [l] % Prediction error 
            CLtot Vdss CLtotu Vdssu 
               [ml/min] [l] [ml/min] [l] 




















   Prediction errors Regression  





%RMSE Slope (±SE) r2 
No. of 
compounds 








CLtot 16 263 
(± 109 %) 
499 
 
0.54 (± 0.23) 0.29 6/16 
(38 %) 
 Vdss 15 -131  
(± 99 %) 
391 
 
0.54 (± 0.18) 0.43 10/15 
(67 %) 
 CLtotu 5 114 







 Vdssu 4 37 








   Prediction errors Regression  





%RMSE Slope (±SE) r2 
No. of 
compounds  







CLtot 12 335 









 Vdss 12 -175 
 (± 119 %) 
435 
 
0.01 (± 0.32) 0.0001 8/12 
(67 %) 
 CLtotu 3 164 





























100 1000600400200 1000050003000 20000
Observed human CLtot (ml/min)
 

































10876 1007050403020 200 300400 600
Observed human Vdss (L)
 




































































1087 10060403020 1000500300200 2000
Observed human Vdss(u) (L)
 






Line of  identity Line with slope = 0.5 Line with slope = 2.0
  222
 
9.1.3.2.Two-species BW Scaling 
Table 9.13 and 9.14 shows the observed human PK parameters and predicted human 
PK parameters from two species, rat and dog, for CLtot and Vdss. Table 9.15-9.16 
show that CLtot was predicted more accurately and precisely when drugs undergoing 
extra-hepatic metabolism were excluded as indicated by their % MPE and % RMSE.  
In terms of no. of compounds in the 0.5-2 fold error range, only 6 out 9 β-ARLs (67 
%) showed predicted CLtot in 0.5-2 fold error range, while 6 out of 9 β-ARLs (67 %) 
showed predicted Vdss in 0.5-2 fold error range. PPB was found to be fairly constant 
for β-ARLs across species with exception of propranolol and oxycodone (Table 9.3). 
PPB correction for CLtot and Vdss resulted in very high % prediction errors (Table 
9.17). Rat and dog CLtotu and Vdssu differed to a great extent with rat showing lower 
CLtotu and Vdssu.  Highly species dependent tissue binding and extra-hepatic 






Table 9.13. Two Species Method using Rat and Dog PK for β-ARLs 
 
 

























1.14 0.54 141 150.1 
Atenolol 16.8  
66.3 
 1.35 0.39 121 178.6 
Metoprolol 19.8  
429.8 
 1.76 0.81 1797 799.9 
Amosulalol 11.6  
399.6 
 1.66 0.87 1853 134.8 
Bisoprolol 12.7  
72.8 
 1.39 0.47 178 259.7 
Carvedilol 26.4  
262.7 
 1.81 0.61 859 532 
Landiolol 2.3  
825.0 
 1.32 1.59 18244 2424.5 
Betaxolol 51.3  
180.0 
 1.92 0.35 369 254.6 
Albuterol 7.84  
308.7 




















Observed human CLtot (ml/min)
 
































Line of  identity Line with slope = 0.5 Line with slope = 2.0
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Table 9.14. Two Species Method using Rat and Dog PK 
 
 



























































0.72 0.69 99.7 152.6 
Landiolol 0.1  
3.7 
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Line of  identity Line with slope = 0.5 Line with slope = 2.0
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Table 9.16. Two Species Scaling using Rat and Dog PK (Reduced dataset excluding nafetolol, landiolol and 
esmolol) 
   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds  
In the 0.5-2 
fold error 
range 
Method Parameter n %MPE 
(±SE) 












   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds 
In the 0.5-2 
fold error 
range 
Method Parameter n %MPE 
(±SE) 
%RMSE Slope r2  
Two species  
approach 



























  Human Rat Dog Prediction of  human CLtotu Prediction of human  Vdssu 












  [ml/min] [L] [ml/min] [L] [ml/min] [L]     
Propranolol 12056 2.66 230.7 11.7 3309 432 18093.9 50.1% 4321.5 162363.9% 
Sotalol 152.9 83.4 8.50 0.97 54.28 18.88 139.9 -8.5% 85.6 2.6% 
Bisoprolol 371.0 190.4 14.83 0.70 104 37.4 283.5 -23.6% 287.1 50.8% 
Landiolol 2535 13 2.425 0.125 1006 5 24321.6 859.4% 33.5 157.8% 
           
   Prediction errors 
   Bias Imprecision 
Method Parameter n %MPE (±SE) %RMSE 
Two species  
approach 
CLtotu 4 219 (± 2.1) 430 





9.1.3.3.LBF method   
9.1.3.3.1. LBF method using rat and dog PK for CLtot and CLtot u 
Table 9.19 and 9.20 show the observed human PK parameters and predicted 
human PK parameters from rat and dog PK, respectively. Table 9.21-9.22 and 
Figure 9.15 and 9.16 shows that LBF method using dog PK data predicted CLtot 
more accurately and precisely.  
Table 9.25 and Figure 9.17-9.18 indicate that when CLtot was corrected for 
PPB, lower %MPE and %RMSE were obtained for predictions from both rat and 
dog PK. PPB correction for CLtot increased r2 value indicating improvement in the 
goodness of fit. In terms of no. of compounds predicted in the 0.5- 2 fold error 
range, from rat PK, only 2 out of 10 β-ARLs (20 %) showed predicted CLtotu  in 
0.5-2 fold error range, while from dog PK, 4 out of 4 β-ARLs (100 %) showed 
predicted CLtotu in 0.5-2 fold error range.  
When the drugs undergoing extra-hepatic metabolism were excluded, 























































Figure 9.15. Predicted Human CLtot from Rat PK vs. Observed Human CLtot 






















LBF (ml/min/kg) 21 50    
Timolol 9.2 6.5 2.6 -71.6% 
Carteolol 10.1 16.0 6.4 -36.8% 
Propranolol 13.6 54.0 21.6 58.8% 
Sotalol 2.2 22.5 9.0 309.1% 
Atenolol 2.4 33.4 13.4 456.7% 
Metoprolol 10.8 73.4 29.4 171.9% 
Amosulalol 2.2 56.7 22.7 930.9% 
Acebutolol 6.8 60.2 24.1 254.1% 
Pafenolol 4.3 42 16.8 290.7% 
Bisoprolol 3.7 50.7 20.3 448.1% 
Pindolol 7.4 48.5 19.4 162.2% 
Carvedilol 7.6 114.8 45.9 504.2% 
Landiolol 37.3 9.3 3.7 -90.0% 
Oxprenolol 5.9 280 112.0 1798.3% 
Betaxolol 3.8 205 82.0 2057.9% 
Albuterol 7.8 39.2 15.7 101.0% 
Fenoterol 37.9 53.8 21.5 -43.2% 
     
Line of  identity Line with slope = 0.5 Line with slope = 2.0 
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LBF (ml/min/kg) 21 30     
Xamoterol 3.0 4.49 1.8 -39.9% 
Propranolol 13.6 50.3 20.1 47.9% 
Sotalol 2.2 4.5 1.8 -18.2% 
Atenolol 2.4 4.3 1.7 -28.3% 
Metoprolol 10.8 35.8 14.3 32.6% 
Amosulalol 2.2 33.3 13.3 505.5% 
Nafetolol 19.6 30.4 12.2 -38.0% 
Bisoprolol 3.7 7.0 2.8 -24.3% 
Celiprolol 4.6 46.2 18.5 301.7% 
Carvedilol 7.6 26.3 10.5 38.4% 
Landiolol 37.3 82.5 33.0 -11.5% 
Epanolol 26.8 2.0 0.8 -97.0% 
Esmolol 285 355 142.0 -50.2% 
Betaxolol 3.8 20 8.0 110.5% 
Albuterol 7.8 12.6 5.0 -35.4% 
Line of  identity Line with slope = 0.5 Line with slope = 2.0 
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Table 9.22. LBF method using rat and dog PK (reduced dataset excluding nafetolol, epanolol, landiolol, 















   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds  
In the 0.5-2 fold 
error range 
Method Parameter n %MPE 
(±SE) 









(from dog  
PK) 




   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds  
In the 0.5-2 fold 
error range 
Method Parameter n %MPE 
(±SE) 





















































































Human CLtotu from rat 
[ml/min/kg] 
 
% Prediction error 
LBF (ml/min/kg) 21 50   
Carteolol 12 16.6 6.64 -44.7% 
Propranolol 181.3 490.9 196.36 8.3% 
Sotalol 2.2 23.6 9.44 329.1% 
Atenolol 2.48 33.7 13.48 443.5% 
Metoprolol 11.8 80.1 32.04 171.5% 
Acebutolol 9.2 66.3 26.52 188.3% 
Bisoprolol 5.3 59.3 23.72 347.5% 
Pindolol 17.4 91.9 36.76 111.3% 
Landiolol 39 9.7 3.88 -90.1% 
Esmolol 464.2 483 193.2 -58.4% 
     





































































LBF (ml/min/kg) 21 30   
Propranolol 181.3 390.9 260.6 43.7% 
Sotalol 2.2 4.6 3.07 39.4% 
Bisoprolol 5.3 10 6.7 25.8% 
Landiolol 39 100.6 67.1 72.0% 












Table 9.26. LBF method using rat and dog PK for CLtotu  (reduced dataset excluding nafetolol, epanolol, 








   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds  
In the 0.5-2 fold 
error range 
Method Parameter n %MPE 
(±SE) 

















   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds  
In the 0.5-2 
fold error 
range 
Method Parameter n %MPE 
(±SE) 




















9.1.3.3.2. LBF method using rat and dog PK for CLnonren and CLnonrenu 
Table 9.27 and 9.28 show the observed human PK parameters and predicted 
human PK parameters from rat and dog PK. Table 9.29-9.30 and Figure 9.19 and 
9.20 shows that LBF method using dog PK data predicted CLnonren  more 
accurately and precisely.  
Table 9.29 indicate that when CLtot was corrected for PPB, lower % MPE and % 
RMSE were obtained for predictions from dog PK. PPB correction for CLtot 
increased r2 value indicating improvement in the goodness of fit. None of the 
compounds were in 0.5-2.0 fold range for predictions using rat PK. From dog PK, 
only 3 out of 9 β-ARLs (33 %) showed predicted CLnonren in 0.5-2 fold error range 






Table 9.27. LBF method using rat PK for CLnonren and CLnonrenu 













CLnonrenu CLnonren CLnonrenu 
  [ml/min/kg] [ml/min/kg]  [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] 
                  
Sotalol 0.5 0.5 5.8 6.1 2.3 2.44 338% 356% 
Atenolol 0.1 0.1 10 10.1 4.0 4.04 3900% 3827% 
Amosulalol 1.5  47  18.8  1153%   
Acebutalol 4.0 5.4 45 49.6 18.0 19.82 350% 268% 
Pafenolol 1.9  21  8.4  342%   
Bisoprolol 1.4 2.0 35.5 41.5 14.2 16.61 914% 736% 



























































Table 9.28. LBF method using dog PK for CLnonren and CLnonrenu 













CLnonrenu CLnonren CLnonrenu 
  [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] 
                  
Sotalol 0.5 0.5 0.29  0.2  -64%  
Atenolol 0.1 0.1 0.70 0.71 0.5 0.47 367% 358% 
Metoprolol 9.2 10.0 33.8  22.5  145%  
Amosulalol 1.5  28.8  19.2  1180%  
Nafetolol 16.9  28.9  19.3  14%  
Bisoprolol 1.4 2.0 4.8 6.9 3.2 3.20 129% 61% 
Landiolol 34.4 35.9 82.02 100.0 54.7 54.68 59% 52% 
Epanolol 19.8  14.54  9.7  -51%  



















































Table 9.29. LBF method using rat and dog PK for CLnonren and CLnonrenu 
   Prediction errors 
   Bias Imprecision 
Regression 
Method Parameter n %MPE 
(±SE) 
%RMSE Slope r2 
No. of 
compounds 

































Line of  identity Line with slope = 0.5 Line with slope = 2.0 
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9.1.3.4.GFR ratio method 
9.1.3.4.1. GFR ratio method using rat and dog PK data 
Table 9.30 and 9.31 show the observed human PK parameters and predicted 
human PK parameters from rat and dog PK. Table 9.32 and Figure 9.23-9.26 
shows that GFR ratio method using dog PK data predicted CLren and CLren u more 
accurately and precise. There was an under-prediction when dog PK was used as 
indicated by the negative % MPE values while over-prediction when rat PK was 
used. 
Table 9.32 indicate that when CLren was corrected for PPB, lower % MPE and 
% RMSE were obtained for predictions from dog PK. PPB correction for CLtot 
increased r2 value indicating improvement in the goodness of fit. From rat PK, 
only 1 out of 7β-ARLs (14 %) showed predicted CLren in 0.5-2 fold error range 
while 2 out of 5 β-ARLs (40 %) showed predicted CLrenu in 0.5-2 fold error range. 
From dog PK, only 3 out of 9 β-ARLs (33 %) showed predicted CLren in 0.5-2 
fold error range while 1out of 3 β-ARLs (33 %) showed predicted CLrenu in 0.5-2 








Table 9.30. GFR ratio method using rat PK for CLren and CLrenu 
 
Human (GFR- 1.8 
ml/min/kg) Rat (GFR- 5.24 ml/min/kg)  









CLrenu CLren CLrenu 
  [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] 
              
Sotalol 1.67 1.69 5.4 5.73 225.7% 239.5% 
Atenolol 2.3 2.37 8.0 8.04 245.9% 239.6% 
Amosulalol 0.7   3.3   371.1%   
Acebutalol 2.8 3.77 5.2 5.69 84.6% 51.0% 
Pafenolol 2.4   7.1   197.5%   
Bisoprolol 2.3 3.26 5.2 6.04 124.7% 85.3% 

















Figure 9.23.  Predicted Human CLren from Rat PK  vs. Observed Human CLren 
 


























































Line of  identity Line with slope = 0.5 Line with slope = 2.0
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Table 9.31. GFR ratio method using dog PK for CLren and CLrenu 
 
Human (GFR- 1.8 
ml/min/kg) Dog (GFR- 6.13 ml/min/kg)  









CLrenu CLren CLrenu 
  [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] 
              
Sotalol 1.67 1.69 1.2 1.2 -26.9% -26.9% 
Atenolol 2.3 2.37 1.0   -54.6%   
Metoprolol 1.6 1.74 0.6   -63.8%   
Amosulalol 0.7   1.3   86.4%   
Nafetolol 2.7   0.4   -83.9%   
Bisoprolol 2.3 3.26 0.6 0.9 -72.3% -71.9% 
Landiolol 2.93 3.06 0.1 0.2 -95.2% -94.5% 
Epanolol 6.97   0.1   -98.1%   
Terbutaline 1.91 2.37 2.4   27.5%   



















































































Line of  identity Line with slope = 0.5 Line with slope = 2.0
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6/16 (38 %) CLtot 16 263 
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Vdss 15 423  
(± 208 %) 
887 
 







Vdss 12 -175 
 (± 119 %) 
435 
 






Vdss  9 147 (±121) 372 0.24 
(± 0.42) 
0.04 








Vdssu 9 397 
























9.1.4.  Discussion 
There were large differences in reported, BW-corrected, CLtot and Vdss values across species 
(range: 6 to 80-fold, 3 to 50-fold, respectively) for β-ARLs. PPB was found to be similar 
across different species: only propranolol (human fu = 0.08, rat fu = 0.11) and oxprenolol 
(human fu 0.80, rat fu = 0.42) showed major species differences in the fu. Based on the 
comparison of CLtot to the LBF in each species, hepatic clearance categorization was done 
for each drug in each species. Hydrophilic β-ARLs xamoterol, sotalol, atenolol and 
bisoprolol were found to be low clearance in dog and human. All the β-ARLs (except timolol 
and landiolol) were found to be high clearance in rats This showed that hepatic extraction 
ratios for β-ARL are species dependent and lower in man  and big animals than in small 
animals. Smaller species deliver drugs more frequently and faster to the eliminating organs, 
eliminate the drugs, particularly those wth high clearances, more rapidly.4  This finding was 
similar to the findings from the present research for the interspecies scaling of opioids and 
interspecies scaling of anesthetic drugs.101 Evans et al45categorized a dataset of 21 
compounds (MW > 300 g/mol or clog P > 3) into low clearance (< 30 % LBF), intermediate 
clearance (30 %-70 % LBF) and high clearance (> 70 % LBF).  It was found that 40 % of 
these compounds, though high clearance in the rat, were not high clearance in humans. Most 
of the β-ARL are metabolized by CYP450 (mainly CYP2D6) and UGTs. Some β-ARLs like 
esmolol and landiolol are esters and are known/suspected to undergo extra-hepatic 
metabolism by nonspecific esterases in blood and tissues.78, 105, 106 Quon et al104 found that 
blood esmolol esterase activity is higher in rats and dogs as compared to humans. β-agonist 
like fenoterol shows CLtot more than LBF in both, humans and rats, indicating that it might 
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undergo extra-hepatic metabolism. Fenoterol is an analog of catecholamines like epinephrine 
or noreinephrine and cateholamines are known to undergo metabolism by caetchol o-methyl 
transferases (COMT), which is present in several tissues like brain, liver, kidneys and 
gastrointestinal tract. Human, hamster, guinea pig, dog, rat and monkey erythrocytes contain 
some COMT activity, which is higher in rats and quite low in humans.107 De Wazier et al97 
found that hepatic enzyme levels of CYP1A, CYP2C and CYP3A  in rats were 
approximately 28, 638 and 165 pmol/gm microsomal protein while Guengerich et al98 
reported corresponding values for humans as 37, 55, 87 pmol/gm of microsomal protein 
(Table 8.2). Similarly, Clarke et al102 found that there were interspecies differences in UGT 
activities in rat and humans. Soars et al103 looked at in-vitro glucuronidation of a range of 
structurally diverse chemicals in hepatic and renal microsomes from human and dogs and 
found that gluronidation was several fold more rapid in dog liver microsomes than human 
liver microsomes.  
CLtot (mean slope: 0.62, 0.46-1.31) and Vdss (mean slope: 0.89, 0.50-1.11) scaled well 
with BW, regardless of the number of species. Sotalol and atenolol showed their allometric 
coefficients to be very low (< 0.60) for n =3 as well as for n = all available animals for CLtot. 
Amosulalol, bisoprolol, carvedilol and betaxolol also showed a very low allometric 
coefficient (< 0.60). Out of these β-ARLs showing allometric exponents < 0.60 for CLtot, 
CLren information across species was available on only sotalol, atenolol and amosulalol, 
hence, for these drugs, AS was carried out for CLren too. When CLren was scaled with body 
BW for sotalol, atenolol and amosulalol, low allometric exponents were obtained.  Sotalol 
and atenolol, both, are hydrophilic drugs, show very high fu values (> 90 %) and fe values (> 
60-90 %) across different species like rat, dog, rabbit and humans. CLrenu for sotalol was 
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found to be higher than GFR in rat and dog, while equivalent to GFR in humans, indicating 
that it might undergo net tubular secretion in rat and dog while net filtration in humans. 
CLrenu of atenolol was found to be more than GFR in rat and human, indicating net tubular 
secretion in both the species. Amosulalol showd fe < 20% in mouse, rat, dog, monkey and 
humans while fe = 34 % in human. Due to lack of fu information for amosulalol in different 
species, mechanism at the kidneys cannot be known. Renal blood flow (RBF) and GFR 
(ml/min/kg) decrease as the animal size increases in an allometric manner. The exponent 
values were 0.84 for RBF and 0.78 for GFR 4 were steeper than the slopes obtained from 
allometric relationships for CLtot and CLren  for sotalol, atenolol, bisoprolol, carvedilol, 
amolsulalol and betaxolol. This may be due to the possible involvement of drug transporters 
in the disposition of β-blockers. Transporters like OCT and PGP are known to be involved in 
the elimination of β-blockers.86, 87Mahmood et al43 tried to predict CLtot, CLren  and Vdss  in 
humans from animal data for ten drugs which were mainly renally secreted in humans. The 
exponents for simple allometry for CLtot ranged from 0.71-0.93, however, ofloxacin, a 
suspected OAT substrate, showed a low exponent of 0.583. Sawada et al108 predicted the 
disposition of six β-lactam antibiotics using mouse, rat, rabbit, dog and human PK data. The 
log-log relationship between clearances (CLtot and CLren) and BW showed low slopes, 0.405-
0.662 (n = 5, mean: 0.574) for CLtot and 0.429-0.713 (n = 5, mean: 0.628) for CLren. 
Literature studies show that β-lactam antibiotics like cephalosporins and penicillins show net 
secretion and it is has been reported that some cephalosporins interact with hOAT1, hOAT2 
and hOAT3.22, 93, 94  Jariyawat et al88 showed inhibition of p-aminohippurate transport via rat-
OAT1 by penicllins and cephalosporins. The relation between Vdss and BW showed good 
correlation, but the allometric exponents for amosulalol, carvedilol and betaxolol were found 
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to be low (range: 0.50-0.77). Similar low slopes were obtained for morphine glucuronides 
during interspcecies scaling of opioids. This might be due to the polar nature of compounds 
which limits their distribution. Mahmood et al43 tried to predict  Vdss  in humans from animal 
data for ten drugs which were mainly renally secreted in humans and found a very good 
correlation between Vss and body weight and exponents were found be in the range 0.88-
1.35.  
Various prediction methods like one-species BW scaling, two-species (rat, dog) BW 
scaling, LBF method and GFR ratio methods were used to predict total and unbound CLtot, 
CLren, CLnonren and Vdss. Table 9.33-9.35 shows the summary for the prediction of PK 
variables. Table 9.36 gives the best prediction methods for total and unbound PK parameters. 
Overall, one-species-LBF methods provided acceptable predictions for CLtot and CLtotu and 
one species – BW method for Vdss and Vdssu.  Thus, the use of three or more species does not 
appear justified. This suggests a single, non-rodent species in preclinical PK may be most 
informative. Similar conclusion was made by by Tang et al5 when one- or two- species based 
methods were used to predict human CLtot from rat, dog and monkey in a 26-Wyeth 
compound test dataset using a 102-compound training dataset. In a study on the prediction of 
human PK for 103-compound dataset of structurally diverse compounds; it was found that 
allometric scaling approaches using two species were less successful at predicting CLtot than 
LBF method in an individual species.13 Scaling from a nonrodent species like monkey 
showed that LBF method was the most accurate when 124 compound dataset of structurally 
diverse compounds was studied.45 Ward et al109 showed that single species like monkey gave 
accurate predictions for Vdss as compared to predictions from two or three species for a 103 
compund diverse dataset. Hosea et al56 conducted a retrospective analysis using 50 
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proprietary compounds for which oral single dose human PK data was available and 
concluded that the use of single species lead to more accurate pedictions than using multiple 
species and use of unbound concentrations resulted in accurate predictions.  
In the present research on β-ARLs, in general , the fu correction of CLtot and Vdss: 
increased the r2 value indicating improvement in the goodness of fit; lowered  %MPE and 
%RMSE, thus, improving predictability; and resulted in predictions within acceptable range 
for a larger number of compounds. A study on 36 marketed oral drugs showed that Vdss 
estimated in rat and dog when corrected for PPB, predicted human Vdss successfully with  73 
% of the compounds within 2-fold error range.30 Sawada et al100 reported PPB values for  10 
basic drugs in  different species and found that the interspecies differences in distribution 
maybe attributed to the differences in fu. Feng et al55 predicted human systemic CLtotu for 
eight Parke Davis compounds and 26 literature drugs and it was found that in general, human 
CLtotu was predicted more accurately with reduction in the average fold error. CLren and 
CLrenu were under-predicted, possibly due the associated interspecies differences in the 
metabolic pathways, renal and hepatobiliary drug transporters and partly due to lack of fe and 
fu data on all compounds across all the species. Similar findings are reported by Mahmood et 
al43 in a study which predicted CLtot, CLren and CLnonren in humans from animal data for ten 
drugs which were mainly renally secreted in humans. McGinnity et al30 showed that GFR 
ratio method gave accurate predictions for compounds even when their CLren > GFR.  
For most β-ARLs, body size accounted for most of the observed variability (r2> 0.80) in 
systemic PK variables in the animal species studied. For β-ARLs, the dog was found to be 
the species giving the best prediction of CLtot, Vdss, CLren, CLnonren, CLtotu, Vdssu, CLrenu and 
CLnonrenu.  Similar conclusions were obtained from the interspecies scaling study on opioids. 
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Table 9.36. Best prediction methods for β-ARLs 
PK variable Method n %MPE %RMSE % compounds in 
acceptable range 
Vdss Dog-BW 12 -175 435 
 
67 % 
Vdssu Dog-BW 3 -19.2 22 
 
100 % 
CLtot Dog-LBF 11 251 382 73 % 
CLtotu Dog-LBF 3 36 37 100% 
CLren Dog-GFR ratio 9 -42  72 33% 
CLrenu Dog-GFR ratio 3 -64 70 33 % 
CLnonren Dog-LBF 9 197  418 33 % 


















CHAPTER 10. INTERSPECIES SCALING OF β-LAs 
 
10. β-lactam antibiotics  
10.1. Results 
10.1.1. Comparative pharmacokinetics of β-lactam antibiotics (β-LAs)across different 
species 
Table 10.1 and 10.2 shows the in-vivo, in-vitro and estimated PK parameters for 27 β-LAs, 
respectively. There were large differences in reported, BW-corrected, CLtot and Vdss values 
across species (range: 1 to 80-fold, 1 to 25-fold, respectively) for β-LAs. PPB was not similar 
across different species, with rat fu accounting for only 60 % variability in human fu (Table 
10.3-10.4). Most of the β-LAs showed intermediate PPB (30-70 %) except cefazolin and 
showed fe values > 50 % indicating that these drugs are mainly excreted by kidneys across 
different species. Human CLrenu values for most of the β-LAs in the dataset were higher than 
GFR indicating net tubular secretion in humans, however, the information on fu, CLren, 
CLnonren was available on very few β-LAs for rats and dogs, hence interspecies differences in 






Table 10.1. In-vivo PK parameters of β-LAs 
 
Drug Species BW Dose CLtot  CLtot  Vdss Vdss 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L) 
            
Amoxicillin Rat 0.25 
8.8 
mg/hr 20 5 0.70 0.2 
  Goat 40.5 20 2 81 0.16 6.5 
  Pig 24.7 20 9.67 239 0.34 8.4 
  Human 74.7 26.8 4.28 320 0.21 15.7 
Minimum   0.3 8.8 2.0 5.0 0.2 0.2 
Maximum   74.7 26.8 20.0 319.7 0.7 15.7 
Mean   35.0 22.3 9.0 161.1 0.4 7.7 
SD   31.2 3.9 8.0 143.7 0.2 6.4 
Fold range   299 3 10 64 4 89 
COV   89 18 89 89 69 83 
                
Ampicillin Rat 0.285 75 44.4 12.7 0.57 0.2 
  Human 74.7 40.2 4.86 363.0 0.21 15.9 
                
Mezlocillin Rat 0.425 20 50 21.3 0.39 0.2 
  Human 73.5 27.2 4.78 351.3 0.21 15.4 
                
Azlocillin Dog 13.05 100 5.52 72.0 0.27 3.6 
  Human 71.3 57.4 1.94 138.3 0.15 10.7 
             
Ticarcillin Rat  0.3 300.0 13.0 3.9 0.3 0.09 
  Rabbit 2.3 150.0 7.0 15.8 0.04 0.09 
  Human 77.5 64.2 1.7 131.0 0.2 14.0 
Minimum   0.30 64.2 1.7 3.9 0.04 0.09 
Maximum   77.50 300.0 13.0 131.0 0.3 14.0 
Mean   26.68 171.4 7.2 50.2 0.2 4.7 
SD   44.02 119.3 5.7 70.2 0.14 8.0 
Fold range   258 5 8 34 8 155 
COV   165 70 78 140 77 170 
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Drug Species BW Dose CLtot  CLtot  Vdss Vdss 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L) 
Dicloxacillin Dog 20.5 25 14.96 307 1.42 29.1 
  Human 67.6 24.6 3.06 207 0.30 20.3 
               
Cefepime Rat  0.33 200 11.7 3.8 0.5 0.2 
  Monkey 5.15 300 1.5 7.7 0.2 1.0 
  Goat 29.5 33.9 2.2 64.6 0.4 10.3 
  Human 74.9 26.7 1.5 110.9 0.2 16.5 
Minimum   0.3 26.7 1.5 3.8 0.2 0.2 
Maximum   74.9 300.0 11.7 110.9 0.5 16.5 
Mean   27.5 140.2 4.2 46.8 0.3 7.0 
SD   34.1 133.3 5.0 51.0 0.1 7.8 
Fold range   229 11 8 29 2 110 
COV   124 95 119 109 40 112 
                
Moxalactam Rabbit 3.25 30 0.36 1.17 0.26 0.85 
  Rat 0.285 1052 8.94 2.55 0.21 0.06 
  Monkey 2.95 101.7 2.66 7.85 0.23 0.67 
  Human 66.7 14.9 1.23 82.04 0.28 18.68 
Minimum   0.3 14.9 0.4 1.2 0.2 0.1 
Maximum   66.7 1052.0 8.9 82.0 0.3 18.7 
Mean   18.3 299.7 3.3 23.4 0.2 5.1 
SD   32.3 503.0 3.9 39.2 0.0 9.1 
Fold range   234.0 70.6 24.8 70.1 1.3 312.0 
COV   176.5 167.9 117.6 167.5 12.9 179.4 
             
Cefotaxime Rat 0.261 100 13.1 3.4 0.127 0.03 
  Rabbit 3.25 30 0.58 1.89 0.49 1.59 
  Goat 10.75 50 13.5 145.13 0.51 5.48 
  Human 69 30 3.72 256.68 0.23 15.87 
Minimum   0.3 30.0 0.6 1.9 0.1 0.03 
Maximum   69.0 100.0 13.5 256.7 0.5 15.9 
Mean   20.8 52.5 7.7 101.8 0.3 5.7 
SD   32.4 33.0 6.6 123.2 0.2 7.1 
Fold range   264 3 23 136 4 479 
COV   0.3 0.5 0.6 0.4 0.7 0.4 
                
Cefprozil Dog 10 12.5 2.17 21.7 0.20 2.0 
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Drug Species BW Dose CLtot  CLtot  Vdss Vdss 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L) 
  Human 77.1 6.49 2.94 226.67 0.24 18.5 
                
Ceftizoxime Mice 0.02 20 61.1 1.22 0.79 0.0158 
  Rat 0.25 20 19.3 4.8 0.44 0.1 
  Dog 11.25 20 3.25 36.6 0.27 3.0 
  Monkey 7.45 20 5.93 44.2 0.29 2.2 
  Human 70 30 2.23 156.1 0.172 12.04 
Minimum   0.02 20 2.23 1.2 0.2 0.0 
Maximum   70 30 61.1 156.1 0.8 12.0 
Mean   17.8 22.0 18.4 48.6 0.4 3.5 
SD   29.6 4.5 24.9 63.0 0.2 5.0 
Fold range   3500 1.5 27 128 5 762 
COV   166 20 135 130 62 143 
             
Cephalexin Rat 0.27 50 11.5 3.0 1.32 0.35 
  Dog 12 20 2.5 30 0.215 2.58 
  Human 70 10.71 4.74 331.8 0.18 12.6 
Minimum   0.27 10.71 2.50 3.05 0.18 0.35 
Maximum   70.00 50.00 11.50 331.80 1.32 12.60 
Mean   27.4 26.9 6.2 121.6 0.6 5.2 
SD   37.3 20.5 4.7 182.5 0.6 6.5 
Fold range   264 5 5 109 7 36 
COV   136 76 75 150 113 126 
                
Cefoxitin Rat 0.2 5.2/hr 31.6 6.32    
  Human 68.4 29.2 2.34 160.056 0.15 10.26 
                
Cefazolin Rat 0.3 20 5.51 1.653 0.183 0.0549 
  Human 72.71 13.75 0.88 63.9848 0.12 8.7252 
                
Cefpodoxime Dog 12 10 0.38 4.5 0.15 1.81 
  Human 70 1.43 2.35 164.5 0.36 25.20 
                
Cefuroxime Rat 0.28 6.5 2.1 0.57 0.25 0.07 
  Goat 27 20 6.2 166.9 0.674 18.2 
  Human 72.3 7.1 3.54 255.94 0.28 20.24 
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Drug Species BW Dose CLtot  CLtot  Vdss Vdss 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L) 
Minimum   0.3 6.5 2 1 0 0 
Maximum   72.3 20.0 6 256 1 20 
Mean   33.2 11.2 4 141 0 13 
SD   36.4 7.6 2 130 0 11 
Fold range   263 3 3 450 3 293 
COV   110 68 53 92 59 87 
                
Cefoperazone Rat 0.654 40 9.128 5.97 0.32 0.21 
  Human 70 28.6 1.52 106.40 0.15 10.50 
                
Cephradine Rat 0.654 40 6.17 4.04 0.426 0.28 
  Human 71 7.04 4.21 298.91 0.22 15.62 
                
Ceftazidime Rat 0.225 20       
  Dog 12.4 20 3.58 44.4 0.218 2.7 
  Monkey 5.6 20       
  Human 72 13.9 1.58 113.8 0.21 15.1 
Minimum   0.2 13.9 1.6 44.4 0.2 2.7 
Maximum   72.0 20.0 3.6 113.8 0.2 15.1 
Mean   22.6 18.5 2.6 79.1 0.2 8.9 
SD   33.3 3.0 1.4 49.1 0.0 8.8 
Fold range   320 1 2 3 1 6 
COV   148 17 55 62 3 99 
           
Ceftriaxone Rat        
  Dog 19.6 50 3.61 70.8 0.28 5.4 
  Cat 5.51 25 6.16 33.9 0.57 3.1 
  Monkey 5.6 20 0.44 2.5 0.111 0.6 
  Human 72 13.9 0.2 14.4 0.11 7.9 
Minimum   5.5 0.2 0.2 0.1 0.1 0.6 
Maximum   72.0 50.0 6.2 70.8 0.6 7.9 
Mean   25.7 27.2 2.6 30.4 0.3 4.3 
SD   31.6 15.8 2.8 29.9 0.2 3.1 
Fold range   13 250 31 643 5 13 
COV   123 58 109 98 81 73 
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Drug Species BW Dose CLtot  CLtot  Vdss Vdss 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L) 
Clavulanic 
acid Rat 0.3 10 21.0 6.3 3.3 1.0 
  Goat 40.5 5 2.0 81.0 0.1 5.3 
  Rabbit 2.25 25 7.5 16.9 0.3 0.6 
  Human 69.8 2.4 2.3 157.7 0.2 11.4 
Minimum   0.3 2.0 2.0 0.1 0.1 0.6 
Maximum   69.8 25.0 21.0 157.7 3.3 11.4 
Mean   28.2 10.6 8.2 65.5 1.0 4.6 
SD   33.3 10.1 8.9 69.8 1.6 5.0 
Fold range   233 13 11 1213 25 20 
COV   118 95 109 107 162 110 
                
Imipenem Dog 27.1 5 4.33 117.3 0.32 8.7 
  Human 70 7.1 9.64 674.8 0.58 40.6 
                
Cefpiramdie Mice 0.03 20.0 41.5 1.2 0.030 0.001 
  Rat 0.225 20.0 9.5 2.1 0.3 0.1 
  Rabbits 3 20.0 1.3 3.9 0.1 0.3 
  dog 11 20.0 5.1 56.4 0.5 5.4 
  monkey 4.8 20.0 0.5 2.5 0.1 0.5 
  Human 70 28.6 0.8 57.4 0.2 10.5 
Minimum   0.03 20.0 0.52 1.25 0.03 0.001 
Maximum   70 28.6 41.5 57.4 0.5 10.5 
Mean   14.8 21.4 9.8 20.6 0.2 2.8 
SD   27.3 3.5 15.9 28.1 0.2 4.3 
Fold range   2333 1 80 46 16 11667 
COV   184 16 162 137 86 154 
                
Cefalothin Rat 0.315 50 32.20 10.14 0.15 0.05 
  Human 56.6 17.67 5.83 329.98 0.13 7.36 
                
Cephaloridine Rat 0.315 20 9.5 2.99 0.41 0.13 
  Dog 22.5 20 5.04 113.40 0.44 9.79 
  Human 70 16.7 2.96 207.2 0.31 21.7 
Minimum   0.3 16.7 3.0 3.0 0.3 0.1 
Maximum   70.0 20.0 9.5 207.2 0.4 21.7 
Mean   30.9 18.9 5.8 107.9 0.4 10.5 
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Drug Species BW Dose CLtot  CLtot  Vdss Vdss 
     (kg)  (mg/kg) (ml/min/kg) (ml/min)  (L/kg)  (L) 
SD   35.6 1.9 3.3 102.2 0.1 10.8 
Fold range   222 1 3 69 1 169 
COV   115 10 57 95 17 103 
                
Ceforanide Dog 10 25 6.5 65 0.38 3.80 
  Rabbit 3.5 100 0.4 1.4 0.49 1.72 
  Human 72.5 15.6 1.09 79.0 0.17 12.33 
Minimum   3.5 15.6 0.4 1.4 0.2 1.7 
Maximum   72.5 100.0 6.5 79.0 0.5 12.3 
Mean   28.7 46.9 2.7 48.5 0.3 5.9 
SD   38.1 46.3 3.3 41.4 0.2 5.6 
Fold range   21 6 16 56 3 7 
COV   133 99 125 85 47 95 
                
             
Cephapirin Dog 8.2 30 11.32 92.8 0.32 2.6 
  Human 70 14.3 9.35 654.5 0.22 15.4 























 Table 10.2. Estimated in-vivo PK parameters of β-LAs 
 
Drug Species fu  CLtotu  Vdssu fe CLren CLren CLrenu CLnonren 









                    
Mezlocillin Rat 70.0% 71.4 0.56 17% 8.6 3.7 12.3 41.4 
  Human 65.0% 7.4 0.32 67% 3.2 235.4 4.9 1.6 
                  
Ticarcillin Rat  58.3% 22.3 0.5         
  Rabbit 50.4% 13.9 0.1         
  Human 33.5% 5.0 0.5         
Minimum   33.5% 5.0 0.1           
Maximum   58.3% 22.3 0.5         
Mean   47.4% 13.7 0.4         
SD   12.7% 8.6 0.3         
Fold range   2 4 7         
COV   27 63 69         
                    
Moxalactam Rabbit 74.9% 0.48 0.35         
  Rat       74.8% 6.69 1.91   2.25 
  Monkey       74.9% 1.99 5.88   0.67 
  Human 38.2% 3.22 0.73 61.0% 0.75 50.05   0.48 
Minimum   38.2% 0.5 0.3 61.0% 0.8 1.9   0.5 
Maximum   74.9% 3.2 0.7 74.9% 6.7 50.0  2.3 
Mean   56.6% 1.9 0.5 70.2% 3.1 19.3  1.1 
SD   26.0% 1.9 0.3 8.0% 3.1 26.7  1.0 
Fold range   2.0 6.7 2.1 1.2 8.9 26.3  4.7 
COV   45.9 104.7 50.5 11.4 99.6 138.6   85.9 
                  
Cefotaxime Rat 48.0% 27.3 0.26         
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Drug Species fu  CLtotu  Vdssu fe CLren CLren CLrenu CLnonren 









  Rabbit 14.9% 3.89 3.29         
  Goat 53.7% 25.14 0.95         
  Human 70.0% 5.31 0.33         
Minimum   14.9% 3.9 0.3         
Maximum   70.0% 27.3 3.3         
Mean   46.7% 15.4 1.2         
SD   23.1% 12.5 1.4         
Fold range   5 7 12         
COV   0.7 0.6 0.4         
                    
Cefprozil Dog       62.2% 1.35 13.5   0.82 
  Human       71.4% 2.1 161.91   0.84 
                    
Ceftizoxime Mice 87.0% 70.2 0.91         
  Rat 68.0% 28.4 0.65 80.1% 15.5 3.86   3.84 
  Dog 83.0% 3.9 0.33 93.8% 3.0 34.30   0.20 
  Monkey       80.3% 4.8 35.48   1.17 
  Human 69.0% 3.2 0.25           
Minimum   68.0% 3.2 0.2 80% 3.0 3.9   0.2 
Maximum   87.0% 70.2 0.9 94% 15.5 35.5  3.8 
Mean   76.8% 26.4 0.5 85% 7.8 24.5  1.7 
SD   9.7% 31.4 0.3 0.1 6.7 17.9  1.9 
Fold range   1 22 4 1 5 9  19 
COV   13 119 57 9 87 73   109 
                  
Cephalexin Rat 82.0% 14.02 1.61         
  Dog               
  Human 87.6% 5.41 0.21         
Minimum   82.0% 5.41 0.21         
Maximum   87.6% 14.02 1.61         
Mean   84.8% 9.7 0.9         
SD   4.0% 6.1 1.0         
Fold range   1 3 8         
COV   5 63 109         
                  
Cefoxitin Rat 66.0% 47.9           
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Drug Species fu  CLtotu  Vdssu fe CLren CLren CLrenu CLnonren 









  Human 48.0% 4.9 0.3         
                    
Cefazolin Rat 17.0% 32.5 1.1 89.8% 4.95 1.485   0.56 
  Human 10.3% 8.5 1.2 98.9% 0.87 63.2577   0.01 
                    
Cefuroxime Rat               
  Goat 83.0% 7.4 0.81         
  Human 55.3% 6.40 0.51           
Minimum   55.3% 6.40 0.51           
Maximum   83.0% 7.45 0.81         
Mean   69.2% 6.92 0.66         
SD   19.6% 0.74 0.22         
Fold range   2 1 2         
COV   28 11 33           
                    
Cefoperazone Rat 44.0% 20.75 0.73         
  Human                 
                    
Cephradine Rat 82.0% 7.52 0.52         
  Human 86.2% 4.88 0.26           
                    
Ceftazidime Rat       97.1%       
  Dog       86.3% 3.09 38.31  0.49 
  Monkey               
  Human       88.61% 1.4 100.80   0.18 
Minimum         86.3% 1.4 38.3   0.2 
Maximum        97.1% 3.1 100.8  0.5 
Mean        90.7% 2.2 69.6  0.3 
SD        0.1 1.2 44.2  0.2 
Fold range        1 2 3  3 
COV         6 53 64   65 
                 
Ceftriaxone Rat      32.0%       
  Dog      62.5% 2.26 44.22  1.35 
  Cat              
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Drug Species fu  CLtotu  Vdssu fe CLren CLren CLrenu CLnonren 









  Monkey      29.3% 0.13 0.72  0.31 
  Human      50.0% 0.10 7.20  0.10 
Minimum         10.0% 0.1 0.7   0.10 
Maximum       62.5% 2.3 44.2  1.35 
Mean       43.5% 0.8 17.4  0.59 
SD       0.2 1.2 23.5  0.67 
Fold range       6 23 61  14 
COV         36 149 135   114 
                  
Clavulanic 
acid Rat 83.0% 25.3           
  Goat               
  Rabbit 78.9% 9.5           
  Human               
Minimum   78.9% 9.5             
Maximum   83.0% 25.3           
Mean   81.0% 17.4           
SD   0.0 11.2           
Fold range   1 3           
COV   4 64             
                    
Imipenem Dog               
  Human                 
                    
Cefpiramdie Mice       31.7% 13.2 0.4   28.3 
  Rat       35.2% 3.3 0.8   6.2 
  Rabbits       74.1% 1.0 2.9   0.3 
  dog       70.6% 3.6 39.8   1.5 
  monkey       44.6% 0.2 1.1   0.3 
  Human       17.1% 0.1 9.8   0.7 
Minimum         14.0% 0.1 0.4   0.3 
Maximum        74.1% 13.2 39.8   28.3 
Mean        45.6% 3.6 9.1   6.2 
SD        22.6% 4.9 15.4   11.1 
Fold range        5 94 101   98 
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Drug Species fu  CLtotu  Vdssu fe CLren CLren CLrenu CLnonren 









COV         50 138 169   178 
                    
Cefalothin Rat 50.7% 63.51 0.29         
  Human 28.8% 20.24 0.45           
                    
Cephaloridine Rat 46.1% 20.6 0.3         
  Dog 90.0% 5.6 10.9         
  Human 63.0% 4.7 34.4           
Minimum   46.1% 4.7 0.3         
Maximum   90.0% 20.6 34.4         
Mean   66.4% 10.3 15.2         
SD   0.22 8.9 17.5         
Fold range   2 4 124         
COV   33 87 115         
                    
Ceforanide Dog       76.9% 5.0 50.0   1.5 
  Rabbit       50.0% 0.2 0.7   0.2 
  Human       76.1% 0.8 60.2   0.3 
Minimum         50.0% 0.2 0.7     
Maximum         76.9% 5.0 60.2     
Mean         67.7% 2.0 37.0     
SD         0.2 2.6 31.8     
Fold range         2 25 86     
COV         23 130 86     
                    
                  
Cephapirin Dog       32.0% 3.6 29.7   7.7 
  Human       48.5% 4.5 317.4   4.8 
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Figure 10.1. Human fu vs. Rat fu 
 
 
Drug Human fu Rat fu Dog fu 
Mezlocillin 0.65 0.70  
Ticarcillin 0.34 0.58  
Cefotaxime 0.70 0.48  
Ceftizoxime 0.69 0.68 0.83 
Cefalexine 0.88 0.82  
Cefoxitin 0.48 0.66  
Cefazolin 0.10 0.17  
Cephradine 0.86 0.82  
Cefalothin 0.29 0.51  
Cefaloridine 0.63 0.46 0.90 
  Regression 
     







(0.4, 1.7) 0.62 
Line of regression  Line of  identity 
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10.1.2.  Simple Allometry 
For a set of 11 β-LAs, simple allometry was conducted using all available species and using 
only three species (rat, dog), both including human. Allometric plots are shown in the 
Appendix III (c). Table 10.5 shows the slopes for CLtot and Vdss for β-LAs. The slopes 
obtained were compared with a scaling factor 0.75 for CLtot and 1.0 for Vdss. Figure 10.2-
10.3 shows interspecies scaling plots for a prototypical β-LA like amoxicillin. Most of the β-
LAs showed low slopes (< 0.70) for n =3 as well as for n = all available animals for CLtot. In 
general, a good correlation was obtained between the PK paramters like CLtot and Vdss and 
body weight, except for few β-LAs moxalactam and ceftriaxone. PPB correction improved 
the good-of-fit, as indicated by the improvement in the r2 value. CLren information across 
species was available on only cefpiramide, and AS was carried out for CLren for cefpiramide. 
Table 10.5 shows that low slopes were obtained even for CLren for cefpiramide. 
Overall for β-LAs, CLtot (mean slope: 0.65, 0.29-0.88) and Vdss (mean slope: 0.95, 0.48-

































































Drug (ml/min) n r2 Slope ± SE (L) n r2 Slope ± SE 
Amoxicillin CLtot 4 0.9023 0.69 ± 0.16 Vdss 4 0.9828 0.77 ± 0.07 
         
Ticarcillin CLtot 3 0.9984 0.63 ± 0.02 Vdss 3 0.8835 0.96 ± 0.35 
 CLtotu 3 0.9996 0.73 ± 0.01 Vdssu 3 0.8837 1.06 ± 0.39 
         
Cefepime CLtot 4 0.9043 0.65 ± 0.15 Vdss 4 0.9793 0.90 ± 0.09 
         
Moxalactam CLtot 4 0.6369 0.66 ± 0.35 Vdss 4 0.9994 1.05 ± 0.02 
         
Cefotaxime CLtot 4 0.6676 0.88 ± 0.44 Vdss 4 0.9481 1.14 ± 0.19 
 CLtotu 4 0.8104 0.79 ± 0.27 Vdssu 4 0.8128 1.03 ± 0.35 
         
Ceftizoxime CLtot 3 0.9889 0.60 ± 0.06 Vdss 3 0.9988 0.84 ± 0.03 
  5 0.9922 0.59 ± 0.03  5 0.9977 0.80 ± 0.02 
 CLtotu 3 0.9719 0.59 ± 0.10 Vdssu 3 0.9999 1.02 ± 0.008 
  4 0.9884 0.59 ± 0.05  4 0.9999 0.83 ± 0.004 
         
Cefalexine CLtot 3 0.9514 0.81 ± 0.18 Vdss 3 0.9800 0.63 ± 0.09 
         
Ceftriaxone CLtot 4 0.063 0.29 ± 0.81 Vdss 4 0.5981 0.71 ± 0.41 
         
Clavulanic acid CLtot 4 0.9880 0.57± 0.04 Vdss 4 0.7685 0.48 ± 0.19 
         
Cefpiramide CLtot 3 0.9029 0.61 ± 0.20 Vdss 3 0.9599 0.94 ± 0.19 
  6 0.6887 0.51 ± 0.17  6 0.9442 1.18 ± 0.14 
 CLren 3 0.6082 0.54 ± 0.43     
  6 0.5374 0.49 ± 0.19     
         
Cefaloridine CLtot 3 0.9953 0.80 ± 0.06 Vdss 3 0.9969 0.97 ± 0.05 
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10.1.3.  Prediction of PK of β-lactam antibiotics   
10.1.3.1. One-species BW Scaling 
10.1.3.1.1. One-species BW Scaling using rat PK 
Table 10.6 shows the observed human PK parameters and predicted human PK 
parameters from rat PK. Table 10.7 and Figure 10.4-10.5 show that there was an 
overprediction from rat PK and PPB correction decreased % MPE and % RMSE 
for both, CLtot and Vdss. Table 10.8 shows the observed human PK parameters 
and predicted human PK parameters from dog PK. Table 10.9 and Figure 10.8-
10.9 shows that dog gave better predictions than rat, in terms of both, the 
prediction errors and number of compounds in the 0.5-2.0 fold error range.  PPB 
information for β-LAs in the dog was not available and hence, predictions could 





Table 10.6 One Species Scaling using Rat PK for β-LAs 
 
 
Drug Observed   Observed   CLtotu Vdssu CLtot Vdss CLtotu Vdssu 
  Human CLtot  Human Vdss  [ml/min] [L] [ml/min] [L] [ml/min] [L] % Prediction error 
  [ml/min] [L]             CLtot Vdss CLtotu Vdssu 
                  [ml/min] [L] [ml/min] [L] 
Amoxicillin 320.0 15.7    1400.0 49    338% 212%   
Ampicillin 363.0 15.9    3108.0 39.9    756% 151%   
mezlocillin 351.3 15.4 540.5 23.7 3500.0 27.3 5000 39.0 896% 77% 825% 65% 
Ticarcillin 131.0 14.0    910.0 22.4 1560.9 38.4 595% 60%   
cefepime 110.9 16.5    819.0 0.469    639% -97%   
Moxalactam 82.0 18.7 214.8 48.9 625.8 14.7    663% -21%   
Cefotaxime 256.7 15.9 366.7 22.7 917.0 8.89 1910.4 18.5 257% -44% 421% -18% 
Ceftizoxime 156.1 12.0 226.2 17.4 1351.0 30.8 1986.8 45.3 765% 156% 778% 160% 
Cefalexine 331.8 12.6 378.8 14.4 805.0 92.4 981.7 112.7 143% 633% 159% 683% 
Cefoxitin 160.1 10.3 333.5 21.4 2212.0  3351.5   1282% -100% 905% -100% 
cefazolin 64.0 8.7 621.2 84.8 385.7 12.81 2268.8 75.4 503% 47% 265% -11% 
Cefuroxime 255.9 20.2 462.8 36.6 147.0 700.25    -43% 3360%   
Cefoperazone 106.4 10.5    639.1 22.4 1452.5 50.9 501% 113%   
Cephradine 298.9 15.6 346.8 18.1 431.9 29.82 526.7 36.4 44% 91% -62% 101% 
Clavulanic 
acid 157.7 11.5    1470.0 231 1771.1 278.3 832% 1917%   
cefpiramide 57.4 10.5    665.7 18.2    1060% 73%   
Cefalothin 330.0 7.4 1145.8 25.6 2254.0 10.5 4445.8 20.7 583% 43% 288% -19% 
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Figure 10.4. Predicted Human CLtot from Rat PK  vs. Observed Human CLtot 
 
   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds  
In the 0.5-2 
fold error 
range 










CLtot 18 557 









 Vdss 18 372  
(± 206 %) 
929 
 
14.0 (± 10.5) 0.10 8/18 
(44 %) 
 CLtotu 9 435 







 Vdssu 8 130 








































Observed human Vdss (L)
 

















Figure 10.6. Predicted human CLtotu from rat PK  vs. Observed human CLtotu
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Table 10.8 One Species Scaling using Dog PK for β-LAs 
 

















Vdssu % Prediction error 
  [ml/min] [L] [ml/min] [L] [ml/min] [L] [ml/min] [L] CLtot Vdss CLtotu Vdssu 
                  [ml/min] [L] [ml/min] [L] 
Azlocillin 138.3 10.7 412.8 31.9 386.4 18.9    179% 76.6%    
Dicloxacillin 207.0 20.3    1047.2 99.4    406% 389.7%    
Cefprozil 226.7 18.5    151.9 14    -33% -24.3%    
Ceftizoxime 156.1 12.0 226.2 17.4 227.5 18.9 274.1 22.8 46% 57.0% 21.2% 30.5% 
Cefalexine 331.8 12.6 378.8 14.4 175 15.05    -47% 19.4%    
cefpodoxime 164.5 25.2    26.6 10.5    -84% -58.3%    
Ceftazidime 113.8 15.1    250.6 15.26    120% 1.1%    
Ceftriaxone 14.4 7.9    252.7 19.6    1655% 148.1%    
Imipenem 674.8 40.6    303.1 22.4    -55% -44.8%    
cefpiramide 57.4 10.5    359.1 34.3    526% 226.7%    
Cephaloridne 207.2 21.7 328.9 34.4 352.8 30.8 392.0 34.2 70% 41.9% 19.2% -0.6% 
Ceforanide 79.0 12.3    455 26.6    476% 115.7%    
Cephapirin 654.5 15.4    792.4 22.4    21% 45.5%    
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Figure 10.8. Predicted Human CLtot from Dog PK vs. Observed Human CLtot 
 
   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds  
In the 0.5-2 
fold error 
range 










CLtot 13 252 









 Vdss 13 76 
(± 34 %) 
141 
 


























10.1.3.2. Two-species BW Scaling 
10.1.3.2.1. Two-species BW Scaling for CLtot 
Table 10.10 and 10.11 shows the observed human PK parameters and predicted 
human PK parameters using two species BW scaling method. Table 10.12 and 
Figure 10.10-10.11 show that there was an overprediction from this method. The 
analysis was carried out for a very small number of compounds due to lack of 
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Ceftizoxime 4.83 36.56 1.00 0.53 96.6 156.10 
Cefalexine 3.05 30.00 0.83 0.60 86.8 331.80 
Cefpiramide 2.14 56.43 0.88 0.84 267.7 57.40 
Cephaloridine 2.99 113.40 0.90 0.85 298.1 207.20 
       
Line of  identity Line with slope = 0.5 Line with slope = 2.0
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Observed human Vdss (L)
 














Ceftizoxime 0.11 3.04 -0.43 0.87 15.0 12.0 
Cefalexine 0.35 2.58 -0.16 0.53 6.5 12.6 
Cefpiramide 0.06 5.37 -0.47 1.16 45.6 10.5 
Cephaloridine 0.13 9.79 -0.38 1.02 31.0 21.7 
       
Line of  identity Line with slope = 0.5 Line with slope = 2.0
  282
 




10.1.3.3. GFR ratio method  
10.1.3.3.1. GFR ratio method using rat and dog PK 
Table 10.13 and 10.14 shows the observed and predicted human CLren using GFR 
ratio method. Table 10.15 and Figure 10.12-10.13 show that there was an overall 
overprediction. In comparison with predictions using dog data, GFR ratio method 
using rat PK data showed lower prediction errors as well as more number of 
compounds in the 0.5-2.0 fold error range. The analysis gave was carried out for a 








   Prediction errors 
   Bias Imprecision 
Regression No. of 
compounds in 
0.5-2 fold error 
range 
Method Parameter n %MPE 
(±SE) 




CLtot 4 75 (± 100) 189 -0.51 
(± 0.59) 
0.27 2/4  
(50 %) 





Table 10.13. GFR Ratio Method using Rat PK 









CLrenu CLren CLrenu 
  [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] [ml/min/kg] 
              
Mezlocillin 3.2 4.92 2.92 4.2 -9% -15% 
Moxalactam 0.75   2.27   203%   
Cefazolin 0.87 8.7 1.68 9.9 93% 14% 

















































Line of  identity Line with slope = 0.5 Line with slope = 2.0 
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Table 10.14. GFR Ratio Method using Dog PK 
Drug Observed   Predicted % Prediction error 
  Human CLren 
Human 
CLren CLren 
  [ml/min/kg] [ml/min/kg] [ml/min/kg] 
        
Cefprozil 2.1 0.4 -81% 
Ceftazidime 1.4 0.9 -36% 
Ceftriaxone 0.1 0.7 555% 
Cefpiramide 0.14 1.0 646% 
Ceforanide 0.8 14.5 1713% 












































Line of  identity Line with slope = 0.5 Line with slope = 2.0
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There were considerable differences in reported, BW-corrected, CLtot and Vdss values across 
species (range: 1 to 80-fold, 1 to 25-fold, respectively) for β-LAs. PPB was not similar across 
different species, with rat fu accounting for only 60 % variability in human fu. Sawada et al99 
found a good correlation between fu- human and fu-rats for weakly acidic and basic drugs (n 
= 14, Slope = 1.85, r2 = 0.92). β-LAs are acidic and hydrophilic drugs with log D (at pH 7.4) 
less than 1.0 and thus, most of the β-LAs showed fe values > 50 % indicating that these drugs 
are mainly excreted by kidneys across different species. Most of the β-LAs showed 
intermediate PPB (30-70 %). Acidic drugs bind strongly to serum albumin.110 Based on the fu 
and Vt/fut values, Sawada et al99 showed that acidic drugs weakly bind to the tissues and a 
little difference with regards to Vt/fut between rat and human. A good correlation was found 
between V or Vdss (rat) and V or Vdss (human) (n = 15, Slope = 0.848, r = 0.848). The 
relationship between (Vt/fut)human and (Vt/fut)rat was found to be better (n = 15, Slope = 0.951, 
r = 0.958).  In-addition, Sawada attributed interspecies differences in t1/2, metabolic clearance 
   Prediction errors 
   Bias Imprecision 
Regression 
Method Parameter n %MPE 
(±SE) 
%RMSE Slope r2 
No. of 
compounds 







CLren 4 247  














and Vdss to differences in fu. In the present analysis on β-LAs, fu correction lead to 
improvement r2 values, decrease in prediction errors and resulted in more number of 
compounds in the 0.5-2.0 fold error range. Sawada et al108 studied prediction of six β-LAs in 
humans from PK paramters in animals and showed that there was a positive relationship 
between Vss and fu  (slope = 0.173-0.644, r = 0.401-0.967). Simple allometry showed that 
most of the β-LAs have low slopes (< 0.70) for n =3 as well as for n = all available animals 
for CLtot. Renal blood flow (RBF) and GFR (ml/min/kg) decrease as the animal size 
increases in an allometric manner. The exponent values were 0.84 for RBF and 0.78 for GFR 
4 were steeper than the slopes obtained from allometric relationships for CLtot and CLren  for 
β-LAs. This might be due to the possible involvement of drug transporters in the disposition 
of β-LA. Mahmood et al43 tried to predict CLtot, CLren  and Vdss  in humans from animal data 
for ten drugs which were mainly renally secreted in humans. The slopes for simple allometry 
for CLtot ranged from 0.71-0.93, however, ofloxacin, a known OAT substrate, showed a 
lower slope of 0.583. Sawada et al108 predicted the disposition of six β-lactam antibiotics 
using mouse, rat, rabbit, dog and human PK data. The log-log relationship between 
clearances (CLtot and CLren) and body weight showed low slopes, 0.405-0.662 (n = 5, mean: 
0.574) for CLtot and 0.429-0.713 (n = 5, mean: 0.628) for CLren. It was also found that 
unbound intrinsic clearance (CLintu) was proportional to the 0.45-0.74 power of body weight. 
Literature studies show that β-lactam antibiotics like cephalsporins and penicillins show net 
secretion and it is has been reported that some cephalosporins interact with hOAT1, hOAT2 
and hOAT3.22, 93, 94  Jariyawat et al88 showed inhibition of p-aminohippurate transport via rat-
OAT1 by penicllins and cephalosporins. 
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       Various prediction methods like one-species BW scaling, two-species (rat, dog) BW 
scaling and GFR ratio methods were used to predict CLtot, CLren, and Vdss. Due to lack of fu 
information available across different species, predictions for CLtotu and Vdssu could be made 
only for few compounds using one-species method. Similar to the earlier findings from 
opioid and β-ARL interspecies scaling study, dog was found to be the best species using the 
one species method for prediction of CLtot, Vdss, CLtotu and Vdssu and plasma protein binding 
correction decreased prediction errors and resulted in more number of compounds in the 0.5-
2.0 fold error range. 
              It is known that renal physiology has a good relationship with BW. Thus, renal 
excretion in humans can be extrapolated from animal PK. Ceftizoxime and aztreonam PK 
and plasma concentration profiles have been extrapolated from the animal data using 
allometric approach.111-113 GFR ratio method has been successfully used to predict CLren of 
famotidine and ACE inhibitors like enalapril and lisinopril.114-116 In the present research on β-
LAs, GFR ratio method using rat PK gave better predictions for human CLren than those 
obtained using dog PK, however, these conclusions are based on a small number of drugs.   
Like opioids and β-ARLs, body size accounted for most of the observed variability 
(r2> 0.80) in systemic PK variables in the animal species studied for β-LAs. Like hydrophilic 
β-ARLs, CLtot and CLren for β-LAs showed good correlation with the BW, however, the 
slopes were shallow, which may be attributed to involvement of hepatobiliary and renal 
transporters. Dog was found to be the species giving the best prediction of CLtot, Vdss, CLtotu, 
Vdssu using the one species methos while rat was the best species for prediction of CLren 







11. Comparative Analysis of Opioids, β-ARLs and  β-LAs 
11.1. Comparison of physicochemical properties of opioids, β-ARLs and  β-LAs 
Figure 11.1-11.7 shows the distribution for the molecular descriptors for opioids, β-ARLs 
and the β-LAs. Both opioids and β-ARLs, are basic compounds with molecular weights 
ranging from 200-500 Dalton. The opioid dataset is more skewed towards lipophilic 
compounds (log (D)7.4 values ranging from -4.1 to 3.7), while the β-ARL dataset is a 
combination of hydrophilic as well as lipophilic compounds (log (D)7.4 values ranging from -
2.9 to 3.1). Morphine is a prototypical opioids, and most of the opioids in the dataset were 
found to be based on the typical morphine-like, rigid scaffold. Hence, the opioid dataset has 
smaller nRot values compared to the β-ARL dataset, which contains drugs with one or more 
aromatic rings and long side chains, making the structures more flexible.  Since β-ARL 
dataset is a combination of hydrophilic and lipophilic compounds, they also show HBAs, 
HBDs and PSA values higher than for opioids. In contrast to the opioid and β-ARL datasets, 
β-LAs are acidic, hydrophilic molecules (log (D)7.4 values ranging from -7.3 to 2.5) with 
larger MWs ranging from 199-700 Dalton, showing higher HBAs, HBDs and PSA values. 
Most of the β-LAs have structures which had fused rings as well as long side-chains, thus, 
nRot were the highest of the three classes. Overall, opioids and β-ARLs had a large diversity 
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in log (D)7.4 values while β-LAs show less diversity in log (D)7.4 values, but show slightly 






   
 
      
Figure 11.1. MW Distribution by Drug Class 
                                                                      
                                                      








































































































































































Figure 11.5. HBA Distribution by Drug Class 





























   
 









11.2. Comparison of PK Properties for Opioids, β-ARLs and  β-LAs 
Figure 11.8-11.16 shows the distribution for PK variables for opioids, β-ARLs and the β-
LAs. On average, the opioid dataset has more lipophilic compounds; as a result, most of them 
were cleared by nonrenal elimination, i.e., hepatic and extrahepatic clearance. 
Glucuronidation and phase I metabolism are known to be the main metabolic pathways.  
Amongst them, UGT2B7, CYP2D6, CYP3A, CYP2C9, and CY2C19 play the major role in 
opioid metabolism.  In addition, membrane transporters like P-glycoprotein (P-gp) determine 
the hepatic/renal/efflux of some opioids like morphine, alfentanil, fentanyl, loperamide and 
sufentanil.85 Out of 38 opioids, only two opioids, M3G and M6G, showed fe values above 
50%, while all others were mainly non-renally cleared (fe < 50%); fourteen opioids showed 
CLtot or CLnonrenblood values exceeding LBF or even CO, indicating extrahepatic/nonrenal 
clearance, e.g., ester hydrolysis, in blood and other body tissues. Compared to the opioids, 
the β-ARL dataset was a combination of hydrophilic as well as lipophilic compounds. Out of 
49 β-ARLs, 14 compounds showed fe values exceeding 50% while all others were mainly 
metabolized (fe < 50%), and seven compounds showed CLtot or CLnonrenblood values exceeding 
LBF or CO, indicating extrahepatic/nonrenal clearance.  Thus, for most β-ARL, similar to 
opioids, CLtot was primarily due to nonrenal elimination, i.e., hepatic and extrahepatic 
clearance.  For both the datasets, the median Vdss and Vdssu values exceeded BW and total 
body water, indicating extensive tissue sequestration for most compounds.  
Unlike opioids and β-ARLs, β-LAs are hydrophilic molecules with larger molecular 
weights, thus show lower Vdss and Vdssu, indicating a low extent of tissue distribution. They 
also have lower values for CLtot, CLtotu and CLnonren and more number of compounds 
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showing fe above 50 %;  indicating they are low ERhep drugs (with low CLint, with the 
possibility of biliary excretion and involvement of hepatic drug transporters), mainly 
excreted unchanged by kidneys, again involving drug transporters. The median CLren u values 
for β-LA and β-ARL dataset was more than GFR, indicating net tubular secretion. Membrane 
transporters like P-gp, OCTs and MRP2 are involved in transport of some β-ARL86, 87 while 
literature studies reports that β-LAs like cephalsporins and penicillins show net tubular 
secretion, and it is has been reported that some cephalosporins interact with hOAT1, hOAT2 
and hOAT3.22, 93, 94  Hydrophobicity and basicity have been indicated to be the major 
determinants of substrate interaction with OCTs, while hydrophobicity and acidity have been 
shown to be associated with OAT interactions.  Futhermore, hydrogen bonding ability have 
also been shown to stabilize the substrate-transporter complex.95 Thus, it is speculated that 
the involvement of drug transporters in the disposition of β-ARLs and β-LAs is due to the 




































Figure 11.9. CLtot Distribution by Drug Class

















Figure 11.10. CLren Distribution by Drug Class 
 



























Figure 11.11. CLnonren Distribution by Drug Class 
 




































































Figure 11.13. Vdssu  Distribution by Drug Class (Note: Log values plotted in the graphs for visual inspection) 
 
 















































































Figure 11.15. CLnonrenu Distribution by Drug Class 

















































12. Pooled Data Analysis for Opioids, β-ARLs and  β-LAs 
12.1. Characterization of molecular descriptor space 
Figure 12.1 shows the relationship between log (D)7.4 and other molecular descriptors such as 
MW, HBA, HBD and nRot across all three classes of drugs. 
The effect of log (D)7.4 on the MW was studied by dividing the pooled dataset into number of 
MW bins. This allowed us to come up with average cut-offs. It was observed that when the 
log (D)7.4 is less than approximately -2.0 and MW  greater than the value of approximately 
350 Dalton (D), MW decreases with increase log (D)7.4 (Figure 12.1 (A)). Above log (D)7.4 ~ 
- 2.0 and MW < 350 D, there is no apparent relation between log (D)7.4 and MW. The space 
below log (D)7.4 < - 2.0 is occupied by  β-LAs, mainly second and third cephalosporins and 
few penicillins like mezlocillin and furazlocillin. β-LA structures evolved over time in the 
quest of achieving better broad spectrum activity, or acid/ β-lactamase stability and in doing 
so, long side chains were added with many HBAs and HBDs, giving rise to second and third 
cephalosporins and resulting in a increase in MW and a decrease in polarity.  Figure 12.1 (B) 
shows that there is a significant relationship between log (D)7.4 and HBA (n =146, r2 =  0.57, 
slope =-1.06 units). Hydrophilic β-LA show larger number of HBAs and lipophilic opioids 
show the least number of HBAs. There is also a significant relationship between log (D)7.4 




the relationship between HBA and log (D)7.4, probably due to the smaller range of HBA 
values as compared to HBDs. For the pooled data, there was no trend observed between nRot 
and log (D)7.4 (Figure 12.1(D)), however, within the individual classes, nRot tends to increase 
with increase in log (D)7.4 for opioids while they decrease with increase in log (D)7.4 for β-
LAs. Opioids with lower log (D)7.4  have morphine-like, rigid structure and less nRot, while 
more lipophilic opioids don’t have the morphine-like, rigid structure, instead, have long side 
chains, making those flexible. Hydrophilic β-LAs have long side chains as compared to the 
less hydrophilic β-LAs, resulting in β-LAs with low log (D)7.4 values with more flexibility. 
The pooled dataset shows that there is a significant relation between MW and number of 
HBA (n = 146, r2 = 0.74, slope = 0.03 units) and HBDs (n = 146, r2 = 0.18, slope = 0.007 
units) (Figure 12.2(A) and (B)). Larger MW β-LAs show higher HBA and HBD values while 
low MW opioids show least number of HBA and HBD values. For the pooled dataset, there 
is a significant relationship between MW and nRot (n =146, r2 = 0.12, slope = 0.01 units) 
(Figure 12.2 (C)). To summarize the molecular descriptor space: 
 
• MW and log (D)7.4 appear to be the  most important properties. (see next chapter) 
• The effect of log (D)7.4 on the MW was studied by dividing the pooled dataset into 
number of MW bins and the average cut offs are: When the log (D)7.4 < -2.0, MW 
decreases with increase in log (D)7.4, while, when log (D)7.4 > -2.0, MW is 
independent of log (D)7.4.  























































Figure 12.1. Effect of log (D)7.4 on the Other Molecular Properties 
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Figure 12.2.  Effect of MW on the Other Molecular Properties 
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12.2. Effect of Molecular Descriptors on the fu for the Pooled Dataset 
Figure 12.3 (A-E) shows the effect of different molecular descriptors such as log (D)7.4 , 
MW, HBA, HBD and nRot on the fu values for the pooled dataset. Figure 12.3 (A) shows 
that below log (D)7.4 ~ -2.0, there is no relationship between fu and log (D)7.4, however, as the 
log (D)7.4 exceeds -2.0, there is an apparent decrease in fu with increase in log (D)7.4.  Figure 
12.3 (B) shows that below MW ~ 350 D, there is no relationship between fu and MW, 
however, as the MW exceeds -350 D there is an apparent decrease in fu with increase in MW. 
The observed relationships between fu and the rest of the molecular descriptors such as HBA, 
HBD and nRot are a consequence of collinearity amongst the molecular descriptors (HBA- 
log (D)7.4, HBA- MW and nRot-MW).  
Thus, overall, it appears that log (D)7.4 is an important determinant for fu of compounds 
with log (D)7.4 values above -2.0 and MW less than 350 D, while MW is an important 
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12.3. Effect of log (D)7.4 on the PK variables for the Pooled Dataset 
Figure 12.4 (A-D) shows the effect of log (D)7.4 on the biologically relevant PK variables 
Vdss u, CLtot u, CLren u and CLnonrenu.   
Below log (D)7.4 values of  -2.0, Vdss u is independent of log (D)7.4, however, above log (D)7.4  
values of -2.0, there is a strong relationship between the Vdss u and log (D)7.4; as  log (D)7.4  
increases, Vdssu increases, indicating increase in tissue sequestration (Figure 12.4(A)). For the 
compounds with log (D)7.4 below -2.0, Vdss u is small, approaching to plasma volume values 
below 0.04 L/kg, indicating limited extravascular distribution.   
Figure 12.4 (B) shows that for log (D)7.4 value below -2.0, CLtot u is independent of log 
(D)7.4 , however, above a log (D)7.4 value of  -2.0, there is a strong positive relationhip 
between the CLtot u and log (D)7.4. Above a log (D)7.4  value of  -2.0,  CLtot u depends on 
CLrenu and CLnonrenu. For these compounds with log (D)7.4 above -2.0, there is no change in 
CLrenu with log (D)7.4 (Figure 12. 4(C)), while CLnonrenu increases with log (D)7.4 (Figure 12. 4 
(D)). For compounds with log (D)7.4 above -2.0, the fe declines with log (D)7.4 due to 
increased importance of metabolic clearance, making the estimates for fe or CLren less 
accurate for those compounds. Thus, the relationship between CLtotu and log (D)7.4 is 
dominated by CLnonrenu, which, in turn, increases with log (D)7.4, due to increase in CLint.  
 Figure 12.5 (A-D) shows the effect of log (D)7.4 on  PK variables Vdss , CLtot , CLren  and 
CLnonren.  As log (D)7.4 increases above -2.0, Vdss increases, while below log (D)7.4, Vdss is 
independent of log (D)7.4 (Figure 12.5 (A)). Above log (D)7.4 value of -2.0, two opposing 
forces act on Vdss; fu decreasing with log (D)7.4 and Vdssu increasing with log (D)7.4 (Figure 
12.3 (A), Figure 12.4(A)); , however, the effect of Vdssu dominates the effect of fu.  
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Similarly, as  log (D)7.4 increases above -2.0, CLtot increases, while below log (D)7.4, CLtot 
is independent of log (D)7.4 (Figure 12.5 (B)). Above log (D)7.4 value of -2.0, two opposing 
forces act on CLtot; CLtotu increasing with log (D)7.4 and fu decreasing with log (D)7.4, 
however, the effect of CLtotu and in turn, the effect of CLint  dominates the effect of fu. Below 
log (D)7.4 value of -2.0, fu  and CLtotu are independent of log (D)7.4 (Figure 12.3 (A), Figure 
12.4 (B)). This may be due to the dominant effect of low ERhep drugs below log (D)7.4 of -2.0 
and high ERhep drugs above log (D)7.4 of -2.0.   
 CLren is independent of log (D)7.4  below log (D)7.4 value of -2.0, however, above log 
(D)7.4  of  -2.0, CLren decreases with log (D)7.4 (Figure 12.5 (C)). The CLren of the drugs above 
log (D)7.4 of -2.0  is dependent on fu and CLrenu ; fu decreasing with log (D)7.4 (Figure 12.3 
(A)) and CLrenu independent of log (D)7.4 (Figure 12.4 (C)), resulting in CLren decreasing with 
log (D)7.4, due to the dominant effect of log (D)7.4 on fu .  
Figure 12.5 (D) shows that CLnonren is independent of log (D)7.4  below log (D)7.4 value of 
-2.0, however, above log (D)7.4 value of -2.0, CLnonren increases with log (D)7.4. The CLnonren 
of the drugs above log (D)7.4  value of -2.0  is dependent on fu and CLnonrenu ; fu decreasing 
with log (D)7.4 (Figure 12.3 (A))and CLnonrenu increasing with log (D)7.4 (Figure 12.4 (D)), 
resulting in CLnonren increasing with log (D)7.4, due to the dominant effect of CLnonrenu. Below 
log (D)7.4 value of -2.0, the compounds have large MWs, are hydrophilic and have low 
CLnonrenu (low ERhep). In addition, their fu is independent of log (D)7.4 ((Figure 12.3 (A)). 




Figure 12.4. Effect of log (D)7.4 on the Biologically Relevant Variables for the Pooled Dataset 
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12.4. Effect of MW on the PK variables for the Pooled Dataset 
Figure 12.6 (A-D) shows the effect of MW on the biologically relevant PK variables like Vdss 
u, CLtot u, CLren u and CLnonrenu. There is no apparent effect of MW on Vdss u, CLtot u, CLren u 
and CLnonrenu.  
Figure 12.7 (A-D) shows the effect of MW on the PK variables Vdss , CLtot , CLren  and 
CLnonren. For the entire dataset, there is a significant relation between Vdss and MW (n = 146, 
r2= 0.32, slope =-0.008 units) (Figure 12.7(A)), the regression being governed by very high 
Vdss values below MW~ 350 D and very low Vdss values above MW~ 350 D. The Vdss 
values are dependent on Vdssu and fu, both of which are independent of MW for compounds 
below MW~ 350 D (Figure 12.3 (B), Figure 12.6 A), thus, there is no relation between Vdss 
and MW for compounds below MW~ 350 D. Above MW~ 350 Da, the Vdss values are 
dependent on fu, which decreases with MW (Figure 12.3 (B)) and Vdssu independent of MW 
(Figure 12.6 A), thus, resulting in overall decrease in Vdss, due to the dominant effect of fu.  
For the entire dataset, there is a significant relation between CLtot and MW (n = 145, r2= 
0.23, slope =-0.006 units) (Figure 12.7(B)), the regression being governed by very high CLtot 
values below MW~ 350 D and very low CLtot values above MW~ 350 D. The CLtot values 
are dependent on CLtot u and fu, both of which are independent of MW for compounds below 
MW~ 350 D (Figure 12.3 (B), Figure 12.6 B), thus, there is no relation between CLtot and 
MW for compounds below MW~ 350 D.  Above MW~ 350 D, the CLtot values are dependent 
on fu, which decreases with MW (Figure 12.3 (B)) and  CLtot u independent of MW (Figure 
12.6 (B)), thus, resulting in a decrease in CLtot with MW, overall relation being dominated by 
the effect of MW on  fu.        
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The CLren values are dependent on CLren u and fu, both of which are independent of MW 
for compounds below MW~ 350 D (Figure 12.3 (B), Figure 12.6(C)), thus, there is no 
relation between CLren and MW for compounds below MW~ 350 D.  Above MW~ 350 D, 
the CLren values are dependent on fu, which decreases with MW (Figure 12.3 (B)) and CLren u 
independent of MW (Figure 12.6 (C)); resulting in CLren  decreasing with MW (Figure 12.7 
(C)), the overall relation being dominated by effect of MW on fu.   
For the entire dataset, there is a significant relation between CLnonren and MW (n = 119, 
r2= 0.25, slope =-0.009 units) (Figure 12.7(D)), the regression being governed by very high 
CLnonren values below MW~ 350 D and very low CLnonren values above MW~ 350 D. The 
CLnonren values are dependent on CLnonren u and fu, both of which are independent of MW for 
compounds below MW~ 350 D (Figure 12.3 (B), Figure 12.6 (D)), thus, there is no relation 
between CLnonren and MW for compounds below MW~ 350 D.  Above MW~ 350 D, the 
CLnonren values are dependent on fu, which decreases with MW (Figure 12.3 (B)) and CLnonren 
u independent of MW (Figure 12.6 (D)), thus, resulting in CLnonren  independent of MW 
(Figure 12.7 (D)), the overall relation being dominated by effect of MW on CLnonren u. 
Thus, for the pooled dataset, log (D)7.4 and MW are the only statistically significant and 
biologically plausible molecular descriptors affecting the biologically relevant PK properties 
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Figure 12.7. Effect of MW on the PK Variables for the Pooled Dataset 
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12.5. Effect of Molecular descriptors on the AS-PK Slopes for CLtot for the Pooled 
Dataset 
Figure 12.8 (A-E) shows the effect of different molecular descriptors like log (D)7.4 , MW, 
HBA, HBD and nRot on the AS-PK CLtot slopes for the pooled dataset. There is no particular 
trend between the slopes for CLtot and the molecular descriptors for the pooled dataset. 
However, as the log (D)7.4  increases , CLtot slopes for β-LAs show an upward trend (Figure 
12.8 (A)), while as MW and HBA increases (Figure 12.8 (B) and (C)), CLtot slopes for β-LAs 
shows a downward trend, though not significant. As the nRot increases, there is a siginificant 
decrease in CLtot slope for opioids (n =18, r2 = 0.24, slope = -0.03 units) (Figure 12.8 (E)).  
 Figure 12.9 (A-E) shows the effect of different molecular descriptors like log (D)7.4 , 
MW, HBA, HBD and nRot on the AS-PK Vdss slopes for the pooled dataset. There is no 
particular trend between the Vdss slopes and the molecular descriptors for the pooled dataset. 
However, as the MW and HBAs increase, Vdss slope decreases for β-LAs, though not 
significant (Figure 12.9 (B) and (C)). As the nRot increases, there is a siginificant increase in 
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Figure 12.9. Effect of Molecular Descriptors on the PK-AS slope of Vdss for the Pooled Dataset 
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13. Overall Conclusions 
The majority of chemical drug candidates entering clinical testing for safety and efficacy 
ultimately fail to reach the market place, among other things due to the lack of better 
understanding of their ADME properties in early drug development.1, 2 The overall process of 
drug development is extremely time consuming and expensive, making early screening of drug 
candidates imperative.  Human and animal PK databases have been used succesfully to 
understand the relationhip between chemical structure and PK behavior of the drugs.13, 19, 39, 40, 109 
For such analyses, it is a prerequisite that the physicochemical and biological properties in the 
database should have a wide range, distribution, and published information on PK variables 
should be available for a sufficient number of analogs belonging to the same class of compounds. 
Most of the QSPKR studies in the literature are either on homologous series of compounds 
(resulting from systematic variation in the structure of the lead compounds) or on heterogenous 
datasets which have compounds from different structural and pharmacological classes.16, 21-23 
The use of a homologous series, which enables to identify the contribution of each 
substituent/functional group, results in a narrow range of molecular properties, which makes 
identification of important molecular properties difficult; on the other hand, the widespread use 
of MLLR/univariate regression on heterogenous datasets may neglect major interaction(s) 




Foral since they used the systemic exposure data after oral administration in 
humans/animals.26, 30, 31 The involvement of a complex phenomenon such as oral absorption can 
make these predictions difficult, even more compared to systemic ADME.  Therefore in the 
present research, the focus was on systemic PK properties (i.e., after IV administration) to get rid 
of the confounding effects of pral absorption, which may depend on different molecular 
properties. In the present research, a database of human PK parameters was gathered for 146 
drugs. Each value was obtained after critical evaluation of study design, dosage regimen, 
sampling schedule, methods of sample analysis and PK analysis methods. Most of the databases 
in the literature built models for total PK properties, i.e., not corrected for PPB. However, it is 
assumed that only unbound drug is available for distribution, excretion and metabolism and 
interaction with the target drug receptors and hence, this research built QSPKR and AS-PK 
models using biologically relevant, i.e., unbound PK variables. In-addition, the selected drugs 
were structural analogs, acted on a common pharmacological target and, at the same time, 
showed considerable diversity in their physicochemical and PK properties. Moreover, the effect 
of more than one molecular property on the PK variables was studied at a time, thus, also 
exploring the possibility of interactions amongst the molecular properties. However, the 
following limitations of this database should also be acknowledged: 
(i) The database was a “convenience sample” based on the available information in 
literature; not a result of systematic variation of structure. Each drug in the final database 
had human PK information after I.V. administration. Limited information was available 
on animal (rat and dog) PK and the dataset shrunk furthermore for unbound PK variables 
due to lack of information on PPB across different species.   
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(ii) Primary PK variables, obtained from literature references, varied from drug to drug with 
regard to dose level, number of subjects, sampling times, analytical methods and thus, 
were subject to potential bias and imprecision as a result of study design and methods. 
(iii) The final values for PK variables were means of PK property values obtained from 
different studies, and the methods did not account for intersubject variability. Interspecies 
differences in the metabolic pathways and drug transporters could not taken into account 
in PK-AS methods other than a change in allometric relationship. 
(iv) Dose-proportional systemic PK was assumed.  
(v) For some drugs, extrahepatic clearance could only be suspected based on high 
CLnonrenblood values without mechanistic proof.  
(vi) For some drugs, especially with high log (D)7.4, fe or CLren may have been poorly 
estimated due to its small value.  
Nevertheless, this QSPKR database should be able to provide an insight into relationship 
between structure and PK and interspecies differences. Opioids were selected as the dataset for 
preliminary studies because they are structural analogs and, at the same time, show considerably 
diverse physicochemical and PK properties. To make this research project more generalizeable 
in terms of types of compounds studied, this research was extended to two additional classes of 
compounds belonging to two different chemical and pharmacological classes: β-ARLs and β-
LAs.  The final dataset contains small MW (200-500 D), highly lipophilic, basic compounds 
which are primarily eliminated by liver as well as large MW (500-700 D), highly hydrophilic, 
acidic compounds which are primarily excreted by kidneys. Though the molecular property 
space of the present database is quite large, addition of neutral molecules, compounds having 
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MW more than 700 D and lesser than 200 D and compounds from other pharmacological classes 
will increase the diversity and generalizability of the database. QSPKR and AS-PK models were 
built for the datasets for the individual drug class; however, only trend/discriminatory analysis 
was done on the pooled dataset. Overall conclusions of the initial efforts towards predicting 
human PK using QSPKR and interspecies scaling are given below.  
 Using available information for the three pharmacological classes of drugs, namely 
opioids, β-ARLs and β-LAs, it was hypothesized that: 1) molecular properties can be used to 
quantitatively to predict systemic human PK; however, the molecular properties responsible for 
the biologically relevant PK properties differ by class of drugs. 2) Human PK can be successfully 
allometrically scaled from rat and dog PK; however, the allometric scaling coefficient depends 
on the molecular properties drug properties. 
 To prove the first hypothesis, the relationship between molecular properties and PK 
properties was studied. Chapter 11 compares the molecular and PK properties across the three 
different dataset: opioids, β-ARLs and β-LAs. It was found that opioids and β-ARLs have a large 
diversity in log (D)7.4 values, while β-LAs show less diversity in log (D)7.4 values, but show 
slightly more diversity in MW, HBA, HBD and nRot values compared to opioids and  β-ARLs. 
For most β-ARL and opioids, CLtot was primarily due to nonrenal elimination, i.e., hepatic and 
extrahepatic clearance.  For both β-ARL and opioid, the median Vdss and Vdssu values exceeded 
BW and total body water, indicating extensive tissue sequestration for most compounds. In 
contrast, β-LAs show lower Vdss and Vdssu, some approaching blood/plasma volume, indicating 
a low extent of tissue distribution. β-LAs also have lower values for CLtot, CLtotu and CLnonren, 
their median CLrenu was higher than GFR and a larger number of compounds showed fe above 50 
%;  this indicates they are low ERhep drugs (with low CLint, and the possibility of biliary 
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excretion and involvement of hepatic drug transporters), mainly excreted unchanged by kidneys, 
undergoing tubular secretion, again involving drug transporters.22, 93, 94  Chapter 12 concentrates 
on defining the molecular property space for the pooled dataset; it was found that MW and log 
(D)7.4 were the most important molecular properties. The pooled dataset was divided into 
different ranges of MW bins (e.g. 200-400 D, 400-700 D) and the effect of log (D)7.4 was studied 
on those MW bins using a number of linear regressions to define the  cut-off values. In the past, 
studies carrying out discriminatory/trend analysis have divided the QSPKR databases into 
different categories such as charge/ionization state, therapeutic area or into different range of 
MW bins.16, 21, 22 The present trend analysis showed that on average, when the log (D)7.4 value 
was below -2.0 and MW value above 350 D, MW decreased with an increase in log (D)7.4, while, 
when log (D)7.4 was above -2.0 and MW value below 350 Dalton, MW was independent of log 
(D)7.4. HBA and HBD showed collinearity with MW and log (D)7.4. Generally, it is observed that 
the transit of the drug in the body involves movement of drug across several biological 
membranes which are composed of phospholipids layers and interaction with membrane bound 
proteins such as transporters, enzymes or receptors in order to elicit pharmacological action. This 
transit is a result of interplay amongst the different molecular descriptors.15, 26, 73 Based on the in-
vitro solubility and permeability studies for 2245 compounds in United States Adopted Name 
(USAN) database, Lipinski came up with a ‘Rule of Five’ concept which utilizes cut offs of log 
(P), MW, HBA and HBD to classify oral absorption. 17 The rule states that a compound is likely 
to have poor pral absorption if MW is more than 500 D, clog P> 5, there are more than five 
HBDs and more than 10 HBAs. The final dataset in this research contained 146 drugs (38 
opioids, 48 β-ARLs and 60 β-LAs) with a wide range of molecular properties; median clog(P): 
1.2 (-6.1 to 7.2), median clog (D)7.4: -0.95 (-7.3-3.7), median MW; 365 D (199-672), median: 
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nRot: 7 (1-15), median HBD: 3 (0-7) and median HBA: 6 (0-17). This database has a relatively 
small number of compounds and median values for clog(P), MW, HBD and HBAs are well 
below Lipinsiki’s ‘Rule of Five’, however, it contains information about compounds which have 
been approved by FDA or which were/are used in clinical settings. 
In the present trend analysis, using the average cut-off of log (D)7.4 value of -2.0 and MW 
value of 350 D, it was found that log (D)7.4 was found to be the statistically, the most significant 
and biologically plausible molecular property affecting the biologically relevant, systemic PK 
properties, namely fu, Vdssu, CLnonrenu for compounds with log (D)7.4 values exceeding  -2.0 and 
MW values below 350 Dalton. This cut-off included most of the opioids (n= 23) and β-ARLs (n= 
34) but very few while β-LAs (n = 2); thus, it was biased towards basic compounds. Figure 13.1 
shows the mechanistic paradigm, explaining the effect of log (D)7.4 on both biologically relevant 
and total PK variables. Table 13.1 shows the effect of log (D)7.4 on compounds with log (D)7.4  
values above -2.0 and MW value below 350 D.  
As log (D)7.4 increased, fu decreased, while Vdssu, CLtotu, CLnonrenu increased. Increasing 
lipophilicity resulted in increase in PPB due to hydrophobic interactions with plasma proteins. 
Basic compounds show high affinity towards α-acid glycoprotein due to an electrostatic 
interaction with the acidic residues.117 The unbound fraction in tissues is dependent on 
nonspecific hydrophobic interactions with lipids and tissue proteins. However, it is also 
speculated that bases show ion-pair interactions with the charged polar head groups of the 
phospolipids, resulting in increase in tissue binding and increase in Vdss and Vdssu.20, 21, 92 By 
converting Vdss, CLtot and CLnonren into Vdssu, CLtotu and CLnonrenu, the confounding impact of 
PPB was removed. This led to improvement in the trend between log (D)7.4 and the unbound PK 
variables, as shown by the increased/ steeper slopes for the unbound PK parameters. As log 
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(D)7.4 increased, due to the dominating effect of increase in Vdssu, there was an increase in Vdss, 
while the resultant increase in CLint lead to an increase in CLtot and CLnonren. CLrenu is 
independent of log (D)7.4, however, due to the dominating effect of fu, CLren decreases with log 
(D)7.4. These findings are corroborated by number of studies in the literature which studied the 
effect of log (D)7.4 on the PK variables.16, 20, 21 The order of effect of log (D)7.4 as indicated by the 
r2 on the PK variables is: Vdssu > CLnonrenu  > CLtotu > CLnonren > Vdss > CLtot. Overall, PPB 
(which increases with log (D)7.4  itself) tended to obscure the log (D)7.4 dependence of Vdss, CLtot, 
but was responsible for the decrease in CLren with log (D)7.4.  
 
Table 13.1.Effect of log (D)7.4 on compounds with log (D)7.4 >- 2.0 and MW < 350 D 
PK variable n Slope r2 
fu 49 -0.15 0.37 (p<0.05) 
log(Vdss) (L/kg) 57 0.16 0.26 (p<0.05) 
log(Vdssu) (L/kg) 48 0.35 0.54 (p<0.05) 
log(CLtot) (ml/min/kg) 59 0.14 0.15 (p<0.05) 
log(CLtotu) (ml/min/kg) 49 0.29 0.38 (p<0.05) 
log(CLnonren) (ml/min/kg) 46 0.28 0.34 (p<0.05) 
log(CLnonrenu) (ml/min/kg) 38 0.44 0.52 (p<0.05) 
log(CLren) (ml/min/kg) 46 -0.18 0.14 (p<0.05) 




Figure 13.1. Effect of log (D)7.4 on PK variables of Compounds with log (D)7.4 > -2.0 and MW < 350 D 
 
 
For compounds with log (D)7.4 less than  -2.0 and MW more than 350 D, .MW was found 
to be the statistically, the most significant  and biologically plausible molecular property, 
affecting fu. This cut-off included most of the β-LAs (n= 45) and very few β-ARLs (n= 2) 
and opioids (n = 3), and, thus, was biased towards acidic compounds. Figure 13.2 shows the 
mechanistic paradigm, explaining the effect of MW on both biologically relevant and total 
PK variables. Table 13.2 shows the effect of MW on the compounds with log (D)7.4 value 
less than -2.0 and MW value more than 350 D. 
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 For these compounds, as the MW increased, fu decreased, indicating increased hydrogen 
bonding interaction, resulting due to higher number of HBAs and HBDs in these large and 
polar compounds. Gleeson 21 determined structure-property guides for diverse molecules in 
the GSK database, which was divided into different ranges of MW bins. On an average, it 
was found that molecules with MW < 300 D were 72 % bound, molecules with MW between 
300 and 500 D were 54 % bound while molecules with MW between 500-700 D were 98.2 % 
bound. The multivariate PLS model results by Gleeson on the same dataset showed that MW 
had a significant, independent effect on PPB above lipophilicity. 118 In the present research, 
MW does not show any apparent effect on Vdssu, CLtotu, CLnonrenu and CLrenu. As the MW 
increased, due to the dominating effect of a decrease in fu, there was a decrease in Vdss, CLtot 
and CLren. These compounds have small volumes of distribution, approaching blood/plasma 
volumes, as well as lower values for CLtot, CLtotu and CLnonren and CLrenu greater than GFR. 
This indicates limited extravascular distribution, low ERhep ratio and net tubular secretion as 
the main mechanism at the kidneys, respectively. Varma et al22 studied the relationship 
between physicochemical properties and human renal clearance, which showed that in 
general, secreted compounds are hydrophilic, have higher MW, PSA, nRot and HBA/HBD 
count and and ionized at physiological pH. Thus, the small extent of distribution and 
elimination appears to be determined by interaction of HBAs and HBDs. Unlike the effect of 
log (D)7.4, effect of MW was significant on the total PK properties like Vdss, CLtot and CLren, 
due to the confounding significant effect of MW on fu.  




Table 13.2.Effect of MW on compounds with log (D)7.4 < - 2.0 and MW > 350 D 
PK variable n Slope r2 
fu 47 -0.001 0.15 (p<0.05) 
log(Vdss) (L/kg) 49 -0.002 0.19 (p<0.05) 
log(Vdssu) (L/kg) 47 0.00004 0.00006 (N.S.) 
log(CLtot) (ml/min/kg) 50 -0.003 0.29 (p<0.05) 
log(CLtotu) (ml/min/kg) 47 -0.001 0.03 (N.S.) 
log(CLnonren) (ml/min/kg) 48 -0.002 0.06 (N.S.) 
log(CLnonrenu) (ml/min/kg) 46 0.0006 0.005 (N.S.) 
log(CLren) (ml/min/kg) 48 -0.002 0.17 (p<0.05) 




Figure 13.2. Effect of MW on PK Variables of Compounds with log (D)7.4 <-2.0 and MW > 350 D 
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 To prove the second hypothesis, human PK properties (CLtot, Vdss and their unbound 
counterparts) were scaled from rat and dog PK properties for the three different datasets: 
opioids, β-ARLs and β-LAs. For most compounds, animal body size accounted for most of 
the observed variability (r2>0.80) in systemic PK variables in the animal species studied. 
Single-animal (rat, dog) methods provided acceptable predictions for CLtot, Vdss, CLren and 
their unbound counterparts; thus, these findings suggest that the use of three or more species 
may not be necessary. Overall, the dog was found to be the species giving the best prediction 
of CLtot, Vdss, CLren, CLtotu, CLrenu and Vdssu. However, these predictions were based on the 
limited amount of data available in the literature. Prediction methodologies in the literature 
concentrate on more than one species because it is believed that  high r2 values among three 
species is an indication of achieving better prediction of human PK. However, Boxenbaum 
showed that human antipyrine CLtot was poorly predicted despite high r2 values and use of 
multiple species.37 Similar observations have been made by Ward et al13 for a database of 
103 marketed compounds. Studies have been published which have shown that r2 is not a 
good measure of predictive ability of the allometric relationship.36, 46 In fact, allometry often 
leads to large overpredictions which can be reduced by incorporating PPB differences 
amongst different species.52, 119, 120 This corroborated our findings which showed that fu 
correction of CLtot, Vdss and CLren improved goodness of fit, lowered prediction errors and 
resulted in human predictions within acceptable range for a larger number of compounds. 
Hosea et al 56 predicted human PK from rat, dog and monkey data for 50 proprietary 
compounds that had progressed to clinical studies; the database spanned several chemical 
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classes and therapeutic areas with a range of physicochemical properties and elimination 
routes by metabolism and non-metabolism processes. The findings were similar to the 
present research, wherein single species methods were found to be at least as accurate as in 
predicting human PK than allometric methods using multiple species, regardless of clearance 
mechanism. The use of unbound concentrations resulted in more accurate predictions. 
However, Hosea et al 56 obtained poor predictions for the class of compounds showing 
involvement of active transport and attributed this to the possible differences in drug 
transporters. The database in the present research has compounds which are substrates for 
drug transporters like P-gp, MRP2, OATs and OCT. 86-88, 121, 122 The present research also 
showed that, in general, CLnonren and CLnonrenu were most difficult parameters to predict, 
possibly due the associated interspecies differences in the metabolic pathways and 
hepatobiliary drug transporters. Thus, with the objective of improving accuracy of 
interspecies predictions, associations between prediction errors and allometric coefficients 
were explored (Section 12.5). It was hypothesized that understanding of molecular properties 
for inliers or outliers for each species would increase the accuracy of the interspecies 
predictions. In the past, Jolivette et al51 tried to determine whether calculated molecular 
properties may be used to predict the extrapolative success and failure of rat, dog and 
monkey data to predict human PK. It was found that extrapolation from rat and dog is more 
likely to accurately predict human CLtot for molecules that are relatively small and 
hydrophilic compared to larger, more lipophilic compounds. Jolivette et al51 also found that 
rat CLtot will not be predictive of human for molecules that have a clog(P) value more than 0 
and that molecules with high CLtot in rat but with clog(P) more than 3 will not have high 
CLtot in humans. However, in the present research, no apparent relationship was found 
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between AS slopes/inter-species predictions across different classes and the molecular 
properties, although this conclusion was based on limited amount of data available from 
literature. For hydrophilic β-ARLs and β-LAs, CLtot and CLren showed good correlation with 
BW; however, the allometric slopes were shallow, which may be attributed to involvement of 
hepatobiliary transporters. Irrespective of the species, high CLtot and Vdss were found to be 
associated with high log (D)7.4, low MW, low number of  HBA/HBDs and low nRot, while 
low CLtot and Vdss were associated with low log (D)7.4,  high MW, high number of 
HBA/HBD and high nRot. Thus, the effect of molecular descriptors such as log (D)7.4 , MW, 
HBA, HBD and nRot on the PK properties of the pooled dataset for rat and dog were similar 
to humans, which may also a plausible reason for the lack of apparent relationship between 
AS slopes/inter-species predictions across different classes and the molecular properties.   
 Overall, QSPKR and Interspecies Scaling provided acceptable predictions for PK 
variables for individual datasets of opioids and β-ARLs. However, predicting human PK of 
large and polar β-LAs was found to be difficult due to the possible involvement of active 
transport. Overall, the results were based on relatively limited dataset and should be 
interpreted with caution. Though the molecular property space of the present database is 
quite large, addition of compounds from other pharmacological and chemical classes may 
increase the diversity and generalizability of the database. Despite the limitations, this 
research should be able to provide an initial insight into relationship between structure and 
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Appendix I (a) 
 







Morphine is a basic drug and a potent analgesic used in severe acute and chronic pain. It is the most studied opioid. It is hydrophilic 
with log D (pH 7.4) of 0.14 (n-octanol-pH 7.4 buffer) and pka of 7.9(determined by microcalorimetic titration).1 At physiologic pH, 
24% molecules are non-ionized. Morphine shows a lot of interdividual variability. It is widely distributed in the body. Morphine is 
highly extracted by liver2 and some studies show moderate to high clearance values. These clearance values are greater than the 
hepatic blood flow. It undergoes rapid glucuronidation to form two main metabolites morphine-3-glucuronide and morphine-6-
glucuronide. Morphine also undergoes extrahepatic metabolism, about 38 % of the clearance of morphine maybe due to extrahepatic 
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Urinary excretion study:  
• Mazoit at al4  calculated urinary clearance by rate method –  
CLren = Σ [(∆Ae/∆t)/C]n/1.2 where n = number of data points (6) and 1.2 is blood/plasma conc. ratio. Urine samples were drawn every 
30 mins for first 3 hrs and then each hr till 8 hrs. 
 
• Hasselstrom et al5 calculated CLren by using CLren = Ae/AUC (Urine was collected 2 hr fractions for first 12 hrs and then in 12 hr 
fractions upto 72 hr) 
 
•    Milne et al6 calculated renal clearance as the urinary excretion rate divided by the mean of two plasma concentrations spanning the 
urine collection interval (mean = 0.048-0.33µmol/l) 
 
Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




n = 5 
(healthy), 25-
39 yrs 
Ultrafiltration 266 nmol/l HPLC fu =0.74  ± 0.01 
Leow et 
al10 




(4000 rpm for 
20 min, pH 
7.4, 37ºC) 
20, 60, 100 ng/ml HPLC 
LOQ = 4.5 
ng/ml 
Protein binding = 
35. 3% (± 0.2 %) 
Hollt et 
al11 
n = 4 Equilibrium 
Dialysis 
(equilibriation 
time - 4 hrs, 
pH 7.4, 37ºC) 
 
10-7 M RIA Protein binding = 
23.4 (± 1.1 %) 
 
 












- RIA 16 pg  Compar
tmental 
(2) 








    Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 




n= 6 In-vitro 10 and 40 ng/ml RIA 1.21 (± 0.08) 
 
Receptor binding studies:  
 
1. Emmerson et al12 carried out studies in C6 glioma cells of the cloned rat µ-opioid receptor to determine binding affinities and 
activation of G-protein. Activation of G-protein by opioid agonists was examined by measuring the stimulation of GTP binding and 
intrinsic activity was expressed as the percent stimulation relative to DAMGO (100 %). The intrinsic activity of Morphine was 83 %.  
[3H]sufentanil (0.04nM) were used as high affinity ligand and [3H]naltrexone (0.5 nM) as low affinity ligand in the displacement 
studies to determine the affinity to receptors. 
 
Ki (high affinity) = 0.16 (± 0.002) 
Ki (low affinity) = 132 (± 6) 
 
2. Chen et al13 studied the binding affinity of opioids at µ-receptor in rat brain homogenates using [3H] DAMGO.  
Morphine Ki (nM) = 1.2 
M3G        Ki (nM) = 37.1 
M6G        Ki (nM) = 0.6 
 
Morphine metabolites: 
Morphine undergoes variety of metabolic pathways, in particular glucuronidation of the 3-OH phenolic group and 6-OH alcoholic 
group to yield morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) resp. The pka values for carboxylic acids for M3G 
and M6G are 2.83 (±0.05) and 3.23 (±0.05) determined by titrimetry. It has been suggested that M6G is a molecular chameleon that 
exists both in extended and folded forms, latter providing an unexpected liophilicity to it14.  Both the metabolites are highly 
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et al 7 
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Urinary excretion study: 
• Milne et al6 calculated renal clearance as the urinary excretion rate divided by the mean of two plasma concentrations spanning the 
urine collection interval (mean = 0.093-11 µmol/l) 
• Osborne et al8 collected urine samples for 24 hrs (time points not specified).  
 
 
Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 




n = 5 
(healthy), 25-
39 yrs 
Ultrafiltration 1020 nmol/l HPLC fu =0.89  ± 0.02 
 
 
  Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 




Healthy In-vitro 250 ng/ml HPLC 0.54 
 
 
PGP substrates: Primary cultures of porcine brain capillary endothelial cells were used to study brain penetration of M6G.  Uptake of 

















Urinary excretion study: 
• Milne et al6 calculated renal clearance as the urinary excretion rate divided by the mean of two plasma concentrations spanning the 
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Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 




n = 5 
(healthy), 25-
39 yrs 
Ultrafiltration 2170 nmol/l HPLC fu =0.85  ± 0.02 
 
 
Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 













Hydromorphone (HM) is a ketone of morphine.  The log D of hydromorphone is -0.5 (± 0.027) (by shake flask method) and pka of 
8.01 (± 0.012) (by potentiometry). (Coyle et al. Anesthesiology. ASA abstracts 1984). Another study reports log D of 0.089.21 At 














Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Coyle et al 
(Anesthesiology 
ASA abstracts) 
Normal male Ultrafiltration 2.5, 10, 20, 31, 






































n = 9 
20-30 
yrs 
50-86 0.026 Bolus 0-12 hr - RIA - - Compar
temntal  
(2) 


















n = 12 
29.4 yrs 


















n = 10 
21-38 
yrs 

















Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 
Assay B:P ratio 
 
Coyle et al 
(Anesthesiology 
ASA abstracts) 




1.497 (± 0.096) 
 
 
Metabolism: It is metabolized mainly in liver by glucuronidation at 3- and 6-position to form HM-3-glucuronide (major) and HM-6-
glucuronide. At 6-position, HM also undergoes reduction to dihydromorphine and dihydroisomorphine via NADPH 




Receptor binding studies: 
Chen et al13 studied the binding affinity of opioids at µ-receptor in rat brain homogenates using [3H] DAMGO.  







Remifentanil is a synthetic opioid. It has a log D of 1.2 26and pka of 7.327. An ester linkage in the chemical structure makes this 
compound susceptible to rapid metabolism by blood and tissue esterases. Approximately 98% of an administered dose is metabolized 














Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 






In-ivo - GC 
LOQ -0.1 
Calculated  
































































58.2 (± 1.22) 
57.4 (± 1.20) 
60.9 (± 0.93) 
0.299(±0.14) 
0.44 (± 0.27) 
0.77(±0.065) 
























































n = 13 





























patients ng/ml plasma clearance 
0.93 
 
Metabolism: It is metabolized by rapidly by non-specific tissue and blood esterases to carboxylic acid metabolite which has 1/4600 






Sufentanil is a thienyl analogue of fentanyl. It is highly lipophilic with log D of 3.22 and pka of 8.0 (Bovill et al. Baillere’s clinical 






























































et al 39 
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- RIA 5 ng/ml - Compar
tmental 
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Urinary excretion study:  
Scholz et al40 calculated renal clearance from the urinary recovery of sufentanil divided by the corresponding AUC value monitored 
over 72 hr. The renal clearance was found to be 0.6 % of the total clearance. The urine samples were collected for 72 hrs. 
 
 
Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Meuldermans 





(20 rpm at 
37ºC, 4hrs) 
1 ng/ml Liquid 
scintillation 







(20 rpm at 
37ºC, 4hrs) 
1 ng/ml HPLC fu = 7.8 % (± 1.5%) 
 
 
Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 
Assay B:P ratio 
 
Meuldermans 
et al 41 
Healthy 
n =6 
In-vitro 1 ng/ml Liquid 
scintillation 
0.741 (± 0.049) 
 
Metabolism: A study by Lavrijsen et al using liver microsomes demonstrates that the major metabolites formed were by oxidative N-
dealkylation at the piperidine nitrogen, oxidative N-dealkylation of the piperidine ring from the phenylpropanamide nitrogen, 







Receptor binding studies:  
 
1. Emmerson et al12 carried out studies in C6 glioma cells of the cloned rat µ-opioid receptor to determine binding affinities and 
activation of G-protein. Activation of G-protein by opioid agonists was examined by measuring the stimulation of GTP binding and 
intrinsic activity was expressed as the percent stimulation relative to DAMGO (100 %). The intrinsic activity of sufentanil was 97 %.  
[3H]sufentanil (0.04nM) were used as high affinity ligand and [3H]naltrexone (0.5 nM) as low affinity ligand in the displacement 
studies to determine the affinity to receptors. 
 
Ki (high affinity) = 0.034 (± 0.009) nm 
Ki (low affinity) = 4.51 (± 0.14) nm 
 
2. Leysen et al44 carried out receptor binding studies for different opioids using membrane preparations of rat brain and spinal cord 
and radiolabeled sufentanil. The equilibrium inhibition constant Ki was calculated with 0.5 nm of sufentanil in the binding assay run in 
sodium free Tris-HCl buffer at pH 7.4 at 37ºC. 





















Alfentanil is a short acting analgesic. It is lipophilic with log D of 2.121and pka of 6.5.27 At physiological pH 7.4, 89% of the 
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Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 








37ºC for 4 hr 
1-100 µg/ml Liquid 
scintillation 
% Free alfentanil: 5.5 









(20 rpm at 
37ºC, 4hrs) 
1 ng/ml Liquid 
scintillation 
fb = 0.921 (± 0.013) 
Ferrier at al45 Healthy 
n = 10 
45(± 13) yrs 
Equilibrium 
dialysis 
(20 rpm at 
37ºC, 4hrs) 
50 and 500 ng/ml RIA 
Sensitivity 
= 0.1 ng/ml 
Free alfentanil : 11.5 
(± 3.9) % at 50 ng/ml 










(20 rpm at 
37ºC, 4hrs) 
50 and 500 ng/ml RIA  Binding: 92.3 (± 1.3) 
% at 50 ng/ml and 
91.8 (± 1.5) % at 500 
ng/ml 
Macfie et al47 Healthy 







Bolus dose  
0.050 mg/kg 












n = 8 


















(2 or 3) 







Hug et al48 Surgery  
n =3 









Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 
Assay B:P ratio 
 
Meuldermans 
et al 41 
Healthy 
n =6 
In-vitro 1 ng/ml Liquid 
scintillation 
0.630 (± 0.021) 
 
 
Metabolism: Alfentanil is predominantly metabolized by the CYP3A4 and CYP 3A3.50 A study by Lavrijsen et al using liver 
microsomes demonstrates that the major metabolites formed were by oxidative N-dealkylation at the piperidine nitrogen, oxidative N-
dealkylation of the piperidine ring from the phenylpropanamide nitrogen, oxidative O-demethylation and aromatic hydroxylation.43  
 
 
Receptor binding study: 
1. Leysen et al44 carried out receptor binding studies for different opioids using membrane preparations of rat brain and spinal cord 
and radiolabeled sufentanil. The equilibrium inhibition constant Ki was calculated with 0.5 nm of sufentanil in the binding assay run in 
sodium free Tris-HCl buffer at pH 7.4 at 37ºC. 
















Fentanyl is a short acting analgesic. It is lipophilic with log D of 2.9 and pka of 8.4.51 At  physiological pH 7.4, 9.1% of the molecules 





Urinary excretion studies52: Urine and stool were collected for 72 hrs. These were analyzed in duplicate or triplicate for 3H-fentanyl 
and for total 3H-radioactivity (3H-fentanyl and 3H-metabolite) and analyzed by paper chromatography. 





































n et al52 
Healthy 





























n et al 53 
Healthy 
adults 
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Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Mclain et al52 Healthy 








Binding =81 ± 2% 
Meuldermans 





(20 rpm at 
37ºC, 4hrs) 
10 ng/ml Liquid 
scintillation 
fb = 0.844 (± 0.019) 
   1-100 ng/ml Liquid 
scintillation 
Binding = 85.7 ± 
0.8% 
Hollt et al11 n = 4 Equilibrium 
Dialysis 
(equilibriation 
time - 4 hrs, 
pH 7.4, 37ºC) 
 
10-7 M RIA Protein binding = 




Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 
Assay B:P ratio 
 
Meuldermans 
et al 41 
Healthy 
n =6 
In-vitro 1 ng/ml Liquid 
scintillation 
0.965 (± 0.055) 
 
 
Metabolism: Fentanyl undergoes phase I metabolism by oxidative N-dealkylation and O-dealkylation. Other metabolites are 







Receptor binding studies:  
 
1. Emmerson et al12 carried out studies in C6 glioma cells of the cloned rat µ-opioid receptor to determine binding affinities and 
activation of G-protein. Activation of G-protein by opioid agonists was examined by measuring the stimulation of GTP binding and 
intrinsic activity was expressed as the percent stimulation relative to DAMGO (100  %). The intrinsic activity of fentanyl was 97 %.  
[3H]sufentanil (0.04nM) were used as high affinity ligand and [3H]naltrexone (0.5 nM) as low affinity ligand in the displacement 
studies to determine the affinity to receptors. 
 
Ki (high affinity) = 0.16 (± 0.002) nm 
Ki (low affinity) = 157 (± 7) nm 
 
2. Leysen et al44 carried out receptor binding studies for different opioids using membrane preparations of rat brain and spinal cord 
and radiolabeled sufentanil. The equilibrium inhibition constant Ki was calculated with 0.5 nm of sufentanil in the binding assay run in 
sodium free Tris-HCl buffer at pH 7.4 at 37ºC. 
Ki (nm) = 1.6  
 
3. Cassel et al54 carried out an assay to measure binding to the cloned human µ-opioid receptor contained 3[H]diprenorphine (0.4-1 
nm) or 3[H]alvimopan (0.86-1.1 nm), test compounds at concentrations ranging 36 pM to 10 µm in 20 µg protein/well. After 
incubation of 90 mins, the bound radioactivity was determined. Ki values are the geometric means with confidence intervals in 
paranthesis.  
Using 3[H] diprenorphine, Ki (nm) = 14 (6.6-30)  





Oxycodone is a synthetic derivative of thebaine. The log D (determined by shake flask method) of oxycodone is 0.2121 and another 
paper reports as -0.15.55  Lalovic et al56 reports the log D in the range of 1.2-1.7 (determined computationally or experimentally at pH 








Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Poyhia et al 
55 












































n = 10 
  NA 0.05 Bolus 0-24 hrs 0-24 
hrs 



























0.05 Bolus 5min-12 
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n = 10 
19-28 
yrs 
67  0.044 Bolus 2 min-
10hrs 































3 ng/ml - Compar
tmental 






 incubated at 
37ºC/30 min. 





for 20 min, 
pH 7.4, 37ºC) 
20, 60, 100 ng/ml HPLC 
LOQ = 10 
ng/ml 
Protein binding = 
45.1% (± 0.4 %) 
 
Urinary excretion studies:  
 
1. Kirvela at al study58 :  
Subjects: n =10, healthy 
Urine samples were collected 0-3, 3-6, 6-12, 12-24 hrs. Urine samples were analysed using GC (LOQ-3 ng/ml). The urinary recovery 
of unconjugated oxycodone was 1% (0-5%).  
 
Metabolism: 
In a study done by Lalovic et al56, it was found that oxycodone is metabolized via CYP3A-mediated N-demethylation (noroxycodone, 
noroxymorphone, and α- and β-noroxycodol) which accounted for 45 ± 21% of the dose There are other pathways mediated by CYP 
2D6 as O-demethylation (Oxymorphone, and α- and β-oxymorphol), and 6-keto reduction (α- and β-oxycodol) which accounted for 
11± 6% and 8± 6% dose.  
 
Receptor binding studies: 
Chen et al13 studied the binding affinity of opioids at µ-receptor in rat brain homogenates using [3H] DAMGO.  






Codeine is a derivative of morphine. Kauffmann et al1 reported log D of codeine is 0.35 
(at pH 7.4 by shake-flask method) and its pka 8.10 (determined potentiometrically). Avdeef at al15 reported the log D (shake flask 










Urinary excretion studies:  
 
• Guay et al62 determined urinary excretion of codeine. All the urine produced during 24 hrs was collected and analysed using RIA. 
The total renal clearance was calculated using the equation CLren = Aet1-t2/AUCt1-t2 where Aet1-t2 is the codeine dose administered 













































0.62 Bolus 0-12 hrs 0-24 
hrs 
































- 0.0231 10.8 






Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Vree at al64 n = 8 Centrifugation 






56.1 % (± 2.5) 
 n = 6 Centrifugation 















HPLC 29.2%  (± 3.4) 




HPLC 30.5%  (± 2.7) 
 
Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 






In-vitro 50-500 ng/ml HPLC 0.96 (± 0.04) 
 
Metabolism: Codeine is metabolized to 6 metabolites: Codeine-6-glucuronide (81.0 ±9.3%), Norcodeine (2.16 ± 1.44%), Morphine 
(0.56 ± 0.39%), M3G (2.10 ± 1.24%), M6G(0.80 ± 0.63%) and normorphine(2.44± 2.42%). It undergoes O-dealkylation to morphine 
by CYP2D6.64  
 
Receptor binding studies: 
Chen et al13 studied the binding affinity of opioids at µ-receptor in rat brain homogenates using [3H] DAMGO.  









Diacetylmorphine is a semisynthetic derivative of morphine, it’s a prodrug and has active metabolites, 6-monoacetylmorphine and 
morphine which are responsible for analgesic effects. The heroin ester bonds undergo rapid hydrolysis in plasma. Rook et al66 reported 
pka as 7.6. At physiological pH 38.7 % molecules are non-ionized. Avdeef at alError! Bookmark not defined. have reported log D of 0.85 
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(± 60.1 ) 
1.01 







n = 10 
32 yrs  




1 nmol/l - Non-
compart
mental 
- 0.0127 173.1 
(± 41.8 ) 
0.55 
















GC - - - Cummu
lative 
- - - fe =  
0.13 
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Urinary excretion study 69:  
All the urine was collected at 30 specified times for 40.5 hrs from the time heroin infusion. The bladder was emptied zero time and 
urine samples were collected at 0.5 hr intervals for 2.5 hr, then hourly until hour 24.5. The catheters were removed and accumulated 
urine is collected at 32.5 and 40.5 hrs. 
% dose excreted in urine = 0.13  
 
Metabolism: Heroin is rapidly metabolized to 6-monoacetylmorphine hydrolysis by nonspecific esterases and finally to morphine. 
Morphine is gluronidated and forms M3G and M6G. (Rook et al. Current Clin Pharmacology 2006) 
 
Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 





37ºC for 20 hr 
with 9000dpm 
of heroin-14C 
0.008-0.4 mg/ml Liquid 
scintillation 




Receptor binding studies: 
Chen et al13 studied the binding affinity of opioids at µ-receptor in rat brain homogenates using [3H] DAMGO.  





Meperidine (Pethidine) is a non-polar, lipophilic drug with a pka 8.68 (by potentiometry) and log D 1.6 (by shake flask method).1, 71 
Another study reports pka as 8.5 and log D as 1.59.Error! Bookmark not defined. Error! Bookmark not defined. At physiological pH 7.4, 7.4 


















































(± 16 ) 
 
0.61 Bolus 0-360 
mins 
- GLC - - Compar
tmental 
(2) 
- 0.051 12 







n = 6 
Age-
NA 
75.2 5 Bolus 0-600 
mins 
- GLC - - Compar
tmental 
(2) 
- 0.48 10.4 
(± 3.54 ) 
Vdpss = 
3.74 
(± 1.43 ) 
- 
Verbeec
k et al74 
healthy 














- 0.0365 7.66 
(± 1.92 ) 
 
4.43 























Bolus - 0-24 
hrs 
GC - - - Fraction
ated 






Urinary excretion study 75: 
Analysis: Urine was collected for periods of 0-6, 6-12, 12-24 hrs. For each sample creatinine and creatinine clearance was calculated. 
The urinary content of meperidine was measured by GC-MS. Renal clearance was calculated using midpoint values of individual 
plasma-concentration time curves.  
CLren = 1.2 ml/min/kg (± 0.96) 
The renal clearance of meperidine is inversely correlated with urinary pH (r = -0.73, p<0.05) 
 
Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Mather at al72 surgery 
n = 19 
Ultrafiltration 0.96 µg/ml GLC fu = 0.27 ± 0.03  
 
Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 





n = 5 
25-33 yrs 




n = 6 
23-31 yrs 
In-vivo 0.28 mg/kg as IV 
bolus 
GC-MS 1.04  ± 0.03 
 
  
Metabolism: The drug is metabolized to pethidinic acid, norpethidine, and norpethidinic acid. Norpethidine is an active metabolite.72, 
75 
 
Receptor binding studies: 
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1. Emmerson et al12 carried out studies in C6 glioma cells of the cloned rat µ-opioid receptor to determine binding affinities and 
activation of G-protein. Activation of G-protein by opioid agonists was examined by measuring the stimulation of GTP binding and 
intrinsic activity was expressed as the percent stimulation relative to DAMGO (100 %). The intrinsic activity of meperidine was 64%.  
[3H]sufentanil (0.04nM) were used as high affinity ligand and [3H]naltrexone (0.5 nM) as low affinity ligand in the displacement 
studies to determine the affinity to receptors. 
 
Ki (high affinity) = 38.1 (± 0.002) 
Ki (low affinity) = 132 (± 6) 
 
2. Leysen et al44 carried out receptor binding studies for different opioids using membrane preparations of rat brain and spinal cord 
and radiolabeled sufentanil. The equilibrium inhibition constant Ki was calculated with 0.5 nm of sufentanil in the binding assay run in 
sodium free Tris-HCl buffer at pH 7.4 at 37ºC. 





Methadone is a synthetic opioid, its structure being distinctly different than other opioids. It is a lipophilic drug with log D of 2.1 (by 
shake flask method) and pka 9.26 (determined by potentiometry).1 Another study reports pka 9.26 and log D as 2.06.44 At physiological 
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Urinary excretion studies77: 
Urine samples were collected for 24 hrs. Renal clearance was calculated using the equation:  
CLren = Xu (0-24)/ AUC (0-24) where Xu is amount of methadone excreted in the urine.  
 
CLren  = 0.059 ml/min/kg 
 
Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 











0.073 µg/ml Liquid 
scintillation 





 n = 48 




for 30 mins 
100-1000 µg/ml GC % Free methadone = 
10.1 % (± 3.4) 
 
 
Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 






50 ± 12 
 




0.75 ± 0.03 
 
et al77 pain 
n =8 
50 ± 12 
 







Metabolism: Methadone is demethylated by CYP3A4 to 2-ethylidene-1,5-dimethyl -3-3-dephenyl pyrrolidine (EDDP). It is also 
metabolized by other CYPs like CYP2D6, CYP1A2, CYP2C9 and CYP2C19.  
 
 
Receptor binding studies:  
 
1. Chen et al13 studied the binding affinity of opioids at µ-receptor in rat brain homogenates using [3H] DAMGO.  
Methadone Ki (nM) = 28.8(±10.4) 
 
2. Leysen et al44 carried out receptor binding studies for different opioids using membrane preparations of rat brain and spinal cord 
and radiolabeled sufentanil. The equilibrium inhibition constant Ki was calculated with 0.5 nm of sufentanil in the binding assay run in 
sodium free Tris-HCl buffer at pH 7.4 at 37ºC. 
Ki  (nm) for Methadone = 2.2 
 
3. Cassel et al54 carried out an assay to measure binding to the cloned human µ-opioid receptor contained 3[H]diprenorphine (0.4-1 
nm) or 3[H]alvimopan (0.86-1.1 nm), test compounds at concentrations ranging 36 pM to 10 µm in 20 µg protein/well. After 
incubation of 90 mins, the bound radioactivity was determined. Ki values are the geometric means with confidence intervals in 
paranthesis.  
Using 3[H] diprenorphine, Ki (nm) = 14 (9.4-21)  






Dextropoxyphene is a a synthetic opioid derived from methadone. It has a pka 6.3 (Glare et al. Dextropropxyphene. Opioids in cancer 
pain (ed: Mellar D, Glare P, Hardy J.) 2005, Oxford University Press, NY) and log P of 4.81 obtained from Chemdraw software and 












Urinary excretion studies82:  
Urine was collected at intervals 3-9 hr during first day and then at 24 hrs intervals until end of day 7. 
The rate of urinary elimination of radioactivity was quantitated by calculating ratio between the excretion at 0-12 hr, 48-168 hr. The 
total urinary excretion of radioactivity at the end of day 7 was 55-75% of dose.  
Fraction excreted unchanged at the end of 7 days = 0.65 
 
 
Plasma protein binding studies: 
 
Study Subjects Method Concentration 
range 









7.4, 37ºC, 12 
228, 510, 1046 
ng/ml 
GC Free fraction of 
propoxyphene = 
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Metabolism: There are three metabolic pathways: N-demethylation (major), aromatic hydroxylation (minor) and ester hydrolysis 






Tramadol is a centrally acting analgesic with dual mode of action comprising both µ-opioid and monoaminergic agonism. The pKa 
value is 9.44 ± 0.03 (determined by UV spectrophotometry at 25°C).83 The log P (from ChemDraw software) is 2.53 and the 
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Urinary excretion study85: 
Urine was collected in intervals 0-1, 1-2, 2-3, 3-4, 4-6, 6-8, 8-10, 10-12, 12-24, 24-27, 27-30 h to determine cumulative renal 
excretion. At the end of each period, volume and pH were determined.  
The cumulative excretion of unchanged tramadol was extrapolated to infinity (Ae∞) was calculated by adding the amount determined 
experimentally until 30h (Ae0-30) to the residual amount Ae30-∞ which was computed from the renal excretion rate of the last sampling 
interval (Ae27-30/3) and the terminal rate constant (β) determined by the equation  
Ae30-∞ = (Ae27-30/3)*e-β* 1.5/ β 
For calculation of renal clearance, CLren = CLtot*Ae∞ (% dose)/100  
CLren = 0.96 ml/min/kg (± 0.24) 
 
Gibson et al88 reports a CLren of 1.12 ml/min/kg. 
 
Plasma protein binding: Gibson et al reports plasma protein binding of 20% 88 
 
Metabolism: Biotransformation of tramadol in man and animals takes place via N- and O-demethylation (phase I reactions) and 
conjugation of O-demethylated compounds (phase II reactions). The phase metabolites are mono-Odemethyl-tramadol (M1), mono-N-
demethyl-tramadol (M2), di-N-demethyl-tramadol (M3), tri-N,O-demethyl-tramadol (M4) and di-N,O-demethyl-tramadol (M5). M1-
conjugates and M5-conjugates formed by glucuronidation and sulphation are the main phase II metabolites84 
 
 
Receptor binding study: 
 
Gillen et al84 determined affinity and efficacy of tramadol at the cloned human opioid receptor. The affinity of tramadol was 
determined by competitive inhibition of 3[H]-naloxone under high and low salt conditions. The agonist-induced (DAMGO) 
stimulation was used to determine relative intrinsic efficacy.  
Ki (nm) low salt: 2400 ± 1100 
Ki (nm) high salt: > 10000 
Efficacy (%): DAMGO - 100 % ± 4 
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Urinary excretion study: (Kietzman et al2) 
Urine was collected in 12 hr portions upto 72 hr. CLR = Ae/AUC0-∞, Ae = total amount excreted unchanged 
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Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 












30-5000 ng/ml GC % Bound in patients - 
94.5 (±1.3) 
% Bound in healthy - 
93.8 
In the pH range 7.0-
7.8, the free fraction 
was markedly 
influenced by pH. 
The unbound fraction 
was 4.7% at pH 7.4 
and 6.4% at pH 7.0 
4% albumin solution 
- % bound – 70 
0% AAG solution - 
% bound – 90 
Wiesner et 
al1 
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Tilidine is a cyclohexane derivative. It is a prodrug which gets demethylated in the liver to give active metabolite nortilidine which is 




Urinary excretion study: (Vollmer et al4) 
Urine was collected in 0-2, 2-4, 4-8, 8-12, 12-24, 24-36, 36-48 hr. CLR = Ae/AUC, Ae = total amount excreted unchanged, AUC- area 
under the curve during one dosing interval under steady state conditions.  
Ae – 1.6% (± 1.4) 
 
Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 
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Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 









25-250 ng/ml Liquid 
scintillation 
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Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
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Butorphanol is a mixed agonist-antagonist opioid analgesic.  It has a pka of 8.6 and log P of 3.48 obtained from Chemdraw software 
and the calculated log D (7.4) is 2.25 (using formula log D(7.4) = log P –log [1 + 10 (pka-7.4)]). 
 
Metabolism: Butorphanol undergoes metabolism to form hydroxybutorphanol and norbutorphanol, hydroxybutorphanol being the 







































n = 12 
41 yrs 





































0.018 Bolus 2min-24 
hr 















n = 18 
34 yrs 
78.5 0.025 Bolus 3 min-
16 hrs 



















n = 12 
20-40 
yrs 
NA 0.014 Bolus 3 min-
16 hrs 










(± 6.9 ) 
7.1 
(± 2.7 ) 
- 
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Urinary excretion studies: 
 
• Gaver et al1 collected urine samples at each hr for the first 4 hrs (after administration of IV dose of  1mg of  3H-butorphanol) and 
then at 4-6, 6-8, 8-10, 10-24, 24-32, 32-48, 48-72, 72-96 and 96-120. Volume was determined at the end of 120 hrs.  
Analysis: Samples were counted in scintillation medium. Urinary butorphanol was extracted and analysed by HPLC, TLC, MS and 
GC. The concentrations of butorphanol were calculated from specific activities.  
Results:  
Urinary excretion of radioactivity- main route is renal. The mean cumulative percentage of tritium excreted in urine after IV was 72 ± 
4 %. The percentage excreted in feces was 14 ± 2 %. 4-5 % butorphanol was excreted as unchanged drug in urine. 
 
• In a study by Vachcharajani et al2, urine samples were collected at 0-2, 2-4, 4-6, 6-12, 12-16 hrs.  
Analysis:  HPLC  
% dose excreted unchanged in urine = 1.94 ± 1.5 
 
 
Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Smyth et al 









- Ultrafiltration - - 80% 
Gaver et al1 - centrifuged at 
5ºC for 10 
min at 2000 
rpm 







Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 






27.9 (± 3.9 
)yrs 
 
In-vivo 0.018 mg/kg iv 
dose 
RIA 1.14 (±0.17) 
 
 
Receptor binding study:  
 
Emmerson et al6 carried out studies in C6 glioma cells of the cloned rat µ-opioid receptor to determine binding affinities and activation 
of G-protein. Activation of G-protein by opioid agonists was examined by measuring the stimulation of GTP binding and intrinsic 
activity was expressed as the percent stimulation relative to DAMGO (100%). The intrinsic activity of butorphanol was 12 %.  
[3H]sufentanil (0.04nM) were used as high affinity ligand and [3H]naltrexone (0.5 nM) as low affinity ligand in the displacement 
studies to determine the affinity to receptors. 
 
Ki (high affinity) = 0.088 (± 0.005) nm 







Nalbuphine is agonist and antagonist opioid analgesic agent that is structurally related to naloxone, an antagonist and to oxymorphone, 
an analgesic agonist of opiate receptors. The log D of 0.26 (from Chemdraw software) and pka 8.71 (obtained from prescribing 
information from Nubain-nalbuphine hydrochloride-Endo Pharmaceuticals).  
 
Metabolism: Nalbuphine undergoes hepatic metabolism. The major metabolite is N-hydroxycetocyclobutyl-methylnornalbuphine and 







Urinary excretion study7: 
The renal clearance calculated using the equation: CLren = Ae∞/AUC, in which Ae∞ was the amount of unchanged nalbuphine excreted 
into 48 hr.  
CLren = 1.26 ml/min/kg (4.3% of the CLtot) 
 































































Fractionated 0.306 29.7 



























































-  6.1 x10-3 




(± 5.43 ) 
Vdpss= 





Receptor binding study:  
 
Emmerson et al6 carried out studies in C6 glioma cells of the cloned rat µ-opioid receptor to determine binding affinities and activation 
of G-protein. Activation of G-protein by opioid agonists was examined by measuring the stimulation of GTP binding and intrinsic 
activity was expressed as the percent stimulation relative to DAMGO (100%). The intrinsic activity of nalbuphine was 11 %.  
[3H]sufentanil (0.04nM) were used as high affinity ligand and [3H]naltrexone (0.5 nM) as low affinity ligand in the displacement 
studies to determine the affinity to receptors. 
 
Ki (high affinity) = 0.048 (± 0.005) nm 
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n = 4, 
23-42 
- 0.34 Bolus - 0-32 
hrs 
Faece
GC - 1.0 
µg/ml 






Urinary excretion study13:  
Urine samples were collected half hourly for the first 4 hrs, hourly for next 4 hrs, 2 hourly for next 6 hrs, then at 24 hrs, and 4-hourly 
thereafter up to 32 hr.. Faeces were also collected as passed for 48 hrs. 
% dose excreted unchanged in 32 hr in urine:  8-24% 
% dose excreted unchanged in 48 hr in faeces: 0.1-2% 
 
Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




Healthy, n = 




220 ng/ml Liquid 
scintillation 





Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 




Healthy, n = 
3, 22-45 yrs 





Metabolism: It sis extensively metabolized. The dimethyl allyl side chain is oxidized to two isomeric alcohols and the phenolic 
hydroxyl is conjugated. Both alcohols maybe conjugated and the trans-isomer is oxidized to carboxylic acid.  This acid is also 












Receptor binding study: 
Leysen et al16 carried out receptor binding studies for different opioids using membrane preparations of rat brain and spinal cord and 
radiolabeled sufentanil. The equilibrium inhibition constant Ki was calculated with 0.5 nm of sufentanil in the binding assay run in 
sodium free Tris-HCl buffer at pH 7.4 at 37ºC. 







Buprenophine is a semisynthetic analgesic with mixed agonist-antagonist properties. It has a log D of 3.93 (shake flask method) and 














































(± 2.4 ) 
 


















n = 6 
 




















Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




- - 0-7 ng/ml - 96% 
 
Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 
Assay B:P ratio 
 
Bulling-
ham et al18 
- - - - ~1.00 
 
Metabolism: Extensively metabolized by N-dealkylation to norbuprenorphine by CYP3A4. Norbuprenorphine is the active metabolite 
with potency 1/5 th pf the parent compound. Norbuprenorphine and buprenorphine, both, undergo glucuronidation.21 
 
Receptor binding studies: 
 
1. Leysen et al16 carried out receptor binding studies for different opioids using membrane preparations of rat brain and spinal cord 
and radiolabeled sufentanil. The equilibrium inhibition constant Ki was calculated with 0.5 nm of sufentanil in the binding assay 
run in sodium free Tris-HCl buffer at pH 7.4 at 37ºC. 
       Ki  (nm) for Methadone = 26 
 
2. Cassel et al22 carried out an assay to measure binding to the cloned human µ-opioid receptor contained 3[H]diprenorphine (0.4-1 
nm) or 3[H]alvimopan (0.86-1.1 nm), test compounds at concentrations ranging 36 pM to 10 µm in 20 µg protein/well. After 
incubation of 90 mins, the bound radioactivity was determined. Ki values are the geometric means with confidence intervals in 
parenthesis.  
      Using 3[H] diprenorphine, Ki (nm) = 0.52 (0.41-0.67)  












































































- - 29.6 





































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




- Ultrafiltration 12.8-522 ng/ml. 
 
HPLC % Bound – 88.3-
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Urinary excretion study2:  
Urine was collected at intervals: 0-3, 3-6, 6-12, 12-24, 24-48, 48-72 hr. The urine was analyzed by liquid scintillation spectrometry. 
Renal clearance calculated by Cu = du/dt/Pt 
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Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 











Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 
Assay B:P ratio 
 
Wall et al2 Healthy 
n =5 
 
In-vivo IV Bolus  







Metabolism: The major metabolite is unconjugated 6β-naltrexol. The other metabolites are 6α-naltrexol, 2-hydroxy-3-O-
methylnaltrexone and 2-hydroxy-3-O-methyl-6β-naltrexol.2  
 
Receptor binding studies: 
 
1. Emmerson et al5 carried out studies in C6 glioma cells of the cloned rat µ-opioid receptor to determine binding affinities and 
activation of G-protein. Activation of G-protein by opioid agonists was examined by measuring the stimulation of GTP binding 
and intrinsic activity was expressed as the percent stimulation relative to DAMGO (100%). The intrinsic activity of naltrexone was 
0.  
[3H]sufentanil (0.04nM) were used as high affinity ligand and [3H]naltrexone (0.5  nM) as low affinity ligand in the displacement 
studies to determine the affinity to receptors. 
      Ki (high affinity) = 0.087 (± 0.002) nm 
      Ki (low affinity) = 0.28 (± 0.01) nm 
 
2. Cassel et al6 carried out an assay to measure binding to the cloned human µ-opioid receptor contained 3[H]diprenorphine (0.4-1 
nm) or 3[H]alvimopan (0.86-1.1 nm), test compounds at concentrations ranging 36 pM to 10 µm in 20 µg protein/well. After 
 411
incubation of 90 mins, the bound radioactivity was determined. Ki values are the geometric means with confidence intervals in 
parenthesis.  
      Using 3[H] diprenorphine, Ki (nm) = 1.1 (0.74-1.5)  











Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 










HPLC % Free naloxone = 
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0.36  Bolus  2-120 
mins 
- RIA - - Compar
tmental 


















0.012 Bolus 1-180 
mins 













Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 




n = 3 
Healthy 
 





7,8-dihydro-14-hydroxynormorphinone and N-allyl-7,8-dihydro-14-hydroxynrmorphine are the major metabolites identified in human 
urine. 
 
Receptor binding studies:  
 
1. Leysen et al12 carried out receptor binding studies for different opioids using membrane preparations of rat brain and spinal cord 
and radiolabeled sufentanil. The equilibrium inhibition constant Ki was calculated with 0.5 nm of sufentanil in the binding assay run in 
sodium free Tris-HCl buffer at pH 7.4 at 37ºC. 
Ki (nm) = 3.1  
 
2. Cassel et al6 carried out an assay to measure binding to the cloned human µ-opioid receptor contained 3[H]diprenorphine (0.4-1 nm) 
or 3[H]alvimopan (0.86-1.1 nm), test compounds at concentrations ranging 36 pM to 10 µm in 20 µg protein/well. After incubation of 
90 mins, the bound radioactivity was determined. Ki values are the geometric means with confidence intervals in paranthesis.  
Using 3[H] diprenorphine, Ki (nm) = 3.3 (2.7-4.1)  













































































































































































Bolus 0-48 hrs 0-48 
hrs 


















   









































Urinary excretion studies: 
 
1. Matzke et al14 
Urine samples were collected: 0-4, 4-8, 8-12, 12-24, 24-36 hrs 
Analysis: RIA 
Range: 1.25-40 ng/ml 
Renal clearance was calculated as the quotient of total amount recovered in urine and AUC from 0-48 hrs. 
CLren = 1.35 ± 0.85 ml/min/kg 
 
2. Frye et al15 
All urine was collected from 0-4, 4-8, 8-12, 12-24, 24-36, 36-48 hr 
The renal clearance of nalmefene was calculated as the quotient of the total amount recovered in urine and the AUC from 0-48 hrs. 
 
3. Dixon et al16 
Urine samples were collected over 0-6, 6-12, 12-24, 24-48 hrs 
% dose excreted unchanged in the urine: 3.8% (± 2.0) – 2mg IV dose 
                                                                  5.5% (± 1.1) – 6 mg IV dose 
                                                                  5.7% (± 1.7) – 12 mg IV dose 
                                                                  5.0% (± 3.1) - 24 mg IV dose 













































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 










Ultrafiltration IV Bolus 
2 mg/kg 
RIA 34.4% (± 13.6) 
 
 
Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 





Humans In-vitro 0.376 to 30 
ng/mL 
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Appendix I (b) 
 











Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 






































62 0.21 Bolus 0-24 hrs 0-48 
hr 













fe = 65% 




Urine excretion study: 
• Ishizaki et al1:  
Urine collection: 0-2, 2-4, 4-8, 8-12, 12-24, 24-48 hr 
Renal clearance CLren = Ae(48)/[AUC]048 where Ae48 is cumulative amount of drug excreted unchanged in urine upto 48 hrs 
 
Bioavailability study:  
Ishizaki et al1: Formulation : Not mentioned (17.785 mg) 
Sampling: 0-24 hrs 
Analysis: HPLC 



























































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




n = 5 Equilibrium 
dialysis 
125 ng/ml of (+)-
P and (-)- P 
Liquid 
scintillation 
fu (+) = 0.203 
 (SE =0.008) 
 
 






















n = 6 
45 yrs 


































l et al7 
Healthy 
n = 9 



















n = 9 























n =7 Equilibrium 
dialysis 
125 ng/ml of (+)-
P and (-)- P 
GC-MS fu (+) = 25.3% 
 (SE =1.9) 
 
AGP = 16.2% ± 1.7 
HSA = 60.7% ± 1.3 
 
 
fu (-) = 22.0% 
(SE =2.0) 
AGP = 12.7% ± 1.3 











n = 9 




n = 10 






























5 ng/ml Liquid 
scintillation 





n =6  
27.3 ± 5 yrs 
Equilibrium 
dialysis 
Oral 80 mg dose 
twice daily for 14 
days 








Blood –to –plasma ratio studies: 
 
Study Subjects Method Assay B:P ratio 
Olanoff et 
al4 
n = 5 -  For (+) = 0.99 
RBC/fu = 2.95 ± 0.39 
 
For (-) = 0.99 
RBC/fu = 2.83 ± 0.39 




n =6  
27.3 ± 5 yrs 
Ex-vivo 
Oral 80 mg dose twice 
daily for 14 days 
 
Fluorimetry 0.74 ± 0.03 
 




Bioavailability study:  
 
Watson et al5: Formulation : Not mentioned (80 mg twice daily) 
Sampling: 0-24 hrs 
Analysis: GLC 
Foral = 54 ± 82 % 
 
Cid et al8: Formulation : Tablets (40 mg twice daily) 
Sampling: 0-12 hrs 
Analysis: GC 
Foral = 17.80 ± 3.58 % 
  
Wilson et al3: Formulation : Tablet (3.2 mg/kg) 
Sampling: 0-8 hrs 
Analysis: GLC 






























































































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 









100 ng/ml Liquid 
scintillation 
59.7 % 
(53.2 – 64.1) 
 
 
Urinary excretion study:  
 
Kubota et al 15 : Urine collection: 0-48 hr 
Renal clearance CLren = Ae(48)/[AUC]048 where Ae48 is cumulative amount of drug excreted unchanged in urine upto 48 hrs 
 
Bioavailability study:  
Wilson et al3: Formulation : Tablet (0.4 mg/kg) 
Sampling: 0-8 hrs 
Analysis: GLC 





























































n et al16 
Healthy 
male 















































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 





n = 95 




500 ng/ml Liquid 
scintillation 




Bioavailability study:  
Dreyfuss et al18: Formulation : Capsules  (80 mg) 
Analysis: Liquid scintillation 
Average amount absorbed = 28.4 ± 6.6% (SE) 
 
 
Dreyfuss et al19: Formulation : Capsules  (2 mg) 
Analysis: Liquid scintillation 
Average amount absorbed (from urinary excretion data) = 33.6 ± 2.4 % (SE) 
























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 









500 ng/ml Liquid 
scintillation 
92.0 








500 ng/ml Liquid 
scintillation 
fu – (R)- 0.22 ± 0.02 
fu – (S)- 0.18 ± 0.01 
 













































Bolus 0-8 hr - GC - - Compartm
ental 







m et al21 
Healthy 










HPLC - - - Cumulative - - - (R )- 0.15  
(± 0.02) 
 










Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 









Bioavailability study:  
Mason et al20: Formulation : Capsule (20, 40, 80, 160 mg) 
Sampling: 0-8 hrs 
Analysis: GC 
Foral (20 mg) = 0.38 
Foral (40 mg) = 0.45 
Foral (80 mg) = 0.42 


























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 













n =7  




Oral 10 mg dose 
once/twice daily 
for 6-7 days 
 



















































0-24 hrs 0-24 
hrs 
UV - - Compartm
ental  













n = 6 
28 ± 2.3 
yrs 














- fe = 54.2 





Blood –to –plasma ratio studies: 
 






n =7  
42.0 ± 13.6 
yrs 
Ex-vivo 
Oral 10 mg dose 
once/twice daily for 6-7 
days 
 
Fluorimetry 0.69 ± 0.08 
RBC: Plasma - 
0.37 ± 0.14 
 
 
Urinary excretion study:  
 
Gugler et al22 : Urine collection: 0-4, 4-8, 8-12, 12-24 hr 
Renal clearance CLren = Ae(24)/[AUC]024 where Ae24 is cumulative amount of drug excreted unchanged in urine upto 24 hrs 
 
Guerret et al23: : Urine collection: 0-48  hr 
 
 
Bioavailability study:  
Guerret et al23: Formulation : Not mentioned (5 mg) 
Sampling: 0-10 hrs 
Analysis: GLC-ECD 
























Plasma protein binding studies: Bonelli et al24 
 
Plasma protein binding was calculated by correlation of plasma and salivary data, the concentration in the saliva was taken to be identical to the concentration in 
plasma water. The concentration in the saliva was plotted against that of plasma concentration for all the volunteers and a straight line of slope α was obtained. 
Plasma protein binding is then 1 – α.   
 


































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 









- - 49 % 
 
Urinary excretion study:  
Bonelli et al24: Urine collection: 0-96 hr 
 
Gugler et al25: Urine collection: 0-4, 4-8, 8-12, 12-24 hr 
Renal clearance CLren = Ae(∞)/[AUC] where Ae∞ is cumulative amount of drug excreted unchanged in urine 
 
Bioavailability study:  
Gugler et al25:  
Formulation: Wafers (10mg)  
Sampling: 0-24 hrs 
Analysis: UV 
Foral  = 88.3% (±  9.6) 
 
 
Bonelli et al26 : Formulation : Oral tablet (20 mg Mepindolol Sulphate) 
Sampling: 0-24 hrs 
Analysis: Liquid Scintillation 


















































































































n = 12 
21-45 
yrs 



































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 






1-20 µg/ml quantitative 
TLC 
88 ± 4 % 
 
 
Urinary excretion study:  
 
Bernard et al30: Urine collection: 0-4, 4-10, 10-24, 24-48 hr 
Renal clearance CLren = Ae(48)/[AUC]048 where Ae48 is cumulative amount of drug excreted unchanged in urine upto 48 hrs 
 
 
Jun et al28: Urine collection : 0-2, 2-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-60, 60-72 hrs 






























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 














Urinary excretion study:  
 
Poirier et al31: Urine collection: 0-48 hr 
Renal clearance CLren = Ae(∞)/[AUC] where Ae∞ is cumulative amount of drug excreted unchanged in urine  
 
 
Bioavailability study:  
Deneer et al32:  
Formulation: Solution (80mg)  
Sampling: 0-48 hrs 
Analysis: HPLC 





































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 





n = 5 















Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 






In-vitro 60 ng/ml Liquid 
scintillation 
0.98 ± 0.10 
 
Bioavailability study:  
Alvan et al33: Formulation : Oral tablet (200 mg Alprenolol) 
Sampling: 0-10 hrs 
Analysis: GC 


































n = 5 
22-33 yr 


























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 





n = 24 
Equilibrium 
dialysis 
50-400 ng/ml Liquid 
scintillation 
fu = 7.4 % ± 1.6 
 
 
Bioavailability study:  
Campbell et al35: Formulation : Not mentioned (2.5 mg) 
Sampling: 0-12 hrs 
Analysis: GC-MS 








































































































































































Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 











































n = 9 
26.2 yrs 
78.5 0.57 Bolus 0-24 
hrs 


















































Urinary excretion study:  
 
Kramer et al39: Urine collection: 0-60 hr 
Renal clearance CLren = Ae(∞)/[AUC] where Ae∞ is cumulative amount of drug excreted unchanged in urine 
 
 
Bioavailability study:  
Tenero et al38: Formulation : Oral – formulation not mentioned (360 mg Dilevalol) 
Sampling: 0-72 hrs 
Analysis: HPLC 
Foral =  29.6 ± 14.3 %  
 
 
Kramer et al39: Formulation : Oral tablets ( 200 mg Dilevalol) 
Sampling: 0-60 hrs 
Analysis: HPLC 































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 





n = 4 
 




Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 





n = 4 
 









































r et al40 
Healthy 







0.28 Bolus 0-8 hrs - - sensitiv













Bioavailability study:  
Faulkner et al40: Formulation : Oral Tablet(100 mg) 
Sampling: 0-8 hrs 
Analysis:  











































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Shastri  et 
al42 
Healthy 









RBC binding = 20% 
(0.1- 170 µM) 
 
Bioavailability study:  
Bastain et al43: Formulation : Suspension (120, 240, 480, 960 mg)  
Sampling: 0-167 hrs 
Analysis: GLC 
Foral (120 mg) = 0.46 ± 0. 09 
Foral (240 mg ) = 0.40 ± 0.08  
Foral (480 mg ) = 0.29 ± 0.06 




































l et al41 
Healthy 
n = 6 
26-34 yrs 


























Bioavailability study:  
Kolle et al44: Formulation : Tablets ( 4 mg x 3)  
Analysis: HPLC 














































n = 6 
- 0.11 Infu-
sion 
















Bioavailability study:  
Wiedemann et al45:  
 
Formulation : Tablet (100, 200 mg)  
Sampling: 0-48 hrs 
Analysis: HPLC 
Foral (100 mg) = 42.9 ± 10.8% 
Foral (200 mg) = 52.3 ± 18.6% 
 
Formulation : Capsule (200 mg)  
Sampling: 0-48 hrs 
Analysis: HPLC 











































n = 6 
37.3 








- HPLC - - Compart
mental 
- 9735 
(±  5461) 
2.49 











Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Foti et al48 Healthy 




20 µM HPLC fu = 0.19 ± 0.06 
 
Bioavailability study:  
Balant et al46:  
Formulation : Capsule (20mg)  
Sampling: 0-24 hrs 
Analysis: GC-MS 





















     Plasm
a 
































































Balant et al47 
Formulation : Capsule (20mg)  
Sampling: 0-24 hrs 
Analysis: GC-MS 










































Bioavailability study:  
Carruthers et al49:  
Formulation : Not mentioned (50mg)  
Sampling: 0-24 hrs 
Analysis: GLC 























































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 







Ultrafiltration 70, 140, 200 
ng/ml 
GC-MS 69.7 ± 2.3 % 
 
 
Urinary excretion study:  
Abshagen et al50: Urine collection: 0-4, 4-8, 8-12, 12-24 hr 












































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 










n = 4 
Ultrafiltration 20 ng/ml HPLC S (-) – 34.5 %  
(± 6 %) 
R (+) – 36.4 % 
(± 6.7 %) 






























et al 51 
Healthy 
male  
n = 12 







































n = 8 
25 ± 3 
yrs 























Urinary excretion study: Kubota et al 15 
Urine collection: 0-48 hr (0-6, 6-12, 12-24, 24-48 h) 
Renal clearance CLren = CL* Ae∞/dose ,  where Ae∞ is cumulative amount of drug excreted unchanged in urine upto 48 hrs 
 
 








Plasma protein binding studies:  
Study Subjects Method Concentration 
range 






0-6 µg/ml HPLC R-(+)- 35.58% 
S-(-)- 41.69% 
 
Mean S(-)/R(+) for bound drug = 1.16 

















































































Urinary excretion study: Flaherty et al58:  
Subjects: Healthy (n =6), Age - 41 yrs, Weight – 82.3 yrs (normal CLcr – 114 ml/min) 
Rate: Infusion (150 µg/kg/ml) 
Urine collection: 0-4, 4-8, 8-12, 12-24 hr 
Analysis: HPLC 
LOD: 0.05 µg/ml 




















































1.62 Bolus 0-48 hrs 0-48 
hrs 












































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 















Blood –to –plasma ratio studies: 
 








Oral 200 mg dose  
 
Fluorimetry 1.07 ± 0.25 
 
RBC: Plasma – 
1.15 ± 0.55 
 
 
Urinary excretion study: Mason et al60 
Urine collection: 0-48 hr (0-2, 2-4, 4-8, 8-12, 12-24, 24-48 h) 
Renal clearance CLren = CL* Ae∞/dose ,  where Ae∞ is cumulative amount of drug excreted unchanged in urine upto 48 hrs 
 
Bioavailability study:  
Mason et al60:  
Formulation : Solution (25, 50, 100 mg)  
Sampling: 0-24 hrs 
Analysis: HPLC 
Foral (25mg) = 0.52 ± 0.18 
Foral (50 mg) = 0.54 ± 0.12  











































































55-85 0.14 Bolus 0-72 hrs 0-72 
hrs 




























































-  0.150 Bolus - 0-24 
hrs 




es et al65 
Healthy 





0.14 Bolus 0-48 hrs - Liquid 
scintill
ation 




















































































- 0.28 Bolus 0-72 hrs 0-72 
hrs 










Plasma protein binding studies:  Just mentioned as 50% (Warrington et al66) 
 
Bioavailability study:  
 
Stagni et al61 : Formulation : Oral capsules (40 mg Betaxalol HCl) 
Sampling: 0-48 hrs 
Analysis: HPLC 
Foral = 84 ± 6 % 
 
Bianchetti et al62: Formulation : Oral tablet (20 mg Betaxalol HCl) 
Sampling : 0-72 hrs 
Analysis: HPLC 
Foral = 75.8 ± 7.3 % 
 
Ludden et al63: Formulation: Oral capsules (10, 20, 40 mg) 
Sampling: 0-72 hrs 
Analysis: GC 
Foral = 87.5 ± 7.9 % (for 10 mg dose) 
           82.3 ± 6.0 % (for 20 mg dose) 
           83.9 ± 6.6 % (for 40 mg dose) 
 
Bianchetti et al 64: Formulation: Not mentioned (0.150 mg/kg) 
Analysis: GLC 
Foral = 89 ± 5% 
 
Morselli et al67: : Formulation: Not mentioned (20 mg) 
Foral = 76 ± 7% 
 
 
Urinary excretion study: (Bianchetti et al62) 
Urine was collected from 012, 12-24, 24-48, 48-72 hrs 
Analysis: GC 












Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Tsunekawa 
et al 69 
Healthy 
human serum 




Average = 4.3% 
 
 HAS (43.2 
ng/ml) 




Urinary excretion study: (Murakami et al68) 





















































































Bioavailability study:  
 
Nakashima et al70 : Formulation :  (12.5, 25. 50, 100, 150 mg Amosulalol) 
Sampling: 0-24 hrs 
Analysis: HPLC and GC 
































     Plasma Urine  Plas
ma  



























































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 


































     Plasma Urine  Plas
ma  




























Cumulative -  4.5 
(calcu-
lated) 


























n = 6 
22-28 
 yrs 


















































Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 





n = 3 
 



















1.08 ± 0.02 
 
Bioavailability study:  
 
Regardh et al71: Formulation :  Solution (1.95 mg Metoprolol) 
Sampling: 0-12 hrs 
Analysis: Liquid Scintillation 
Foral = 40 % 
 
Regardh et al72: Formulation :  Tablet (50 mg b.i.d Metoprolol) 
Sampling: 0-30 hrs 
Analysis: GC-MS 
Foral = 55 % 
 
Jordo et al73: Formulation :  Tablets (50 mg Metoprolol orally twice daily for 5 days) 
Sampling: 0-430 mins 
Analysis: GC-MS 
Foral (single dose) = 0.50 (± 0.11) 
Foral (at steady state) = 0.55 (± 0.07) 
 
Schaaf et al74: Formulation: Not mentioned ( 100 mg and 200 mg) 
Sampling: 0-10 hrs 
Analysis: HPLC 
Foral (100 mg) = 0.454 (± 0.182) 










Plasma protein binding studies:  
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Zschiesche 




Ultrafiltraton 30 mg by IV HPLC (S)-(-) -78.2 ± 1.2 % 
 




n = 6 Ultrafiltration 30 mg IV infusion HPLC 60.9 ± 7.5 % 
 
Urinary excretion study: (Trausch et al75) 
Urine was collected from 0-4, 4-8, 8-12, 12-24, 24-36 hrs 
Analysis: HPLC 
CL ren = Ae∞/ AUC ∞ 
 
Bioavailability study:  
Trausch et al75: Formulation :  Dragee (50 mg Talinolol) 
Sampling: 0-36 hrs 
Analysis: HPLC 



















     Plasma Urine  Plas
ma  



















































Plasma protein binding studies:  
MacNeil et al78: just mentioned as 98% 
 
Urinary excretion study: (MacNeil et al78) 
Subjects: n =4 
Urine was collected from 0-24 hrs 
Analysis: GC 
fe = 0.2-1.4% 
 
Bioavailability study:  
MacNeil et al78: Formulation :  Capsules (50 mg Bevantolol) 
Sampling: 0-12 hrs 
Analysis: GC 



























     Plasma Urine  Plas
ma  























































Plasma protein binding studies: (Public assessment report – Glenmark Generics (Europe) Limited.  
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     Plasma Urine  Plas
ma  


























HPLC - - Compart
mental 


















n = 5  
29-46 
yrs 




HPLC - - Compart
mental 























0.35 Bolus 0-8 hrs 0-72 
hrs 













fe = 40.4 




Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 









0.02 - 9 µg/ml Liquid 
scintillation 











Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 





n = 3 
In-vitro 0.05 – 5 µg/ml Liquid 
scintillation 
0.617 





In-vitro 1.0-10 mg/l Flurorimetry 0.50 ± 0.04 
 
Urinary excretion study:  
 
Meffin et al80 
Subjects: n =9 
Urine was collected from 0-24 hrs 
Analysis: HPLC 
fe = 0.405 
Renal clearance calculated from measured acebutolol urinary excretion rates and mean blood concentrations 
 
Roux et al82: 




Bioavailability study:  
MacNeil et al78: Formulation :  Tablet (400 mg) 
Sampling: 0-48 hrs 
Analysis: HPLC 









Urinary excretion study: (Flouvat et al85) 
 
Urine was collected from 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96 hrs 
Analysis: HPLC 
CL ren = Ae∞/ AUC ∞ 
 
Bioavailability study:  
 
Flouvat et al85: Formulation :  Tablets (100, 400, 800 mg) 
Sampling: 0-48 hrs 
Analysis: HPLC 
Foral = 0.302 (SE = ± 0.052) after 100 mg dose 
           0.363 (SE = ± 0.052) after 400 mg dose 




































n = 6 





































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 













































et al 86 
Healthy 
male 
n = 8 









































GC - - Compart
mental 


































fe = 43% 
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Urinary excretion study:  
 
Regardh et al 86: 
Urine was collected from 0-72 hrs 
Analysis: GC 
CL ren = Ae∞/ AUC ∞ 
 
Regardh et al 87: 
Urine was collected from 0-24 hrs 
Analysis: GC 
CL ren = Ae∞/ AUC ∞ 
 
 
Bioavailability study:  
 
Regardh et al 86: Formulation :  Solution (40 mg) 
Sampling: 0-24 hrs 
Analysis: GC 
Foral = 27.5 (SD = ± 15.5)  
 
Regardh et al 87: Formulation :  Solution (25, 50, 100 mg) 
Sampling: 0-24 hrs 
Analysis: GC 
Foral = 27.0 (SD = ± 4.9)  
Foral = 30.4 (SD = ± 7.6)  






















Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 






n = 2 
 








































n = 2 








































fe = 14 
% 
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Urinary excretion study:  
 
Goldaniga et al88: 
Urine was collected from 0-120 hrs 
Analysis: Liquid scintillation 










































































































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 










20 µg/ml HPLC S (-)- carvedilol 
fu = 0.0063 ± 0.007 
 
 
R (+)- carvedilol 
fu = 0.0045 ± 0.002 
 
 
Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 












40 ng/ml Liquid 
scintillation 
S (-)- carvedilol 
0.74 
 





















































Urinary excretion study:  
 
Giesmann et al91: 
Urine was collected from 0-72 hrs 
Analysis: HPLC 
CL ren = Ae∞/ AUC ∞ 
 
Bioavailability study:  
 
Giesmann et al91: Formulation:  not mentioned (12.5 mg) 
Sampling: 0-24 hrs 
Analysis: HPLC 
PM Foral = 36.0 (SD = ± 7.66)  
EM Foral = 21.5 (SD = ± 6.25)  
Significant difference between PM and EM 
 
 
Mollendorf et al89:  
Formulation: Capsule (25 mg and 50 mg), Suspension (50 mg) 
Analysis: HPLC 
Foral = 22% (25 mg capsule)  
Foral = 24% (50 mg capsule)  


















































et al 93 
Healthy 
male 



















l et al7 
Healthy 
n = 9 




























n = 6 
2-24 yrs 
- 0.5 Bolus 0-360 
mins 











n = 3 
31.6 yrs 















1.5 Bolus 0-720 
mins 




























- - 10.48 
  (± 5.96) 
-  





Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 












Blood –to –plasma ratio studies: 
 
Study Subjects Method Concentration 
range 




- In-vitro 30-120 ng/ml HPLC 1.36 ± 0.18 
 
 
Bioavailability study:  
 
Lalonde et al93: Formulation: Not mentioned 
Sampling: 0-24 hrs 
Analysis:  HPLC 
Foral: 44 ±  14 % 
 
Nyberg et al97: Formulation: Tablets (200 and 400 mg) 
Sampling: 0-480 mins 
Analysis: Fluorimetry 
Foral: 9 % (200 mg) 
Foral: 16 % (400 mg) 
 
 
Luke et al98: Formulation: Capsules (200 mg) 
Sampling: 0-48 hrs 
Analysis: HPLC 
Foral: 0.26 ± 0.15 (200 mg) 
al98 Control 




















Urinary excretion study: (Bastain et al43) 
Urine was collected from 0-3, 3-6, 6-12, 12-24, 24-36, 36-48, 48-60, 60-72 hrs 
Analysis: RIA 
CL ren = Ae (72 hr)/ AUC (72 hr) 
 
Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 













3.0 ± 0.4 % 
(0.1-5.9%) 
 
Bioavailability study:  
Bastain et al43: Formulation : Oral Tablet (50 mg and 200 mg) and solution (200 mg) 
Sampling: 0-48 hrs 
Analysis: RIA 
Foral (50 mg tablet) = 4.5 ± 0.4 % 
Foral (200 mg tablet) = 4.8 ± 0.3 % 
























































fe = 61.6 











Bioavailability study:  
 
Haegele et al100: Formulation: Capsules (400, 800 and 1200 mg) 
Sampling: 0-25 hrs 
Analysis:  HPLC 
Foral: 27.2 ± 9.1 (400 mg) 
        31.3 ± 13.6 (800 mg) 
        37.4 ± 9.1 (1200 mg) 
 
Urinary excretion study: (Haegele et al100) 
Urine was collected from 0-48 hrs 
Analysis: HPLC 




































n = 8 



























Bioavailability study:  
 
Aellig et al101: Formulation: not mentioned (4 mg) 
Sampling: 0-72 hrs 
Analysis:  HPLC 
















































n = 9 
29 ± 3 
yrs 























Plasma protein binding studies: 50% (Cockshott et al102) – just mentioned, no details provided 
 
Urinary excretion study: (Cockshott et al102) 
Urine was collected from 0-96 hrs 
Analysis: HPLC 
 
Bioavailability study:  
Cockshott et al102: 
Formulation: solution (200 mg) 
Sampling: 0-72 hrs 
Analysis:  RIA 
Foral: 7.06 % 
 
Formulation: tablet (200 mg) 
Sampling: 0-72 hrs 
Analysis:  RIA 
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n = 12 
21-45 
yrs 
  78.4 
(64.4-
92.3)  
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n = 5 
67.2 ± 
6.2 
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n = 4 




























Urinary excretion study: (Nyberg et al104) 
Urine was collected from 0-4, 4-12, 12-18, 18-24  hrs 
Analysis: GC-MS 
CL ren = Ae (24 hr)/ AUC (24 hr) 
 
 
Bioavailability study:  
 
Nyberg et al104: Formulation : Solution (668 nmol/kg) 
Sampling: 0-48 hrs 
Analysis: GC-MS 












































































Urinary excretion study: (Boulton et al105) 
Urine was collected every hour from 0-8 hrs 
Analysis: HPLC 
CL ren = Ae (8 hr)/ AUC (8 hr) 
 
Bioavailability study:  
Boulton et al105: Formulation : Salbutamol sulphate elixir Solution (4 mg) 
Sampling: 0-8 hrs 
Analysis: HPLC 
(+)-S Foral  = 0.71± 0.09 
































et al 105 
Healthy 
male 
n = 7 









































































































































































n = 6 
64 0.004 IV 
infusi




2 pmol - Noncom
partment










Plasma protein binding studies:  
 
Borga et al110: 14-25% (just mentioned) 
 
 
Blood-to-plasma ratio studies: 
 
Study Subjects Method Concentration 
range 





n = 3 
In-vivo 5 mg terbutaline 
sulfate  3 times 
daily for 4 days 
GC-MS 1.44 
 
RBC: Plasma – 
2.27 
 
Urinary excretion study: (Borgstrom et al108) 
Urine was collected every hour from 0-8 hrs 
Analysis: HPLC 





























































































































Blood-to-plasma ratio studies: 
 
Study Subjects Method Concentration 
range 





n = 3 










1.14 ± 0.01 
RBC: Plasma:  1.30 ± 0.03 
 
1.09 ± 0.10 
RBC: Plasma:  1.19 ± 0.10 
 
 
0.98 ± 0.01 



















































fe = 60 ± 
3% 
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Urinary excretion study: (Graffner et al112) 
Urine was collected every hour from 0-24 hrs 
Analysis: GC-MS 
CL ren = Ae∞/ AUC∞  
 
Bioavailability study:  
Graffner et al112: Formulation : Solution (2.5, 5.0, 10.0 mg) 
Sampling: 0-8 hrs 
Analysis: GC-MS 
Foral  = 0.26± 0.02 (2.5 mg) 
Foral  = 0.23± 0.04 (5.0 mg) 
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Urinary excretion study:  
 
Spyker et al 1 
Urine collection: 0-1, 1-2, 2-3, 3-4, 4-6 hr 
fe = 56.4 % (SD = ± 26.9%) 
 
Sjovall et al (1985)2: 
Urine collection: 0-0.05, 0.5-1, 1-1.5, 1.5-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10 10-11,11-12 hr 
Renal clearance CLren = (dXu/dt )/Cp 
 
Bioavailability study:  Spyker et al 1 
Healthy (n = 8) 
Formulation : Not mentioned (250, 500, 1000 mg sodium amoxicillin) 
Sampling: 0-6 hrs 
Analysis: Plate assay 






















































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Fiegel et al 
(1978)6  
Healthy 









































n = 6 




60 Bolus 0-14 hrs 0-24 
hrs 
HPLC - - Noncomp
artmental 




































 (± 1.23) 
 
fe = 69.6 
(± 14.2) 
Tartaglio
ne et al5 
Healthy 
n = 12 


































Urine excretion study: 
Urine collection: 0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hr 













































































































































fe = 0.80 
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Plasma protein binding studies:  
  
Study Subjects Method Concentration 
range 









Therapeutic dose Cup Plate 
method 














Blood –to –plasma ratio studies: 
 















Urine excretion study: 
Ehrnebo et al (1979)9: 
Urine collection: 0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-8, 8-10, 10-12 hr 
Renal clearance CLren = Ae(12)AUC]06 here Ae6 is cumulative amount of drug excreted unchanged in urine upto 6 hrs 
 
Sjovall et al (1985)2: 
Urine collection: 0-0.05, 0.5-1, 1-1.5, 1.5-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10 10-11,11-12 hr 
Renal clearance CLren = (dXu/dt )/Cp 
 
Bioavailability study:  Ehrnebo et al (1979)9 
Healthy (n = 8) 
Formulation : Tablets (495 mg ampicillin) 
Sampling: 0-6 hrs 
Analysis: Microbiological assay 































































































































































































Urine excretion study:  
 
Tjandramaga et al13: 
Urine collection: 0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hr 
Renal clearance CLren = Ae(24)AUC]024here Ae24 is cumulative amount of drug excreted unchanged in urine upto 24 hrs 
 
Aronoff et al14: 
Urine collection: 0-2, 2-4, 4-6, 6-12, 12-24, 24-36, 36-48 hr 
Renal clearance CLren = Ae(48)AUC]048  where Ae48  is cumulative amount of drug excreted unchanged in urine upto 48 hrs 
 
 
Tartaglione et al5: 
Urine collection: 0-12 hr 




























ne et al5 
Healthy 
n = 12 


































Plasma protein binding studies:  
  
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Li et al17 Healthy 
n = 2 









































































64.5 Bolus 0-6 hrs 0-24 
hrs 






















































































































n = 10 
22-29 
yrs 































- - Not 
mentioned 












































































Urine excretion study:  
 
Itoh et al21: 
Urine collection: 0-0.5, 0.5-1, 1-2, 2-3, 3-4, 4-6, 6-12, 12-24 hr 
Renal clearance CLren = (dU/dt )/C(mid-point of urine collection interval) 
 
Plasma protein binding studies:  
  
Study Subjects Method Concentration 
range 





n = 6 
4% HSA on 
sephadex 
column 











































S – 2.16 
(± 0.22)) 
 











Plasma protein binding studies:  
  
Study Subjects Method Concentration 
range 





n = 6 
4% HSA on 
sephadex 
column 

















































































Plasma protein binding studies:  
  
Study Subjects Method Concentration 
range 









Therapeutic dose Cup Plate 
method 













































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 









Therapeutic dose Cup Plate 
method 








15 µg/ml Liquid 
scintillation 
















































































































Urine excretion study:  
 
Kampf et al23: 
Urine collection: 0-4, 4-8, 8-12, 12-24, 24-36 hr 















































 7.02 Bolus 0-8 hrs 0-24 
hrs 
HPLC - - Noncom-
partmental 
































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 





























Bioavailability study:  Gath et al27 
Healthy (n = 7) 
Formulation : Capsule  (500 mg sodium flucloxacillin) 
Sampling: 0-8 hrs 
Analysis: HPLC 

























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 









Therapeutic dose Cup Plate 
method 
94.2 ± 2.1 % 
 
Urine excretion study:  
 
Kampf et al23: 
Urine collection: 0-4, 4-8, 8-12, 12-24, 24-36 hr 


























































































































































































































n = 6 





























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 



















Urine excretion study:  
 
Bergan et al18 
Urine collection: 0-2, 2-4, 4-6, 6-8 hr 
 
Aronoff et al30: 
Urine collection: 0-2, 2-4, 4-6, 6-12, 12-24 hrs 
 
Pancoast et al20: 
Urine collection: 0-3, 3-6, 6-12 hrs 






























































Urine excretion study:  
 
Urine collection: 0-2, 2-4, 4-6, 6-8, 8-10 hr 




Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 















































n = 6 
22-28 
yrs 





























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 







- - 5-10% 
 
Urine excretion study: Gambertoglio et al (1980)33 
Urine collection:  Half hourly for first 3 hrs and then hourly every 6 hrs and then pooled from 6 -24 hrs 



















































HPLC - - Compart-
mental 



















































h et al35 
Healthy 

























































































n = 6 
46 yrs 























n = 10 
26.7 yrs 



































































































fe = 68.1 
% (± 6.0) 
 
Overbosc
h et al38 
Healthy 

























































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




















































Urine excretion study:  
Boelaert et al36: 
































Bioavailability study:  Bergan et al39 
Healthy (n = 9) 
Formulation : Tablets (375, 750, 1500 mg azidocillin sodium) 
                       Suspension (750 mg azidocillin sodium) 
Sampling: 0-8 hrs 
Analysis: HPLC 
Foral (tablet) = 59.5 % 

































































































Urine excretion study:  
 
Hinderling et al40 
Urine collection: 0-12 hr 
Renal clearance CLren = Ae(∞)AUC]0∞ where Ae∞ is cumulative amount of drug excreted unchanged in urine  
 
Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 





n = 2 
In-vitro 50, 100, 200, 400 
µg/ml 
HPLC 66 % 
 
 
Blood –to –plasma ratio studies: 
 




n = 5 
In-vitro 
 



































g et al40 
Healthy 







































Urine excretion study: Kozawa et al41 
Urine collection: 0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hr 





















































Bolus 0-24 hrs 0-24 
hrs 




















































































































































































































































fe = 45.6 







fe = 44.4 




















Urine excretion study: Majumdar et al (2002) 42 
Urine collection: 0-24 hr 


















   
fe = 44.1 































al (2008)43  
Healthy 















Cumulative - 4.7 0.26 2.38 









Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




















































n = 12 








0-8 hrs 0-12 
hrs 








Cumulative 70 x 106 





















Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Boswell et 
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Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range(µg/ml) 













































































































































































Urine excretion study: Pfeffer et al51 
Urine collection: 0-1, 1-2, 2-3,3-4, 4-6, 6-9, 9-12, 12-24 hr 

































n = 18 
 
n= 6 











n = 6 





































































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 




















Bioavailability study:  Pfeffer et al51 
Healthy (n = 6/group) 
Formulation : Capsule  (252.5, 505, 1010 mg Cefatrizine) 
Sampling: 0-6.5 hrs 
Analysis: Cylinder plate bioassay method  
Foral = 76.8 ± 6.8 % (252.5 mg) 
           75.0 ± 10.2 % (505 mg) 






























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




































































n = 8 
   0-6 hrs 0-6 
hrs 




























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 





















































































n = 8 
22-39 
yrs 























n = 8 
19-23 
yrs 


















Bioavailability study:  Schwinghammer et al56 
Healthy (n = 19) 
Formulation : Two 500 mg Capsule  (Dose = 1 gm) 
Sampling: 0-12 hrs 
Analysis: Microbiological assay 









Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 










































































n = 20 
21-42 
yrs 
























Urine excretion study:  
Pabst et al60 
Urine collection: 0-2, 2-4, 4-6, 6-8, 8-24 hr 
Renal clearance CLren = Ae(12)AUC]024here Ae24 is cumulative amount of drug excreted unchanged in urine upto 24 hrs 
 
Ungethum et al61: 


































































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 

























































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 










Urine excretion study: Ohkawa et al63 
Urine collection: 0-2, 2-4, 4-6 hr 














































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 





n = 5 
In-vitro 
Ultrafiltration 
2-250 µg/ml HPLC 62 % 












































n = 10 












































     fe = 
 48.6 % 







Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
































Urine excretion study: Westenfelder et al67 











































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 















n = 5 
In-vitro 
Ultrafiltration 
2-250 µg/ml HPLC 37 % 









































n = 10 
28 yrs 






























     fe = 




































































































































































































































































Urine excretion study: Ko et al73 
Urine collection: 0-1, 1-2, 2-4, 4-8, 8-12, 12-24 hr 




























fe = 0.86 
(± 0.18) 
 
Ko et al73 Healthy 







Bolus 0-12 hrs 0-24 
hrs 






















n = 7 
24-27 
yrs 
























































n = 8 
23 yrs 






































































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 























































n = 8 
59.4 yrs 






































































Urine excretion study: Ohkawa et al (1983)78 
Urine collection: 0-2, 2-4, 4-6, 6-8, 8-24 hr 
 
 
Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Carver  et 
al81 
Healthy 





























































Bolus 0-24 hrs 0-48 
hrs 






















































Plasma protein binding studies:  
 
 Subjects Method Concentration 
range 
Assay Protein binding 
 


















5-40 µg/ml Cup plate 
method 
32% (17-58%) 
(SE ± 11 %) 
 
Urine excretion study:  
Barza et al (1976)59 
Urine collection: 0-2, 2-6 hr 


































Barza et al 
(1976)59 
Healthy 




































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 



























































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 






















































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 







10 and 25 µg/ml HPLC 42 % 
(± 4.8%) 
 
Urine excretion study:  
Shyu et al84 
Urine collection: 0-2, 2-4, 4-6,6-8, 8-12, 12-24 hr 
Renal clearance CLren = (dXu/dt )/Cp 
 
































n = 24 






































































Healthy (n = 7) 
Formulation : capsule  (500 mg cefprozil) 
Sampling: 0-8 hrs 
Analysis: HPLC 







Urine excretion study:  
Pfeffer et al62 
Urine collection: 0-2, 2-4, 4-6, 6-9, 9-12, 12-24 hr 
Renal clearance CLren = (dXu/dt )/Cp 
 
Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 

























































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




















































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Carver  et 
al81 
Healthy 








































































































































































































0-24 hrs 0-48 
hrs 











































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 







< 100 µg/ml 
 
 
> 400  µg/ml 




  In-vivo 2 gm infusion 
 
166-209 µg/ml 
HPLC 82.2 – 89.0% 
Stoeckel 




















Dose – 1500 mg 


































Plasma protein binding studies:  30% ± 10% (just mentioned)  
 
Urine excretion study: 
Rodondi et al92 
Urine collection: 0-6, 6-8, 8-12, 12-24 hr 

































Fu et al 
(1979)91 
Healthy 


































(SE ±  
0.43 ) 
 




n = 8 





























fe = 49.6 
% 
(± 5.4 ) 
Kemmeric
h et al93 
Healthy 
n = 10 
32 yrs 









































































































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
 Mouton 






Dose – 25 mg/kg  
every 8 hrs over 
24 hrs 




Urine excretion study: LeBel et al (1985)94 
Urine collection: 0-2, 2-4, 4-8, 8-12, 12-24 hr 
















































0-36 hrs 0-36 
hrs 

































































































Urine excretion study: Blouin et al96 
Urine collection: 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-24 and 24-36 hr 
Renal clearance CLren = Ae(24)AUC]024 where Ae24 is cumulative amount of drug excreted unchanged in urine upto 24 hrs 
 
Koup et al97: 
Urine collection: 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36 hr 




Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




























































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 









declines to 2% 








































n = 8 












































































Urine excretion study:  
 
Kemmerich et al101 
Urine collection: 0-3, 3-6, 6-24 hr 
Renal clearance CLren = Ae(24)AUC]024 where Ae24 is cumulative amount of drug excreted unchanged in urine upto 24 hrs 
 
Kemmerich et al93: 






























h et al101 
Healthy 




























h et al93 
Healthy 
n = 10 
32 yrs 
































0-24 hrs 0-8 
hrs 
HPLC - - Compart-
mental 







fe = 21% 




n = 12 
 
65.4 30.6 Bolus 0-240 
mins 














Renal clearance CLren = fe * CLtot 
 
 
Boscia et al102: 
Urine collection: 0-8 hr 










Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 


















































h et al93 
Healthy 
n = 10 
32 yrs 



































Plasma protein binding studies:  
 











































n et al104 
Heathy 
adults 




































































































































































































































































Urinary excretion data: 
 
Lenfant et al105:  
Urine collection: 0-2, 2-4, 4-6, 6-10, 10-15, 15-24 and 24-34 hr 
Renal clearance CLren = Ae(34)AUC]034 where Ae34 is cumulative amount of drug excreted unchanged in urine upto 34 hrs 
 
Conte et al106: 
Urine collection: 0-2, 2-4, 4-8, 8-12, 12-24, 24-36, 36-48 hr 
Renal clearance CLren = Ae(48)AUC]048 where Ae48 is cumulative amount of drug excreted unchanged in urine upto 48 hrs 
 
Bryskier et al107 
Urine collection: 0-2, 2-4, 4-6, 6-8, 8-12, 12-24, 24-36, 36-48 hr 
Renal clearance CLren = Ae(36)AUC]036 where Ae36 is cumulative amount of drug excreted unchanged in urine upto 36 hrs 
 
Plasma protein binding studies:  
 
Lenfant et al105:  Conc < 180 mg/l – 89% 
                            180 mg/l  - 83% 
                            260 mg/l – 78% 
                            350 mg/l – 73% 
                             470 mg/l – 69% 
Average – 78.4 % 
 






















0-24 hrs 0-48 
hrs 


























































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
















HPLC 95.2 ± 1.4 
 









































































































0-48 hrs 0-48 
hrs 
HPLC - - Compart-
mental 








fe = 17.1 


































































































0-36 hrs 0-24 
hr 
HPLC - - Compartm
ental 





















Urinary excretion data: 
 
Lakings et al113:  
Urine collection: 0-0.5, 0.5-0.75, 0.75-1.0, 1-2, 2, 2-6, 6-12, 12-24 and 24-48 hr 









































































Cumulative - 1.69 
(± 0.29) 
 












Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Liu et al116 pooled 
plasma 
Ultrafiltration 400 mg oral dose HPLC 65 %  





Ultrafiltration 0.5-500 µg/ml HPLC fu = 31.3 ± 3.3 % 
 
Urinary excretion data: 
Faulkner et al114:  
Urine collection: 0-2, 2-4, 4-8, 8-12, 12-24 hr 






































n = 16 





2.82 Bolus 0-24 hrs 0-24 
hrs 


















n = 8 
22-25 
yrs 






































































30 Bolus 0-240 
mins 













































n for 2 
hrs 























Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
Liu et al116 pooled 
plasma 
Ultrafiltration 0.5-8 µg/ml HPLC 21%  









































































n = 16 





26.7 Bolus 0-12 hrs 0-12 
hrs 























28.6 Bolus 0-12 hrs 0-24 
hrs 

































































































Urine excretion study: Barbhaiya et al120 
Urine collection: 0-4, 4-8, 8-12, 12-24 hr 
Renal clearance CLren = Ae(24)AUC]024 where Ae24 is cumulative amount of drug excreted unchanged in urine upto 24 hrs 
 
Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 










































n = 8 
26.5 yrs 













































































0-12 hrs 0-24 
hrs 






















































































n for 1 
hr 









































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 








































































































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 
Assay Protein binding 
 
























































































































































































































































































































































































































Plasma protein binding studies:  
 
Study Subjects Method Concentration 
range 




Healthy Ultracentrifugation 0.5, 5, 24, 100 
µg/ml 
HPLC 17.3% 
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Urinary excretion studies: 
 
1. Dogs: Langguth et al1 estimated renal clearances by regression of the cumulative amount excreted in the urine and plotting against 
AUC (ΣU = CLren .AUC + Intercept). 
 
Garrett et al4: Urine was collected every 10 min upto 1 hr, then hourly upto 12 hr and then every 12 hr upto 100 hr. Renal 
clearance is estimated  from the slope of dU/dt versus plasma concentration plots. 
 




































































2. Rats: Sloan et al9 estimated renal clearance.   
 
Urine was collected from 0-6 h, 6-24 h, 24-48 h.      
Analysis: HPLC (sensitivity- 0.5 ng/ml) 
      Direct CLren = product of renal extraction ratio and renal blood flow – 11.88    ml/min/kg (± 1.46) 
      Indirect CLren = product of CL and urinary recovery of unmetabolized morphine – 
      4.38 ml/min/kg (± 1.46) % dose excreted unchanged in urine in 48 hrs = 12.3% (± 2.7) 
 
3. Sheep: Milne et al8 estimated renal clearance: 
      Urine was collected 0-6 h, 6-24 h, 24-48 h, urine volume and pH were measured.  
      Analysis: HPLC 




Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 





n = 6 












0.177 x 10-6 M - 




 Goat (n =15)    14.0 ± 0.87 
 Sheep (n = 
12) 
   15.4 ± 1.53 
 Ox (n =6)    23.6 ± 1.83 
 Horse (n= 7)    17.5 ± 0.98 
 Pony (n =8)    20.1 ± 1.13 
 Swine (n = 7)    10.6 ± 0.89 
 Dog (n =15)    12.1 ± 0.94 
 Cat (n = 10)    11.8 ± 2.01 
 Monkey (n =    19.0 ± 0.71 
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12) 
 Rat (n =12)    14.3 ± 0.62 
 Rabbit (n =7)    16.0 ±1.63 
 Opossum (n= 
4) 
   16.0 ± 1.96 
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  Blood –to –plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 
Assay Protein binding 
 





Ultrafiltration 1000 ng/ml HPLC 0.85 
Wu et al5 Male 
Sprague 
Dawley rats 
n =3  
Equilibrium 
dialysis 
10 nM Liquid 
scintillation 
Mean ± SE 
73.4 ± 7.1% 
(4%HSA) 
76.4 ± 1.3% 
(4%RSA) 




Sheep Ultrafiltration 81.5 nM HPLC 0.90 ± 0.09 
 





Ultrafiltration 2000 ng/ml HPLC 0.92 
Garrett et 
al4 










Blood –to –plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 
Assay B:P ratio 
 
M3G      
Garrett et 
al4 
Dog  In-vitro 50-500 ng/ml Liquid 
scintillation 





In-vitro 558 nM HPLC 0.88  ± 0.11 
n =5  
 594
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Milne et 
al19 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 









n = 9 
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Blood –to –plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 







n = 9 
In-vivo - GLC 0.77 
Meuldermans 
et al30 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 
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Blood–to–plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 










0.891 ± 0.042 
 Male Beagle 
dogs 
In-vitro   0.939 ± 0.083 
Bjorkman et 
al41 


















Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 







dialysis (20 rpm, 
37ºC/ 4hrs, pH 
7.35) 









dialysis (20 rpm, 
37ºC/ 4hrs, pH 
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Blood–to–plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 










0.744 ± 0.016 
 Male Beagle 
dogs 
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Excretion studies: Ishida et al46 carried excretion studies in 4 species: 
 
Male rabbits (2.8-3.5 kg), n = 4, % dose- urine-0.4(SE ± 0.4), feces – 0.8 (SE ± 0.3)  
Guinea pigs (450-500 kg), n = 4, % dose- urine-2.7(SE ± 0.3), feces – 2.2 (SE ± 0.6) 
Male rats (150-200 kg), n = 4, % dose- urine-1.3(SE ± 0.3), feces – 2.0 (SE ± 0.3) 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 














Blood–to–plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 
Assay Protein binding 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 
Assay Protein binding 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 
Assay Protein binding 
 
Baggot et al16 Goat (n=12) Equilibrium 
dialysis 
0.167 x 10-6 M 




9.2 ± 1.21 
 Sheep 
(n=12) 
   7.2 ± 0.76 
 Ox (n=6)    14.2 ± 1.50 
 Horse (n=7)    12.8 ± 1.84 
 Pony (n=8)    13.1 ± 1.57 
 Swine (n 
=9) 
   7.9 ± 0.90 
 Dog (n= 12)    9.6 ± 1.06 
 Cat (n= 10)    7.6 ± 0.81 
 Monkey (n= 
12) 
   8.2 ± 1.19 
 Rat (n =12)    7.5 ± 1.00 
 Rabbit (n 
=7) 
   15.6 ±1.69 
 Opossum 
(n= 4) 
   23.1 ± 1.91 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 




Cat Ultrafiltration - HPLC 15.59 ± 0.59 
























Plasma protein binding studies: 
 
Study Animal Method Concentration 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 
Assay Protein binding 
 
Garrett et al68 Dog         Ultrafiltration 9-5500 ng/ml Liquid 
scintillation 
0.40 ± 0.06 































































Blood–to–plasma ratio studies: 
                                                                                           Study Animal Method Concentration 
range 
Assay B:P ratio 
 
Garrett et al68 Dog  In-vitro - Liquid 
scintillation 
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Urinary excretion study (Garett et al8): 
Mongrel dogs, n = 6 
Urine was collected at intervals 15-60 min to 24 hrs 
 
Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 











0.5-500 ng/ml Liquid 
scintillation 
fu = 0.07 (± 0.001) 
 
 
Blood –to –plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 









In-vitro 0.5-500 ng/ml Liquid 
scintillation 










n = 48 
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a et al 17 
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0-6 hrs - GLC LOD 
5 ng/ml 







Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 





dialysis (37ºC / 15 
hr) 




dialysis (37ºC / 15 
hr) 
10-1000 ng/ml GC 80% 
 
 
Blood –to –plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 

























n = 4 





















Urinary excretion study: (Sisenwine et al.) 
 
Urine was collected for 0-6, 6-12, 12-24, 24-48 hrs. 
Monkeys: % dose excreted as dezocine: 2.1 ± 0.5  












































1 Bolus 0-12 hrs 0-48 
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n = 5 
10  5 Bolus 0-120 
mins 
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Urinary excretion studies: 
 
Monkeys(Reuning et al20): Urine was collected  at time points 0-30, 30-60, 60-90, 90-120, 120-150, 150-210, 210-270, 270-330, 330-
390, 390-450, 450-510, 510-1440 and 1440-2280 min after IV dose.   
Analysis: GC  
% dose excreted unchanged = 2.26% (±1.37) 
 
Dogs: Garrett et al23 studied urinary excretion studies in dogs. Urine was collected 15, 30, 45, 60, 90, 120, 180 min and then every 60 
min upto 720 min, then every 12 h for upto 6-15days. Renal clearance is estimated fro the slope of du/dt vs tmid plot.  
% dose excreted in urine = 7 ± 1% 
 
Plasma protein binding studies: 
 
Study Animal Method Concentration 
range (ng/ml) 








18.9 ± 2.49 
   7.73  21.3 ± 2.86 
   527  20.7 ± 0.23 
 Guinea pig Equilibrium 
dialysis 
0.104  20.4 ± 2.78 
   7.50  20.9 ± 2.43 
   512  21.9 ± 4.46 
 Rat  0.0995  19.8 ± 2.3 
   7.80  19.9 ± 1.35 
   514  19.4 ± 1.82 









21-71 4 Bolus 0-120 
hrs 
- LC-MS - - Non-
compart
mental 









   7.80  21.9 ± 2.25 
   517  23.3 ± 1.20 
Derendorf 
et al26 
Dog Ultracentrifugation 10-3500  HPLC 30.1 (± 5.1) 
 
 















Blood –to –plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 

















Humans 3 13.5 20.7 ± 0.47 
Monkey 3 7.73 21.3 ± 2.86 
Dogs    
Mongrel 2 13.8 26.2 
Beagles 14 13.3 26.8 ± 2.12 
Foxhounds 2 12.7 20.2 
Guinea pigs 6 7.50 20.9 ± 2.43 
Rat 6 7.80 19.9 ± 1.35 







Urinary excretion study: (Garrett et al29 ) 
Urine was collected at 15, 30, 45, 60, 75, 90, 120, 180 min, then every 60 min upto 720 min and then every 12h for upto 4 days. 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range (ng/ml) 











0.5-500 ng/ml Liquid 
scintillation 
fu = 0.62 (± 0.07) 
 
 
Blood –to –plasma ratio studies: 
                                                                                                                                                                                                                               
Study Animal Method Concentration 
range 









In-vitro 0.5-500 ng/ml Liquid 
scintillation 
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- LC-MS 1 ng/ml - - - - - Vd=  
4.6  
 






























n = 4 
9 ± 4 yrs 
- 1 Bolus 0-240 
mins 
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1 Bolus 0- 120 
mins 
- HPLC - - compart-
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Fractionated - - - 0.01 
(± 0.01) 
Vu et al5 Dog 
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9-13 yrs 
























Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 





n = 7 
Equilibrium 
dialysis 




 n =5 
Equilibrium 
dialysis 
50 ng/ml HPLC fu = 0.27 ± 0.03 
 Rabbit 
n = 8 








10 µg/ml HPLC Binding = 67.7 % 
Bai et al11 Mongrel 
Dogs 









n = 4 
Equilibrium 
dialysis 
In-vivo Fluorimetry Binding = 99.2% 
(98.9-99.5) 
 Dog    Binding = 96.6% 
(95.2-98.5) 


















5 Bolus 0-90 
mins 
- HPLC - - Compart-
mental 








3-5 1 Bolus 0-360 
mins 











Blood –to –plasma ratio studies: 
 
Study Animal Method Assay B:P ratio 
Vu et al5 Dogs In-vitro Liquid 
scintillation 
0.87 
(SE ± 0.03) 
 
fu = 0.152 
(SE ± 0.012) 
 
Bai et al11 Mongrel 
Dogs 








Monkey In-vivo Fluorimetry 0.85 
 
 Dog   0.85 
 Rat   0.80 
 
Urinary excretion study:  
 
Dog: 
Vu et al5: Urine collection: 0-72 hr 
 
Bioavailability study:  
 
Dog: 
Vu et al5: Formulation : Capsule (40 mg) 
Sampling: 0-300 mins 
Analysis: Fluorimetry 


















































5 Bolus 0-6 hrs 0-24 
hrs 


















































5 Bolus 0-6 hrs 0-6 
hrs 
















































10 Bolus - 0-48 
hrs 





















Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 








n = 8  
8 weeks 













Blood –to –plasma ratio studies: 
 



























































































Urinary excretion study:  
Rat:  
Carr et al13: Urine collection: 0-24 hrs 
Renal clearance CLren = Ae(24)/[AUC]0∞ where Ae24 is cumulative amount of drug excreted unchanged in urine upto 24 hrs 
Dog: 
Ishizaki et al17: Urine collection: 0-8 hr 
















































































10 Bolus 0-12 hr 0-24 
hr 
HPLC sensitivi






















10 Bolus 0-12 hrs 0-24 
hrs 
HPLC sensitivi


























Urinary excretion study:  
 
Rat:  
Mehvar et al21: Urine collection : 0-24 hrs 
Renal clearance CLren = Ae(24)/[AUC]024 where Ae24 is cumulative amount of drug excreted unchanged in urine upto 24 hrs 
 
Dog: 





Belpaire et al3: Formulation : Not mentioned (5mg/kg), n= 22 
Sampling: 0-8 hrs 
Analysis: HPLC 
Foral = 33.5 (SE ± 1.7) 
 
Cat: 
Quinones et al23: Formulation : capsules (3 mg/kg), n= 9 
Sampling: 0-12 hrs 
Analysis: HPLC 















2 Bolus 0- 3 hrs 0-24 
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HPLC - - compart
mental 











s et al23 
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n = 9 






































































n = 7 
0.542 
 
2 Bolus 0- 120 
mins 
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partmen
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GC-MS - - Non-
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Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 












HPLC 8.3 % 
Bortolottti 
et al 28 
New Zealand 
Rabbits 
n = 6 
Ultrafiltration 3-9 mg/l HPLC 32 % 
 
Blood –to –plasma ratio studies: 
 
Study Animal Method Assay B:P ratio 
Bortolottti 
et al 28 
New Zealand 
Rabbits 
n = 6 





































n = 6 
2.5-
3.0 




HPLC - - Compar
tmental 

















































































1 Bolus 0-6 hrs 0-24 
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n = not 
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Bioavailability study:  
Rat:  
Kamimura et al30: Formulation : Solution (10 mg/kg, 30 mg/kg, 100 mg/kg) , n= 3/dose group 
Sampling: 0-10 hrs 
Analysis: HPLC 
Foral = 22.1 (10 mg/kg) 
Foral = 31.4 (10 mg/kg) 
Foral = 26.8 (10 mg/kg) 
 
Monkeys:  
Kamimura et al30: Formulation : Solution (10 mg/kg, 30 mg/kg), n= 3/dose group 
Sampling: 0-10 hrs 
Analysis: HPLC 
Foral = 65.9 (10 mg/kg) 
Foral = 57.4 (30 mg/kg) 
 
Dog:  
Kamimura et al30: Formulation : capsules (3 mg/kg, n= 4, 10 mg/kg, n=6, 30 mg/kg, n =3) 
Sampling: 0-10 hrs 
Analysis: HPLC 
Foral = 65.9 (10 mg/kg) 




Suzuki et al31: Formulation : not mentioned (10 mg/kg) 
Sampling: 0-8 hrs 
Analysis: HPLC 





















Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 

























































n = 5 











































































n = 2  

























































































































































































































R – 14.6 
(± 2.2) 
fe = 23.5% 
(± 3.1) 
 
S – 15.7 
(± 2.2) 




R – 12.0 
(± 3.2) 
fe = 26.6% 
(± 8.5) 
 
S – 14.2 
(± 3.7) 





Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 


















HPLC R-AC 8.0 ± 0.8 % 
S-AC 7.0 ± 1.2 % 
Avg – 7.5% 
 
 
R-AC 10.0 ± 4.6 % 
S-AC 12.0 ± 5.0 % 




















































     Plasma Urine  Plas
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fe = 53% 
± 3.4 
 






















































































































































n = 3 









S – 326 





R – 224 
(± 23) 
S –4.12 






( ± 0.65) 
 
 
- S –1.63 
( ± 0.12) 
 




( ± 0.21) 
 
















- - 50.7 





















- 133680 7 


































Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 




Rat Ultrafiltration 0.01-5 µg/ml Liquid 
scintillation 
13-16% 
 Dog    23-26% 

























HPLC S – 31.6% 
R – 29.7% 
S – 40.1% 
R – 38.2% 
 
S – 29.8% 
R – 29.9% 
S – 26.0% 
R – 23.9% 
 
 
Bioavailability study:  
 
Dog:  
Beddies et al43: Formulation : Capsules (1 mg/kg) 
Sampling: 0-24 hrs 
Analysis: HPLC-MS 




















Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 






n = 8 



















































n = 8 
0.20-
0.25 
3 Bolus 0-60 
min 





























































5 Bolus 0-360 
mins 


















































1.34 Bolus 0-24 hrs 0-24 
hrs 
HPLC - - Non-
compart
-mental 





















Bioavailability study:  
 
Dog:  
Arsenault et al48: Formulation : Small meatball of canned dog food (1.5 mg/kg) 
Sampling: 0-1440 mins 
Analysis: HPLC 









































20-25  0.175 Bolus 0-1440 
mins 























0.16 Bolus 0-360 
mins 













n = 12 
0.22-
0.25 
1 Bolus 0-180 
mins 




















Bioavailability study:  
 
Dog:  
McAish et al51: Formulation : Solution (15 mg/kg) 
Sampling: 0-48 hrs 
Analysis: HPLC 

















































15 Bolus 0-48 hrs 0-48 
hrs 











































































































































































wa et al53 
Rat 











































Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 




Rats Ultrafiltration 0.1, 




HPLC 2.8± 2.4 % 
5.3± 1.9 % 
2.7± 2.6 % 
4.1± 1.2 % 
 
 
Mean – 3.73% 
 Dog Ultrafiltration 0.1, 




HPLC 21.3± 3.7 % 
19.7 ± 3.4 % 
14.7 ± 4.3 % 
16.3± 1.7 % 
 
 


















































































































Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 













HPLC 22.3 ± 2.8 % 
22.4 ± 6.0 % 
23.8 ± 1.1 % 
23.2 ± 1.6 % 
23.9 ± 0.5 % 













 20.0 ± 4.3 % 
25.3 ± 0.5 % 
28.5 ± 1.3 % 
28.2 ± 0.8 % 
28.9 ± 1.0 % 
28.2 ± 0.3 % 
 
 























Bioavailability study:  
 
Rat:  
Ferrandes et al57: Formulation : Solution (5 mg/kg) 
Sampling: 0-8 hrs 
Analysis: Liquid scintillation 




Ferrandes et al57: Formulation : Solution (5 mg/kg) 
Sampling: 0-24 hrs 
Analysis: Liquid scintillation 







































n = 3 
0.210 
 












n = 3 
7 
 


















Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 













 n =5 
Equilibrium 
dialysis 
50 mg/kg  oral 
dose 
HPLC fu = 0.27 ± 0.03 
 Rabbit 
n = 8 












































0.205 5 Bolus 0-90 
mins 






S - 349.3 
 
 














Plasma protein binding studies:  
 
Study Animal Method Concentration 
range 





n = 6 
Equilibrium 
dialysis 
1-100 ng/ml GC-MS Median- 
11.5% 
 
Bioavailability study:  
Horse:  
Torneke et al58: Formulation : Tablets (0.1 mg/kg) 
Sampling: 0-10 hrs 
Analysis: GC-MS  
Foral = Close to 0 
 































































- - - - - - - fe = 
23.1%  


















































































































































































































n = 4 
2.5 
± 0.2 
0.06 Bolus 0-90 
mins 





















































n = 4 
 
0.2 1 Bolus 0-240 
mins 
- HPLC LOD – 
5 ng/ml 
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Appendix II (c) 
 













































n = 8 
0.28-
0.335 



















 n = 10  









































Reyns et al3:  
Species:  Pigs (n = 8) 
Formulation: Tablets (20 mg/kg) 
Sampling: 0-8 hrs 
Assay: LC-MS/MS 






















































n = 12 
0.27-
0.30 


























































n = 12 
8.6-
17.5 
100  Bolus 0-3hrs - HPLC - - Compar
tmental 







































n = 6 
18-
23 






















Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 



















































































































Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 




Albino rats  
n = 4 
 
 
Ultrafiltration 9.3- 133 µg/ml Agar diffu-
sion 
41.7 ± 3.4 % 
 Rabbits 
n = 3 




























































n = 3 




















Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 







Ultrafiltration 40 mg/kg IV 
bolus 












































n = 4 
0.654 40 Bolus 0-120 
mins 






































































n = 5 
















































































0-65 hrs - HPLC - - Compar
tmental 









































20 Bolus 0-120 
mins 
- HPLC -- - Compar
tmental 










Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 






















Nadai et al12 Wistar rats Equilibrium 
dialysis 
20 mg/kg IV 
Bolus 






























Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 






n = 6 
Microdialysis 50 mg/kg IV 
bolus 


















































50 Bolus 0-120 
mins 





















Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 
Assay Protein binding 
 
Tsai et al15 Sprague 
Dawley rats 
Microdialysis 0.5-1 µg/ml HPLC fu = 46.1 % 
Water-
man et al16 
Dog Ultrafiltration 20 µg/ml Cup plate 
method 
6-15 % 











































20 Bolus 0-150 
mins 
- HPLC - - Non-
compart
mental 













n = 6 




































































a et al17 
Beagle 
dogs 
n = 4 




















Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 








n = 10 
Ultrafiltration 5.25 mg/kg/hr for 
65 hrs 




































































Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 






n = 5 
Inhibition 
zone method 

















































6.15 Bolus 0-210 
mins 




















n = 5 




































































































































































n = 4 











fe = 32 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 







Ultrafiltration 40 mg/kg IV 
bolus 












































n = 4 
0.654 40 Bolus 0-120 
mins 





















Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 





n = 4 























     Plasma Urine  Plas-
ma  




























Cumulative - 8.94 
 






n = 2 
2.4-
3.5 







Cumulative - 2.66 0.229 fe = 
74.9% 
Ganzin-
ger et al23 
Rabbits 
n = 4 





















Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 





n = 4 






























































ger et al23 
Rabbits 
n = 4 









































Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 








 Rat 32 % 
 Dog 17 % 
 Rabbit 






































 20 Bolus 0-4 hrs 0-24 
hrs 
HPLC - - Compartm
ental 




 20 Bolus 0-4 hrs 0-24 
hrs 







20 Bolus 0-4 hrs 0-24 
hrs 






20 Bolus 0-4 hrs 0-24 
hrs 


















































































































































n = 3 
12.2-
12.6 
20  0-6 hrs 0-24 
hrs 






















































































n = 3 
12.2-
12.6 
20  0-6 hrs 0-24 
hrs 

















20  0- 6 hrs 0-24 
hrs 
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n = 9 
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Plasma protein binding studies: 
 
Study Animal Method Concentration 
range 




Albino rats  



































































n = 3 
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